{
  "results": [
    {
      "id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "created_at": "2025-12-14T21:05:22.906428+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_0bb5e1bfb414f1c800693f1f1e491c8197960913ff57de2b81",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 73466,
          "total_tokens": 80693,
          "output_tokens": 7227,
          "input_tokens_details": {
            "cached_tokens": 0
          },
          "output_tokens_details": {
            "reasoning_tokens": 6493
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f1eca0881979bfc470205e77570",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f2028ec8197b051c126ad607ad0",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CDK12 臨床試験 NCT"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f21a52c81978c32e565d5ac9786",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f2577b48197b46ca789c8a8520b",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CDK12 mutation prostate cancer NCT"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f285a448197b033e11da70727dd",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f288b3881979d73048461df6547",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "IMPACT trial CDK12 NCT"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f2a77f48197b5ffa7821a1066dd",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f2f65188197b40654e334fee7b1",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "INSPIRE trial nivolumab ipilimumab CDK12i NCT"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f31acfc81979b7d3f190c85dba7",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f383a7481979b0c0d1d31f20e1e",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "site:clinicaltrials.gov NCT06600789 CT7439 CDK12"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f3aac788197877995d197d44e01",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f3b937481979fc8186985567c55",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "NCT06600789 clinicaltrials.gov study"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f3dfcc08197afc88c1eede03d00",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f3f206081978f37c08e8343f188",
            "type": "web_search_call",
            "action": {
              "url": "https://clinicaltrials.gov/study/NCT06600789",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f40d1a8819799616dbee33a2218",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f440aac8197a30771757d512594",
            "type": "web_search_call",
            "action": {
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f46a038819791c910ecbf2522a9",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f4f55e88197a757a3461b26a2b6",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"IMPACT\" trial CDK12-altered mCRPC NCT"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f52484881978f4cddeb3f6d68fa",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f53ac1881978babf75636ff0fb2",
            "type": "web_search_call",
            "action": {
              "url": "https://clinicaltrials.gov/show/NCT04104893",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f56702881979655d7457c7cff13",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f5889548197b884ceae4c5b92c1",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "site:cdek.pharmacy.purdue.edu NCT02952534"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f5b95608197bbf14623c69707e8",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f6ba8188197ac5c34138904e0ca",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f6e86b88197a7305cebc4bd15a1",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f6fabd481979140d8c7ffdc729e",
            "type": "web_search_call",
            "action": {
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f717ba48197a730e0b477e2b034",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f72380c8197a445f51472838830",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f73409481978e9d4c8921da81d6",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f76b364819784546cdbedc8d530",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f7813a88197987729a1523c6aae",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f78e2888197916f869a196ec846",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
              "type": "find_in_page",
              "pattern": "NCT02952534"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f7b0f5881979a74287afe2332e5",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f7db6e881979fc28cdde54bd4d4",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f80c2708197a24d56e3e1d6bbef",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f81ddc08197be396fb288093f39",
            "type": "web_search_call",
            "action": {
              "url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f83726c8197ae555f6438b8bc14",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0bb5e1bfb414f1c800693f1f84c7f88197831e401fb8982066",
            "type": "web_search_call",
            "action": {
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0bb5e1bfb414f1c800693f1f86a7a8819786b068e89d43774e",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_0bb5e1bfb414f1c800693f1f94747c8197af1704ddcc992697",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)\",\n      \"url\": \"https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase\",\n      \"snippets\": [\n        \"the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor\",\n        \"Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789.\"\n      ]\n    },\n    {\n      \"title\": \"Trial | NCT06600789\",\n      \"url\": \"https://cdek.pharmacy.purdue.edu/trial/NCT06600789/\",\n      \"snippets\": [\n        \"Trial | NCT06600789\",\n        \"* Prior therapy with a specific CDK12/13 inhibitor, within any timeframe prior to the first dose of CT7439.\"\n      ]\n    },\n    {\n      \"title\": \"Clinical Trial: NCT04104893 - My Cancer Genome\",\n      \"url\": \"https://www.mycancergenome.org/content/clinical_trials/NCT04104893/\",\n      \"snippets\": [\n        \"#### NCT04104893\",\n        \"metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-).\"\n      ]\n    },\n    {\n      \"title\": \"Trial | NCT04717154\",\n      \"url\": \"https://cdek.pharmacy.purdue.edu/trial/NCT04717154/\",\n      \"snippets\": [\n        \"Trial | NCT04717154\",\n        \"Phase 2 INSPIRE Trial: Ipilimumab With Nivolumab for Molecular- Selected Patients With Castration-resistant Prostate Cancer\"\n      ]\n    },\n    {\n      \"title\": \"Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/37277275/\",\n      \"snippets\": [\n        \"Background:  Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID\",\n        \"TRITON2 had enrolled 277 patients, grouped by mutated gene: BRCA (n = 172), ATM (n = 59), CDK12 (n = 15)\"\n      ]\n    },\n    {\n      \"title\": \"TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in mCRPC - Health Research Authority\",\n      \"url\": \"https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/\",\n      \"snippets\": [\n        \"Eudract number 2016-003162-13\",\n        \"Clinicaltrials.gov Identifier NCT02952534\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765744414,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
        "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
        "https://www.mycancergenome.org/content/clinical_trials/NCT04104893/",
        "https://cdek.pharmacy.purdue.edu/trial/NCT04717154/",
        "https://pubmed.ncbi.nlm.nih.gov/37277275/",
        "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/"
      ]
    },
    {
      "id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "created_at": "2025-12-14T21:05:23.613625+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_02be76e2773eed8900693f1f1e57888194b76ce722d65fdc13",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 50973,
          "total_tokens": 56054,
          "output_tokens": 5081,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 4256
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_02be76e2773eed8900693f1f1ede048194999e6f61a37475d9",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_02be76e2773eed8900693f1f1fd1208194b8c4d36e293f9bb7",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CDK12 PROTAC 蛋白降解 专利 WO"
            },
            "status": "completed"
          },
          {
            "id": "rs_02be76e2773eed8900693f1f2149d88194b1b999231fb7eaec",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_02be76e2773eed8900693f1f24febc81949532b1e70da89416",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/WO2024008097A1/zh",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_02be76e2773eed8900693f1f26049c819490d0f7175426c8f7",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_02be76e2773eed8900693f1f2989c881949eff33ccee954b20",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "WO CDK12 degrader"
            },
            "status": "completed"
          },
          {
            "id": "rs_02be76e2773eed8900693f1f2b7c9c8194a2373c58a8ca86c9",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_02be76e2773eed8900693f1f2f86608194bd8683a434e3e9e4",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "WO CDK12/13 degrader WO2024"
            },
            "status": "completed"
          },
          {
            "id": "rs_02be76e2773eed8900693f1f31690081949720af47980c0ff3",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_02be76e2773eed8900693f1f34dcd081948191ff5da8c1fa9b",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "YJ1206 CDK12 CDK13 PROTAC degrader"
            },
            "status": "completed"
          },
          {
            "id": "rs_02be76e2773eed8900693f1f38977481948c2ea9f410baebf7",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_02be76e2773eed8900693f1f419c008194a0a54cc6207f379a",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/WO2020219650A1/zh",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_02be76e2773eed8900693f1f448ccc8194adaf3919a2ee0bd7",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_02be76e2773eed8900693f1f45c8f08194ab5a7563bcb8cb44",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/WO2024222726A1/zh",
              "type": "find_in_page",
              "pattern": "WO2024222726A1"
            },
            "status": "completed"
          },
          {
            "id": "rs_02be76e2773eed8900693f1f48e6c8819481eddd53ff6da0ab",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_02be76e2773eed8900693f1f4c0de481948f5fe72ea2a6bdc9",
            "type": "web_search_call",
            "action": {
              "url": "https://www.medkoo.com/products/60512",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_02be76e2773eed8900693f1f4f3c408194ae6f3deaf9f93ea2",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_02be76e2773eed8900693f1f518be0819495b1806505d34706",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
              "type": "find_in_page",
              "pattern": "Abstract"
            },
            "status": "completed"
          },
          {
            "id": "rs_02be76e2773eed8900693f1f5470d08194b3c72bf06f8511cc",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_02be76e2773eed8900693f1f5520288194ab9b8cf6878eaa94",
            "type": "web_search_call",
            "action": {
              "url": "https://www.medkoo.com/products/60512",
              "type": "find_in_page",
              "pattern": "CAS#3053716-98-3"
            },
            "status": "completed"
          },
          {
            "id": "rs_02be76e2773eed8900693f1f5737b08194bc46ed820642b744",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_02be76e2773eed8900693f1f5a1f3c8194ae880c36b368e2e1",
            "type": "web_search_call",
            "action": {
              "url": "https://www.glpbio.com/pp-c8.html",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_02be76e2773eed8900693f1f5ca02881949b9436df18e1fa25",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_02be76e2773eed8900693f1f6a74bc81949b2f575344aaa451",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"WO2020219650A1 - Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof - Google Patents\",\n      \"url\": \"https://patents.google.com/patent/WO2020219650A1/zh\",\n      \"snippets\": [\n        \"Publication number WO2020219650A1\",\n        \"PCT/US2020/029483\"\n      ]\n    },\n    {\n      \"title\": \"WO2024222726A1 - 细胞周期蛋白依赖性激酶12/13的降解剂、组合物及其应用 - Google Patents\",\n      \"url\": \"https://patents.google.com/patent/WO2024222726A1/zh\",\n      \"snippets\": [\n        \"Publication number WO2024222726A1\",\n        \"PCT/CN2024/089497\"\n      ]\n    },\n    {\n      \"title\": \"WO2024175065A1 - Agent de dégradation contenant un substituant aryle pour cdk12/13 - Google Patents\",\n      \"url\": \"https://patents.google.com/patent/WO2024175065A1/fr\",\n      \"snippets\": [\n        \"Publication number WO2024175065A1\",\n        \"PCT/CN2024/078146\"\n      ]\n    },\n    {\n      \"title\": \"Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34864331/\",\n      \"snippets\": [\n        \"we have synthesized a potent PROTAC degrader PP-C8\",\n        \"DOI:  10.1016/j.ejmech.2021.114012\"\n      ]\n    },\n    {\n      \"title\": \"Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/39353441/\",\n      \"snippets\": [\n        \"we develop a selective CDK12/13 PROTAC degrader, YJ9069\",\n        \"yielded an orally bioavailable CDK12/13 degrader, YJ1206\"\n      ]\n    },\n    {\n      \"title\": \"Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34289372/\",\n      \"snippets\": [\n        \"NCT02 is identified as a candidate with minimal risk of non-specific toxicity.\",\n        \"NCT02 acts as molecular glue that induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12.\"\n      ]\n    },\n    {\n      \"title\": \"PP-C8|Cas# - GlpBio\",\n      \"url\": \"https://www.glpbio.com/pp-c8.html\",\n      \"snippets\": [\n        \"Catalog No.GC69730\",\n        \"PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM, respectively.\"\n      ]\n    },\n    {\n      \"title\": \"YJ1206 | CAS#3053716-98-3 | CDK12/CDK13 PROTAC degrader | MedKoo\",\n      \"url\": \"https://www.medkoo.com/products/60512\",\n      \"snippets\": [\n        \"CAS#3053716-98-3\",\n        \"MedKoo Cat#: 128339  | Name:  YJ1206\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765744414,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://patents.google.com/patent/WO2020219650A1/zh",
        "https://patents.google.com/patent/WO2024222726A1/zh",
        "https://patents.google.com/patent/WO2024175065A1/fr",
        "https://pubmed.ncbi.nlm.nih.gov/34864331/",
        "https://pubmed.ncbi.nlm.nih.gov/39353441/",
        "https://pubmed.ncbi.nlm.nih.gov/34289372/",
        "https://www.glpbio.com/pp-c8.html",
        "https://www.medkoo.com/products/60512"
      ]
    },
    {
      "id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "created_at": "2025-12-14T21:05:25.008792+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_0eedb829e85bf36800693f1f1e6b608190bdf8d8599dee1d5c",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 17001,
          "total_tokens": 19498,
          "output_tokens": 2497,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 1528
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_0eedb829e85bf36800693f1f1ed0108190bc3a798fcaabb663",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0eedb829e85bf36800693f1f23288c81909b438a379a84ebe1",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CDK12 inhibitor first patient dosed phase 1 press release"
            },
            "status": "completed"
          },
          {
            "id": "rs_0eedb829e85bf36800693f1f24cb4c8190a7df5bd93ba0e6cd",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0eedb829e85bf36800693f1f2773d48190bc51035b45c35af5",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 첫 환자 투여 1상 보도자료"
            },
            "status": "completed"
          },
          {
            "id": "rs_0eedb829e85bf36800693f1f29086c8190b756db0f766ff784",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0eedb829e85bf36800693f1f2a72608190895d80ccfa0c3f1e",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "clinicaltrials.gov NCT06600789 CT7439"
            },
            "status": "completed"
          },
          {
            "id": "rs_0eedb829e85bf36800693f1f2c417c8190aff2f84961c784f0",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0eedb829e85bf36800693f1f2d950481908de23d4f46a708e7",
            "type": "web_search_call",
            "action": {
              "url": "https://clinicaltrials.gov/study/NCT06600789",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0eedb829e85bf36800693f1f2e30a4819099b318b845f94cf3",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_0eedb829e85bf36800693f1f37218481909b8b9e31631029be",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)\",\n      \"url\": \"https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html\",\n      \"snippets\": [\n        \"“the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439”\",\n        \"“Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789.”\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.\",\n      \"url\": \"https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase\",\n      \"snippets\": [\n        \"“the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439”\",\n        \"“study ID: NCT06600789.”\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) - BioSpace\",\n      \"url\": \"https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor\",\n      \"snippets\": [\n        \"“first patient has been dosed in the Phase 1 clinical trial evaluating CT7439”\",\n        \"“under study ID: NCT06600789.”\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics announces first patient dosed in Phase 1 Clinical Trial - Cambridge Innovation Capital\",\n      \"url\": \"https://www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/\",\n      \"snippets\": [\n        \"“CT7439 is the first CDK12/13 inhibitor to enter clinical development”\",\n        \"“Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789.”\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13\",\n      \"url\": \"https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html\",\n      \"snippets\": [\n        \"“FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439”\",\n        \"“CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.”\"\n      ]\n    },\n    {\n      \"title\": \"FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor | CancerNetwork\",\n      \"url\": \"https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor\",\n      \"snippets\": [\n        \"“clearance to an investigational new drug (IND) application for CDK12/13 inhibitor CT7439”\",\n        \"“a planned phase 1 trial will examine CDK12/13 inhibitor CT7439”\"\n      ]\n    },\n    {\n      \"title\": \"CT7439 Capsules (0.5 mg, 1mg, 3mg) in Solid Malignancies - Clinical Trials Registry - ICH GCP\",\n      \"url\": \"https://ichgcp.net/clinical-trials-registry/NCT06600789\",\n      \"snippets\": [\n        \"“NCT06600789”\",\n        \"“Other Study ID Numbers  * CT7439_001”\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765744414,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
        "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
        "https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor",
        "https://www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/",
        "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
        "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
        "https://ichgcp.net/clinical-trials-registry/NCT06600789"
      ]
    },
    {
      "id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "created_at": "2025-12-14T21:05:25.369314+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_026300134bde412500693f1f1e3ea4819493b085525dca3a94",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 42426,
          "total_tokens": 45974,
          "output_tokens": 3548,
          "input_tokens_details": {
            "cached_tokens": 3456
          },
          "output_tokens_details": {
            "reasoning_tokens": 2740
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_026300134bde412500693f1f1ed04c8194a7d92ae7b63934ce",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_026300134bde412500693f1f22e2e88194a7315ca0c6d6df38",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CDK12 inhibitor press release \"Phase 1\" \"first patient\""
            },
            "status": "completed"
          },
          {
            "id": "rs_026300134bde412500693f1f24bc248194bae4d22fd36a651b",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_026300134bde412500693f1f26eea48194996554e76965f026",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "NCT06600789 CT7439 CDK12/13"
            },
            "status": "completed"
          },
          {
            "id": "rs_026300134bde412500693f1f28f1e48194be6b8df509ef7052",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_026300134bde412500693f1f2c3f508194a7fbf8d5f1358607",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "clinicaltrials.gov NCT06600789 CT7439"
            },
            "status": "completed"
          },
          {
            "id": "rs_026300134bde412500693f1f2de1f48194ac03defeccd62f68",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_026300134bde412500693f1f31d1708194aab039224e0dcd32",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 first patient dosed Phase 1 site:fiercebiotech.com"
            },
            "status": "completed"
          },
          {
            "id": "rs_026300134bde412500693f1f3422048194bfb7d47220525ae5",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_026300134bde412500693f1f3d616c8194a63beef314cb7918",
            "type": "web_search_call",
            "action": {
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_026300134bde412500693f1f3eaf40819494df2c989b8df860",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_026300134bde412500693f1f3f46e88194832a52f65e801900",
            "type": "web_search_call",
            "action": {
              "url": "https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_026300134bde412500693f1f40cb908194a2f7b1f23a802de6",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_026300134bde412500693f1f41bc5481948fcfa2bcb101c027",
            "type": "web_search_call",
            "action": {
              "url": "https://www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_026300134bde412500693f1f42fdd88194a351eae55be19c50",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_026300134bde412500693f1f43a5188194bf9b7d0307400517",
            "type": "web_search_call",
            "action": {
              "url": "https://ichgcp.net/clinical-trials-registry/NCT06600789",
              "type": "find_in_page",
              "pattern": "CT7439_001"
            },
            "status": "completed"
          },
          {
            "id": "rs_026300134bde412500693f1f44b874819492dd776e8b1ae6d2",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_026300134bde412500693f1f45e4048194a4214823c0932f91",
            "type": "web_search_call",
            "action": {
              "url": "https://ichgcp.net/clinical-trials-registry/NCT06600789",
              "type": "find_in_page",
              "pattern": "Other Study ID Numbers"
            },
            "status": "completed"
          },
          {
            "id": "rs_026300134bde412500693f1f470cf48194a5a5e0511fbb0348",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_026300134bde412500693f1f50deb481949aa87e910adc22d7",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) - GlobeNewswire\",\n      \"url\": \"https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html\",\n      \"snippets\": [\n        \"the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439\",\n        \"under study ID: NCT06600789.\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.\",\n      \"url\": \"https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase\",\n      \"snippets\": [\n        \"the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439\",\n        \"under study ID: NCT06600789.\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) - BioSpace\",\n      \"url\": \"https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor\",\n      \"snippets\": [\n        \"the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439\",\n        \"under study ID: NCT06600789.\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics announces first patient dosed in Phase 1 Clinical Trial - Cambridge Innovation Capital\",\n      \"url\": \"https://www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/\",\n      \"snippets\": [\n        \"the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor\",\n        \"under study ID: NCT06600789.\"\n      ]\n    },\n    {\n      \"title\": \"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies - ICH GCP (Clinical Trial NCT06600789)\",\n      \"url\": \"https://ichgcp.net/clinical-trials-registry/NCT06600789\",\n      \"snippets\": [\n        \"Clinical Trial NCT06600789\",\n        \"Other Study ID Numbers\\n\\n  * CT7439_001\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13 :: Carrick Therapeutics, Inc.\",\n      \"url\": \"https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind\",\n      \"snippets\": [\n        \"the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439\",\n        \"a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765744414,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
        "https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
        "https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor",
        "https://www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/",
        "https://ichgcp.net/clinical-trials-registry/NCT06600789",
        "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind"
      ]
    },
    {
      "id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "created_at": "2025-12-14T21:05:25.70705+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_00f300c2903b2ac200693f1f1e52748194bef78b0c818f20e0",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 88439,
          "total_tokens": 98658,
          "output_tokens": 10219,
          "input_tokens_details": {
            "cached_tokens": 3456
          },
          "output_tokens_details": {
            "reasoning_tokens": 9544
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_00f300c2903b2ac200693f1f1ed014819494f7bc2882b635d0",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f2353048194b7f3ba7049e897ea",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CDK12 inhibitor pipeline filetype:pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f24a6848194926cacae2c2438ca",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f2a6a688194a447afb94a3f25df",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "SR-4835 THZ531 CDK12 inhibitor filetype:pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f2c49e88194928fdb7cf2ccf3db",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f30db94819480ed94836b300275",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"CDK12\" \"SR-4835\" \"THZ531\" pdf download"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f331b5c8194b85083412bd530ea",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f351ebc8194bdf695d6c6567347",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "HQ461 CDK12 inhibitor filetype:pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f37f51081949b485c516cfc9275",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f3ae48081949a1b083af866efe7",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "SR-4835 patent US filetype:pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f3cc6e481949a58892e289a7496",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f43d5288194818cc424f4f8f971",
            "type": "web_search_call",
            "action": {
              "url": "https://www.nature.com/articles/s41420-023-01754-x",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f459cb08194ab8b0794e6c4b913",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f480fac81948e1ba526264144cf",
            "type": "web_search_call",
            "action": {
              "url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f49d370819485ead30e6da55290",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f4edbe081948fe7c6d82f319825",
            "type": "web_search_call",
            "action": {
              "url": "https://www.nature.com/articles/s41586-020-2374-x",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f5101148194aaf3b82efdcf600b",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f539af48194859b18bffb38c9ef",
            "type": "web_search_call",
            "action": {
              "url": "https://www.nature.com/articles/s41586-020-2374-x",
              "type": "find_in_page",
              "pattern": ".pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f558cdc8194ad7085175af5afa7",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f5807a8819498c00dd8677e5057",
            "type": "web_search_call",
            "action": {
              "url": "https://www.nature.com/articles/s41586-020-2374-x.pdf",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f5b35f081948aabb190a09929c6",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f5e48a48194831a4cba434eda65",
            "type": "web_search_call",
            "action": {
              "url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f5f9e708194b6f1abe1e24ca8a0",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f62f5848194bd9c53f559bfd063",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f65c7cc81949f346c585c09d8bb",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f6987bc81948004b6f1acb945c3",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "SR-4835 Cancer Cell pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f6d0f688194b1e520e8bdd9f46d",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f6db43c8194a50f35cdea943ac4",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f702f388194aeb96eae6525fd8f",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f71ab18819496eda3d340cfecb2",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "SR-4835 datasheet filetype:pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f771a248194ae80c2ed9596b800",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f792ef48194a54b941d6c2bbeb0",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f7ea11c8194977bbbec7d3e8330",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f80b20881948f768939c180b3d0",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/WO2019217421A1/en",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f82d420819492ef99fa97d1591b",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f833a1c8194a5e066e330c28578",
            "type": "web_search_call",
            "action": {
              "url": "https://patentimages.storage.googleapis.com/b6/bf/69/8884082d82590f/WO2019217421A1.pdf",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f8456588194aebc2258019bd5bb",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f956ee0819484be0b62dd7f369d",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CR8 HQ461 dCeMM2 PDF"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f9aa634819485a4266eb492721a",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1f9c272c8194a8a954167bb425d3",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1f9f152c8194863116f89e0d5a56",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1fa163348194a196c3edb53f28a1",
            "type": "web_search_call",
            "action": {
              "url": "https://www.tocris.com/products/dcemm2_7525",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1fa4739c8194b59ae254351d8b1e",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1fa542b081949b9283c0b006c3b2",
            "type": "web_search_call",
            "action": {
              "url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1fa8fa54819490d7ebe0750b5810",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1fb9c62c8194b933e4fe4be8aa30",
            "type": "web_search_call",
            "action": {
              "url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
              "type": "find_in_page",
              "pattern": "SR-4835"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1fbbf37c8194bc2316444057df4d",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00f300c2903b2ac200693f1fc248888194836dfb62f29c82c8",
            "type": "web_search_call",
            "action": {
              "url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00f300c2903b2ac200693f1fc4c3b481948efea6682c559576",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_00f300c2903b2ac200693f1fd909048194bc585848a7478c81",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma (Cell Death Discovery) [PDF]\",\n      \"url\": \"https://www.nature.com/articles/s41420-023-01754-x.pdf\",\n      \"snippets\": [\n        \"concentrations of SR-4835 or THZ531 for 72 h.\",\n        \"D Docking pose of SR-4835 and CR8 in the active site of CDK12 (PDB: 6TD3) with key residues highlighted.\"\n      ]\n    },\n    {\n      \"title\": \"Discovery and design of molecular glue enhancers of CDK12–DDB1 interactions for targeted degradation of cyclin K (RSC Chem. Biol., 2025) [PDF]\",\n      \"url\": \"https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g\",\n      \"snippets\": [\n        \"pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4.\",\n        \"treated with either SR-4835 or the covalent CDK12/13 inhibitor THZ531\"\n      ]\n    },\n    {\n      \"title\": \"ProbeChem THZ531 Data Sheet (PC-6230201) [PDF]\",\n      \"url\": \"https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf\",\n      \"snippets\": [\n        \"Product Name : THZ531\",\n        \"CAS No. : 1702809-17-3\"\n      ]\n    },\n    {\n      \"title\": \"ProbeChem THZ531 Certificate of Analysis (Batch No. PC-6230201) [PDF]\",\n      \"url\": \"https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_COA.pdf\",\n      \"snippets\": [\n        \"Batch No. : PC-6230201\",\n        \"CAS No. : 1702809-17-3\"\n      ]\n    },\n    {\n      \"title\": \"Tocris dCeMM2 Certificate of Analysis / Product Datasheet (Catalog No. 7525) [PDF]\",\n      \"url\": \"https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=\",\n      \"snippets\": [\n        \"Product Name: dCeMM2 Catalog No.: 7525 Batch No.: 1\",\n        \"CAS Number: 296771-07-8\"\n      ]\n    },\n    {\n      \"title\": \"Tocris dCeMM2 Safety Data Sheet (Catalog Number: 7525) [PDF]\",\n      \"url\": \"https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=\",\n      \"snippets\": [\n        \"Product Name: dCeMM2\",\n        \"Catalog Number: 7525\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765744414,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.nature.com/articles/s41420-023-01754-x.pdf",
        "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
        "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
        "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_COA.pdf",
        "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
        "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855="
      ]
    },
    {
      "id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "created_at": "2025-12-14T21:05:26.805592+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_0a4705429f7893c700693f1f1e4d6881948d9a6aa616111e94",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 91473,
          "total_tokens": 100504,
          "output_tokens": 9031,
          "input_tokens_details": {
            "cached_tokens": 0
          },
          "output_tokens_details": {
            "reasoning_tokens": 8375
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_0a4705429f7893c700693f1f1ed03c81949669e27ff5cae087",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f23160081949613585d783d2b8f",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CDK12 compound IC50 filetype:pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f248fec8194a2aade871566fde9",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f27f1f08194b650cf70c707802a",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "THZ531 IC50 158 69 pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f29b3888194884ed358bd9c159c",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f2f90548194bc4d560c2f7ebbbc",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "THZ531 datasheet filetype:pdf IC50 158"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f31370c81949a5764fe2d710e86",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f3615fc81948634f3cd78962f8d",
            "type": "web_search_call",
            "action": {
              "url": "https://www.nature.com/articles/nchembio.2166",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f3706648194a4b7f26c37c85c47",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f37e4f48194b16b429cda5e5c6c",
            "type": "web_search_call",
            "action": {
              "url": "https://www.nature.com/articles/nchembio.2166",
              "type": "find_in_page",
              "pattern": "Supplementary Note"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f39914c81948ced21ecd81cec07",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f3b9c088194a4dc1e4981828773",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "SR-4835 CDK12 CDK13 IC50 99 nM pdf filetype:pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f3e30d88194bd319bbfac0a0390",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f4058bc81949d66f86d7afe28da",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"Therapeutic Targeting of CDK12/CDK13\" SR-4835 filetype:pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f433cdc8194a4189afe3f4f8964",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f447e888194b1e7d0cb1d3ff8a7",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f45554481948210678edd301397",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f4f591081948d99607b29edd2cf",
            "type": "web_search_call",
            "action": {
              "url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f5390588194a3a9166c4559ef14",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f5a3ba88194822a4ea645aee134",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/WO2019217421A1/en",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f5b5b4481948b3a5af34f7e5065",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f5bb3a88194bcaad2977c63e627",
            "type": "web_search_call",
            "action": {
              "url": "https://patentimages.storage.googleapis.com/b6/bf/69/8884082d82590f/WO2019217421A1.pdf",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f5cced4819480bfb73c0e64e4fd",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f5d76948194a47dcb15534097c1",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f61584081948d9ef069d6451a53",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f688d3081948f690e823044f9b0",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "SR-4835 datasheet PDF S8894 filetype:pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f6cdeb48194906d97c8bfc0e02c",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f6d970c81948377abedee111cb9",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"SR-4835\" \"Data Sheet\" filetype:pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f706e108194a88e05a1140c70a5",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f71966c8194aabf106a9dc8242b",
            "type": "web_search_call",
            "action": {
              "url": "https://www.axonmedchem.com/3184-sr-4835",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f74737c819484db2149b79f65ea",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f7543e88194ba0936aef393552e",
            "type": "web_search_call",
            "action": {
              "url": "https://www.axonmedchem.com/3402-thz531",
              "type": "find_in_page",
              "pattern": "Certificate of Analysis"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f76e9e8819489378b6493853946",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f7db5ac8194abeb012c1c674d7e",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "S6595 THZ531 DataSheet pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f81deec8194a998d992ac4e3652",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f83a8808194bbe9197abc89644d",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "site:selleck.cn datasheet SR-4835 S8894 filetype:pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f87620081948c878104a4ae37c2",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f8d943c8194b93e21b5003c9fc5",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "WO 2015 058126 THZ531 pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f929cf48194be20f1e4e3ab574c",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f94e420819487a1c4db25c027c9",
            "type": "web_search_call",
            "action": {
              "url": "https://www.probechem.com/products_THZ531.html",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f9655f081948e9c6062598d75f1",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f96d2448194bab1d92e479805a4",
            "type": "web_search_call",
            "action": {
              "url": "https://www.probechem.com/products_THZ531.html",
              "type": "find_in_page",
              "pattern": ".pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f998f64819498120beb75d577ef",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1f9b2d748194b34adf7696a16945",
            "type": "web_search_call",
            "action": {
              "url": "https://www.probechem.com/products_THZ531.html",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1f9da92c8194b428ee2c8812ad26",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1faabe8081949a9805a51b99efb9",
            "type": "web_search_call",
            "action": {
              "url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1fac08f08194aae4fd09c0217180",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1facc1908194aaa782ae0f87210c",
            "type": "web_search_call",
            "action": {
              "url": "https://patentimages.storage.googleapis.com/b6/bf/69/8884082d82590f/WO2019217421A1.pdf",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1fae1b5081949820800bdee52ac8",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0a4705429f7893c700693f1fc1154c81948c2e7dcc8a4dd9c5",
            "type": "web_search_call",
            "action": {
              "url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0a4705429f7893c700693f1fc26d84819484e54064ce9629e7",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_0a4705429f7893c700693f1fce531c8194bc2470a26274b6d2",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"THZ531产品说明书 (Selleck.cn) — thz531-S659503-DataSheet.pdf\",\n      \"url\": \"https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf\",\n      \"snippets\": [\n        \"目录号：S6595 批次号：S659503\",\n        \"产品描述  | THZ531是CDK12和CDK13的选择性抑制剂，IC50值分别为158 nM和69 nM。\"\n      ]\n    },\n    {\n      \"title\": \"SR-4835 Datasheet (Selleck.co.jp) — sr-4835-S889402-DataSheet.pdf\",\n      \"url\": \"https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf\",\n      \"snippets\": [\n        \"製品コードS8894 バッチS889402\",\n        \"製品説明  | SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13 with IC50 of 99 nM and Kd of 98 nM for CDK12 and IC50 of 4.9 nM for CDK13.\"\n      ]\n    },\n    {\n      \"title\": \"ProbeChem THZ531 DataSheet — PC-6230201_DataSheet.pdf\",\n      \"url\": \"https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf\",\n      \"snippets\": [\n        \"Cat. No. : PC-62302\",\n        \"THZ531 (THZ-531) isa first-in-class, selective CDK12 and CDK13 covalent inhibitor with IC50 of 158 nM and 69 nM,\"\n      ]\n    },\n    {\n      \"title\": \"Nature Chemical Biology Supplementary Note 1 (Synthetic Procedures) — nchembio2166_MOESM153_ESM.pdf\",\n      \"url\": \"https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf\",\n      \"snippets\": [\n        \"Scheme 1. The synthesis of THZ531\",\n        \"Scheme 2. The synthesis of BioTHZ531\"\n      ]\n    },\n    {\n      \"title\": \"ORA (Oxford University Research Archive) Supplementary note — Accepted manuscript, pdf\",\n      \"url\": \"https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852\",\n      \"snippets\": [\n        \"Scheme 1. The synthesis of THZ531\",\n        \"Scheme 3. The synthesis of THZ531R\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765744414,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
        "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
        "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
        "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
        "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852"
      ]
    },
    {
      "id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "created_at": "2025-12-14T21:11:48.21827+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_08c497e785240c4900693f20dcbba08190b7b91a5a90bc6bec",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 47197,
          "total_tokens": 52147,
          "output_tokens": 4950,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 4063
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_08c497e785240c4900693f20dd06388190af4ee78c9e4e8266",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_08c497e785240c4900693f20de55b88190b5f1f8cd7af45129",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 target"
            },
            "status": "completed"
          },
          {
            "id": "rs_08c497e785240c4900693f20e0b7088190a952701036b5be3d",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_08c497e785240c4900693f20e308748190bcd65ed527781fa1",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 Cyclin-K glue degrader"
            },
            "status": "completed"
          },
          {
            "id": "rs_08c497e785240c4900693f20e513ec8190a85607e5952c84bf",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_08c497e785240c4900693f20e702e88190a97b21bb3457e0c3",
            "type": "web_search_call",
            "action": {
              "url": "https://clinicaltrials.gov/study/NCT06600789",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_08c497e785240c4900693f20e790388190946174921f5e5ac8",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_08c497e785240c4900693f20ec1b2c8190bfae46db8e710063",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_08c497e785240c4900693f20edd0d08190b76af9f431ca828d",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_08c497e785240c4900693f20ef38748190b05213390fcd4c48",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "clinicaltrials.gov api query full_studies NCT06600789"
            },
            "status": "completed"
          },
          {
            "id": "rs_08c497e785240c4900693f20f157548190a75518643f87e4ff",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_08c497e785240c4900693f20f2bd3c81909f76c1250f2a41e7",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "https://clinicaltrials.gov/api/v2/studies/NCT06600789"
            },
            "status": "completed"
          },
          {
            "id": "rs_08c497e785240c4900693f20f4935c8190b4eb243333b693ea",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_08c497e785240c4900693f20f595808190837dd703932aea1f",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "api/legacy/public-xml/NCT06600789"
            },
            "status": "completed"
          },
          {
            "id": "rs_08c497e785240c4900693f20f8c5188190ad04ca404431311c",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_08c497e785240c4900693f20f9e1048190b0dfb03d3504647b",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "NCT06600789 CT7439 site:clinicaltrials.gov"
            },
            "status": "completed"
          },
          {
            "id": "rs_08c497e785240c4900693f20fcb24c8190be5d7c332ff4c1dc",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_08c497e785240c4900693f21020a948190af4fcd35ca50cfb3",
            "type": "web_search_call",
            "action": {
              "url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_08c497e785240c4900693f2103b4cc81908009ac35f12ff9e1",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_08c497e785240c4900693f210791748190bc00d07a7a130592",
            "type": "web_search_call",
            "action": {
              "url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_08c497e785240c4900693f210a2ee0819080d7dab5d259701f",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_08c497e785240c4900693f21112a148190bceec46421f0b431",
            "type": "web_search_call",
            "action": {
              "url": "https://ichgcp.net/clinical-trials-registry/NCT06600789",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_08c497e785240c4900693f2113a4ec81908edfe5982c0dc02e",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_08c497e785240c4900693f2113f2308190912847ffe5224e04",
            "type": "web_search_call",
            "action": {
              "url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_08c497e785240c4900693f211549588190a8309ce823a7cf15",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_08c497e785240c4900693f2123ad5881908cc1d177b4efe7aa",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"CDK12/13 Inhibitor :: Carrick Therapeutics, Inc.\",\n      \"url\": \"https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor\",\n      \"snippets\": [\n        \"## CT7439: CDK12/13 inhibitor/Cyclin-K Degrader\",\n        \"CT7439 is a CDK12/13/Cyclin-K degrader, which potently inhibits the cellular activity of CDK12/13.\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)\",\n      \"url\": \"https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html\",\n      \"snippets\": [\n        \"the Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader.\",\n        \"Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789.\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13 :: Carrick Therapeutics, Inc.\",\n      \"url\": \"https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind\",\n      \"snippets\": [\n        \"the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.\",\n        \"CT7439 is an inhibitor of CDK12/13 as well as a 'glue degrader' of Cyclin-K, which is the obligate co-factor for CDK12/13, giving both first-in-class and best-in-class potential.\"\n      ]\n    },\n    {\n      \"title\": \"FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor | CancerNetwork\",\n      \"url\": \"https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor\",\n      \"snippets\": [\n        \"A planned phase 1 trial will examine CDK12/13 inhibitor CT7439 in patients with several types of solid tumors, including breast and ovarian cancer, as well as Ewing’s sarcoma.\",\n        \"The compound is a “glue degrader” of Cyclin-K, a known obligate co-factor of CDK12/13;\"\n      ]\n    },\n    {\n      \"title\": \"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies | Clinical Research Trial Listing (CenterWatch)\",\n      \"url\": \"https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies\",\n      \"snippets\": [\n        \"CT7439 Capsules (0.5 mg, 1mg, 3mg)\",\n        \"NCT06600789\\n\\nCT7439_001\"\n      ]\n    },\n    {\n      \"title\": \"CT7439 Capsules (0.5 mg, 1mg, 3mg) in Solid Malignancies - Clinical Trials Registry - ICH GCP\",\n      \"url\": \"https://ichgcp.net/clinical-trials-registry/NCT06600789\",\n      \"snippets\": [\n        \"Clinical Trial NCT06600789\",\n        \"*  Drug: CT7439 Capsules (0.5 mg, 1mg, 3mg)\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765744860,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
        "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
        "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
        "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
        "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
        "https://ichgcp.net/clinical-trials-registry/NCT06600789"
      ]
    },
    {
      "id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "created_at": "2025-12-14T21:11:48.737311+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_09a47a2572d6119300693f20dcbaa481958ea437541528ca78",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 53928,
          "total_tokens": 59755,
          "output_tokens": 5827,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 4970
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_09a47a2572d6119300693f20dd088c8195b4e4312787463839",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f20de48f08195a0be1c70a51bd540",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 Phase 1"
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f20dfa4d4819591e29d5c48e9f16e",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f20e275f8819598fc9b0c41bcc3e1",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "site:clinicaltrials.gov NCT06600789 CT7439"
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f20e3babc81959dbd603e081f802d",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f20e63efc8195b02ae2e3dfeda1c1",
            "type": "web_search_call",
            "action": {
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f20e790408195b7e78b42d72dccdd",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f20ea1c088195a6824c6cbc70c4f7",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f20ecfe98819597d674c7c172018b",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f20ede594819599bad4daaf7bd0c0",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "clinicaltrials.gov api query full_studies NCT06600789 fmt=json"
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f20ef9ba48195b67de166dd46daf1",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f20f1187881958d4b61a5e6d3423c",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "https://clinicaltrials.gov/api/v2/studies/NCT06600789"
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f20f2d7c48195b22e964df6d16c8b",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f20f72c9c8195bd0737e1bea3b45f",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "site:clinicaltrials.gov \"NCT06600789\""
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f20f9182c8195bce1557335d2e94e",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f20f9f38081959b35442f9e9b328c",
            "type": "web_search_call",
            "action": {
              "url": "https://clinicaltrials.gov/ct2/show/NCT06600789",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f20fb3bc88195be3456267cdfa870",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f2100c44881959986c02c4dbf6246",
            "type": "web_search_call",
            "action": {
              "url": "https://link.springer.com/article/10.1186/s13058-025-02101-x",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f2102ff0481958a9e91f417503b60",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f2103b4048195bccfaec6d65adf4f",
            "type": "web_search_call",
            "action": {
              "url": "https://link.springer.com/article/10.1186/s13058-025-02101-x",
              "type": "find_in_page",
              "pattern": "CT7439"
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f21062b0481959825dcf4e07b46d1",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f210746608195a1a03c692f4756b2",
            "type": "web_search_call",
            "action": {
              "url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f2109694c8195b6ced202d2d0d0fd",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f210ac3908195aadb9e68db8c69f2",
            "type": "web_search_call",
            "action": {
              "url": "https://link.springer.com/article/10.1186/s13058-025-02101-x",
              "type": "find_in_page",
              "pattern": "NCT06600789"
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f210ce2a881958b4e4956c6dabff1",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09a47a2572d6119300693f210e63d481959989e76e4092f456",
            "type": "web_search_call",
            "action": {
              "url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
              "type": "find_in_page",
              "pattern": "CT7439_001"
            },
            "status": "completed"
          },
          {
            "id": "rs_09a47a2572d6119300693f2110c07c8195ab025c8e3451b434",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_09a47a2572d6119300693f212cf2b081959599b12a51585e57",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)\",\n      \"url\": \"https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html\",\n      \"snippets\": [\n        \"the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439\",\n        \"Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789.\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13\",\n      \"url\": \"https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind\",\n      \"snippets\": [\n        \"the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439\",\n        \"The Phase 1 clinical trial is a modular design, beginning with a dose escalation for the initial administration of CT7439 to patients.\"\n      ]\n    },\n    {\n      \"title\": \"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies | CenterWatch\",\n      \"url\": \"https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies\",\n      \"snippets\": [\n        \"NCT06600789\\nCT7439_001\",\n        \"Primary Treatment:  CT7439 Capsules (0.5 mg, 1mg, 3mg)\"\n      ]\n    },\n    {\n      \"title\": \"CT7439 Capsules (0.5 mg, 1mg, 3mg) in Solid Malignancies - Clinical Trials Registry - ICH GCP\",\n      \"url\": \"https://ichgcp.net/clinical-trials-registry/NCT06600789\",\n      \"snippets\": [\n        \"Clinical Trial NCT06600789\",\n        \"Drug: CT7439 Capsules (0.5 mg, 1mg, 3mg)\"\n      ]\n    },\n    {\n      \"title\": \"Trial | NCT06600789 (Clinical Drug Experience Knowledgebase)\",\n      \"url\": \"https://cdek.pharmacy.purdue.edu/trial/NCT06600789/\",\n      \"snippets\": [\n        \"Trial | NCT06600789\",\n        \"CT7439 Capsules (0.5 mg, 1mg, 3mg)\"\n      ]\n    },\n    {\n      \"title\": \"Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K | Breast Cancer Research\",\n      \"url\": \"https://link.springer.com/article/10.1186/s13058-025-02101-x\",\n      \"snippets\": [\n        \"CT7439, a dual inhibitor of CDK12/13 and a cyclin K glue degrader\",\n        \"including breast cancer (NCT06600789).\"\n      ]\n    },\n    {\n      \"title\": \"NCT06600789: An ongoing trial by Carrick Therapeutics Limited (FDAAA TrialsTracker)\",\n      \"url\": \"https://fdaaa.trialstracker.net/trial/NCT06600789/\",\n      \"snippets\": [\n        \"NCT06600789: An ongoing trial by Carrick Therapeutics Limited\",\n        \"Title  A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765744860,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
        "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
        "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
        "https://ichgcp.net/clinical-trials-registry/NCT06600789",
        "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
        "https://link.springer.com/article/10.1186/s13058-025-02101-x",
        "https://fdaaa.trialstracker.net/trial/NCT06600789/"
      ]
    },
    {
      "id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "created_at": "2025-12-14T21:11:48.968071+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_0f54002b4fb6602700693f20dcb9dc8190a53c31693733066a",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 54183,
          "total_tokens": 59047,
          "output_tokens": 4864,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 3796
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_0f54002b4fb6602700693f20dd0c708190b799b7e82023d782",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f20de0d20819080208671c71323b3",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 patent"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f20df57d481909b7728efc1b9d927",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f20e1af188190827a71e7bc562c8e",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 WO patent CDK12/13 Cyclin-K"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f20e4aa2081909ed47b7a31c0617a",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f20eb0b648190b588ef3f3efcd783",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"CT7439\" WO202 patent"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f20ee5dc481908ab1888867d7e052",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f20f140508190a40409a090d1ab78",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 site:patentscope.wipo.int"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f20f29a908190853632c07f191198",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f20f56bb881908ce5249a0c46302e",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "Carrick Therapeutics Cyclin-K glue degrader patent WO"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f20f7387c8190a92c82b6644e1984",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f20facc9081908bc968e5e3f7d83e",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "Carrick Therapeutics WO patent CDK12 CDK13 cyclin K degrader"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f20fd0ab08190a200085b79ea8d70",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f21000e3c8190a4c089388a9472a9",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 patent WO site:carricktherapeutics.com pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f2102851c8190bf4f00f0a81bffa4",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f2107aa8481908eb1b3f73caaf0e2",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "NCT06600789 CT7439"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f210b161481908e4fc7bbd68596ba",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f210ffc0c8190bbab921461b2ae27",
            "type": "web_search_call",
            "action": {
              "url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f211361b48190967337c4fb36bc73",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f211410288190bb09665c7b20a614",
            "type": "web_search_call",
            "action": {
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
              "type": "find_in_page",
              "pattern": "NCT06600789"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f2115e95c81908a90a06388b8db82",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f2116adf88190b783650f34e2fd2d",
            "type": "web_search_call",
            "action": {
              "url": "https://fdaaa.trialstracker.net/trial/NCT06600789/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f2117efe8819099854d911b495a40",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f2118b0ec8190bda4eb8b0a9a31c3",
            "type": "web_search_call",
            "action": {
              "url": "https://clinicaltrials.gov/study/NCT06600789",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f2119b02481908412bce76d43ea45",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f211adf2881908d5b9b176eea3b52",
            "type": "web_search_call",
            "action": {
              "url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f211c5dec8190942c7820a71410f4",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f211cc5908190bbc251d940f706f8",
            "type": "web_search_call",
            "action": {
              "url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f211e214481908475f56d7db6d40e",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f54002b4fb6602700693f211e664c81909c5a41d8fac25576",
            "type": "web_search_call",
            "action": {
              "url": "https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f54002b4fb6602700693f211f50588190acf49a122bdda12a",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_0f54002b4fb6602700693f21293e048190bbb46ed71a52fde9",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13\",\n      \"url\": \"https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind\",\n      \"snippets\": [\n        \"the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.\",\n        \"CT7439 is an inhibitor of CDK12/13 as well as a 'glue degrader' of Cyclin-K, which is the obligate co-factor for CDK12/13, giving both first-in-class and best-in-class potential.\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)\",\n      \"url\": \"https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase\",\n      \"snippets\": [\n        \"today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader.\",\n        \"Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789.\"\n      ]\n    },\n    {\n      \"title\": \"CDK12/13 Inhibitor :: Carrick Therapeutics, Inc.\",\n      \"url\": \"https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor\",\n      \"snippets\": [\n        \"CT7439: CDK12/13 inhibitor/Cyclin-K Degrader\",\n        \"CT7439 is a CDK12/13/Cyclin-K degrader, which potently inhibits the cellular activity of CDK12/13.\"\n      ]\n    },\n    {\n      \"title\": \"Trial | NCT06600789 (Clinical Drug Experience Knowledgebase - Purdue)\",\n      \"url\": \"https://cdek.pharmacy.purdue.edu/trial/NCT06600789/\",\n      \"snippets\": [\n        \"Trial | NCT06600789\",\n        \"A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439 Alone and in Combination With Anticancer Treatments in Participants With Solid Malignancies\"\n      ]\n    },\n    {\n      \"title\": \"NCT06600789: An ongoing trial by Carrick Therapeutics Limited (FDAAA TrialsTracker)\",\n      \"url\": \"https://fdaaa.trialstracker.net/trial/NCT06600789/\",\n      \"snippets\": [\n        \"NCT06600789: An ongoing trial by Carrick Therapeutics Limited\",\n        \"Title  A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439 Alone and in Combination With Anticancer Treatments in Participants With Solid Malignancies\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Declares the U.S. FDA Approval the IND for CT7439, a First-In-Class Inhibitor of CDK12/13 (PatSnap Synapse)\",\n      \"url\": \"https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439\",\n      \"snippets\": [\n        \"Carrick Therapeutics Declares the U.S. FDA Approval the IND for CT7439, a First-In-Class Inhibitor of CDK12/13\",\n        \"As of September 13, 2023, there are 1 investigational drugs for the CDC7 and CDK12 and CDK13 target, including 4 applicable indications,2 R&D institutions involved, and as many as 29 patents.\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) - BioSpace\",\n      \"url\": \"https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor\",\n      \"snippets\": [\n        \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)\",\n        \"Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789.\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765744860,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
        "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
        "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
        "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
        "https://fdaaa.trialstracker.net/trial/NCT06600789/",
        "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
        "https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor"
      ]
    },
    {
      "id": "5c478f1a-59eb-4cb1-900e-0267627cafd7",
      "created_at": "2025-12-14T21:11:49.451105+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "a0262855-a203-489b-873f-25c60d7f6499",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_0f39e0c97151f8b500693f20dcb8fc819091482cb8a6650466",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 68276,
          "total_tokens": 73756,
          "output_tokens": 5480,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 4504
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_0f39e0c97151f8b500693f20dd1368819098fa1c11bedccd24",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f20defc748190842097e8d5c81467",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 company pipeline pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f20e0996881909a55a163c2de2d94",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f20e165a481909ebef211b38174ae",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "Carrick Therapeutics pipeline PDF CT7439"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f20e33f548190ac2c5304d09a55bf",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f20e3ea848190b6d5d8a17457608d",
            "type": "web_search_call",
            "action": {
              "url": "https://www.carricktherapeutics.com/investors",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f20e4a4988190864be3475e13463a",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f20e4f95c8190bbd29ea5c421b1db",
            "type": "web_search_call",
            "action": {
              "url": "https://www.carricktherapeutics.com/investors/news-events/presentations",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f20e5bc0881908acffbbf7b443dc8",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f20e7aa148190ad1c1a36efce4cc3",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 poster pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f20e9a0ec81909a394b01c187247f",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f20eb7ea481908b9e66e0a435847c",
            "type": "web_search_call",
            "action": {
              "url": "https://www.carricktherapeutics.com/news-media/posters-publications",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f20ec159881908b8e13406e21ea49",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f20ed6c648190901ab7c8a784c001",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f20eead348190b1f6ab4caeea27e6",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f20f018148190a4581fd753fc59f8",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 AACR 2025 pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f20f2e4288190a076356dd7831f8e",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f20f91be88190a17f48410e4d98e3",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 site:aacrjournals.org Cancer Research supplement"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f20fd0cb0819088b03ba417b71cbd",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f20fd4e908190b43d24b73481825b",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "site:clinicaltrials.gov NCT06600789 CT7439"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f20fef9d481908532db3ab35ad8e8",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f2102f75081909520513dcbb2a21a",
            "type": "web_search_call",
            "action": {
              "url": "https://www.aacr.org/meeting/aacr-annual-meeting-2025/meeting-resources/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f2104177881909939d756f8a7b5d3",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f2104809c8190bc92f4378b34b99b",
            "type": "web_search_call",
            "action": {
              "url": "https://www.aacr.org/meeting/aacr-annual-meeting-2025/meeting-resources/",
              "type": "find_in_page",
              "pattern": "PDF Proceedings"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f2105af5081908e5c8b7aba0840e1",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f2106435c8190a445b54a257abe9d",
            "type": "web_search_call",
            "action": {
              "url": "https://www.aacr.org/wp-content/uploads/2025/04/AACR_2025_Program_Guide_0424.pdf",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f2107ef2c819089aad27bc1e56e72",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f210902248190a346e58046a8e77e",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f210a61248190b3e32e864f958f70",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f210d8f608190b977fbee2031b112",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "CT7439 WO patent"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f21118dcc8190a0bcec4319660439",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f2117794c8190a658022130183000",
            "type": "web_search_call",
            "action": {
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f211b49248190bca153cc364e6758",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f211d9844819083de08df6a393448",
            "type": "web_search_call",
            "action": {
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f211eb0dc8190856a20aeeb851d17",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f211fb0948190a11d31db240a7afb",
            "type": "web_search_call",
            "action": {
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
              "type": "find_in_page",
              "pattern": "CT7439 Capsules"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f212290408190bd1ff028e94790d0",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f2124801881909022abdd242b1c0d",
            "type": "web_search_call",
            "action": {
              "url": "https://link.springer.com/article/10.1186/s13058-025-02101-x",
              "type": "find_in_page",
              "pattern": "NCT06600789"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f2126f8408190aa4323ad82c53de4",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0f39e0c97151f8b500693f212a3844819084f911099bf6c930",
            "type": "web_search_call",
            "action": {
              "url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0f39e0c97151f8b500693f212b62688190805977a903163d22",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_0f39e0c97151f8b500693f213ec13481908452de3c175d5ad4",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.\",\n      \"url\": \"https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase\",\n      \"snippets\": [\n        \"Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader.\",\n        \"study ID: NCT06600789.\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) | GlobeNewswire\",\n      \"url\": \"https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html\",\n      \"snippets\": [\n        \"Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader.\",\n        \"study ID: NCT06600789.\"\n      ]\n    },\n    {\n      \"title\": \"Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13 :: Carrick Therapeutics, Inc.\",\n      \"url\": \"https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind\",\n      \"snippets\": [\n        \"Investigational New Drug (IND) application for CT7439\",\n        \"CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.\"\n      ]\n    },\n    {\n      \"title\": \"Trial | NCT06600789 (Purdue University Clinical Trials/Drug Knowledgebase)\",\n      \"url\": \"https://cdek.pharmacy.purdue.edu/trial/NCT06600789/\",\n      \"snippets\": [\n        \"CT7439 Capsules (0.5 mg, 1mg, 3mg)\",\n        \"CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg\"\n      ]\n    },\n    {\n      \"title\": \"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies | CenterWatch\",\n      \"url\": \"https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies\",\n      \"snippets\": [\n        \"Clinical Study ID NCT06600789\",\n        \"CT7439_001\"\n      ]\n    },\n    {\n      \"title\": \"Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K | Breast Cancer Research (Springer)\",\n      \"url\": \"https://link.springer.com/article/10.1186/s13058-025-02101-x\",\n      \"snippets\": [\n        \"CT7439, a dual inhibitor of CDK12/13 and a cyclin K glue degrader\",\n        \"(NCT06600789).\"\n      ]\n    },\n    {\n      \"title\": \"CDK12/13 Inhibitor :: Carrick Therapeutics, Inc.\",\n      \"url\": \"https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor\",\n      \"snippets\": [\n        \"CT7439: CDK12/13 inhibitor/Cyclin-K Degrader\",\n        \"CT7439 is a CDK12/13/Cyclin-K degrader\"\n      ]\n    },\n    {\n      \"title\": \"CT-7439 - Drug Targets, Indications, Patents - Synapse (PatSnap)\",\n      \"url\": \"https://synapse.patsnap.com/drug/8fb030514b004a0eb2b730b10ce2bbd0\",\n      \"snippets\": [\n        \"Synonyms CT-7439, CT7439\",\n        \"Clinical Trials associated with CT-7439 NCT06600789\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765744860,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
        "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
        "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
        "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
        "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
        "https://link.springer.com/article/10.1186/s13058-025-02101-x",
        "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
        "https://synapse.patsnap.com/drug/8fb030514b004a0eb2b730b10ce2bbd0"
      ]
    },
    {
      "id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "created_at": "2025-12-14T21:11:50.18308+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_00d8d7de7947ca5c00693f20dcbb8c8195a98d7a4a3d1fd779",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 41944,
          "total_tokens": 46102,
          "output_tokens": 4158,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 3189
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_00d8d7de7947ca5c00693f20dd1e248195a1c774e3e2664177",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00d8d7de7947ca5c00693f20e123508195b82b0fd3d564d617",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "TRITON2 Phase 1"
            },
            "status": "completed"
          },
          {
            "id": "rs_00d8d7de7947ca5c00693f20e4321c81959ced2dafb51a9083",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00d8d7de7947ca5c00693f20e643ec8195ac522b8c1a459a55",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"TRITON2\" \"Phase 1\""
            },
            "status": "completed"
          },
          {
            "id": "rs_00d8d7de7947ca5c00693f20e805cc819595b269832ebd75fa",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00d8d7de7947ca5c00693f20eacc248195ac703c9b90609d7d",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"TRITON2\" \"phase I\""
            },
            "status": "completed"
          },
          {
            "id": "rs_00d8d7de7947ca5c00693f20ecef3481958fdf1d1b1e0f9f15",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00d8d7de7947ca5c00693f20f48e748195af85f506c17ef3f4",
            "type": "web_search_call",
            "action": {
              "url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00d8d7de7947ca5c00693f20f747ec819585d6e7e29c7607c1",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00d8d7de7947ca5c00693f20f84eb48195b61cc6197acce7eb",
            "type": "web_search_call",
            "action": {
              "url": "https://stanfordhealthcare.org/trials/a/NCT02952534.html",
              "type": "find_in_page",
              "pattern": "NCT02952534"
            },
            "status": "completed"
          },
          {
            "id": "rs_00d8d7de7947ca5c00693f20fa686c81959f372a4f3747affb",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00d8d7de7947ca5c00693f20fbf6b481958315b8675c8676a1",
            "type": "web_search_call",
            "action": {
              "url": "https://stanfordhealthcare.org/trials/a/NCT02952534.html",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00d8d7de7947ca5c00693f20fda21c81959abd8c382140b470",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00d8d7de7947ca5c00693f20fed9e48195864db9f9bea71131",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
              "type": "find_in_page",
              "pattern": "NCT02952534"
            },
            "status": "completed"
          },
          {
            "id": "rs_00d8d7de7947ca5c00693f2100d10081959668d3b88afe0a84",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00d8d7de7947ca5c00693f21028c7c81958a2a58c439307a24",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00d8d7de7947ca5c00693f2103f1388195b4b69d70d7a8e853",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00d8d7de7947ca5c00693f210656c08195956ed4a5a0312d1b",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "site:clinicaltrials.gov NCT02952534 TRITON2"
            },
            "status": "completed"
          },
          {
            "id": "rs_00d8d7de7947ca5c00693f2108add8819593c7263c94d4cc6a",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_00d8d7de7947ca5c00693f210a0d508195b2fc164ca153555f",
            "type": "web_search_call",
            "action": {
              "url": "https://clinicaltrials.gov/study/NCT02952534",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_00d8d7de7947ca5c00693f210b40e481959e87319f845180e9",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_00d8d7de7947ca5c00693f211a2f588195b4fd45d5e768f4e5",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"ICH GCP - EU Clinical trials Registry - 2016-003162-13 (IT)\",\n      \"url\": \"https://ichgcp.net/eu-clinical-trials-registry/trial/2016-003162-13/IT\",\n      \"snippets\": [\n        \"EudraCT Number:2016-003162-13\",\n        \"Sponsor's Protocol Code Number:CO-338-052\"\n      ]\n    },\n    {\n      \"title\": \"TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in mCRPC - Health Research Authority\",\n      \"url\": \"https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/\",\n      \"snippets\": [\n        \"IRAS ID\\n\\n219516\",\n        \"Eudract number\\n\\n2016-003162-13\"\n      ]\n    },\n    {\n      \"title\": \"A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency - Stanford Health Care\",\n      \"url\": \"https://stanfordhealthcare.org/trials/a/NCT02952534.html\",\n      \"snippets\": [\n        \"### Trial ID or NCT#\\n\\nNCT02952534\",\n        \"TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency\"\n      ]\n    },\n    {\n      \"title\": \"Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/37277275/\",\n      \"snippets\": [\n        \"Background:  Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID\",\n        \"DOI:  10.1016/j.eururo.2023.05.021\"\n      ]\n    },\n    {\n      \"title\": \"Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32086346/\",\n      \"snippets\": [\n        \"doi: 10.1158/1078-0432.CCR-20-0394.\",\n        \"To test this hypothesis, the phase II TRITON2 study of rucaparib included patients with mCRPC\"\n      ]\n    },\n    {\n      \"title\": \"Étude TRITON2 : étude de phase 2 évaluant l’efficacité du rucaparib... - Institut National du Cancer (cancer.fr)\",\n      \"url\": \"https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c\",\n      \"snippets\": [\n        \"EudraCT/ID-RCB : 2016-003162-13\",\n        \"Liens d'intérêt : http://clinicaltrials.gov/show/NCT02952534\"\n      ]\n    },\n    {\n      \"title\": \"Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)... - Mayo Clinic\",\n      \"url\": \"https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in\",\n      \"snippets\": [\n        \"doi: 10.1093/annonc/mdy284.002\",\n        \"Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii272. doi: 10.1093/annonc/mdy284.002\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765744860,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://ichgcp.net/eu-clinical-trials-registry/trial/2016-003162-13/IT",
        "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
        "https://stanfordhealthcare.org/trials/a/NCT02952534.html",
        "https://pubmed.ncbi.nlm.nih.gov/37277275/",
        "https://pubmed.ncbi.nlm.nih.gov/32086346/",
        "https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
        "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in"
      ]
    },
    {
      "id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "created_at": "2025-12-14T21:11:49.684483+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_05a43608d63079ac00693f20dd2760819389fc9ca5feb70fac",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 26195,
          "total_tokens": 31175,
          "output_tokens": 4980,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 4078
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_05a43608d63079ac00693f20dd80f88193be80b9259c991350",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_05a43608d63079ac00693f20e63b4481938f41fb83c3bb4867",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "TRITON2 trial rucaparib NCT02952534 BRCA1 BRCA2"
            },
            "status": "completed"
          },
          {
            "id": "rs_05a43608d63079ac00693f20e86bc8819388769de18945a5f6",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_05a43608d63079ac00693f20eac4f48193949d9fa7f0ad4b6a",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "TRITON2 NCT02952534 FDA accelerated approval rucaparib Rubraca prostate cancer"
            },
            "status": "completed"
          },
          {
            "id": "rs_05a43608d63079ac00693f20ecdbf88193b805b47ed18e2d32",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_05a43608d63079ac00693f20f2835c8193a22a9df50935eec5",
            "type": "web_search_call",
            "action": {
              "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_05a43608d63079ac00693f20f3b57881938de1d3cd35273eef",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_05a43608d63079ac00693f20f92ba081938243ac1852421ba4",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
              "type": "find_in_page",
              "pattern": "NCT02952534"
            },
            "status": "completed"
          },
          {
            "id": "rs_05a43608d63079ac00693f20fad6a88193ae53ace0898563ce",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_05a43608d63079ac00693f2100189481938a5862e5bf209bb7",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_05a43608d63079ac00693f21011cac8193b7b19f90ecfdd989",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_05a43608d63079ac00693f2101f7e88193af77f0c22e0f02e9",
            "type": "web_search_call",
            "action": {
              "url": "https://clinicaltrials.gov/study/NCT02952534",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_05a43608d63079ac00693f2102b19c81939700c967f3905095",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_05a43608d63079ac00693f21035cc08193ab58128f02b62b55",
            "type": "web_search_call",
            "action": {
              "url": "https://clinicaltrials.gov/study/NCT02952534",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_05a43608d63079ac00693f2104776881939a55cc70855589f7",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_05a43608d63079ac00693f211b37288193a6c2d0d3be3e1846",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer | FDA\",\n      \"url\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate\",\n      \"snippets\": [\n        \"On May 15, 2020, the Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.)\",\n        \"Efficacy was investigated in TRITON2 (NCT02952534)\"\n      ]\n    },\n    {\n      \"title\": \"Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/37277275/\",\n      \"snippets\": [\n        \"Background:  Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID\",\n        \"TRITON2 had enrolled 277 patients, grouped by mutated gene: BRCA (n = 172), ATM (n = 59)\"\n      ]\n    },\n    {\n      \"title\": \"Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32086346/\",\n      \"snippets\": [\n        \"the phase II TRITON2 study of rucaparib included patients with mCRPC and deleterious non-BRCA DDR gene alterations.\",\n        \"TRITON2 enrolled 78 patients with a non-BRCA DDR gene alteration [ATM (n = 49), CDK12 (n = 15), CHEK2 (n = 12)\"\n      ]\n    },\n    {\n      \"title\": \"TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in mCRPC - Health Research Authority\",\n      \"url\": \"https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/\",\n      \"snippets\": [\n        \"Eudract number 2016-003162-13\",\n        \"129,840, IND\"\n      ]\n    },\n    {\n      \"title\": \"Clinical Trials Register (EU CTR) - Trial 2016-003162-13\",\n      \"url\": \"https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT\",\n      \"snippets\": [\n        \"A.4.1  | Sponsor's protocol code number  | CO-338-052\",\n        \"A.5.4  | Other Identifiers  | Name: IND Number: 129,840\"\n      ]\n    },\n    {\n      \"title\": \"793PD Preliminary results from TRITON2: A phase II study of rucaparib... | Annals of Oncology | Oxford Academic\",\n      \"url\": \"https://academic.oup.com/annonc/article/29/suppl_8/mdy284.002/5140957\",\n      \"snippets\": [\n        \"Clinical trial identification: NCT02952534.\",\n        \"Rucaparib has encouraging antitumour activity in mCRPC pts with a deleterious alteration in BRCA1 or BRCA2.\"\n      ]\n    },\n    {\n      \"title\": \"Clinical Trial: NCT02952534 - My Cancer Genome\",\n      \"url\": \"https://www.mycancergenome.org/content/clinical_trials/NCT02952534/\",\n      \"snippets\": [\n        \"ORG STUDY ID: CO-338-052\",\n        \"Rucaparib  | CO-338\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765744861,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
        "https://pubmed.ncbi.nlm.nih.gov/37277275/",
        "https://pubmed.ncbi.nlm.nih.gov/32086346/",
        "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
        "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT",
        "https://academic.oup.com/annonc/article/29/suppl_8/mdy284.002/5140957",
        "https://www.mycancergenome.org/content/clinical_trials/NCT02952534/"
      ]
    },
    {
      "id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "created_at": "2025-12-14T21:19:21.178187+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_0808a39728b605fc00693f281714fc81959e4b087e28c4e225",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 48620,
          "total_tokens": 53086,
          "output_tokens": 4466,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 3645
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_0808a39728b605fc00693f28177c4c81958d88daf8faf684a1",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0808a39728b605fc00693f281d13f88195852bca62206dae3d",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "TRITON2 patent"
            },
            "status": "completed"
          },
          {
            "id": "rs_0808a39728b605fc00693f281ea45c8195bf8fa6123c06c8f5",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0808a39728b605fc00693f2822cbd88195a1ef758b51a7c2c0",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "TRITON2 NCT02952534 Rubraca patents Orange Book"
            },
            "status": "completed"
          },
          {
            "id": "rs_0808a39728b605fc00693f282546548195a195eaebe2e57083",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0808a39728b605fc00693f2825929c8195b388bc875b6f89b8",
            "type": "web_search_call",
            "action": {
              "url": "https://www.1stoncology.com/blog/clovis-oncology-announces-second-u-s-patent-issued-in-rucaparib-high-dosage-strength-tablet-patent-family-with-expiration-in-2035/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0808a39728b605fc00693f282646b88195a1c3d16a1f273d4b",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0808a39728b605fc00693f282887dc81958996cf8c4bdfbe48",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "Orange Book RUBRACA rucaparib patent 209115"
            },
            "status": "completed"
          },
          {
            "id": "rs_0808a39728b605fc00693f282b5c0c81959496674922a4dec5",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0808a39728b605fc00693f2835d8cc81959331f2763bb3fe26",
            "type": "web_search_call",
            "action": {
              "url": "https://drugcentral.org/drugcard/5203",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0808a39728b605fc00693f2839889c819585775dc4a050fea2",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0808a39728b605fc00693f283b85d481958c5e67a78c7fb7c7",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "US 10,130,636 rucaparib camsylate patent"
            },
            "status": "completed"
          },
          {
            "id": "rs_0808a39728b605fc00693f283e01d881959544a3173c03ddda",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0808a39728b605fc00693f283ff09c8195b301101ed9716922",
            "type": "web_search_call",
            "action": {
              "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
              "type": "find_in_page",
              "pattern": "TRITON2"
            },
            "status": "completed"
          },
          {
            "id": "rs_0808a39728b605fc00693f284284ac819582390980f6cc4d6a",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0808a39728b605fc00693f284434188195a022c9a8bdef8f48",
            "type": "web_search_call",
            "action": {
              "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0808a39728b605fc00693f284639b48195a3ef0fae38276a56",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0808a39728b605fc00693f284837ec8195bb29c113a11bdc8c",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/US10130636B2/en",
              "type": "find_in_page",
              "pattern": "US10130636B2"
            },
            "status": "completed"
          },
          {
            "id": "rs_0808a39728b605fc00693f284b586c8195b60220eab567cdac",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0808a39728b605fc00693f284bdcf88195b54c86641c01e97a",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/WO2016028689A1/en",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0808a39728b605fc00693f284e1f8c8195ab5a6d9b4a7ff3c0",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0808a39728b605fc00693f285014a0819590de7fa6b2a917cd",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "TRITON2 NCT02952534 ClinicalTrials.gov"
            },
            "status": "completed"
          },
          {
            "id": "rs_0808a39728b605fc00693f2853f3c08195914d1b1da28abd1c",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_0808a39728b605fc00693f2861cf2c8195b9a592fd4bc8465b",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer | FDA\",\n      \"url\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate\",\n      \"snippets\": [\n        \"Efficacy was investigated in TRITON2 (NCT02952534), an ongoing, multi-center, single arm clinical trial\",\n        \"On May 15, 2020, the Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.)\"\n      ]\n    },\n    {\n      \"title\": \"FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33145877/\",\n      \"snippets\": [\n        \"This approval was based on data from the ongoing multicenter, open-label single-arm trial TRITON2.\",\n        \"doi: 10.1002/onco.13585.\"\n      ]\n    },\n    {\n      \"title\": \"rucaparib (DrugCentral) - Orange Book patent data\",\n      \"url\": \"https://drugcentral.org/drugcard/5203\",\n      \"snippets\": [\n        \"EQ 200MG BASE RUBRACA ZR PHARMA N209115 Dec. 19, 2016 RX TABLET ORAL 7351701 July 23, 2024\",\n        \"EQ 200MG BASE RUBRACA ZR PHARMA N209115 Dec. 19, 2016 RX TABLET ORAL 7531530 July 23, 2024\"\n      ]\n    },\n    {\n      \"title\": \"clvs-20211231x10k.htm (SEC EDGAR) - Patent disclosures\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm\",\n      \"snippets\": [\n        \"We were granted patent term extension to November 22, 2023 ... for U.S. Patent 6,495,541 directed to the rucaparib composition of matter.\",\n        \"These patents and patent applications include the rucaparib camsylate salt/polymorph patent family ... expires in 2031 ... high dosage strength rucaparib tablets ... expires in 2035.\"\n      ]\n    },\n    {\n      \"title\": \"Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent | American Pharmaceutical Review\",\n      \"url\": \"https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/\",\n      \"snippets\": [\n        \"Notice of Allowance ... in United States Patent Application 14/828,065 with claims directed to high dosage strength rucaparib camsylate formulations.\",\n        \"Upon issuance, the high dosage strength rucaparib formulation patent will expire in 2035 ... the 10th Orange Book-listed patent for rucaparib.\"\n      ]\n    },\n    {\n      \"title\": \"US10130636B2 - High dosage strength tablets of rucaparib - Google Patents\",\n      \"url\": \"https://patents.google.com/patent/US10130636B2/en\",\n      \"snippets\": [\n        \"Publication number\\n    US10130636B2\",\n        \"Application number\\n    US15/920,643\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765746711,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
        "https://pubmed.ncbi.nlm.nih.gov/33145877/",
        "https://drugcentral.org/drugcard/5203",
        "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
        "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
        "https://patents.google.com/patent/US10130636B2/en"
      ]
    },
    {
      "id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "created_at": "2025-12-14T21:19:22.457209+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_0c9e1cd9b5d3f26600693f281723588194a4781bc9bb42ce84",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 70820,
          "total_tokens": 79379,
          "output_tokens": 8559,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 7536
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_0c9e1cd9b5d3f26600693f28177b6881949459c08b13c83104",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f281afc1c8194ad628070186e36d4",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "TRITON2 pipeline pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f281c87a88194b48e6f96c51d108a",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f281e3b5c819494741f53e29fb9a0",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"TRITON2\" rucaparib investor presentation filetype:pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f282035d0819486d79e4d3452a24c",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f28232204819490e18ce8be2e4729",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "Clovis Oncology pipeline TRITON2 PDF"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f282589ac8194890b22d92ac8ae11",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f2829b4788194946ce71f1a2300df",
            "type": "web_search_call",
            "action": {
              "url": "https://www.biospace.com/clovis-oncology-presents-data-from-triton3-phase-3-trial-of-rubraca-rucaparib-at-the-29th-annual-prostate-cancer-foundation-scientific-retreat",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f282dccd48194a9ce06f2e99c27e5",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f282ee2a08194af6041a5983443ec",
            "type": "web_search_call",
            "action": {
              "url": "https://cts.businesswire.com/ct/CT?anchor=https%3A%2F%2Fclovisoncology.com%2Fpipeline%2Fscientific-presentations%2F&esheet=52953630&id=smartlink&index=1&lan=en-US&md5=0f59b5f0d6121900b911845d76a1d7a7&newsitemid=20221027005119&url=https%3A%2F%2Fclovisoncology.com%2Fpipeline%2Fscientific-presentations%2F",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f282fde7081949d2d636f15a370f6",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f2832cdcc8194b9b7ab2bb5793524",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "clovisoncology corporate presentation pdf Rubraca TRITON2"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f2835edb48194a2e3ff420d556d3a",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f28377e1c8194b4bbe100e7335f38",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "TRITON2 site:sec.gov filetype:pdf CLVS"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f283c761c8194b27b0f2326b88bcb",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f284034b08194a610f544f8a5fc23",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "site:sec.gov \"clvs\" \"presentation\" pdf \"Rubraca\""
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f284385488194bbd355d954fbbc75",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f2845298c8194975469d5b4726347",
            "type": "web_search_call",
            "action": {
              "url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
              "type": "find_in_page",
              "pattern": "TRITON2"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f2847b2b0819481fb896c7e29e354",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f284d3e0c8194b820f80a53b1ff80",
            "type": "web_search_call",
            "action": {
              "url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f284f9dac81949a8789a427741fdc",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f2852ff4881948f2057800246add7",
            "type": "web_search_call",
            "action": {
              "url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f2856860c81949ec688b01a2bc658",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f2858c1008194839bd60ec76cff96",
            "type": "web_search_call",
            "action": {
              "url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
              "type": "find_in_page",
              "pattern": "NCT02952534"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f285bd03c8194aa362f993329af74",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f285fa8048194805ddc1fdd309ad4",
            "type": "web_search_call",
            "action": {
              "url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837021001668/clvs-20201231x10k.htm",
              "type": "find_in_page",
              "pattern": "TRITON2 study"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f2862f5d481949a0ea9cf11ee6cf3",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f2879dea88194a9684fe463bbbb00",
            "type": "web_search_call",
            "action": {
              "url": "https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f287c32788194bcbe45f17d655473",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f287d19d88194b5eb3bbf95f25425",
            "type": "web_search_call",
            "action": {
              "url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f287ec44081949d04c416130ea81b",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f287f4cf08194be84c95535c4f150",
            "type": "web_search_call",
            "action": {
              "url": "https://www.mdpi.com/1718-7729/29/6/333",
              "type": "find_in_page",
              "pattern": "TRITON2"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f2882a0c48194a048b65864e66cdd",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f288717f4819486a4281bcdfc2c83",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "PubMed TRITON2 NCT02952534 European Urology 2023 rucaparib final results"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f288af1f48194a8a60530fb85c955",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f2891664c8194bfb4e93f7f0618f5",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f28936ad0819484d1bd602b08c967",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0c9e1cd9b5d3f26600693f2896dd688194917ccb707fd02c96",
            "type": "web_search_call",
            "action": {
              "url": "https://ascopost.com/issues/august-25-2020-supplement-genitourinary-cancers-almanac/phase-ii-triton2-study-in-metastatic-castration-resistant-prostate-cancer/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0c9e1cd9b5d3f26600693f2898bcfc8194b4c47043f442cb4c",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_0c9e1cd9b5d3f26600693f28b2f2a08194aaa4f97adc0bf458",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"Clovis Oncology, Inc. Annual Report (Form 10-K) for fiscal year ended December 31, 2021\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm\",\n      \"snippets\": [\n        \"The TRITON2 study (NCT02952534) is a multicenter Phase 2 single-arm study of Rubraca in men with mCRPC\",\n        \"The TRITON3 study (NCT02975934) is a Phase 3 comparative study in men with mCRPC\"\n      ]\n    },\n    {\n      \"title\": \"Clovis Oncology, Inc. Annual Report (Form 10-K) for fiscal year ended December 31, 2020\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1466301/000155837021001668/clvs-20201231x10k.htm\",\n      \"snippets\": [\n        \"The TRITON2 study (NCT02952534) is a multicenter Phase 2 single-arm study of Rubraca in men with mCRPC\",\n        \"The Alliance for Clinical Trials in Oncology is sponsoring the Phase 3 CASPAR study (NCT04455750)\"\n      ]\n    },\n    {\n      \"title\": \"TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in mCRPC - Health Research Authority\",\n      \"url\": \"https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/\",\n      \"snippets\": [\n        \"IRAS ID\\n\\n219516\",\n        \"Eudract number\\n\\n2016-003162-13\"\n      ]\n    },\n    {\n      \"title\": \"Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations - BioSpace\",\n      \"url\": \"https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations\",\n      \"snippets\": [\n        \"data from the Phase 2 TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations\",\n        \"Most common adverse reactions in TRITON2 (≥ 20%; Grade 1-4) were fatigue/asthenia (62%), nausea (52%), anemia (43%)\"\n      ]\n    },\n    {\n      \"title\": \"A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration - MDPI\",\n      \"url\": \"https://www.mdpi.com/1718-7729/29/6/333\",\n      \"snippets\": [\n        \"TRITON2 was funded by Clovis Oncology.\",\n        \"Grant W81XWH-17-1-0124\"\n      ]\n    },\n    {\n      \"title\": \"Phase II TRITON2 Study in Metastatic Castration-Resistant Prostate Cancer - The ASCO Post\",\n      \"url\": \"https://ascopost.com/issues/august-25-2020-supplement-genitourinary-cancers-almanac/phase-ii-triton2-study-in-metastatic-castration-resistant-prostate-cancer/\",\n      \"snippets\": [\n        \"Results from the study (ClinicalTrials.gov identifier NCT02952534) led to the approval of rucaparib in this setting.\",\n        \"Rucaparib is an inhibitor of the PARP1, PARP2, and PARP3 enzymes\"\n      ]\n    },\n    {\n      \"title\": \"A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency - Stanford Health Care\",\n      \"url\": \"https://stanfordhealthcare.org/trials/a/NCT02952534.html\",\n      \"snippets\": [\n        \"Trial ID or NCT#\\n\\nNCT02952534\",\n        \"Have a deleterious mutation in BRCA1/2 or ATM\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765746711,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
        "https://www.sec.gov/Archives/edgar/data/1466301/000155837021001668/clvs-20201231x10k.htm",
        "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
        "https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations",
        "https://www.mdpi.com/1718-7729/29/6/333",
        "https://ascopost.com/issues/august-25-2020-supplement-genitourinary-cancers-almanac/phase-ii-triton2-study-in-metastatic-castration-resistant-prostate-cancer/",
        "https://stanfordhealthcare.org/trials/a/NCT02952534.html"
      ]
    },
    {
      "id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "created_at": "2025-12-14T21:19:23.124737+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_016d830f3bfe67f800693f28171fcc8195ad7eb2fb65373abd",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 52967,
          "total_tokens": 60178,
          "output_tokens": 7211,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 6446
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_016d830f3bfe67f800693f281794c48195980e9c8f55b377e1",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_016d830f3bfe67f800693f2819502881958836df94ded2fd39",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"600 mg\" BID target trial"
            },
            "status": "completed"
          },
          {
            "id": "rs_016d830f3bfe67f800693f281b0b3481959cd2c8b0d736ab2f",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_016d830f3bfe67f800693f2820e52c81958547689b3ad9f60d",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"600 mg\" bid \"NCT\" hydroxychloroquine"
            },
            "status": "completed"
          },
          {
            "id": "rs_016d830f3bfe67f800693f282372fc819593c1fec5e5a1dfee",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_016d830f3bfe67f800693f28245200819584eabba63c60e508",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "site:clinicaltrials.gov NCT04613596 600 mg BID"
            },
            "status": "completed"
          },
          {
            "id": "rs_016d830f3bfe67f800693f282638348195b4dbd8901a472bd4",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_016d830f3bfe67f800693f28287eb48195834b29b928531b90",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "alectinib 600 mg twice daily label"
            },
            "status": "completed"
          },
          {
            "id": "rs_016d830f3bfe67f800693f282b5b148195972b3bce9b206a21",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_016d830f3bfe67f800693f2833b2b88195b0cf2a9764cb53e1",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_016d830f3bfe67f800693f2835544881958afc09333b7fea69",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_016d830f3bfe67f800693f283602a4819584a7f724e25445f8",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/16740761/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_016d830f3bfe67f800693f28394044819591e70f54690efa98",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_016d830f3bfe67f800693f2841abe881959ebc6ef7e1001d5a",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/16740761/",
              "type": "find_in_page",
              "pattern": "600 mg"
            },
            "status": "completed"
          },
          {
            "id": "rs_016d830f3bfe67f800693f2843e56081959b1f79c45afa0e39",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_016d830f3bfe67f800693f2844f1488195a603ea2cdda326e3",
            "type": "web_search_call",
            "action": {
              "url": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_016d830f3bfe67f800693f284692fc819580a423558bbde36e",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_016d830f3bfe67f800693f28613a0c819591139d73a4d098f1",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_016d830f3bfe67f800693f286374708195b7fa8e58d30122c6",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_016d830f3bfe67f800693f286739088195a0626151cf2de3f9",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
              "type": "find_in_page",
              "pattern": "ClinicalTrials.gov/NCT"
            },
            "status": "completed"
          },
          {
            "id": "rs_016d830f3bfe67f800693f286a9af4819582c2afcbd435dcf7",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_016d830f3bfe67f800693f286d0978819588f5e0867c1e75f4",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
              "type": "find_in_page",
              "pattern": "ClinicalTrials.gov/NCT03785249"
            },
            "status": "completed"
          },
          {
            "id": "rs_016d830f3bfe67f800693f286e7b7081959251f5c3d073a37a",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_016d830f3bfe67f800693f286fdc288195aa7554625f0c8e8f",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/40783289/",
              "type": "find_in_page",
              "pattern": "ClinicalTrials.gov/NCT04685135"
            },
            "status": "completed"
          },
          {
            "id": "rs_016d830f3bfe67f800693f287165948195a37fd16d1c0dc562",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_016d830f3bfe67f800693f2884973c819591c0270ccd522e04",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1) - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/35167329/\",\n      \"snippets\": [\n        \"Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRAS^{G12C}.\",\n        \"600 mg once daily, 1,200 mg once daily, or 600 mg orally twice a day\"\n      ]\n    },\n    {\n      \"title\": \"Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/40783289/\",\n      \"snippets\": [\n        \"receive 600 mg adagrasib (twice a day orally) or 75 mg/m^{2} docetaxel\",\n        \"ClinicalTrials.gov/NCT04685135\"\n      ]\n    },\n    {\n      \"title\": \"Targeting autophagy plus high-dose CDK4/6 inhibitors in advanced HR+HER2- breast cancer: A phase 1b/2 trial - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/39731909/\",\n      \"snippets\": [\n        \"The recommended phase 2 dose (RP2D) was HCQ (600 mg, bid) plus palbociclib (200 mg, qd).\",\n        \"ClinicalTrials.gov/NCT05953350\"\n      ]\n    },\n    {\n      \"title\": \"A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/16740761/\",\n      \"snippets\": [\n        \"received increasing doses of celecoxib from 200 to 800 mg twice daily (bid) and a fixed dose of erlotinib.\",\n        \"with an OBD of celecoxib of 600 mg bid.\"\n      ]\n    },\n    {\n      \"title\": \"FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer | FDA\",\n      \"url\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer\",\n      \"snippets\": [\n        \"Efficacy was demonstrated in a global, randomized, open-label trial (ALINA, NCT03456076)\",\n        \"to receive alectinib 600 mg orally twice daily or platinum-based chemotherapy\"\n      ]\n    },\n    {\n      \"title\": \"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | MedPath\",\n      \"url\": \"https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer\",\n      \"snippets\": [\n        \"Registration Number     NCT05853575\",\n        \"two dosing regimens of adagrasib (600 mg BID versus 400 mg BID)\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765746711,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://pubmed.ncbi.nlm.nih.gov/35167329/",
        "https://pubmed.ncbi.nlm.nih.gov/40783289/",
        "https://pubmed.ncbi.nlm.nih.gov/39731909/",
        "https://pubmed.ncbi.nlm.nih.gov/16740761/",
        "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
        "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer"
      ]
    },
    {
      "id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "created_at": "2025-12-14T21:19:24.051544+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_09c069b4cd269f6700693f281720788197990fa2a51f199ffc",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 21935,
          "total_tokens": 25900,
          "output_tokens": 3965,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 3184
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_09c069b4cd269f6700693f281762c88197a8a9d1062d9212be",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09c069b4cd269f6700693f2818b6f48197b1558f23cf10b658",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"600 mg\" BID \"Phase 1\""
            },
            "status": "completed"
          },
          {
            "id": "rs_09c069b4cd269f6700693f281a6294819787a0f9a68b8d964c",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09c069b4cd269f6700693f282395a48197b7f2c1016774a9d5",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_09c069b4cd269f6700693f28246d608197a3acbc97fbc69c6e",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09c069b4cd269f6700693f2825222c8197923112e2a877a9a2",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
              "type": "find_in_page",
              "pattern": "600 mg"
            },
            "status": "completed"
          },
          {
            "id": "rs_09c069b4cd269f6700693f2827b4788197853e97bdcc6dacba",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_09c069b4cd269f6700693f2830e0908197ae182f2f5eff0404",
            "type": "web_search_call",
            "action": {
              "url": "https://pubmed.ncbi.nlm.nih.gov/15613696/",
              "type": "find_in_page",
              "pattern": "BAY 43-9006 ("
            },
            "status": "completed"
          },
          {
            "id": "rs_09c069b4cd269f6700693f28325de08197814268b90431a5b1",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_09c069b4cd269f6700693f284b06888197817d4cf7fa40e74a",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1) - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/35167329/\",\n      \"snippets\": [\n        \"Conclusion: Adagrasib 600 mg twice a day was well tolerated and exhibited antitumor activity in patients with advanced solid tumors harboring the KRAS G12C mutation.\",\n        \"Trial registration: ClinicalTrials.gov NCT03785249.\"\n      ]\n    },\n    {\n      \"title\": \"Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/15613696/\",\n      \"snippets\": [\n        \"Patients and methods: BAY 43-9006 (50 to 800 mg) was administered once or twice daily on a varying weekly schedule.\",\n        \"Dose-limiting toxicities were grade 3 diarrhea and fatigue at 800 mg bid, and grade 3 skin toxicity at 600 mg bid.\"\n      ]\n    },\n    {\n      \"title\": \"Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/18477034/\",\n      \"snippets\": [\n        \"Sorafenib (100-600 mg) was given as a single dose followed by a 7-day wash-out period, and then administrated twice daily (bid).\",\n        \"Dose-limiting toxicities (DLTs) were grade 3 diarrhea at 200 mg bid and grade 3 fatigue at 600 mg bid.\"\n      ]\n    },\n    {\n      \"title\": \"Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/22827973/\",\n      \"snippets\": [\n        \"polyphenon E (Poly E) 400, 600, 800 twice daily\",\n        \"Trial registration: ClinicalTrials.gov NCT00516243.\"\n      ]\n    },\n    {\n      \"title\": \"Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/19484470/\",\n      \"snippets\": [\n        \"Methods: Patients with advanced cancers received salirasib twice daily for 21 days every 4 weeks.\",\n        \"The recommended dose for phase II studies is 600 mg twice daily.\"\n      ]\n    },\n    {\n      \"title\": \"Targeting autophagy plus high-dose CDK4/6 inhibitors in advanced HR+HER2- breast cancer: A phase 1b/2 trial - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/39731909/\",\n      \"snippets\": [\n        \"hydroxychloroquine (HCQ; 600 mg, bis in die [bid]) plus increasing doses of palbociclib (100, 150, or 200 mg, quaque die [qd]).\",\n        \"The clinical trial registration number is ClinicalTrials.gov: NCT05953350.\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765746711,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://pubmed.ncbi.nlm.nih.gov/35167329/",
        "https://pubmed.ncbi.nlm.nih.gov/15613696/",
        "https://pubmed.ncbi.nlm.nih.gov/18477034/",
        "https://pubmed.ncbi.nlm.nih.gov/22827973/",
        "https://pubmed.ncbi.nlm.nih.gov/19484470/",
        "https://pubmed.ncbi.nlm.nih.gov/39731909/"
      ]
    },
    {
      "id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "created_at": "2025-12-14T21:19:24.412341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_0dc28b7e434fd45000693f28171ee08196a3e0ac705f40db76",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 63501,
          "total_tokens": 73360,
          "output_tokens": 9859,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 9287
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_0dc28b7e434fd45000693f281784b8819690d70f9b3cc3a6a3",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f2819627c8196870771a67a49e9ed",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"600 mg\" BID patent"
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f281abff88196a2351a66e228ebf2",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f281ffc0c8196a13c00dc2bfb2f91",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/US20210393527A1/en",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f28231da8819697ba68b4504fef65",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f2824b80c8196b51054a479f4e67e",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/US20210393527A1/en",
              "type": "find_in_page",
              "pattern": "600 mg BID"
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f282699cc81968989daef01e4e80d",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f2828fa94819688206c3b95d2a42a",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"600 mg BID\" \"A1\" site:patents.google.com"
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f282b3f088196bf52a24674bba38b",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f282c42a08196b851f19d68306c41",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"600 mg BID\" \"Publication number\""
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f282e93c08196934185e6dd97f709",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f283295408196bc3cac8c67d23d12",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"600 mg BID (i.e., twice per day)\" patent"
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f28347db88196b1c287cd45db7544",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f2839d34881969cb969961d24dc2f",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"600 mg BID\" site:patents.google.com/patent/US \"600 mg BID\""
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f283cee788196bc4fbddfa8d4a489",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f2845bde881969e62a7378d4d8d4f",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/WO2023034916A1/ko",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f2847f554819680f1b89c6857e517",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f284893208196bfe03ead547dfe61",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/WO2021231792A1/fr",
              "type": "find_in_page",
              "pattern": "Publication number"
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f284c5f90819688faebf855ce3a6e",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f284f35ec8196b84ed2386b1bbafb",
            "type": "web_search_call",
            "action": {
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f28502794819684684393d8e800f6",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f28539fa88196b01d2f0d8933becf",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/WO2021231792A1/fr",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f28558e10819696df0afc46034862",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f28ab41e481969a42d70c0a0605d8",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"600 mg BID\" administered \"A1\" \"mg BID\" \"Publication number\""
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f28af10248196ba7aedc8f56faed1",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f28b099948196958f36edfd877233",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/EP4504192A1/en",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f28b19064819694447c4d6b157060",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0dc28b7e434fd45000693f28b21ab88196aabb71c964ca89cc",
            "type": "web_search_call",
            "action": {
              "url": "https://patents.google.com/patent/EP4504192A1/en",
              "type": "find_in_page",
              "pattern": "600 mg BID"
            },
            "status": "completed"
          },
          {
            "id": "rs_0dc28b7e434fd45000693f28b491d88196b8c59a0d2a6c87ac",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_0dc28b7e434fd45000693f28bfbe788196aa723f88bdcfd177",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"US20210393527A1 - Pharmaceutical formulations and uses thereof - Google Patents\",\n      \"url\": \"https://patents.google.com/patent/US20210393527A1/en\",\n      \"snippets\": [\n        \"US20210393527A1 US17/333,528\",\n        \"* the dose of the compound or pharmaceutically acceptable salt thereof is about 600 mg BID (i.e., twice per day); 1.2 g BID; or about 2.4 g BID.\"\n      ]\n    },\n    {\n      \"title\": \"WO2023034916A1 - Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof - Google Patents\",\n      \"url\": \"https://patents.google.com/patent/WO2023034916A1/ko\",\n      \"snippets\": [\n        \"WO2023034916A1 PCT/US2022/075838\",\n        \"Compound A is administered at a daily dose of about 400 mg BID, about 600 mg BID, or about 800 mg BID\"\n      ]\n    },\n    {\n      \"title\": \"WO2021231792A1 - Formulations pharmaceutiques et leurs utilisations - Google Patents\",\n      \"url\": \"https://patents.google.com/patent/WO2021231792A1/fr\",\n      \"snippets\": [\n        \"WO2021231792A1 PCT/US2021/032335\",\n        \"in a dose of about 50 mg BID, 150 mg BID, 350 mg BID, or 600 mg BID,\"\n      ]\n    },\n    {\n      \"title\": \"US20230226030A1 - Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc - Google Patents\",\n      \"url\": \"https://patents.google.com/patent/US20230226030A1/en\",\n      \"snippets\": [\n        \"US20230226030A1 US17/760,298\",\n        \"Compound A is administered once daily ora dosage of 300 mg, 400 mg or 600 mg is administered BID.\"\n      ]\n    },\n    {\n      \"title\": \"EP4504192A1 - Methods of treating head and neck squamous cell carcinoma - Google Patents\",\n      \"url\": \"https://patents.google.com/patent/EP4504192A1/en\",\n      \"snippets\": [\n        \"EP4504192A1 EP23720027.4A\",\n        \"In some embodiments, the dose of tipifarnib is about 600 mg BID.\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765746711,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://patents.google.com/patent/US20210393527A1/en",
        "https://patents.google.com/patent/WO2023034916A1/ko",
        "https://patents.google.com/patent/WO2021231792A1/fr",
        "https://patents.google.com/patent/US20230226030A1/en",
        "https://patents.google.com/patent/EP4504192A1/en"
      ]
    },
    {
      "id": "2771207e-89f9-4b7c-96df-390649b80311",
      "created_at": "2025-12-14T21:19:25.852442+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "tool_name": "web_search",
      "response_json": {
        "id": "resp_0279c12c5e11a77700693f28171f548193bc3ecd176f33c6be",
        "text": {
          "format": {
            "type": "text"
          },
          "verbosity": "medium"
        },
        "user": null,
        "error": null,
        "model": "gpt-5.2-2025-12-11",
        "store": true,
        "tools": [
          {
            "type": "web_search",
            "filters": null,
            "user_location": {
              "city": null,
              "type": "approximate",
              "region": null,
              "country": "US",
              "timezone": null
            },
            "search_context_size": "medium"
          }
        ],
        "top_p": 0.98,
        "usage": {
          "input_tokens": 60672,
          "total_tokens": 67629,
          "output_tokens": 6957,
          "input_tokens_details": {
            "cached_tokens": 4480
          },
          "output_tokens_details": {
            "reasoning_tokens": 6286
          }
        },
        "object": "response",
        "output": [
          {
            "id": "rs_0279c12c5e11a77700693f28176a688193b817f80f6448a212",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f281898e48193abae302942e623b7",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"600 mg\" BID pipeline pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f281a69b88193b4364ad864caca28",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f281d359081938f209de97cc51f82",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"600 mg BID\" filetype:pdf \"pipeline\" \"Phase\""
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f281eed8c8193b282b35393f681f9",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f2825c3f48193950c23fc79592045",
            "type": "web_search_call",
            "action": {
              "url": "https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f2826b8488193861a6d400f00082b",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f2827390c81938b63ee9082c53749",
            "type": "web_search_call",
            "action": {
              "url": "https://ir.opusgtx.com/sec-filings/all-sec-filings/content/0001140361-21-028006/brhc10027978_ex99-2.htm",
              "type": "find_in_page",
              "pattern": "600"
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f2828775c8193b36b992c9279ae3e",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f28300c54819380a8ac90fe7817f6",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"Adagrasib\" \"600 mg BID\" pdf"
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f2831ed148193b135a2cac8664708",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f2836b5b081939166e3c31bdfeabb",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "site:clinicaltrials.gov adagrasib 600 mg BID"
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f28392aa48193a2fbc1222f70e4e2",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f283b6e0c8193b32146d384c9edb0",
            "type": "web_search_call",
            "action": {
              "url": "https://clinicaltrials.gov/study/NCT03785249",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f283c977c8193a4b351b763928141",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f283fb55c81938cf85a0a596cd28a",
            "type": "web_search_call",
            "action": {
              "type": "search",
              "query": "\"NCT03785249\" \"600 mg\" twice daily adagrasib"
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f2842ee908193839a361a2475b30e",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f284cec5c819380498ccc4d2860eb",
            "type": "web_search_call",
            "action": {
              "url": "https://www.krazatihcp.com/nsclc/dosing",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f284ff49c8193822c1859dc59ee09",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f285050e8819396d74fd984d9930e",
            "type": "web_search_call",
            "action": {
              "url": "https://www.prnewswire.com/news-releases/mirati-therapeutics-presents-first-clinical-data-of-phase-12-trial-of-mrtx849-at-the-2019-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-300946509.html",
              "type": "find_in_page",
              "pattern": "600 mg BID"
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f2853e34c81938606b726ea5b4c1a",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f2856c7e08193bf5b75dbf7ad0c86",
            "type": "web_search_call",
            "action": {
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT05263986/",
              "type": "find_in_page",
              "pattern": "BID"
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f28584560819398e74de54a09ba66",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f286e572081939cb0ac90fb337c64",
            "type": "web_search_call",
            "action": {
              "url": "https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
              "type": "open_page"
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f286fb1888193ad6defee27fde8ac",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "ws_0279c12c5e11a77700693f287023508193a550f1a7eb30fb79",
            "type": "web_search_call",
            "action": {
              "url": "https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
              "type": "find_in_page",
              "pattern": "600 mg BID"
            },
            "status": "completed"
          },
          {
            "id": "rs_0279c12c5e11a77700693f28720b548193bf0e4bc98059d787",
            "type": "reasoning",
            "summary": []
          },
          {
            "id": "msg_0279c12c5e11a77700693f2880214481938ea9e48a8293b644",
            "role": "assistant",
            "type": "message",
            "status": "completed",
            "content": [
              {
                "text": "{\n  \"sources\": [\n    {\n      \"title\": \"EX-99.1 Mirati Therapeutics J.P. Morgan Healthcare Conference January 11, 2021\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm\",\n      \"snippets\": [\n        \"Phase 1/1b, NSCLC 600 mg BID (n=14)\",\n        \"KRYSTAL-1: Adagrasib (MRTX849) KRAS G12C Inhibitor in NSCLC\"\n      ]\n    },\n    {\n      \"title\": \"Dosing | KRAZATI® (adagrasib) for NSCLC\",\n      \"url\": \"https://www.krazatihcp.com/nsclc/dosing\",\n      \"snippets\": [\n        \"The recommended dosage of KRAZATI is 600 mg orally twice daily until disease progression or unacceptable toxicity.^{1}\",\n        \"## KRAZATI RECOMMENDED DOSAGE: 600 MG BID^{1}\"\n      ]\n    },\n    {\n      \"title\": \"Study Designs | KRAZATI® (adagrasib) for NSCLC\",\n      \"url\": \"https://www.krazatihcp.com/nsclc/study-design\",\n      \"snippets\": [\n        \"KRYSTAL-1 and KRYSTAL-12 STUDY DESIGNS\",\n        \"### KRAZATI 600 mg BID\"\n      ]\n    },\n    {\n      \"title\": \"Trial | NCT05263986 | Clinical Drug Experience Knowledgebase (CDEK)\",\n      \"url\": \"https://cdek.pharmacy.purdue.edu/trial/NCT05263986/\",\n      \"snippets\": [\n        \"Trial | NCT05263986\",\n        \"Following the PK lead-in period, patients will receive MRTX849 600 mg BID (an interval of approximate 12 hours between 2 doses)\"\n      ]\n    },\n    {\n      \"title\": \"Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation - PubMed\",\n      \"url\": \"https://pubmed.ncbi.nlm.nih.gov/37099736/\",\n      \"snippets\": [\n        \"KRYSTAL-1 study (ClinicalTrials.gov identifier: NCT03785249; phase Ib cohort)\",\n        \"we evaluated adagrasib (600 mg orally twice daily)\"\n      ]\n    },\n    {\n      \"title\": \"Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer - PRNewswire\",\n      \"url\": \"https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html\",\n      \"snippets\": [\n        \"registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib 600 mg BID\",\n        \"About Adagrasib (MRTX849)\"\n      ]\n    }\n  ]\n}",
                "type": "output_text",
                "logprobs": [],
                "annotations": []
              }
            ]
          }
        ],
        "status": "completed",
        "billing": {
          "payer": "developer"
        },
        "metadata": {},
        "reasoning": {
          "effort": "medium",
          "summary": null
        },
        "background": false,
        "created_at": 1765746711,
        "truncation": "disabled",
        "temperature": 1.0,
        "tool_choice": "auto",
        "instructions": null,
        "service_tier": "default",
        "top_logprobs": 0,
        "max_tool_calls": null,
        "prompt_cache_key": null,
        "max_output_tokens": null,
        "safety_identifier": null,
        "incomplete_details": null,
        "parallel_tool_calls": true,
        "previous_response_id": null,
        "prompt_cache_retention": null
      },
      "urls": [
        "https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
        "https://www.krazatihcp.com/nsclc/dosing",
        "https://www.krazatihcp.com/nsclc/study-design",
        "https://cdek.pharmacy.purdue.edu/trial/NCT05263986/",
        "https://pubmed.ncbi.nlm.nih.gov/37099736/",
        "https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html"
      ]
    }
  ],
  "mentions": [
    {
      "id": "b4385b4d-8028-4e9a-80b8-bd0c473752e9",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "target",
      "raw_text": "BRCA",
      "normalized_text": "brca",
      "context": "grouped by mutated gene: BRCA (n = 172)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "fingerprint": "0ce13fc269899dd84a55df760a78e2ffd15bbf87b993be8f9cc3e2a64476a2d8",
      "canonical_text": "BRCA",
      "mention_class": "junk"
    },
    {
      "id": "50359495-60be-4fb2-ae8a-f7b4d218bfad",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "target",
      "raw_text": "ATM",
      "normalized_text": "atm",
      "context": "ATM (n = 59)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "fingerprint": "3ff333135843f740f88ba73a081bf26a82dc9db40ada1e17d2d3b9cbbdc1442b",
      "canonical_text": "ATM",
      "mention_class": "junk"
    },
    {
      "id": "32915d8d-109e-43f8-8456-cd74864f1efc",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "trial_id",
      "raw_text": "NCT06600789",
      "normalized_text": "nct06600789",
      "context": "nical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789.",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "790f6978e9947a48c024ce9ae3460feaba1196c78ee079b774850cc43bb69783",
      "canonical_text": "NCT06600789",
      "mention_class": "trial_id_like"
    },
    {
      "id": "74f75da4-8cf5-4438-92d3-a3a13c9e7a1f",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "drug_code",
      "raw_text": "CT7439",
      "normalized_text": "ct7439",
      "context": "the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor Clinical trial deta",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "63f4201620b4455c7eab7a8650c8c8f24afbf9fabe2ac67ff5d79c3762b56dd9",
      "canonical_text": "CT7439",
      "mention_class": "drug_code_like"
    },
    {
      "id": "4329c718-e860-4075-a142-09c8d92ff85c",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "drug_code",
      "raw_text": "CDK12",
      "normalized_text": "cdk12",
      "context": "hase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor Clinical trial details can also be found on www.clinicaltrials.go",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "e2c17a2f4a9c9582a3abaf6ae0e405c68bfcc3cf117c4474fa5657a3429fe878",
      "canonical_text": "CDK12",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "2b525551-cd38-47a9-a32d-c3bc83e77e14",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "trial_id",
      "raw_text": "NCT04104893",
      "normalized_text": "nct04104893",
      "context": "#### NCT04104893 metastatic castration-resistant prostate cancer (mCRPC) characterized by either",
      "source_url": "https://www.mycancergenome.org/content/clinical_trials/NCT04104893/",
      "fingerprint": "61ab63f8abbb191974bc874a4d007ba89e4b9618c8207d6da3b8ce4cee802658",
      "canonical_text": "NCT04104893",
      "mention_class": "trial_id_like"
    },
    {
      "id": "cde306a9-0dfb-471c-a159-847c1bcad964",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "trial_id",
      "raw_text": "NCT04717154",
      "normalized_text": "nct04717154",
      "context": "Trial | NCT04717154 Phase 2 INSPIRE Trial: Ipilimumab With Nivolumab for Molecular- Selected Patien",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT04717154/",
      "fingerprint": "70fc6501202c8c2ad3d752c2e70b59d8cca6cc2f7793f4ee1aa0d9315ea6e73c",
      "canonical_text": "NCT04717154",
      "mention_class": "trial_id_like"
    },
    {
      "id": "24c8e219-0a43-4983-a5cc-a3e4f6489c6f",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "trial_id",
      "raw_text": "NCT02952534",
      "normalized_text": "nct02952534",
      "context": "Background:  Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID TRITON2 had enrolled",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "fingerprint": "32451f3f15008c3d7fc9ad6600c93fb4c009b7cde7635fe88b809458a047ad6b",
      "canonical_text": "NCT02952534",
      "mention_class": "trial_id_like"
    },
    {
      "id": "bb8dd1e9-0b2a-4609-ab77-ee09dad74c36",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "trial_id",
      "raw_text": "2016-003162-13",
      "normalized_text": "2016-003162-13",
      "context": "Eudract number 2016-003162-13 Clinicaltrials.gov Identifier NCT02952534",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "8f16f58d010cb84a709c7c92ab4f000badd729defbc02abc5884e4509da9a723",
      "canonical_text": "201600316213",
      "mention_class": "trial_id_like"
    },
    {
      "id": "4d14f63c-99c5-457c-b586-ac0cf71f3291",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "target",
      "raw_text": "cyclin dependent kinase 12/13",
      "normalized_text": "cyclin dependent kinase 12/13",
      "context": "CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "c447de9be577117c7f8317271951afeef433ba3fb14c366a5974a0b60d809162",
      "canonical_text": "CYCLINDEPENDENTKINASE1213",
      "mention_class": "junk"
    },
    {
      "id": "67460782-8707-47bd-9d7e-f9cd31724ae6",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "target",
      "raw_text": "CDK12/13",
      "normalized_text": "cdk12/13",
      "context": "cyclin dependent kinase 12/13 (CDK12/13) inhibitor",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "e4ffc9acaa2b470b4bf5c737318d471e5633ccd1670463d199b1a0049cf3ba2d",
      "canonical_text": "CDK1213",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "107420cd-ce97-4070-add9-9aaf56f33cbc",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "modality",
      "raw_text": "CDK12/13 inhibitor",
      "normalized_text": "cdk12/13 inhibitor",
      "context": "(CDK12/13) inhibitor",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "4b86fd286b9f7cce6196e3e524bbf2254b7bf26ac9cbc09daa480c2c4300d331",
      "canonical_text": "CDK1213INHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "ba7b28fd-86fc-4caf-ad63-4bb9e55cdb17",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "Phase 1",
      "normalized_text": "phase 1",
      "context": "dosed in the Phase 1 clinical trial evaluating CT7439",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "c67496f275b9ed5d1571b108bd09182c46d55b7f533fcd10c5f543b7e84d7222",
      "canonical_text": "PHASE1",
      "mention_class": "junk"
    },
    {
      "id": "1ef07558-f920-42cd-bd7e-be837b1a78c4",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "www.clinicaltrials.gov",
      "normalized_text": "www.clinicaltrials.gov",
      "context": "found on www.clinicaltrials.gov under study ID: NCT06600789.",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "e6ae55c60cc211c982302195cce124c108a5eae247b074eb1f6dace3377f1bee",
      "canonical_text": "WWWCLINICALTRIALSGOV",
      "mention_class": "junk"
    },
    {
      "id": "a49905d5-9ad9-44eb-bdf7-1b51124af080",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "sponsor",
      "raw_text": "carricktherapeutics.com",
      "normalized_text": "carricktherapeutics.com",
      "context": "URL: https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "19475aead62e8a9bffff215c7771ca2677a12ed8641a96e54f0e2e6b3b1c6049",
      "canonical_text": "CARRICKTHERAPEUTICSCOM",
      "mention_class": "junk"
    },
    {
      "id": "96b968b0-3fb1-42c1-bce5-411db4c242f6",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "sponsor",
      "raw_text": "carrick-therapeutics",
      "normalized_text": "carrick-therapeutics",
      "context": "URL: https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "f6ccdb7aeeb1c081efc89818e34078dc6d2d48d25b5a34d6bd7f05be9f572fd4",
      "canonical_text": "CARRICKTHERAPEUTICS",
      "mention_class": "junk"
    },
    {
      "id": "4120d346-60e1-42dc-aef8-54ef0c1c3fff",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "indication",
      "raw_text": "metastatic castration-resistant prostate cancer",
      "normalized_text": "metastatic castration-resistant prostate cancer",
      "context": "metastatic castration-resistant prostate cancer (mCRPC)",
      "source_url": "https://www.mycancergenome.org/content/clinical_trials/NCT04104893/",
      "fingerprint": "eebc3a89e40980f1699bfa4454300921d31a648e8194dacc2a664a251667cd36",
      "canonical_text": "METASTATICCASTRATIONRESISTANTPROSTATECANCER",
      "mention_class": "junk"
    },
    {
      "id": "88ae9970-b30e-4964-ae36-bcb61fa70003",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "indication",
      "raw_text": "mCRPC",
      "normalized_text": "mcrpc",
      "context": "prostate cancer (mCRPC)",
      "source_url": "https://www.mycancergenome.org/content/clinical_trials/NCT04104893/",
      "fingerprint": "5590903cb2f6f90023e8f1146712f8c995e010cd6a7dd20e4b1ed41ae778187e",
      "canonical_text": "MCRPC",
      "mention_class": "junk"
    },
    {
      "id": "4fbe7299-3a92-442b-b0f4-855bc1465139",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "target",
      "raw_text": "mismatch repair deficiency",
      "normalized_text": "mismatch repair deficiency",
      "context": "either mismatch repair deficiency (dMMR)",
      "source_url": "https://www.mycancergenome.org/content/clinical_trials/NCT04104893/",
      "fingerprint": "d36e069e0d25d43d91aeeeb1310f7cdf57a1830aa336584097c6eb01f675bbb6",
      "canonical_text": "MISMATCHREPAIRDEFICIENCY",
      "mention_class": "junk"
    },
    {
      "id": "20b62670-f147-4467-93a4-897e7f3c7781",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "target",
      "raw_text": "dMMR",
      "normalized_text": "dmmr",
      "context": "mismatch repair deficiency (dMMR)",
      "source_url": "https://www.mycancergenome.org/content/clinical_trials/NCT04104893/",
      "fingerprint": "dfa64c907f3d1c44bed72b1eaadf1877bda803c0960e9d51e728a558aefa82d2",
      "canonical_text": "DMMR",
      "mention_class": "junk"
    },
    {
      "id": "574a2e08-2caa-478f-a2a4-ad049fdc0bdf",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "target",
      "raw_text": "CDK12",
      "normalized_text": "cdk12",
      "context": "biallelic inactivation of CDK12 (CDK12-/-).",
      "source_url": "https://www.mycancergenome.org/content/clinical_trials/NCT04104893/",
      "fingerprint": "2b3065c9a6e6138163bcb885cbbc69d239ca2b7580b0ef89c737ec36b6582c82",
      "canonical_text": "CDK12",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "bf41730c-f2d2-43b8-858e-3ca62d9b0e03",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "target",
      "raw_text": "CDK12-/-",
      "normalized_text": "cdk12-/-",
      "context": "CDK12 (CDK12-/-).",
      "source_url": "https://www.mycancergenome.org/content/clinical_trials/NCT04104893/",
      "fingerprint": "9ffc1a53c6c45bd525b71c8526ce4d48ff11fa77c9c8a513fc5d9600415e4dd2",
      "canonical_text": "CDK12",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "2f5ce2a3-8b9e-4e91-b389-7c2711ac236d",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "Phase 2",
      "normalized_text": "phase 2",
      "context": "Phase 2 INSPIRE Trial: Ipilimumab With Nivolumab",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT04717154/",
      "fingerprint": "05e331dfe15b65d737bbd986ce9ef8878bec73f250be1ba1e63a44336a1a8ad0",
      "canonical_text": "PHASE2",
      "mention_class": "junk"
    },
    {
      "id": "c34fe8aa-b285-41c1-82e4-9a3c0c252012",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "INSPIRE Trial",
      "normalized_text": "inspire trial",
      "context": "Phase 2 INSPIRE Trial: Ipilimumab With Nivolumab",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT04717154/",
      "fingerprint": "a65b27ac802fd2cdcb4d05e489f9af0ca4954ca7427cb550e51698006a2f467d",
      "canonical_text": "INSPIRETRIAL",
      "mention_class": "junk"
    },
    {
      "id": "6262f6a0-e482-4dc5-8712-da3bcb6ebbcb",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "drug_name",
      "raw_text": "Ipilimumab",
      "normalized_text": "ipilimumab",
      "context": "INSPIRE Trial: Ipilimumab With Nivolumab",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT04717154/",
      "fingerprint": "95073ed50809ebf12b97f0f7ebc9ce3ee71414d16a2e7b8740e6e54695b5559f",
      "canonical_text": "IPILIMUMAB",
      "mention_class": "junk"
    },
    {
      "id": "23b817df-d935-4004-93c2-ebe8b52564bb",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "drug_name",
      "raw_text": "Nivolumab",
      "normalized_text": "nivolumab",
      "context": "Ipilimumab With Nivolumab",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT04717154/",
      "fingerprint": "b6c8ca5ecf8487e5bbc6f87f560ca1788effaef525fa84dc97b233b6445cc0ff",
      "canonical_text": "NIVOLUMAB",
      "mention_class": "junk"
    },
    {
      "id": "03334aae-22ca-4f37-a24f-1a44306754df",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "Molecular- Selected",
      "normalized_text": "molecular- selected",
      "context": "for Molecular- Selected Patients",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT04717154/",
      "fingerprint": "3a5d4748a55c38fa24ff1402c8ed01b5309f3df9e23965b5dd6e4c30bd0d8a05",
      "canonical_text": "MOLECULARSELECTED",
      "mention_class": "junk"
    },
    {
      "id": "4c7c1a4f-36e9-4873-8026-c70dfaa68815",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "indication",
      "raw_text": "Castration-resistant Prostate Cancer",
      "normalized_text": "castration-resistant prostate cancer",
      "context": "With Castration-resistant Prostate Cancer",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT04717154/",
      "fingerprint": "a2749f7fd1bb37e23cf5a49bb146412ab5870c8ad716945da556320b5213b259",
      "canonical_text": "CASTRATIONRESISTANTPROSTATECANCER",
      "mention_class": "junk"
    },
    {
      "id": "f2da0318-6fa4-48ff-8325-cf99e695e174",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "37277275",
      "normalized_text": "37277275",
      "context": "URL: https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "fingerprint": "6186b6be3a0d62990c019454021f85f78c2db3e60ef9595aefd130f600b440f2",
      "canonical_text": "37277275",
      "mention_class": "junk"
    },
    {
      "id": "35f67d53-1be7-4951-a5a3-b6cb874757ab",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "TRITON2",
      "normalized_text": "triton2",
      "context": "Initial TRITON2 (NCT02952534) results",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "fingerprint": "f09a126ee4f74d2f2b8de370fef7d00bcdfec57a6d361423d9fd22f68d1b6b27",
      "canonical_text": "TRITON2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "1027d65d-8a1f-4a51-bdec-f8d771c8c488",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "drug_name",
      "raw_text": "rucaparib",
      "normalized_text": "rucaparib",
      "context": "efficacy of rucaparib 600 mg BID",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "fingerprint": "65e16d4b694c1bb4215a782aaaf74ef459792120466c74a60476257131b771b9",
      "canonical_text": "RUCAPARIB",
      "mention_class": "junk"
    },
    {
      "id": "edc6dbd6-dfb6-4359-b437-dd8e803c19a8",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "600 mg BID",
      "normalized_text": "600 mg bid",
      "context": "rucaparib 600 mg BID",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "fingerprint": "8914b97d2038412a74d60a5d306529449f1859a64e97cc24c46f4babc0034de3",
      "canonical_text": "600MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "c881f1d4-eb05-4f69-bc9d-566ed7f859f9",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "Eudract",
      "normalized_text": "eudract",
      "context": "Eudract number 2016-003162-13",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "8561e00a3aa245063d42778ac385530680a93969a4a40109d5478fbec6cafff9",
      "canonical_text": "EUDRACT",
      "mention_class": "junk"
    },
    {
      "id": "2b32e047-f52e-4b0a-8eb5-0ad305b40e93",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "Clinicaltrials.gov",
      "normalized_text": "clinicaltrials.gov",
      "context": "Clinicaltrials.gov Identifier NCT02952534",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "c9ef8f08f311fcd9a17618d2d5bfdf47d4abfa7a33ebdddea17427b9abc93db5",
      "canonical_text": "CLINICALTRIALSGOV",
      "mention_class": "junk"
    },
    {
      "id": "c400859c-863c-4e52-aa44-c74e572b54f8",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "multicenter",
      "normalized_text": "multicenter",
      "context": "triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "7802e5dfe71163f70fdaacd65af36c131786993e15201cf8b056e127a685ddae",
      "canonical_text": "MULTICENTER",
      "mention_class": "junk"
    },
    {
      "id": "e129cec7-a8cb-4e8f-9e0e-3aa0d7adf09e",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "open-label",
      "normalized_text": "open-label",
      "context": "triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "3fc05b8165c3cab36761a74bbfd511d5983ed49e2071bf1a40bdd3940af5ca2b",
      "canonical_text": "OPENLABEL",
      "mention_class": "junk"
    },
    {
      "id": "8dfb573d-557b-4ea1-ab98-5af66a40ac74",
      "created_at": "2025-12-14T21:05:23.017974+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "result_id": "570c6813-fbfe-4008-bb48-0580f2f58a0a",
      "mention_type": "other",
      "raw_text": "phase-2",
      "normalized_text": "phase-2",
      "context": "triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "a306ca0543d2170e6dba44d86e1896281175af3b023c0b34362dc1ca7ac0eccb",
      "canonical_text": "PHASE2",
      "mention_class": "junk"
    },
    {
      "id": "1cf4ca9b-7578-4ff3-9de7-ee43ec167907",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "patent_id",
      "raw_text": "WO2020219650A1",
      "normalized_text": "wo2020219650a1",
      "context": "Publication number WO2020219650A1 PCT/US2020/029483",
      "source_url": "https://patents.google.com/patent/WO2020219650A1/zh",
      "fingerprint": "76d01a97423c5953b6ef0a76636aff3a13aaa169ab4779fbfa468af3f9210fd1",
      "canonical_text": "WO2020219650A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "0a4454bf-393a-453c-9a24-5764b824725d",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "patent_id",
      "raw_text": "US2020",
      "normalized_text": "us2020",
      "context": "Publication number WO2020219650A1 PCT/US2020/029483",
      "source_url": "https://patents.google.com/patent/WO2020219650A1/zh",
      "fingerprint": "3287520eed68130beb580decad68f5cc2cb47bfa82113a38e14ae9e747ad6709",
      "canonical_text": "US2020",
      "mention_class": "drug_code_like"
    },
    {
      "id": "52fa332b-467f-4f5b-8122-1cf066b6f4d3",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "drug_code",
      "raw_text": "US2020",
      "normalized_text": "us2020",
      "context": "Publication number WO2020219650A1 PCT/US2020/029483",
      "source_url": "https://patents.google.com/patent/WO2020219650A1/zh",
      "fingerprint": "ef1336814b34f995751b7eabfb9403c2a462ac3ee9369af8fd5ad36392e77533",
      "canonical_text": "US2020",
      "mention_class": "drug_code_like"
    },
    {
      "id": "d06d5969-4a72-4296-b9d7-a5f3a832a19b",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "patent_id",
      "raw_text": "WO2024222726A1",
      "normalized_text": "wo2024222726a1",
      "context": "Publication number WO2024222726A1 PCT/CN2024/089497",
      "source_url": "https://patents.google.com/patent/WO2024222726A1/zh",
      "fingerprint": "1627738bb48c8a95c77274da34e4f0976e3d1ab300c6abb96cfc7f31514934dc",
      "canonical_text": "WO2024222726A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "7f7508f3-1fec-46bd-a820-f1b7d3137e24",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "drug_code",
      "raw_text": "CN2024",
      "normalized_text": "cn2024",
      "context": "Publication number WO2024222726A1 PCT/CN2024/089497",
      "source_url": "https://patents.google.com/patent/WO2024222726A1/zh",
      "fingerprint": "162e37971fe5c61d289d867bfe291072db73b4b3030c05001ba30d46b9f34cb0",
      "canonical_text": "CN2024",
      "mention_class": "drug_code_like"
    },
    {
      "id": "c0865f07-9324-485d-9bb4-f8eb575c3a0e",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "patent_id",
      "raw_text": "WO2024175065A1",
      "normalized_text": "wo2024175065a1",
      "context": "Publication number WO2024175065A1 PCT/CN2024/078146",
      "source_url": "https://patents.google.com/patent/WO2024175065A1/fr",
      "fingerprint": "8d1ee90a96c71a08568228c3c0a8414c43d5eec831be9bb852faa94460a4b427",
      "canonical_text": "WO2024175065A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "1ba2eab1-561e-4404-ba7a-1a6885791836",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "drug_code",
      "raw_text": "YJ9069",
      "normalized_text": "yj9069",
      "context": "we develop a selective CDK12/13 PROTAC degrader, YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
      "fingerprint": "44d32933292bed29f991f7d5b0992d74e5918e81fdf08405b6a1dcce738e971a",
      "canonical_text": "YJ9069",
      "mention_class": "drug_code_like"
    },
    {
      "id": "b0515e49-f7d3-4f90-9f81-5cf324527f23",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "drug_code",
      "raw_text": "YJ1206",
      "normalized_text": "yj1206",
      "context": "12/13 PROTAC degrader, YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
      "fingerprint": "a060c9c443344cad211ec02eb435941d1a766d31cfa7e15a9778c35462d46a37",
      "canonical_text": "YJ1206",
      "mention_class": "drug_code_like"
    },
    {
      "id": "70726ce2-995d-4891-9350-7c44b83dd132",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "drug_code",
      "raw_text": "NCT02",
      "normalized_text": "nct02",
      "context": "NCT02 is identified as a candidate with minimal risk of non-specific toxicity. NCT02",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34289372/",
      "fingerprint": "90461c4a52c3615bb40d828061decad63d58386dfd98d4e7447c82622bcc51a1",
      "canonical_text": "NCT02",
      "mention_class": "drug_code_like"
    },
    {
      "id": "1ba64664-8905-4a2e-9f5e-d6b6d2da6721",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "drug_code",
      "raw_text": "GC69730",
      "normalized_text": "gc69730",
      "context": "Catalog No.GC69730 PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM,",
      "source_url": "https://www.glpbio.com/pp-c8.html",
      "fingerprint": "cc6fbf30ce9a3fcdb68c5528cfaba7317c7204b6216ca3c645186cc8d90f2e14",
      "canonical_text": "GC69730",
      "mention_class": "drug_code_like"
    },
    {
      "id": "d4b7729c-5d2e-4f12-8dd1-6eb42644d120",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "drug_code",
      "raw_text": "DC50",
      "normalized_text": "dc50",
      "context": "Catalog No.GC69730 PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM, respectively.",
      "source_url": "https://www.glpbio.com/pp-c8.html",
      "fingerprint": "213385a87316848594c796906382ae2f380bea3adf7facc1abf73f4239654327",
      "canonical_text": "DC50",
      "mention_class": "drug_code_like"
    },
    {
      "id": "d7774a6d-0379-432a-bf1e-afd2311c596e",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "patent_id",
      "raw_text": "PCT/US2020/029483",
      "normalized_text": "pct/us2020/029483",
      "context": "PCT/US2020/029483",
      "source_url": "https://patents.google.com/patent/WO2020219650A1/zh",
      "fingerprint": "b9443fdc46ffdf422f54f75838848f6ee3775ed17a686034690a089e958079df",
      "canonical_text": "PCTUS2020029483",
      "mention_class": "patent_id_like"
    },
    {
      "id": "ec9de1ab-79e0-4cb9-986b-3cc6c49a7ae0",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "patent_id",
      "raw_text": "PCT/CN2024/089497",
      "normalized_text": "pct/cn2024/089497",
      "context": "PCT/CN2024/089497",
      "source_url": "https://patents.google.com/patent/WO2024222726A1/zh",
      "fingerprint": "f7b2cab50df20a431b33bee6b991426d493ad7088f7100630aaca0e043fba9d3",
      "canonical_text": "PCTCN2024089497",
      "mention_class": "patent_id_like"
    },
    {
      "id": "2072e8b9-a859-4b51-865b-45a68d2b9692",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "patent_id",
      "raw_text": "PCT/CN2024/078146",
      "normalized_text": "pct/cn2024/078146",
      "context": "PCT/CN2024/078146",
      "source_url": "https://patents.google.com/patent/WO2024175065A1/fr",
      "fingerprint": "a57a097788cbf9836e235fbd5080a743cbe2037ec24b73f8eafe411b20d3db4e",
      "canonical_text": "PCTCN2024078146",
      "mention_class": "patent_id_like"
    },
    {
      "id": "a5e9987c-91ec-4706-974e-e5dc8505b77d",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "other",
      "raw_text": "34864331",
      "normalized_text": "34864331",
      "context": "https://pubmed.ncbi.nlm.nih.gov/34864331/",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34864331/",
      "fingerprint": "9c59102224020c0359ab57c900553ce9a9dceac8ba40b7cfd2f3dee026bbf4d5",
      "canonical_text": "34864331",
      "mention_class": "junk"
    },
    {
      "id": "1d7ce3ce-127e-41b6-a2d8-fbec0aac8662",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "modality",
      "raw_text": "PROTAC",
      "normalized_text": "protac",
      "context": "we have synthesized a potent PROTAC degrader PP-C8",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34864331/",
      "fingerprint": "9a94d7afad453652ebdef4437643b2b420514e32a51b6c1fc439b70b669fad1c",
      "canonical_text": "PROTAC",
      "mention_class": "junk"
    },
    {
      "id": "e365c654-80c6-4742-9ace-cba244551754",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "modality",
      "raw_text": "PROTAC degrader",
      "normalized_text": "protac degrader",
      "context": "we have synthesized a potent PROTAC degrader PP-C8",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34864331/",
      "fingerprint": "a5227140986a565fd79bd840013c897eebcd84347e8c741e79dde6f6c4fab36e",
      "canonical_text": "PROTACDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "cfe14b3d-cc24-41ce-ac7a-88d250f3c0f8",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "drug_code",
      "raw_text": "PP-C8",
      "normalized_text": "pp-c8",
      "context": "we have synthesized a potent PROTAC degrader PP-C8",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34864331/",
      "fingerprint": "ff299c95f3f451e30407150dc4c29b962c7034e49095aef7746a4c4d2dc4b4ae",
      "canonical_text": "PPC8",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e0598389-f50c-4a1b-aac3-902ab7bb2271",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "other",
      "raw_text": "10.1016/j.ejmech.2021.114012",
      "normalized_text": "10.1016/j.ejmech.2021.114012",
      "context": "DOI:  10.1016/j.ejmech.2021.114012",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34864331/",
      "fingerprint": "6ed75f52bcb22cf996b1622b97821e25c8238fe1449e36e147055915e7f3d81d",
      "canonical_text": "101016JEJMECH2021114012",
      "mention_class": "junk"
    },
    {
      "id": "d0a18d49-02f9-4007-84bf-6c71ee4c1623",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "other",
      "raw_text": "39353441",
      "normalized_text": "39353441",
      "context": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
      "fingerprint": "5a904fe245ea5fa11be62beadaa0b4547e7e50c5aa638fdda90713f1cb92db14",
      "canonical_text": "39353441",
      "mention_class": "junk"
    },
    {
      "id": "6743a46f-9f7d-4016-a22d-d6732421b7ca",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "modality",
      "raw_text": "CDK12/13 PROTAC degrader",
      "normalized_text": "cdk12/13 protac degrader",
      "context": "we develop a selective CDK12/13 PROTAC degrader, YJ9069",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
      "fingerprint": "685e460120266402dd97fe98a285fd3ef71db3b307539ba890b569e8381920bc",
      "canonical_text": "CDK1213PROTACDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "93b54ba1-6f8d-4165-9312-82d6ab55bbd1",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "modality",
      "raw_text": "degrader",
      "normalized_text": "degrader",
      "context": "yielded an orally bioavailable CDK12/13 degrader, YJ1206",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
      "fingerprint": "f6a852769816b0f00c132698776c4376b63d1d24680fa8342bad36eb63069ec0",
      "canonical_text": "DEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "9fa09116-dfd5-4f3a-8bdd-a2d8c0983ba6",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "modality",
      "raw_text": "CDK12/13 degrader",
      "normalized_text": "cdk12/13 degrader",
      "context": "yielded an orally bioavailable CDK12/13 degrader, YJ1206",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
      "fingerprint": "4ca3ef48d1269b679af2d73808c2ecd2d06efa121dd90433e412b565eb8213a8",
      "canonical_text": "CDK1213DEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "b0c30524-8e3a-40c5-8ea9-7f2a87eecbff",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "other",
      "raw_text": "34289372",
      "normalized_text": "34289372",
      "context": "https://pubmed.ncbi.nlm.nih.gov/34289372/",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34289372/",
      "fingerprint": "7e55814bbdfee3554ea44806a3f8011c1f6dc64efc812c5c230f880df5523494",
      "canonical_text": "34289372",
      "mention_class": "junk"
    },
    {
      "id": "bc999ffb-90a5-4ba8-bea8-9431cd7fe529",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "modality",
      "raw_text": "molecular glue",
      "normalized_text": "molecular glue",
      "context": "NCT02 acts as molecular glue that induces ubiquitination of cyclin K (CCNK)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34289372/",
      "fingerprint": "40ae527323509bb856cd9bc1910d7379099497c95dbf6edefcbab36434fd9a84",
      "canonical_text": "MOLECULARGLUE",
      "mention_class": "junk"
    },
    {
      "id": "100a6911-7154-4246-90d4-b9f5d7ebae4e",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "target",
      "raw_text": "ubiquitination",
      "normalized_text": "ubiquitination",
      "context": "induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34289372/",
      "fingerprint": "d56bdcd421d4c98d7c42fbf431cf14566476c7e1444c5394a732f6a6e29644e5",
      "canonical_text": "UBIQUITINATION",
      "mention_class": "junk"
    },
    {
      "id": "ce245cbb-4858-445a-9259-6785d77c9ace",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "target",
      "raw_text": "cyclin K",
      "normalized_text": "cyclin k",
      "context": "induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34289372/",
      "fingerprint": "c8bcfbb031ab607fdf5ff2c68fa4e96b522e75c52eeaeb85d47818cc33d6c7df",
      "canonical_text": "CYCLINK",
      "mention_class": "junk"
    },
    {
      "id": "3d8124e3-3fad-4436-ab23-2766f57c4e5c",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "target",
      "raw_text": "CCNK",
      "normalized_text": "ccnk",
      "context": "induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34289372/",
      "fingerprint": "fdfb68bc1e75f29c56fb8e91270e7d703a4ffb98f90c0d3d25c8ca16a9c2f84d",
      "canonical_text": "CCNK",
      "mention_class": "junk"
    },
    {
      "id": "41d0c24c-7b14-4315-a940-af82c6d37b87",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "target",
      "raw_text": "proteasomal degradation",
      "normalized_text": "proteasomal degradation",
      "context": "proteasomal degradation of CCNK and its complex partner CDK12.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34289372/",
      "fingerprint": "45ba9bf38efefd1c6e603277a8e52c937e36ca939cde3d54165369556ae83065",
      "canonical_text": "PROTEASOMALDEGRADATION",
      "mention_class": "junk"
    },
    {
      "id": "3135af38-ec5b-4642-afba-fbe270cd7044",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "target",
      "raw_text": "cyclin K (CCNK)",
      "normalized_text": "cyclin k (ccnk)",
      "context": "induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/34289372/",
      "fingerprint": "008c1d5b1fba5dc91adc80b7c074f7259be79ff33fef37c53d677f059af7beaa",
      "canonical_text": "CYCLINKCCNK",
      "mention_class": "junk"
    },
    {
      "id": "f3753dc3-e3b0-4195-b072-afde6a17d75a",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "other",
      "raw_text": "pp-c8.html",
      "normalized_text": "pp-c8.html",
      "context": "https://www.glpbio.com/pp-c8.html",
      "source_url": "https://www.glpbio.com/pp-c8.html",
      "fingerprint": "74316b9a5a1c388877c3ea39a73b548ba2a43b22fe7395de755e85f0efc0afaa",
      "canonical_text": "PPC8HTML",
      "mention_class": "drug_code_like"
    },
    {
      "id": "0e95afe0-024f-4bd6-a1d4-53d2dba26b68",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "other",
      "raw_text": "GC69730",
      "normalized_text": "gc69730",
      "context": "Catalog No.GC69730",
      "source_url": "https://www.glpbio.com/pp-c8.html",
      "fingerprint": "5406870614eeebb6d6f3149513e60c5c93cdf849420e7f9f2bded6f8ef58e69e",
      "canonical_text": "GC69730",
      "mention_class": "drug_code_like"
    },
    {
      "id": "9f8de751-78f6-41c8-bf00-43fbcade13b0",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "target",
      "raw_text": "CDK12-Cyclin K",
      "normalized_text": "cdk12-cyclin k",
      "context": "PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM, respectively.",
      "source_url": "https://www.glpbio.com/pp-c8.html",
      "fingerprint": "30e1af63a4bc1a765ed6b8a4ec7ac3de432e993ef4c868046285d48dd95f1b2b",
      "canonical_text": "CDK12CYCLINK",
      "mention_class": "drug_code_like"
    },
    {
      "id": "c275008f-de4d-40ac-bc2c-faad7d5bea30",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "other",
      "raw_text": "DC50",
      "normalized_text": "dc50",
      "context": "PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM, respectively.",
      "source_url": "https://www.glpbio.com/pp-c8.html",
      "fingerprint": "fa40b6298273edd4c1dd52bfaf15e5b6003ac8e9d9cb45be4d3efa8d14d1e8d0",
      "canonical_text": "DC50",
      "mention_class": "drug_code_like"
    },
    {
      "id": "781806b4-4f7f-40cc-a141-0eafe37b5a28",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "other",
      "raw_text": "416",
      "normalized_text": "416",
      "context": "DC50 values of 416 and 412 nM, respectively.",
      "source_url": "https://www.glpbio.com/pp-c8.html",
      "fingerprint": "02d19f3c64c57b70938ec23b3ecf64648838ea538eee54e6c1e1eab6e0c817cd",
      "canonical_text": "416",
      "mention_class": "junk"
    },
    {
      "id": "79c44b1f-e936-486d-89a2-a524c3da6682",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "other",
      "raw_text": "412 nM",
      "normalized_text": "412 nm",
      "context": "DC50 values of 416 and 412 nM, respectively.",
      "source_url": "https://www.glpbio.com/pp-c8.html",
      "fingerprint": "4f8081a5cb3e8f1b059107a38130b5772d36f8ef2ed1adb2d09ae9644f658b0b",
      "canonical_text": "412NM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "9d751bbb-d9e8-4019-a53a-330f45071393",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "other",
      "raw_text": "60512",
      "normalized_text": "60512",
      "context": "https://www.medkoo.com/products/60512",
      "source_url": "https://www.medkoo.com/products/60512",
      "fingerprint": "e8eaaff7787c6254765d298d875a5c56666c73d21401e1316f1dd95784192fe8",
      "canonical_text": "60512",
      "mention_class": "junk"
    },
    {
      "id": "aee4c5ed-211d-4307-b0b0-da4fcbbc2267",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "other",
      "raw_text": "CAS#3053716-98-3",
      "normalized_text": "cas#3053716-98-3",
      "context": "CAS#3053716-98-3",
      "source_url": "https://www.medkoo.com/products/60512",
      "fingerprint": "bdbae8c055a2bc3b031ffa8bdf08c9c31fc639d311167969f3ba3839ecd10b07",
      "canonical_text": "CAS3053716983",
      "mention_class": "drug_code_like"
    },
    {
      "id": "044466ef-6639-4c25-bb72-089df27c0703",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "sponsor",
      "raw_text": "MedKoo",
      "normalized_text": "medkoo",
      "context": "MedKoo Cat#: 128339  | Name:  YJ1206",
      "source_url": "https://www.medkoo.com/products/60512",
      "fingerprint": "00d70f461fd2e4f2dfc2cea5bfc727ed819f440d0ad7a7d186dbd225a8fe17b2",
      "canonical_text": "MEDKOO",
      "mention_class": "junk"
    },
    {
      "id": "2b926cf1-3008-412c-9999-897fd094a929",
      "created_at": "2025-12-14T21:05:23.696489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "result_id": "5edbd7cf-52ba-4201-ac5b-52da13d85e21",
      "mention_type": "other",
      "raw_text": "128339",
      "normalized_text": "128339",
      "context": "MedKoo Cat#: 128339  | Name:  YJ1206",
      "source_url": "https://www.medkoo.com/products/60512",
      "fingerprint": "e3550711e11fb7169d3b4d018d09a5de5e10ff0141a989d13e12d4f107f2024d",
      "canonical_text": "128339",
      "mention_class": "junk"
    },
    {
      "id": "d7b30eef-fd4e-4cbc-900f-ef1124c8dd09",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "Phase 1 clinical trial",
      "normalized_text": "phase 1 clinical trial",
      "context": "the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "34efcb0ba3067eb2159310787c8a55873397fdd5c784ddf76b95cca15db147b2",
      "canonical_text": "PHASE1CLINICALTRIAL",
      "mention_class": "junk"
    },
    {
      "id": "9a0d9e76-f2f6-4d24-9fac-35479898b113",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "Phase-1",
      "normalized_text": "phase-1",
      "context": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "c603fc58e5e6c36116bed7c8e62b38335337b4e4f02d7f3aa64032541a7ec7f2",
      "canonical_text": "PHASE1",
      "mention_class": "junk"
    },
    {
      "id": "a72921f4-c2fe-4a1d-8974-4dd85fdb2c36",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "target",
      "raw_text": "CDK12-13",
      "normalized_text": "cdk12-13",
      "context": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "590f522e35cd998af8b055197e86cebc59ecb914dd15080912f90783722121a7",
      "canonical_text": "CDK1213",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "0c0e62ad-8582-4dae-9ef9-698db739958e",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "modality",
      "raw_text": "Inhibitor",
      "normalized_text": "inhibitor",
      "context": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "24221260918483e64eb523a6721d571e4dea4aba6422fa18a027b5a5417b1407",
      "canonical_text": "INHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "91a3b293-61a0-4d1c-a56b-d4ff68760fcb",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "CT7439-CDK12-13-Inhibitor.html",
      "normalized_text": "ct7439-cdk12-13-inhibitor.html",
      "context": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "331715c0301d60b84d5d842f054433d5909c1a70a6eb82b5618742f1097ba153",
      "canonical_text": "CT7439CDK1213INHIBITORHTML",
      "mention_class": "junk"
    },
    {
      "id": "3fd1535a-d425-4f3f-ab49-6d7694e8948b",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "2951333",
      "normalized_text": "2951333",
      "context": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "5c8d09c26eeb5030896f2e0f86cdce3b0592526125d04b0cd19c470589dc1a48",
      "canonical_text": "2951333",
      "mention_class": "junk"
    },
    {
      "id": "f60b7a79-aed4-489e-b82d-15b7d959897e",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "2024/09/23",
      "normalized_text": "2024/09/23",
      "context": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "e705d727d90e9065aa1a10946f6a8f80105126f930fc4cc9bd26014df4479524",
      "canonical_text": "20240923",
      "mention_class": "junk"
    },
    {
      "id": "a0bb172b-0b05-48c9-8322-1989e31bb040",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "globenewswire.com",
      "normalized_text": "globenewswire.com",
      "context": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "eadd15fef49dd1ed70a72cdb11abd55bf21a4aaafbb6be02dd1a2773f6c9e135",
      "canonical_text": "GLOBENEWSWIRECOM",
      "mention_class": "junk"
    },
    {
      "id": "1a8f11de-92d7-4a26-9e93-6eac1350f26a",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "sponsor",
      "raw_text": "www.carricktherapeutics.com",
      "normalized_text": "www.carricktherapeutics.com",
      "context": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "0f42501105fe06cc952356ddae29441204223b6f72074880ffec0248a4db7e23",
      "canonical_text": "WWWCARRICKTHERAPEUTICSCOM",
      "mention_class": "junk"
    },
    {
      "id": "9f0f6dd9-47b6-440f-8a13-24fcff6acc34",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "25",
      "normalized_text": "25",
      "context": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "0782aaf68dffeed8d5bc5c8500601e84ffb589eabac5aaf4bd5a6a7957bb6911",
      "canonical_text": "25",
      "mention_class": "junk"
    },
    {
      "id": "505acf5c-e800-4efe-a4d1-de4762373116",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "www.biospace.com",
      "normalized_text": "www.biospace.com",
      "context": "https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor",
      "source_url": "https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor",
      "fingerprint": "a8d1553d36ca0fd63756c281ae9d87ad9a13623fc77620af1b021644c0d78833",
      "canonical_text": "WWWBIOSPACECOM",
      "mention_class": "junk"
    },
    {
      "id": "50fa7517-d397-4d39-be72-305625e8eddd",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "www.cic.vc",
      "normalized_text": "www.cic.vc",
      "context": "https://www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/",
      "source_url": "https://www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/",
      "fingerprint": "100155870aea4dcfeee24c26183812c28014eed2070fab0f3a2189af44c9b21e",
      "canonical_text": "WWWCICVC",
      "mention_class": "junk"
    },
    {
      "id": "ec982db4-e1ac-481c-aee4-3c68eee8c920",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "target",
      "raw_text": "CDK12/13 inhibitor",
      "normalized_text": "cdk12/13 inhibitor",
      "context": "CT7439 is the first CDK12/13 inhibitor to enter clinical development",
      "source_url": "https://www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/",
      "fingerprint": "105a0798bc7f8d0b23f7ee00092367cef83d2bf36a4ab111d91fe857c7bafe3a",
      "canonical_text": "CDK1213INHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "efe36144-b615-4945-aa00-dc4556fd34a5",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "clinical development",
      "normalized_text": "clinical development",
      "context": "CT7439 is the first CDK12/13 inhibitor to enter clinical development",
      "source_url": "https://www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/",
      "fingerprint": "b85dd0789fc71fe07655be63395db7b0a21b395573a0eb57846b08644064b55a",
      "canonical_text": "CLINICALDEVELOPMENT",
      "mention_class": "junk"
    },
    {
      "id": "95f4752b-cf67-47e2-b982-96aa836d280c",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "sponsor",
      "raw_text": "FDA",
      "normalized_text": "fda",
      "context": "FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "0ff5c1569cee12ac801d66f482a3ad58fd945e16eaedb58a5411f03ee69b0508",
      "canonical_text": "FDA",
      "mention_class": "junk"
    },
    {
      "id": "ebd891ff-2d3b-4311-803e-ce575a48b7a1",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "Investigational New Drug (IND) application",
      "normalized_text": "investigational new drug (ind) application",
      "context": "FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "077da5b3d681fe02f5f2f2c6a34cb8bcfc3781681456428e53f70a07a863abc8",
      "canonical_text": "INVESTIGATIONALNEWDRUGINDAPPLICATION",
      "mention_class": "junk"
    },
    {
      "id": "4008381f-739e-4f04-80e7-13d60643d960",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "Investigational New Drug (IND)",
      "normalized_text": "investigational new drug (ind)",
      "context": "FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "900d438bb7a890985201e1c51037e52c75c3bf379d782fb718708d92331b0271",
      "canonical_text": "INVESTIGATIONALNEWDRUGIND",
      "mention_class": "junk"
    },
    {
      "id": "f5feb5ab-4b27-4d79-93d0-4d8892dc3426",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "Investigational New Drug",
      "normalized_text": "investigational new drug",
      "context": "FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "20af94086756d60760c6d117fb0a5ab15b16cc8ea914bdab022fa49fe7038d2d",
      "canonical_text": "INVESTIGATIONALNEWDRUG",
      "mention_class": "junk"
    },
    {
      "id": "8defb94e-3b88-4356-819c-c8568b376d08",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "IND",
      "normalized_text": "ind",
      "context": "FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "2807ad4c2bf1b0e95599bac34980939618614bda7cd61024f3dbf8058caa743f",
      "canonical_text": "IND",
      "mention_class": "junk"
    },
    {
      "id": "0c16d338-d196-46ea-9675-afb7b9c34489",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "target",
      "raw_text": "cyclin dependent kinase 12/13 (CDK12/13)",
      "normalized_text": "cyclin dependent kinase 12/13 (cdk12/13)",
      "context": "CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "8c0b1ceb68cf1ca6899fc845fc1b3bf1b679c5b828ec388ea66a374f42e15454",
      "canonical_text": "CYCLINDEPENDENTKINASE1213CDK1213",
      "mention_class": "junk"
    },
    {
      "id": "60c0c280-b439-4d00-9907-bff00961764d",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "target",
      "raw_text": "(CDK12/13) inhibitor",
      "normalized_text": "(cdk12/13) inhibitor",
      "context": "CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "6da22a2598fcd8f0a30252302f77304bea3cacf0a31ccf532619336419410056",
      "canonical_text": "CDK1213INHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "5e8a1912-2da3-41c8-ae1e-11d5ccc848de",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "target",
      "raw_text": "cyclin dependent kinase 12/13 (CDK12/13) inhibitor",
      "normalized_text": "cyclin dependent kinase 12/13 (cdk12/13) inhibitor",
      "context": "CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "5352c94a819cfdebe744a2233c3f54d6a71f5a1d6152b474aac8c6740a04da18",
      "canonical_text": "CYCLINDEPENDENTKINASE1213CDK1213INHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "47b479a1-2bde-41b2-8772-3bbb971f6219",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "sponsor",
      "raw_text": "U-S-FDA",
      "normalized_text": "u-s-fda",
      "context": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "73a3ad2e56e055f22c60f1b54f89c2339167fdbeb051350e4af24781067a1316",
      "canonical_text": "USFDA",
      "mention_class": "junk"
    },
    {
      "id": "c1e3fd49-c00e-40d6-b2aa-8af37909a7b7",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "First-In-Class",
      "normalized_text": "first-in-class",
      "context": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "b66addc6b93f3983426d880d5ed450e7c19f2b5e315e68019f7deb749b72a9d4",
      "canonical_text": "FIRSTINCLASS",
      "mention_class": "junk"
    },
    {
      "id": "7b39c49a-e629-472d-8539-b26f9f76ba78",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "IND-for-CT7439",
      "normalized_text": "ind-for-ct7439",
      "context": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "6af35a6b67674d8e92ccfe0e2e5a75a2fb444904487ccd0f4af91ef6d1ecce9b",
      "canonical_text": "INDFORCT7439",
      "mention_class": "drug_code_like"
    },
    {
      "id": "80174259-f064-44bd-ab27-c65041eff13c",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "normalized_text": "ct7439-a-first-in-class-inhibitor-of-cdk12-13.html",
      "context": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "e9c0d4ddd4fcd70cab4b52474516c7a165cbccc76885e47785a3af2312ad3ebb",
      "canonical_text": "CT7439AFIRSTINCLASSINHIBITOROFCDK1213HTML",
      "mention_class": "junk"
    },
    {
      "id": "83ed4ce9-1f18-4a91-ad97-d0f60b2c879a",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "2739242",
      "normalized_text": "2739242",
      "context": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "a9394a56fe87860c29d6a0b4809cdf78903b9512d642bf5ab5c4f5958fba474a",
      "canonical_text": "2739242",
      "mention_class": "junk"
    },
    {
      "id": "fe102320-2130-4752-b7a5-3ab18a348bfe",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "2023/09/07",
      "normalized_text": "2023/09/07",
      "context": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "source_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "fingerprint": "ac88844b3130c2faf337d24cc5fef08da8a03f3c4fa4ba17a545b3cf400a7acc",
      "canonical_text": "20230907",
      "mention_class": "junk"
    },
    {
      "id": "fe86eeb2-28cf-4260-9dda-bbe7cb00a4b1",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "www.cancernetwork.com",
      "normalized_text": "www.cancernetwork.com",
      "context": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
      "source_url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
      "fingerprint": "51d9f56124148eac4443dcf062714d0fe8b83f1df7966de0a710cb4abba78d53",
      "canonical_text": "WWWCANCERNETWORKCOM",
      "mention_class": "junk"
    },
    {
      "id": "a75231f0-c3dd-4130-9eba-a36e2faa6770",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "fda",
      "normalized_text": "fda",
      "context": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
      "source_url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
      "fingerprint": "f8872051abce3ee82a2e22ef9c9e2f6f025f551878de61656c75f0e506eb17fb",
      "canonical_text": "FDA",
      "mention_class": "junk"
    },
    {
      "id": "c906e272-56ce-414d-a21e-61575027bbe6",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "CDK12/13 inhibitor CT7439",
      "normalized_text": "cdk12/13 inhibitor ct7439",
      "context": "clearance to an investigational new drug (IND) application for CDK12/13 inhibitor CT7439",
      "source_url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
      "fingerprint": "96dd0b63b9b8a9c4975eb5ec8dcb3524674d4d44504a436d92ac6cc94ab45bfa",
      "canonical_text": "CDK1213INHIBITORCT7439",
      "mention_class": "junk"
    },
    {
      "id": "6d95e0c3-200d-4e5d-858e-7f5316ce5ba6",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "planned phase 1 trial",
      "normalized_text": "planned phase 1 trial",
      "context": "a planned phase 1 trial will examine CDK12/13 inhibitor CT7439",
      "source_url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
      "fingerprint": "2c028214a2fed8a0c2b68a5abb64b263d4068f0d6956b6beb0bb6356dd4ce972",
      "canonical_text": "PLANNEDPHASE1TRIAL",
      "mention_class": "junk"
    },
    {
      "id": "889a6c2b-5ef1-43b8-be88-89934de7d96d",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "phase 1 trial",
      "normalized_text": "phase 1 trial",
      "context": "a planned phase 1 trial will examine CDK12/13 inhibitor CT7439",
      "source_url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
      "fingerprint": "2d1f51d4d34eea6052774a2b75b96763877f56357dfbfcd335fd6bd2b25b8204",
      "canonical_text": "PHASE1TRIAL",
      "mention_class": "junk"
    },
    {
      "id": "d4d32a2c-9410-4736-8eea-0f2e9ed645ca",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "ichgcp.net",
      "normalized_text": "ichgcp.net",
      "context": "https://ichgcp.net/clinical-trials-registry/NCT06600789",
      "source_url": "https://ichgcp.net/clinical-trials-registry/NCT06600789",
      "fingerprint": "98d751180726f8a2253a51fa0053477795de5d501938d206a405ef445b72633e",
      "canonical_text": "ICHGCPNET",
      "mention_class": "junk"
    },
    {
      "id": "543f4f8b-0778-4fd2-86dc-6547d45138e6",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "clinical-trials-registry",
      "normalized_text": "clinical-trials-registry",
      "context": "https://ichgcp.net/clinical-trials-registry/NCT06600789",
      "source_url": "https://ichgcp.net/clinical-trials-registry/NCT06600789",
      "fingerprint": "98940fb44d3a02fcbc532a8aa68b9b7e7f57fdf1d8443e598b4f5a3db6e3fa1c",
      "canonical_text": "CLINICALTRIALSREGISTRY",
      "mention_class": "junk"
    },
    {
      "id": "d2226810-2d51-40cc-89fb-65bec6d1877c",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "trial_id",
      "raw_text": "CT7439_001",
      "normalized_text": "ct7439_001",
      "context": "Other Study ID Numbers  * CT7439_001",
      "source_url": "https://ichgcp.net/clinical-trials-registry/NCT06600789",
      "fingerprint": "11469bf47c8324b1be9bb77f93c5b258ddf80362c980223491f9fd09acc3f44f",
      "canonical_text": "CT7439001",
      "mention_class": "drug_code_like"
    },
    {
      "id": "06faa865-05fa-421e-8cca-2bf5e42df4d6",
      "created_at": "2025-12-14T21:05:25.071276+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "result_id": "749ecb2f-141d-4bab-938f-15cd8e09b490",
      "mention_type": "other",
      "raw_text": "Other Study ID Numbers",
      "normalized_text": "other study id numbers",
      "context": "Other Study ID Numbers  * CT7439_001",
      "source_url": "https://ichgcp.net/clinical-trials-registry/NCT06600789",
      "fingerprint": "5fafb5c46ecd427f12db628a840ad51a9561d3055f7aa331f050a85b912361f6",
      "canonical_text": "OTHERSTUDYIDNUMBERS",
      "mention_class": "junk"
    },
    {
      "id": "b614f404-36fa-4fbe-8388-3fb58310e10a",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "other",
      "raw_text": "CT7439-CDK12-13-Inhibitor",
      "normalized_text": "ct7439-cdk12-13-inhibitor",
      "context": "Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "80cd7db49cb8070048a03fb59021dd4c07ddaead7887ef0beb992e182455b3c3",
      "canonical_text": "CT7439CDK1213INHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "6c141619-719e-4355-9e19-a646fdb4ff64",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "other",
      "raw_text": "detail/25",
      "normalized_text": "detail/25",
      "context": "press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "source_url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "fingerprint": "629b7ce481d064e01f1fca7e03418cc7835b9f00141e99cc20e362fe0d6812f5",
      "canonical_text": "DETAIL25",
      "mention_class": "drug_code_like"
    },
    {
      "id": "48047d70-1bb4-4466-bf34-8b9c988c408c",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "other",
      "raw_text": "biospace.com",
      "normalized_text": "biospace.com",
      "context": "www.biospace.com/press-releases/",
      "source_url": "https://www.biospace.com/press-releases/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439-cdk12-13-inhibitor",
      "fingerprint": "562a2b44abebcbf25cee8a403342f6ac4a4231585eaa9bdcb1dcc16d55d6b313",
      "canonical_text": "BIOSPACECOM",
      "mention_class": "junk"
    },
    {
      "id": "8f9b923b-dd56-417f-8c59-9f36a523138e",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "modality",
      "raw_text": "cyclin dependent kinase 12/13 (CDK12/13) inhibitor",
      "normalized_text": "cyclin dependent kinase 12/13 (cdk12/13) inhibitor",
      "context": "CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor",
      "source_url": "https://www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/",
      "fingerprint": "f163aac267b6cb825aa9cf45f928897d00b70f57be66afc77adc3ed0a36f0726",
      "canonical_text": "CYCLINDEPENDENTKINASE1213CDK1213INHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "03a92018-c67d-4a05-9b11-65a63c273c31",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "modality",
      "raw_text": "(CDK12/13) inhibitor",
      "normalized_text": "(cdk12/13) inhibitor",
      "context": "cyclin dependent kinase 12/13 (CDK12/13) inhibitor",
      "source_url": "https://www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/",
      "fingerprint": "40aa63102b84db5b1a8a3767d4e1e5f4373098299be8ca45696eb9e824abbbed",
      "canonical_text": "CDK1213INHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "8e59b33b-e69b-4639-96ed-91e5aba33c29",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "other",
      "raw_text": "cic.vc",
      "normalized_text": "cic.vc",
      "context": "www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/",
      "source_url": "https://www.cic.vc/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial/",
      "fingerprint": "60281b1e90fbb7333c7293b75429589820d7e3c2ec20914fb727180fb9ee7139",
      "canonical_text": "CICVC",
      "mention_class": "junk"
    },
    {
      "id": "85ab2569-5b7a-48cc-864e-e8641fb6804c",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "other",
      "raw_text": "Clinical Trial",
      "normalized_text": "clinical trial",
      "context": "Clinical Trial NCT06600789",
      "source_url": "https://ichgcp.net/clinical-trials-registry/NCT06600789",
      "fingerprint": "b6a0c24c6c2f4df7cf5af3a8631f61c3b30d83c512ffdb3eedae030f69db3dd8",
      "canonical_text": "CLINICALTRIAL",
      "mention_class": "junk"
    },
    {
      "id": "322df9cd-5f75-4918-99e4-4377c4b9de7e",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "sponsor",
      "raw_text": "U.S. Food and Drug Administration (FDA)",
      "normalized_text": "u.s. food and drug administration (fda)",
      "context": "the U.S. Food and Drug Administration (FDA) has cleared",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "0a30d3625b28b52040e19fc376c30f5dfe556c6f5785919b1c43f3eaaa39eaf3",
      "canonical_text": "USFOODANDDRUGADMINISTRATIONFDA",
      "mention_class": "junk"
    },
    {
      "id": "0951abc8-4fc0-411f-a9fd-c654cd43d178",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "sponsor",
      "raw_text": "U.S. Food and Drug Administration",
      "normalized_text": "u.s. food and drug administration",
      "context": "the U.S. Food and Drug Administration (FDA) has cleared",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "2a3cf002fc4a4e946ce8891e25d4fa99c14ad476d3816949109b11e6a6a67931",
      "canonical_text": "USFOODANDDRUGADMINISTRATION",
      "mention_class": "junk"
    },
    {
      "id": "8da1377e-0639-4778-9b6f-88cfefe2f65d",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "other",
      "raw_text": "(IND) application",
      "normalized_text": "(ind) application",
      "context": "Investigational New Drug (IND) application for CT7439",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "965f311c9580bd9b42e22d1d1685e1f2744e927cccb0d498f9b84d5c1942560d",
      "canonical_text": "INDAPPLICATION",
      "mention_class": "junk"
    },
    {
      "id": "a29c962d-3516-4015-90b0-62238500e3fe",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "other",
      "raw_text": "detail/20",
      "normalized_text": "detail/20",
      "context": "press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "1bda3eb62149e4349d06bf94dae6613874fe7285ecfa58ee0b753ba9681da424",
      "canonical_text": "DETAIL20",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e8787301-8505-420f-a4f6-21636bfc60c4",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "other",
      "raw_text": "20",
      "normalized_text": "20",
      "context": "press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "555e06060e5107f5671f572d29d82b695c710c5a69b0259db0f23c30fc556dcb",
      "canonical_text": "20",
      "mention_class": "junk"
    },
    {
      "id": "c9f1dbca-113e-408e-96c7-8a180d05ddeb",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "other",
      "raw_text": "u-s-fda-clearance-of-ind",
      "normalized_text": "u-s-fda-clearance-of-ind",
      "context": "carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "2a503b82dd4c13f6ed15ad6c462c35ad0898606c4835d49307935588567daa0b",
      "canonical_text": "USFDACLEARANCEOFIND",
      "mention_class": "junk"
    },
    {
      "id": "051214c7-133c-4606-bf4b-6d45e3cdd5b4",
      "created_at": "2025-12-14T21:05:25.43019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "result_id": "7471b2c2-6435-4da5-8192-2d4df006bdad",
      "mention_type": "other",
      "raw_text": "u-s-fda",
      "normalized_text": "u-s-fda",
      "context": "carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "ebae31d0de89e9dbe6f197891597d15270d5aaecc7dcb93ec593822e99f029e2",
      "canonical_text": "USFDA",
      "mention_class": "junk"
    },
    {
      "id": "8638cd5b-1724-4f8c-9e23-1abadafb4234",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "drug_code",
      "raw_text": "SR-4835",
      "normalized_text": "sr-4835",
      "context": "concentrations of SR-4835 or THZ531 for 72 h. D Docking pose of SR-4835 and CR8 in the active site of CDK",
      "source_url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
      "fingerprint": "c10b62a1ddb874451147b140b9795baedeea1734a30e9d256db2a310f2902138",
      "canonical_text": "SR4835",
      "mention_class": "drug_code_like"
    },
    {
      "id": "863acc1a-39f7-484b-8bde-2d3af221c2a7",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "drug_code",
      "raw_text": "THZ531",
      "normalized_text": "thz531",
      "context": "concentrations of SR-4835 or THZ531 for 72 h. D Docking pose of SR-4835 and CR8 in the active site of CDK12 (PDB: 6",
      "source_url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
      "fingerprint": "fa30e72a7dcb1a72d15e8d612d4d889ff75e6b79606b1690c6f93f52e8b51a4c",
      "canonical_text": "THZ531",
      "mention_class": "drug_code_like"
    },
    {
      "id": "d0e3f3ee-009d-49a2-bf68-85e249d52baf",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "drug_code",
      "raw_text": "HQ461",
      "normalized_text": "hq461",
      "context": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4. treated with either SR-4835 or the covalent CDK12/13 inhibitor",
      "source_url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
      "fingerprint": "91df0fcb1dac0bf977ad22a4aeb62a64080a73c4a640c92ab03da2b7968fb0b4",
      "canonical_text": "HQ461",
      "mention_class": "drug_code_like"
    },
    {
      "id": "82c9a057-bb2c-4e46-95f1-1146430df3e4",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "drug_code",
      "raw_text": "PC-6230201",
      "normalized_text": "pc-6230201",
      "context": "Batch No. : PC-6230201 CAS No. : 1702809-17-3",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_COA.pdf",
      "fingerprint": "2708ac600b3f7fa10639a16ade5177034cf2b25da690a5636b487b4e3f852164",
      "canonical_text": "PC6230201",
      "mention_class": "drug_code_like"
    },
    {
      "id": "10bfee87-3fc6-4aa2-a651-e6d93d64aa86",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "drug_code",
      "raw_text": "CR8",
      "normalized_text": "cr8",
      "context": "Docking pose of SR-4835 and CR8 in the active site of CDK12 (PDB: 6TD3)",
      "source_url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
      "fingerprint": "67521e25b2c3304c9e8ae7586a8a34bd4a8a99b1f582a9f07378ed0ae34639cd",
      "canonical_text": "CR8",
      "mention_class": "junk"
    },
    {
      "id": "dda70989-ec92-48b9-a379-aabba38e9ba7",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "PDB: 6TD3",
      "normalized_text": "pdb: 6td3",
      "context": "CDK12 (PDB: 6TD3) with key residues highlighted.",
      "source_url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
      "fingerprint": "1d5caa18498c9251cb3dbd26bf2fb787adf262209a8fbb0dd7379b1987e96add",
      "canonical_text": "PDB6TD3",
      "mention_class": "drug_code_like"
    },
    {
      "id": "8093204c-c6fd-44ae-8c27-83dc2e564ecb",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "6TD3",
      "normalized_text": "6td3",
      "context": "CDK12 (PDB: 6TD3) with key residues highlighted.",
      "source_url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
      "fingerprint": "399f9b08a8da8a2a47bc0cfcafa67907656f21288f8ea7f1748f9e9b3e017ba2",
      "canonical_text": "6TD3",
      "mention_class": "drug_code_like"
    },
    {
      "id": "25113d69-e65c-4b95-9b8c-4a0e9774118f",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "modality",
      "raw_text": "pan-CDK/CDK12 inhibitors",
      "normalized_text": "pan-cdk/cdk12 inhibitors",
      "context": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4.",
      "source_url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
      "fingerprint": "63cf4bcb0f9de8e427667d62683310350637a6c86a78d2f7489614caef663633",
      "canonical_text": "PANCDKCDK12INHIBITORS",
      "mention_class": "junk"
    },
    {
      "id": "4e06bc69-d593-46bd-96a1-6b73f56ad7b1",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "target",
      "raw_text": "pan-CDK/CDK12",
      "normalized_text": "pan-cdk/cdk12",
      "context": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4.",
      "source_url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
      "fingerprint": "e68ae91f0bd907b46d5bd93d4f3b346b03a0f8ec07c45504721e86c797bfee64",
      "canonical_text": "PANCDKCDK12",
      "mention_class": "drug_code_like"
    },
    {
      "id": "7bf14fef-f778-420b-bd86-0a658fbcc3ce",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "target",
      "raw_text": "pan-CDK",
      "normalized_text": "pan-cdk",
      "context": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4.",
      "source_url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
      "fingerprint": "c3b48176131f3f23db9496fe2fdea3181f69ecd1947c8f130416487ef01196aa",
      "canonical_text": "PANCDK",
      "mention_class": "junk"
    },
    {
      "id": "2a7a69b5-af72-4af8-a643-238f41b80187",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "drug_code",
      "raw_text": "dCeMM2/3/4",
      "normalized_text": "dcemm2/3/4",
      "context": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4.",
      "source_url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
      "fingerprint": "501132db3bc082e35e63d35287a21930428e1e0648581e11164d46a179ee1a17",
      "canonical_text": "DCEMM234",
      "mention_class": "drug_code_like"
    },
    {
      "id": "d2cbe67a-4f7b-4f23-a7b7-e71561429162",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "modality",
      "raw_text": "covalent CDK12/13 inhibitor",
      "normalized_text": "covalent cdk12/13 inhibitor",
      "context": "treated with either SR-4835 or the covalent CDK12/13 inhibitor THZ531",
      "source_url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
      "fingerprint": "9dbb917f5480c3396d6f4abebfec94ab506b21f47a41770d8d147f6d546968a3",
      "canonical_text": "COVALENTCDK1213INHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "6889f66c-63c8-4c56-b2fb-189419a692df",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "drug_name",
      "raw_text": "THZ531",
      "normalized_text": "thz531",
      "context": "Product Name : THZ531",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "fingerprint": "efdc23d4e156198251d373880723d450732addbe73ebf216bddfbb1028484442",
      "canonical_text": "THZ531",
      "mention_class": "drug_code_like"
    },
    {
      "id": "7d87a12a-9fc3-447f-a155-98085e8b90a6",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "1702809-17-3",
      "normalized_text": "1702809-17-3",
      "context": "CAS No. : 1702809-17-3",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "fingerprint": "cc3b575cca1b9bdff43e3d025ccbac477571d1f52e288915bf6fc62a75f054df",
      "canonical_text": "1702809173",
      "mention_class": "junk"
    },
    {
      "id": "8ca0fcf9-addb-47a7-8a73-d96660689c20",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "PC-62302",
      "normalized_text": "pc-62302",
      "context": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "fingerprint": "aabb1c52be1d7c5261967e168aabb3bd524e63622aea9e8ca6df37d74d009495",
      "canonical_text": "PC62302",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e37731f6-63a2-413f-a569-a30bf15d2829",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "PC-6230201",
      "normalized_text": "pc-6230201",
      "context": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "fingerprint": "36ff0233d616be44bb1bae212b630f20d035d7ff547b5a0e4a0c90e711e2ee4d",
      "canonical_text": "PC6230201",
      "mention_class": "drug_code_like"
    },
    {
      "id": "92bb0ae3-5c1e-4d56-8e03-41e74a5e65f8",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "PC-6230201_DataSheet.pdf",
      "normalized_text": "pc-6230201_datasheet.pdf",
      "context": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "fingerprint": "343e7e468cc1b6641b3286b1a7909614b9e2e694071d8477b3ba3a81a5abb2a7",
      "canonical_text": "PC6230201DATASHEETPDF",
      "mention_class": "junk"
    },
    {
      "id": "9af13add-7ecb-40a9-845f-7eecd1ee3ba1",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "sponsor",
      "raw_text": "www.probechem.com",
      "normalized_text": "www.probechem.com",
      "context": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "fingerprint": "876aadf6b56a9d04c1bf23b2b5339eb02ffd5a0210951f0938b4b0f1ea6c4dac",
      "canonical_text": "WWWPROBECHEMCOM",
      "mention_class": "junk"
    },
    {
      "id": "8d985b10-423e-4122-9bde-3111a6dc60e7",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "PC-6230201_COA.pdf",
      "normalized_text": "pc-6230201_coa.pdf",
      "context": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_COA.pdf",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_COA.pdf",
      "fingerprint": "23e785c7226eea3a0e6225760e5ae3249b8ee39f94ebd335a57e2d561b592f97",
      "canonical_text": "PC6230201COAPDF",
      "mention_class": "drug_code_like"
    },
    {
      "id": "22090a7a-ba1d-41d7-9b1a-49e6381add16",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "drug_name",
      "raw_text": "dCeMM2",
      "normalized_text": "dcemm2",
      "context": "Product Name: dCeMM2 Catalog No.: 7525 Batch No.: 1",
      "source_url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "fingerprint": "c944f0dff0b7cc7079786319b0ac83629c4e773f4bf795abcb6dfb0774f94a20",
      "canonical_text": "DCEMM2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "3472d1c1-bc61-4ffa-b071-1934df81c348",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "Catalog No.: 7525",
      "normalized_text": "catalog no.: 7525",
      "context": "Product Name: dCeMM2 Catalog No.: 7525 Batch No.: 1",
      "source_url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "fingerprint": "e776862e03a07dd0011ea29723c0d669573f6934c3b2cc2fc240eb9bb61d2bb0",
      "canonical_text": "CATALOGNO7525",
      "mention_class": "drug_code_like"
    },
    {
      "id": "14492e5f-a50e-4992-8ce5-ab125a6db39b",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "Batch No.: 1",
      "normalized_text": "batch no.: 1",
      "context": "Product Name: dCeMM2 Catalog No.: 7525 Batch No.: 1",
      "source_url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "fingerprint": "9bf1b59f4e846ef3a366fcf77419f35f637bde0ca17bd8984e1d543b49606b99",
      "canonical_text": "BATCHNO1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "af92e4ad-a956-4c12-bf98-04feaa7c8447",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "296771-07-8",
      "normalized_text": "296771-07-8",
      "context": "CAS Number: 296771-07-8",
      "source_url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "fingerprint": "1b8b7e65c292a2f10bdae002f85b7c7ea753af6efb62ff91736c9d0b232a5093",
      "canonical_text": "296771078",
      "mention_class": "junk"
    },
    {
      "id": "bb342203-fd1b-4d55-8aab-5e39b9baab01",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "7525_1_coa.pdf",
      "normalized_text": "7525_1_coa.pdf",
      "context": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "source_url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "fingerprint": "00725fe6e34ad73997df6cc3e1d9af2e6fb7364aa5ebb0ea685409a813ee21fc",
      "canonical_text": "75251COAPDF",
      "mention_class": "drug_code_like"
    },
    {
      "id": "8b82e20e-5a7f-4bfe-96b1-bcbc06170af1",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "1765531254",
      "normalized_text": "1765531254",
      "context": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "source_url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "fingerprint": "bc1c3bb5ba0b0ff90ddc8d1489504b6a3347e0a88c365bb774919b48de04099a",
      "canonical_text": "1765531254",
      "mention_class": "junk"
    },
    {
      "id": "08082ff2-7610-41aa-815e-18441eaec067",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "sponsor",
      "raw_text": "documents.tocris.com",
      "normalized_text": "documents.tocris.com",
      "context": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "source_url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "fingerprint": "1aab1e09e95f4b11817cb1656757d2a65c03987e7ca4a2dc863362a813449870",
      "canonical_text": "DOCUMENTSTOCRISCOM",
      "mention_class": "junk"
    },
    {
      "id": "76eadbd6-fdb9-45b2-a547-38e0fc7a5d9b",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "tocris_coa",
      "normalized_text": "tocris_coa",
      "context": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "source_url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "fingerprint": "9636e091c8e3f860cf8b275d549d985a808db4cca2306e4d7fe6a2ebf377aa93",
      "canonical_text": "TOCRISCOA",
      "mention_class": "junk"
    },
    {
      "id": "2e148f59-bc85-4139-b2f7-c4f41e194818",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "Catalog Number: 7525",
      "normalized_text": "catalog number: 7525",
      "context": "Catalog Number: 7525",
      "source_url": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=",
      "fingerprint": "c5e017b4e9bdab8ddb92c4efac24f02f362665edf30ae5ba176580cad8f2aef8",
      "canonical_text": "CATALOGNUMBER7525",
      "mention_class": "drug_code_like"
    },
    {
      "id": "9400f914-9e4a-4041-8bda-4a41421f3ced",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "7525_sds.pdf",
      "normalized_text": "7525_sds.pdf",
      "context": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=",
      "source_url": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=",
      "fingerprint": "0b4d7da29f69b5fd06c6c29235f8e0d3a64da5ebe0c922d80f4b24140603facf",
      "canonical_text": "7525SDSPDF",
      "mention_class": "drug_code_like"
    },
    {
      "id": "a67e7acf-0c46-4aca-9075-40e6e74e651b",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "1765505855",
      "normalized_text": "1765505855",
      "context": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=",
      "source_url": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=",
      "fingerprint": "a7e2a2d20cf43abb83022fcf9cc50c7886e6f944232caf04dd6d825525e782e9",
      "canonical_text": "1765505855",
      "mention_class": "junk"
    },
    {
      "id": "07120760-d4fa-4a08-9b69-dd6b8024541d",
      "created_at": "2025-12-14T21:05:25.766839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "result_id": "0ac7352a-2481-44ea-bc20-e8127452260f",
      "mention_type": "other",
      "raw_text": "tocris_msds",
      "normalized_text": "tocris_msds",
      "context": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=",
      "source_url": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=",
      "fingerprint": "50cca6050d87b9dbf8ea278f9349f4c387aa05b9262d7aa35220fa9935b82da8",
      "canonical_text": "TOCRISMSDS",
      "mention_class": "junk"
    },
    {
      "id": "629ea717-c567-4a4a-9850-f232289f05ab",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "drug_code",
      "raw_text": "CDK13",
      "normalized_text": "cdk13",
      "context": "94 バッチS889402 製品説明  | SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13 with IC50 of 99 nM and Kd of 98 nM for CDK12 and IC50 of 4.9 nM for CDK13.",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "930a00424b52a259865604d10925d746082e589b32021ed064014aaa51ed54c6",
      "canonical_text": "CDK13",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "c62356b8-942d-4e9c-986b-1b4b9b64d03b",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "drug_code",
      "raw_text": "IC50",
      "normalized_text": "ic50",
      "context": "02 製品説明  | SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13 with IC50 of 99 nM and Kd of 98 nM for CDK12 and IC50 of 4.9 nM for CDK13.",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "f7c8aebaaa68a643a8395ae9764d1b4ff6e731f5cd2b3e21dc6bd33d8bc23fcb",
      "canonical_text": "IC50",
      "mention_class": "junk"
    },
    {
      "id": "8a3968ba-d59f-4bbe-ab83-3e4cc3e66291",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "drug_code",
      "raw_text": "PC-62302",
      "normalized_text": "pc-62302",
      "context": "Cat. No. : PC-62302 THZ531 (THZ-531) isa first-in-class, selective CDK12 and CDK13 covalent inhibit",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "fingerprint": "0562eff110713d1d5ca5a0e8b03dead53f56cad97fde3a7136101117c19b23b0",
      "canonical_text": "PC62302",
      "mention_class": "drug_code_like"
    },
    {
      "id": "a96d77ff-f95f-4a3f-b680-e63832c69950",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "drug_code",
      "raw_text": "THZ-531",
      "normalized_text": "thz-531",
      "context": "Cat. No. : PC-62302 THZ531 (THZ-531) isa first-in-class, selective CDK12 and CDK13 covalent inhibitor with IC50 of",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "fingerprint": "16cab623ece68d4e8f7c66f8c09a4371ac53f3b9272e858db034b3443562e162",
      "canonical_text": "THZ531",
      "mention_class": "drug_code_like"
    },
    {
      "id": "1d34b568-26c5-43ee-9437-525adf50c3d6",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "drug_code",
      "raw_text": "THZ531R",
      "normalized_text": "thz531r",
      "context": "Scheme 1. The synthesis of THZ531 Scheme 3. The synthesis of THZ531R",
      "source_url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "fingerprint": "8b82ab601262c2be9bbd8814d58b1711ea68a77b10419bfab794eb02ad22325f",
      "canonical_text": "THZ531R",
      "mention_class": "drug_code_like"
    },
    {
      "id": "678f8418-c629-44fa-aaf5-6bf803773674",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "S6595",
      "normalized_text": "s6595",
      "context": "目录号：S6595 批次号：S659503",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "c932cdbaa772e69c52bdbeed0bdcb51f619715773c7ea2d731047f179db96231",
      "canonical_text": "S6595",
      "mention_class": "drug_code_like"
    },
    {
      "id": "a16b4552-c267-4e70-9d61-ca31743cb463",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "S659503",
      "normalized_text": "s659503",
      "context": "目录号：S6595 批次号：S659503",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "a34c9d00b4959c82c215120b71ce86f444542f7de52dca7da1010f2af1ee41f6",
      "canonical_text": "S659503",
      "mention_class": "drug_code_like"
    },
    {
      "id": "72a77726-0ff7-4ee5-8bb1-b65830d07f41",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "target",
      "raw_text": "CDK13",
      "normalized_text": "cdk13",
      "context": "THZ531是CDK12和CDK13的选择性抑制剂",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "f95cc057bb0ce5d956a85b95ddb12ad7db4cc1d507fb6894dc5e862f516b0297",
      "canonical_text": "CDK13",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "ac4abd7c-e638-41ec-8ed5-9313970ddab0",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "target",
      "raw_text": "CDK12和CDK13",
      "normalized_text": "cdk12和cdk13",
      "context": "THZ531是CDK12和CDK13的选择性抑制剂",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "4edb566d3c40de654f614ac374d91da063aeba2065025de5ea7c1a67a2863c93",
      "canonical_text": "CDK12CDK13",
      "mention_class": "drug_code_like"
    },
    {
      "id": "639e91ef-c964-4f56-a766-620d164def36",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "modality",
      "raw_text": "选择性抑制剂",
      "normalized_text": "选择性抑制剂",
      "context": "THZ531是CDK12和CDK13的选择性抑制剂",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "8c4bca6f4d2886e40abae7cf196d4f765df97e9292d8dce97fd071db0ae5bebd",
      "canonical_text": "",
      "mention_class": "junk"
    },
    {
      "id": "62ad9392-2de3-4af7-bf71-dfadfd219a27",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "IC50",
      "normalized_text": "ic50",
      "context": "IC50值分别为158 nM和69 nM。",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "74006160c863531c4790053cb37da93e2e4ad9753a014f3df447103d0cfe06a9",
      "canonical_text": "IC50",
      "mention_class": "junk"
    },
    {
      "id": "97890c83-ccd9-43cc-9742-c1f34e0a62c5",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "IC50值",
      "normalized_text": "ic50值",
      "context": "IC50值分别为158 nM和69 nM。",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "23d7a5214ccb50c88af2fa81cf672c2c6585c10de9440587e54888c902d916f2",
      "canonical_text": "IC50",
      "mention_class": "junk"
    },
    {
      "id": "0715d488-5e4a-4e7c-ab5b-f55921cbb3cb",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "158 nM",
      "normalized_text": "158 nm",
      "context": "IC50值分别为158 nM和69 nM。",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "9f63fb5ffa49c3566f89c569be9357e95d3b72ed989fa9ac8d1a4ac710da6133",
      "canonical_text": "158NM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "fa74e977-4780-44b0-95cb-0e02c368aa90",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "69 nM",
      "normalized_text": "69 nm",
      "context": "IC50值分别为158 nM和69 nM。",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "89bc3cdfb60ca8c302f4718e1a7f8c45da622f6950792a24ce46f709d26021fa",
      "canonical_text": "69NM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e8788d1c-c3e6-4f62-b977-1c9823d03ee5",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "drug_name",
      "raw_text": "polyphenon E",
      "normalized_text": "polyphenon e",
      "context": "polyphenon E (Poly E) 400, 600, 800 twice daily",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/22827973/",
      "fingerprint": "c23efcf3e284ab6ee37196b9658196290f2d9f1f495b340cdf866d2cb8abb73b",
      "canonical_text": "POLYPHENONE",
      "mention_class": "junk"
    },
    {
      "id": "2db601ad-8d96-486a-a21e-e501e0ec9d3c",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "thz531-S659503-DataSheet.pdf",
      "normalized_text": "thz531-s659503-datasheet.pdf",
      "context": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "959d448f5e7c722ebd55a28e01a8c70121e79e5d167fc96eb3180e048ca3a355",
      "canonical_text": "THZ531S659503DATASHEETPDF",
      "mention_class": "junk"
    },
    {
      "id": "c5ddaafc-b906-498c-be3a-14cc3b02381d",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "S659503-DataSheet.pdf",
      "normalized_text": "s659503-datasheet.pdf",
      "context": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "37eb184f4a42d2654ead8f8f13d2407eb2d1a737e468c0098ccee2a172b6c84c",
      "canonical_text": "S659503DATASHEETPDF",
      "mention_class": "drug_code_like"
    },
    {
      "id": "5bb5807b-5027-4e5a-aa71-e259b73779ed",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "thz531",
      "normalized_text": "thz531",
      "context": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "ed02e1192bb23eb94d19c6b166b9dd4587b0267aa83e7feaec8c93c86d0a135f",
      "canonical_text": "THZ531",
      "mention_class": "drug_code_like"
    },
    {
      "id": "01f494ba-757e-4df8-95e1-f7354f4ba9bc",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "sponsor",
      "raw_text": "www.selleck.cn",
      "normalized_text": "www.selleck.cn",
      "context": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "source_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "fingerprint": "6777909291aef163017d0bad99a9da5689884ab9d213714185a5f7642870066a",
      "canonical_text": "WWWSELLECKCN",
      "mention_class": "junk"
    },
    {
      "id": "c82ad802-91e3-4e14-8e47-2210dbcaf2d5",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "S8894",
      "normalized_text": "s8894",
      "context": "製品コードS8894 バッチS889402",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "1ed43b1d2a4e6fa02e55f13b8adf646121af258d628c931b0970d1e6bf83dc32",
      "canonical_text": "S8894",
      "mention_class": "drug_code_like"
    },
    {
      "id": "6a873750-df67-4e03-a988-30f38d6722e2",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "S889402",
      "normalized_text": "s889402",
      "context": "製品コードS8894 バッチS889402",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "b40ee01a0b422f34852cadc97564ed89c4ed627b06ba37de7f5d68499dfbbb75",
      "canonical_text": "S889402",
      "mention_class": "drug_code_like"
    },
    {
      "id": "b6ce1772-003f-4266-ae91-c730719755bf",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "modality",
      "raw_text": "highly selective dual inhibitor",
      "normalized_text": "highly selective dual inhibitor",
      "context": "SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "2f9cc85959fd9e573c3123365f272cc7ff450745fbd9005999648ebc11dcae43",
      "canonical_text": "HIGHLYSELECTIVEDUALINHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "6c3ed97e-918d-47d0-b1f1-4e002a5ee975",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "modality",
      "raw_text": "dual inhibitor",
      "normalized_text": "dual inhibitor",
      "context": "SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "6b3786c1c141913a0e21d48d059389816b8c175e06165fe55b68df2776e3e96a",
      "canonical_text": "DUALINHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "95d32ef5-3422-48a3-872f-69485ed45a12",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "target",
      "raw_text": "CDK12 and CDK13",
      "normalized_text": "cdk12 and cdk13",
      "context": "dual inhibitor of CDK12 and CDK13 with IC50 of 99 nM",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "91094eca799a96b0bea4bf7a5369c86b5e0b282cbd9fc4b82a664bccc4ae1441",
      "canonical_text": "CDK12ANDCDK13",
      "mention_class": "drug_code_like"
    },
    {
      "id": "14a7e866-63e4-46bc-b664-8ad50986dbd7",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "99 nM",
      "normalized_text": "99 nm",
      "context": "with IC50 of 99 nM and Kd of 98 nM for CDK12",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "39d38f72cfa13268dd03ab6cdb8ac256e3c1f0087543a3c0092e0eb0287ad1a3",
      "canonical_text": "99NM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "d61bd08f-8b87-4291-b846-12399e83fea6",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "Kd",
      "normalized_text": "kd",
      "context": "IC50 of 99 nM and Kd of 98 nM for CDK12",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "0d94892c99a6486deac3dc4ece4ef92839d1cb94b6027f2f3a57841c19e258ce",
      "canonical_text": "KD",
      "mention_class": "junk"
    },
    {
      "id": "29587e1f-bb6a-4f62-9443-4ab188bca1df",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "98 nM",
      "normalized_text": "98 nm",
      "context": "Kd of 98 nM for CDK12",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "dbbd449785ad5d7a15c4432c6752f4bb22f547354261334472bd6eae9d4841fa",
      "canonical_text": "98NM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "336f98b7-dc73-45a5-8533-fa398ac9ccaa",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "4.9 nM",
      "normalized_text": "4.9 nm",
      "context": "IC50 of 4.9 nM for CDK13.",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "8838bd5506dea353a966049c8172ed48089271203d51afd1da4f841cf19a2591",
      "canonical_text": "49NM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "c56bd423-94a6-41b7-8af4-f9d71fc8f471",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "sr-4835-S889402-DataSheet.pdf",
      "normalized_text": "sr-4835-s889402-datasheet.pdf",
      "context": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "7f8d5b2cc0fac04ae34eff945f1c5823d2d38e588774ea5be2d37c5cc3be7edd",
      "canonical_text": "SR4835S889402DATASHEETPDF",
      "mention_class": "junk"
    },
    {
      "id": "077c4773-6802-404d-931b-dbb99a62ca41",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "S889402-DataSheet.pdf",
      "normalized_text": "s889402-datasheet.pdf",
      "context": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "8548b0082e051361c5876783d680f4890567aa39914bd2f886803a5cce914760",
      "canonical_text": "S889402DATASHEETPDF",
      "mention_class": "drug_code_like"
    },
    {
      "id": "b8a538f3-7b08-4204-8f47-53fa99a36f23",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "sr-4835",
      "normalized_text": "sr-4835",
      "context": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "4a76b8d2772f50d1e4a4533e024e5e9f6dd9f116e9be688f625067e86e53c1c7",
      "canonical_text": "SR4835",
      "mention_class": "drug_code_like"
    },
    {
      "id": "fa25af0c-7ace-46f8-96d3-3df05de0df0a",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "sponsor",
      "raw_text": "www.selleck.co.jp",
      "normalized_text": "www.selleck.co.jp",
      "context": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "source_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "fingerprint": "9817153bd099e8323374041173f68975c237f99fe4fd408b975e071ac4cfa0a0",
      "canonical_text": "WWWSELLECKCOJP",
      "mention_class": "junk"
    },
    {
      "id": "383061ea-ded6-4db8-b8a4-53f8a6cadd00",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "Cat. No.",
      "normalized_text": "cat. no.",
      "context": "Cat. No. : PC-62302",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "fingerprint": "6148a04d368aab13727211495d1ecde204144cc3f16ccd70d73168df61e5a37a",
      "canonical_text": "CATNO",
      "mention_class": "junk"
    },
    {
      "id": "fd6fa849-5091-4f1d-a152-e47b1baac705",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "modality",
      "raw_text": "covalent inhibitor",
      "normalized_text": "covalent inhibitor",
      "context": "selective CDK12 and CDK13 covalent inhibitor",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "fingerprint": "47c7fe92250903d4dd70c0637fdee95bbf68737366bb21279227f490847e9d7f",
      "canonical_text": "COVALENTINHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "aa3be61c-c90c-4a84-9154-d13c236f10d2",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "modality",
      "raw_text": "selective CDK12 and CDK13 covalent inhibitor",
      "normalized_text": "selective cdk12 and cdk13 covalent inhibitor",
      "context": "isa first-in-class, selective CDK12 and CDK13 covalent inhibitor with IC50",
      "source_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "fingerprint": "53961e7e1cf74770cc8ccd699590183dfaba5c44da611b9f5da0bf5a833f4e8c",
      "canonical_text": "SELECTIVECDK12ANDCDK13COVALENTINHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "0beb593b-8d5c-4b84-922a-f019c2b9cf25",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "Scheme 1",
      "normalized_text": "scheme 1",
      "context": "Scheme 1. The synthesis of THZ531",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "822039c76468df742f4867eef3e90a934c9e5654aaa2cef8f3e88581cad6a473",
      "canonical_text": "SCHEME1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "b8504665-21cb-4e5e-903c-9ec37269da0a",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "Scheme 1.",
      "normalized_text": "scheme 1.",
      "context": "Scheme 1. The synthesis of THZ531",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "59481c96d61cdb798bf49723fdd30e0abc0c9346dc9422cc9bcf90977cb7f139",
      "canonical_text": "SCHEME1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "5127c9cd-2921-4766-a97b-70b1296df133",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "drug_name",
      "raw_text": "Poly E",
      "normalized_text": "poly e",
      "context": "polyphenon E (Poly E) 400, 600, 800 twice daily",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/22827973/",
      "fingerprint": "23e41d20f3b479d6810805a5dbf27489c44630f419357e84c560fc9581200dfb",
      "canonical_text": "POLYE",
      "mention_class": "junk"
    },
    {
      "id": "aaa04ca7-c728-4901-bb3a-0624c08c2612",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "Scheme 2",
      "normalized_text": "scheme 2",
      "context": "Scheme 2. The synthesis of BioTHZ531",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "b3db951cae8637e1f6664bfab3b984f9e9b43a726d872d66416b82bf0f023dfa",
      "canonical_text": "SCHEME2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "caa530f7-3b9b-4e99-8199-a276a156bc5b",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "Scheme 2.",
      "normalized_text": "scheme 2.",
      "context": "Scheme 2. The synthesis of BioTHZ531",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "2d21294ea0c2b7a00c20970ce5d51961e8d3d559d6e60015bb0da652bdba1fab",
      "canonical_text": "SCHEME2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "49bd0b6c-4b0b-464f-92d4-45be171931c8",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "drug_name",
      "raw_text": "BioTHZ531",
      "normalized_text": "biothz531",
      "context": "Scheme 2. The synthesis of BioTHZ531",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "bc36385225cf34e0dcd34ad717e326955d94b24ffd8eb9443a1f88c1f92ea76a",
      "canonical_text": "BIOTHZ531",
      "mention_class": "drug_code_like"
    },
    {
      "id": "18af94e2-188e-430b-b3e7-92ace3f662aa",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "art%3A10.1038%2Fnchembio.2166",
      "normalized_text": "art%3a10.1038%2fnchembio.2166",
      "context": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "9388987abc002762015a9f1ee6ee4c76a3ba9e96f8067f6ad8be1bb1197fe38d",
      "canonical_text": "ART3A1010382FNCHEMBIO2166",
      "mention_class": "junk"
    },
    {
      "id": "2cbe01a9-cea0-4e10-a186-e88d3233eda9",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "10.1038%2Fnchembio.2166",
      "normalized_text": "10.1038%2fnchembio.2166",
      "context": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "c5a547b134dc12fb7ef0226c99b29deacc17b88eb62aa8d528cba42a4f8e9df7",
      "canonical_text": "1010382FNCHEMBIO2166",
      "mention_class": "drug_code_like"
    },
    {
      "id": "da11d7d2-039b-4216-83b0-cee8ce69bb5e",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "normalized_text": "41589_2016_bfnchembio2166_moesm153_esm.pdf",
      "context": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "924f69f0d489d916d6401142ca1d777d54d36ddea85ba924beb360cce799207a",
      "canonical_text": "415892016BFNCHEMBIO2166MOESM153ESMPDF",
      "mention_class": "junk"
    },
    {
      "id": "2cf7b560-6725-4a6c-9e4f-316f4eb3b735",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "41589_2016_BFnchembio2166_MOESM153_ESM",
      "normalized_text": "41589_2016_bfnchembio2166_moesm153_esm",
      "context": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "f8c2bc9d3050e1ebc76b5e45c2e469eb1701523cbf78e084a273f43b4e45df3e",
      "canonical_text": "415892016BFNCHEMBIO2166MOESM153ESM",
      "mention_class": "junk"
    },
    {
      "id": "9f103df7-1f4b-425e-ba14-485fba265a75",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "MOESM153",
      "normalized_text": "moesm153",
      "context": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "b24218d54285e19567b6cf67a059393ce8935ff684bf6b4081c1d50d65e5153d",
      "canonical_text": "MOESM153",
      "mention_class": "drug_code_like"
    },
    {
      "id": "586a9b4e-6c67-4341-8fc2-6f3f0e0ac926",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "BFnchembio2166",
      "normalized_text": "bfnchembio2166",
      "context": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "7d7bc0ebd268ea9aea1e830126dccf934eff0bfd5162bdad20bfb818896ca8e0",
      "canonical_text": "BFNCHEMBIO2166",
      "mention_class": "drug_code_like"
    },
    {
      "id": "099a05e5-10f5-4760-8164-c030970b1413",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "nchembio2166",
      "normalized_text": "nchembio2166",
      "context": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "6032ef229b99b15995f5478f335bb02cfe040d008f617981dfe6dafdc4b595ca",
      "canonical_text": "NCHEMBIO2166",
      "mention_class": "drug_code_like"
    },
    {
      "id": "c718a824-8b08-4b33-9bc2-44a3f992429c",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "41589_2016",
      "normalized_text": "41589_2016",
      "context": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "53d85ba3798358bf8b1752a1bc5e265569a9f98e4ab1a7ae68ec2793d1002485",
      "canonical_text": "415892016",
      "mention_class": "junk"
    },
    {
      "id": "94082ebe-f9a1-4caa-bc1f-7516bab7f480",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "41589",
      "normalized_text": "41589",
      "context": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "9369aec0b969f6da0f9e12ae89fe1a3e60a331edf9c5de42dbdd418b7333dd3d",
      "canonical_text": "41589",
      "mention_class": "junk"
    },
    {
      "id": "477c45f4-f91f-4a13-95b1-e9e6e111483a",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "MediaObjects",
      "normalized_text": "mediaobjects",
      "context": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "1cfef877b82b82d3da0c4d53316915a801e508bd8de049d860e21d8eed8fde64",
      "canonical_text": "MEDIAOBJECTS",
      "mention_class": "junk"
    },
    {
      "id": "ab86f8a2-b974-4e3b-a2ac-4e803de66287",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "sponsor",
      "raw_text": "static-content.springer.com",
      "normalized_text": "static-content.springer.com",
      "context": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "source_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "fingerprint": "2e1a05c63a1b591e27f2653a2160c8a87d2099a47c5b82448ff421ff047790c2",
      "canonical_text": "STATICCONTENTSPRINGERCOM",
      "mention_class": "junk"
    },
    {
      "id": "5e16e62d-b8e4-4dc8-a7be-e91e16c9514c",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "Scheme 3",
      "normalized_text": "scheme 3",
      "context": "Scheme 3. The synthesis of THZ531R",
      "source_url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "fingerprint": "d6ebe7fc885747451eb795cee7b61b3249d15b903f2e485aac8e015eafb16d75",
      "canonical_text": "SCHEME3",
      "mention_class": "drug_code_like"
    },
    {
      "id": "2861059d-4b29-4d0d-be97-f4f29afa674c",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "Scheme 3.",
      "normalized_text": "scheme 3.",
      "context": "Scheme 3. The synthesis of THZ531R",
      "source_url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "fingerprint": "1c5a0354adfc0a52da33694ff489c284f6054a6f15a73240411f4fdda5ac440e",
      "canonical_text": "SCHEME3",
      "mention_class": "drug_code_like"
    },
    {
      "id": "9ee2759a-6d55-49ae-b977-1e78475ba08f",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "drug_name",
      "raw_text": "THZ531R",
      "normalized_text": "thz531r",
      "context": "Scheme 3. The synthesis of THZ531R",
      "source_url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "fingerprint": "246480e65ea44fd7d7d35c2ea20377d96be06429550ad4c520d5417b84fd2b03",
      "canonical_text": "THZ531R",
      "mention_class": "drug_code_like"
    },
    {
      "id": "71bf0a0c-0c24-4f91-af3d-2d66dd83076b",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab",
      "normalized_text": "uuid%3a9d39c81e-0d3a-407a-9fb0-c128870235ab",
      "context": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "source_url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "fingerprint": "965ac214e7e06ef52991175bdfbd8012eed0cbff83e79db0db5c3f2492fb3182",
      "canonical_text": "UUID3A9D39C81E0D3A407A9FB0C128870235AB",
      "mention_class": "junk"
    },
    {
      "id": "0d71a401-c0a9-43f2-9ba2-eb2674e3f60f",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "modality",
      "raw_text": "glue degrader",
      "normalized_text": "glue degrader",
      "context": "as well as a 'glue degrader' of Cyclin-K",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "e24baa257ff8916db0af70dd144518c2c9222064f8e6c7fd3071088511bcfe07",
      "canonical_text": "GLUEDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "9ac67744-ff4a-4d74-bedd-4b7372b84547",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "9d39c81e-0d3a-407a-9fb0-c128870235ab",
      "normalized_text": "9d39c81e-0d3a-407a-9fb0-c128870235ab",
      "context": "uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab",
      "source_url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "fingerprint": "a6c5430430d5d4352c1ce7b2463dfa4e455966e96332f8253f61dd03d22068c3",
      "canonical_text": "9D39C81E0D3A407A9FB0C128870235AB",
      "mention_class": "junk"
    },
    {
      "id": "cdc83e81-fa30-42fa-8204-50d100f98888",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "md370f526b3ac0c2e93055747f79fc852",
      "normalized_text": "md370f526b3ac0c2e93055747f79fc852",
      "context": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "source_url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "fingerprint": "c73f62cbde80fa2b6de76f3d79a5ee38ca0bf7c097d3e54ce0d9c32242df1fe0",
      "canonical_text": "MD370F526B3AC0C2E93055747F79FC852",
      "mention_class": "junk"
    },
    {
      "id": "130d6e31-b45d-43e2-9216-53571a61df2d",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "other",
      "raw_text": "uuid%3A",
      "normalized_text": "uuid%3a",
      "context": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "source_url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "fingerprint": "846f82c9b5d476abfb5ea6dba78587da9ae17e9ba127fab2b4ff183390b950b9",
      "canonical_text": "UUID3A",
      "mention_class": "drug_code_like"
    },
    {
      "id": "4245af78-502f-4187-b9d7-a25531a13a53",
      "created_at": "2025-12-14T21:05:26.868394+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "result_id": "eb9f9ab9-85ad-47e9-91b3-e08b1caee9a7",
      "mention_type": "sponsor",
      "raw_text": "ora.ox.ac.uk",
      "normalized_text": "ora.ox.ac.uk",
      "context": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "source_url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "fingerprint": "4f3702655a4c22db1f4c95113b31a75444c2ef558d925969d5101795146e3ab6",
      "canonical_text": "ORAOXACUK",
      "mention_class": "junk"
    },
    {
      "id": "6a137165-e9f6-4aad-b8d8-1b99300b40fd",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "other",
      "raw_text": "cdk1213-inhibitor",
      "normalized_text": "cdk1213-inhibitor",
      "context": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
      "source_url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
      "fingerprint": "093c6351f86a57f0a394ffc941bc7141034411585408aa562cc76321e6c0741e",
      "canonical_text": "CDK1213INHIBITOR",
      "mention_class": "drug_code_like"
    },
    {
      "id": "76a73538-ebbf-466b-aef6-2895fb8a0c87",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "other",
      "raw_text": "CT7439: CDK12/13 inhibitor/Cyclin-K Degrader",
      "normalized_text": "ct7439: cdk12/13 inhibitor/cyclin-k degrader",
      "context": "## CT7439: CDK12/13 inhibitor/Cyclin-K Degrader",
      "source_url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
      "fingerprint": "6a3050f488f13666065b88ad84dc58dd85ebf4d74f5eb98c9e71c18fc944c31b",
      "canonical_text": "CT7439CDK1213INHIBITORCYCLINKDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "2ac88a92-501c-43d6-b652-dd86ce7373bd",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "modality",
      "raw_text": "Cyclin-K Degrader",
      "normalized_text": "cyclin-k degrader",
      "context": "CT7439: CDK12/13 inhibitor/Cyclin-K Degrader",
      "source_url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
      "fingerprint": "2bad9e2fb2b0aa156cbf936d2609ec831bd7d53f4f3b8b5122521a2bc336ba5b",
      "canonical_text": "CYCLINKDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "a304f143-5501-4fc2-9aae-84c417b603a2",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "modality",
      "raw_text": "CDK12/13 inhibitor/Cyclin-K Degrader",
      "normalized_text": "cdk12/13 inhibitor/cyclin-k degrader",
      "context": "CT7439: CDK12/13 inhibitor/Cyclin-K Degrader",
      "source_url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
      "fingerprint": "03254ee49b61917ce9816887eaa222d875557eb6ce0fb00e2de351a5d5987950",
      "canonical_text": "CDK1213INHIBITORCYCLINKDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "d9e4ebf0-b731-4577-abed-fbaa27500b1f",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "modality",
      "raw_text": "CDK12/13/Cyclin-K degrader",
      "normalized_text": "cdk12/13/cyclin-k degrader",
      "context": "CT7439 is a CDK12/13/Cyclin-K degrader, which potently inhibits the cellular activity of CDK12/13.",
      "source_url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
      "fingerprint": "efdc3f5a81f3b873e1ecf1af0a76bfcff8c21f67db9a247520c283e34ace66dc",
      "canonical_text": "CDK1213CYCLINKDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "6e014926-6e47-4c1d-b90d-6b39fecdf43d",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "target",
      "raw_text": "Cyclin-K",
      "normalized_text": "cyclin-k",
      "context": "CT7439 is a CDK12/13/Cyclin-K degrader, which potently inhibits the cellular activity of CDK12/13.",
      "source_url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
      "fingerprint": "e05152f1026771c48840c08d340cdfeedcef2217f17abf136977ba4fed529eac",
      "canonical_text": "CYCLINK",
      "mention_class": "junk"
    },
    {
      "id": "d92cfaf8-06af-4150-bd30-089f3b47c33f",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "modality",
      "raw_text": "CDK12-13-Inhibitor",
      "normalized_text": "cdk12-13-inhibitor",
      "context": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "e8225c3132fa7b2a3d552c9d4b4cd0853d2859b0fc75e97fd75d11152d3f6f4b",
      "canonical_text": "CDK1213INHIBITOR",
      "mention_class": "drug_code_like"
    },
    {
      "id": "4a871c04-8dca-4a8a-897c-fc9b79aad37e",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "modality",
      "raw_text": "(CDK12/13) inhibitor / Cyclin-K glue-degrader",
      "normalized_text": "(cdk12/13) inhibitor / cyclin-k glue-degrader",
      "context": "cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader.",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "37a07db4f720066488035014ff0a40613c2aa2876ed92e5a0e5f022bab50d99c",
      "canonical_text": "CDK1213INHIBITORCYCLINKGLUEDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "b3cea8fd-cc02-48ed-8ac0-bf4edd464943",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "modality",
      "raw_text": "inhibitor / Cyclin-K glue-degrader",
      "normalized_text": "inhibitor / cyclin-k glue-degrader",
      "context": "cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader.",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "3b3831161013c07e85e7338c23db412af366753af8591a2e690b49e903aaa1c8",
      "canonical_text": "INHIBITORCYCLINKGLUEDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "79fd99bd-2a96-454e-ab98-541f761832c4",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "modality",
      "raw_text": "glue-degrader",
      "normalized_text": "glue-degrader",
      "context": "inhibitor / Cyclin-K glue-degrader.",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "232681d25343ba17ec498f8aca6a5590d72557a8553f741e4f2a2edb9e9eee93",
      "canonical_text": "GLUEDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "f207799f-504b-4b4f-9991-94a6d9b3215b",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "modality",
      "raw_text": "Cyclin-K glue-degrader",
      "normalized_text": "cyclin-k glue-degrader",
      "context": "inhibitor / Cyclin-K glue-degrader.",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "e5c88167a8a0d7dc084cb6a9ad97747e0a3090e8f137277d0dd4a3fab9b59430",
      "canonical_text": "CYCLINKGLUEDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "366be3ec-58a5-492a-908c-79d8ecd13a3e",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "other",
      "raw_text": "study ID",
      "normalized_text": "study id",
      "context": "found on www.clinicaltrials.gov under study ID: NCT06600789.",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "482973e50e74f16023cc57b893d16b3389d47aacad55fd4208ae3ae69a0ba196",
      "canonical_text": "STUDYID",
      "mention_class": "junk"
    },
    {
      "id": "09943cf1-9404-4ced-b488-bda1b765604b",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "modality",
      "raw_text": "inhibitor of CDK12/13",
      "normalized_text": "inhibitor of cdk12/13",
      "context": "CT7439 is an inhibitor of CDK12/13 as well as a 'glue degrader' of Cyclin-K",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "b0b4ed7352adff92b665d79994766a09c2b0105f7a668f36a14ca18e580d72d2",
      "canonical_text": "INHIBITOROFCDK1213",
      "mention_class": "junk"
    },
    {
      "id": "4c689bcc-e450-41f5-bbdd-a3958221fd6f",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "modality",
      "raw_text": "'glue degrader'",
      "normalized_text": "'glue degrader'",
      "context": "as well as a 'glue degrader' of Cyclin-K",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "fe4e00508de819dac07ea81ed42181d0a7d9ef255641138b5467e7cd056d6159",
      "canonical_text": "GLUEDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "156498e5-97f1-4e04-a2ba-e987ada05e34",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "other",
      "raw_text": "obligate co-factor",
      "normalized_text": "obligate co-factor",
      "context": "Cyclin-K, which is the obligate co-factor for CDK12/13",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "de5a2db197cf75ca9bebb8dfeaca605793a4f8a7d1d85edd33b7a6458b308267",
      "canonical_text": "OBLIGATECOFACTOR",
      "mention_class": "junk"
    },
    {
      "id": "cd636310-394a-4d78-abee-46903933a5bd",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "other",
      "raw_text": "best-in-class",
      "normalized_text": "best-in-class",
      "context": "giving both first-in-class and best-in-class potential.",
      "source_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "29eb4fd319c308f5bba0bb5d734b554256060dc721fb898f816987e15e2bbf84",
      "canonical_text": "BESTINCLASS",
      "mention_class": "junk"
    },
    {
      "id": "5546034e-fdd9-4881-ad7b-d3d50334f602",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "indication",
      "raw_text": "solid tumors",
      "normalized_text": "solid tumors",
      "context": "patients with several types of solid tumors, including breast and ovarian cancer",
      "source_url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
      "fingerprint": "f4ff90c7e09f1f75400a8e045efbf4226a90aa6cf42b3be0d51bfd54866e5610",
      "canonical_text": "SOLIDTUMORS",
      "mention_class": "junk"
    },
    {
      "id": "5d35371b-71ca-4f09-9037-00c527d22ee1",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "indication",
      "raw_text": "breast",
      "normalized_text": "breast",
      "context": "including breast and ovarian cancer",
      "source_url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
      "fingerprint": "5af2d2b304f083071d77c96ca1f0bed0082ed05ef6f123f44aa0d779f80858b3",
      "canonical_text": "BREAST",
      "mention_class": "junk"
    },
    {
      "id": "ab318849-3090-4820-8f21-ff225ff2c097",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "indication",
      "raw_text": "ovarian cancer",
      "normalized_text": "ovarian cancer",
      "context": "including breast and ovarian cancer, as well as Ewing’s sarcoma.",
      "source_url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
      "fingerprint": "7557a4bea07cdae3ab1a9a06196a4040ddfb3abce367b3fcc3423069e9e8aa6a",
      "canonical_text": "OVARIANCANCER",
      "mention_class": "junk"
    },
    {
      "id": "1ad2e5f3-069e-44bb-a3e1-c4197e024f18",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "indication",
      "raw_text": "Ewing’s sarcoma",
      "normalized_text": "ewing’s sarcoma",
      "context": "including breast and ovarian cancer, as well as Ewing’s sarcoma.",
      "source_url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
      "fingerprint": "a3ae04ecd7a0a2a635d77c808b765e35245cc4954368d1e33da0a14608bf4159",
      "canonical_text": "EWINGSSARCOMA",
      "mention_class": "junk"
    },
    {
      "id": "f89c9c7f-9782-4976-890b-e1257b87b872",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "modality",
      "raw_text": "“glue degrader”",
      "normalized_text": "“glue degrader”",
      "context": "The compound is a “glue degrader” of Cyclin-K",
      "source_url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor",
      "fingerprint": "e0eb39585f1cd695836088ae3fc20d7b18e75507273ff70c156e47a781f89f4d",
      "canonical_text": "GLUEDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "5ed9c66f-5f09-464f-8ce2-687b532b8cc3",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "other",
      "raw_text": "phase-1-2",
      "normalized_text": "phase-1-2",
      "context": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "source_url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "fingerprint": "89c3fe907968fda9567abdddb8d8dbc5d093cd8f6af82f4b1ad6a28a71aa5235",
      "canonical_text": "PHASE12",
      "mention_class": "junk"
    },
    {
      "id": "6f98e901-ab62-4a2c-b2b7-9c44a5d9676b",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "indication",
      "raw_text": "solid-malignancies",
      "normalized_text": "solid-malignancies",
      "context": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "source_url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "fingerprint": "7287edd9e1cf6b5f9f0c91c1f401bf9044fc6ee6039b5e7a82e042cfb6b7e8f8",
      "canonical_text": "SOLIDMALIGNANCIES",
      "mention_class": "junk"
    },
    {
      "id": "21bbc758-50f6-4fe0-8ce3-f88c12eaed4a",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "drug_name",
      "raw_text": "CT7439 Capsules (0.5 mg, 1mg, 3mg)",
      "normalized_text": "ct7439 capsules (0.5 mg, 1mg, 3mg)",
      "context": "CT7439 Capsules (0.5 mg, 1mg, 3mg)",
      "source_url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "fingerprint": "bd6e3ddfae32bb38016de8a0663cba903eb88512d1ea0b38913cc65f5ac98564",
      "canonical_text": "CT7439CAPSULES05MG1MG3MG",
      "mention_class": "junk"
    },
    {
      "id": "18350a8f-9feb-4ebb-845b-94a76e631e36",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "drug_name",
      "raw_text": "CT7439 Capsules",
      "normalized_text": "ct7439 capsules",
      "context": "CT7439 Capsules (0.5 mg, 1mg, 3mg)",
      "source_url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "fingerprint": "a091b88c3cad3d4ec0716295a16c2467c6c0ba4721f3f45dd9b1edc78d1abd16",
      "canonical_text": "CT7439CAPSULES",
      "mention_class": "drug_code_like"
    },
    {
      "id": "0bf57061-0a4c-4de4-b7f7-fa201c3f78ab",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "other",
      "raw_text": "0.5 mg",
      "normalized_text": "0.5 mg",
      "context": "CT7439 Capsules (0.5 mg, 1mg, 3mg)",
      "source_url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "fingerprint": "bc52e60cf97b4cf4c6934548ff4e014e9f40581ce7aeac1651a16f088e83d01e",
      "canonical_text": "05MG",
      "mention_class": "drug_code_like"
    },
    {
      "id": "0b320f21-cfa0-477f-bb27-8dc43cfc1cb6",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "other",
      "raw_text": "1mg",
      "normalized_text": "1mg",
      "context": "CT7439 Capsules (0.5 mg, 1mg, 3mg)",
      "source_url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "fingerprint": "950c7b3d836d2933bf3590e395b5751e2ae290ce0ba54097d32a11598b1f6ba5",
      "canonical_text": "1MG",
      "mention_class": "junk"
    },
    {
      "id": "75736351-f799-4827-9696-aa6420f8cc5d",
      "created_at": "2025-12-14T21:11:48.342408+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "result_id": "9e9752ba-e29f-491b-9a63-9c8f3d882717",
      "mention_type": "other",
      "raw_text": "3mg",
      "normalized_text": "3mg",
      "context": "CT7439 Capsules (0.5 mg, 1mg, 3mg)",
      "source_url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "fingerprint": "ff6dc24c5e46b58559d4bccdef140b0697a9e7c7619b0b03c13ded77ca5bb647",
      "canonical_text": "3MG",
      "mention_class": "junk"
    },
    {
      "id": "92e5c04a-7d42-411a-a4a7-cddaa7f4561f",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "other",
      "raw_text": "CDK12-13-Inhibitor",
      "normalized_text": "cdk12-13-inhibitor",
      "context": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "source_url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
      "fingerprint": "76a766b03083d1ab7c02905d2fc84cbf0daa64151bfaf8b6fe0937dd587c0bad",
      "canonical_text": "CDK1213INHIBITOR",
      "mention_class": "drug_code_like"
    },
    {
      "id": "34d5cb00-d5b6-4827-961c-eca580b88f2d",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "other",
      "raw_text": "modular design",
      "normalized_text": "modular design",
      "context": "The Phase 1 clinical trial is a modular design, beginning with a dose escalation for the initial administration of CT7439 to patients.",
      "source_url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "bba5f8961a561fe97aea723b272c97858473a372daaade4070264acd144de050",
      "canonical_text": "MODULARDESIGN",
      "mention_class": "junk"
    },
    {
      "id": "22b3bda4-289f-4e50-8f54-97cebb20c1b3",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "other",
      "raw_text": "dose escalation",
      "normalized_text": "dose escalation",
      "context": "The Phase 1 clinical trial is a modular design, beginning with a dose escalation for the initial administration of CT7439 to patients.",
      "source_url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "8c502c1908ead176905fe13fdcfa7ef0b2611d11a8fd08f24cdade650d86d16d",
      "canonical_text": "DOSEESCALATION",
      "mention_class": "junk"
    },
    {
      "id": "dbb77ad4-746c-4ae4-bcdf-9ea6fdcca1b5",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "modality",
      "raw_text": "Capsules",
      "normalized_text": "capsules",
      "context": "Primary Treatment:  CT7439 Capsules (0.5 mg, 1mg, 3mg)",
      "source_url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "fingerprint": "8a2013111d2548cc81a3e2502bf0dffeba749a91e72b9ccac65b089e78b99635",
      "canonical_text": "CAPSULES",
      "mention_class": "junk"
    },
    {
      "id": "41dd2b20-055b-4870-a76a-099094c1e195",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "other",
      "raw_text": "Trial",
      "normalized_text": "trial",
      "context": "Trial | NCT06600789",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
      "fingerprint": "1b5e084b6b0a9c8d72a1758ff1a84a8551c1cd88038c79d8cfcfabb5bb5707eb",
      "canonical_text": "TRIAL",
      "mention_class": "junk"
    },
    {
      "id": "789b433a-054a-4221-a8cb-e10b02ff7d80",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "modality",
      "raw_text": "cyclin K glue degrader",
      "normalized_text": "cyclin k glue degrader",
      "context": "CT7439, a dual inhibitor of CDK12/13 and a cyclin K glue degrader",
      "source_url": "https://link.springer.com/article/10.1186/s13058-025-02101-x",
      "fingerprint": "cd0733e0efb48bc31feabe50ff6d6f00c873f9094a69b963925f638d251c3e78",
      "canonical_text": "CYCLINKGLUEDEGRADER",
      "mention_class": "junk"
    },
    {
      "id": "183596f7-a7db-42c4-b887-feaef398ccf6",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "indication",
      "raw_text": "breast cancer",
      "normalized_text": "breast cancer",
      "context": "including breast cancer (NCT06600789).",
      "source_url": "https://link.springer.com/article/10.1186/s13058-025-02101-x",
      "fingerprint": "8ec2c31742f987b341edfc6cbbba3ea19d6e8e20c75ef3903d87b2a94a131036",
      "canonical_text": "BREASTCANCER",
      "mention_class": "junk"
    },
    {
      "id": "30442cd2-10c6-47d4-b74b-ac6a43efece1",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "other",
      "raw_text": "10.1186/s13058-025-02101-x",
      "normalized_text": "10.1186/s13058-025-02101-x",
      "context": "https://link.springer.com/article/10.1186/s13058-025-02101-x",
      "source_url": "https://link.springer.com/article/10.1186/s13058-025-02101-x",
      "fingerprint": "931dffc7308c5f034104deb71f477dabfb27ced1e9af7fa23e5e4b68e6d9b2f7",
      "canonical_text": "101186S1305802502101X",
      "mention_class": "junk"
    },
    {
      "id": "a202e744-b512-47b2-a542-d537ee26f314",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "sponsor",
      "raw_text": "Carrick Therapeutics Limited",
      "normalized_text": "carrick therapeutics limited",
      "context": "NCT06600789: An ongoing trial by Carrick Therapeutics Limited",
      "source_url": "https://fdaaa.trialstracker.net/trial/NCT06600789/",
      "fingerprint": "f0a01b94d607fb78684004863f790accca13193267904fd2456af3ce36f79de8",
      "canonical_text": "CARRICKTHERAPEUTICSLIMITED",
      "mention_class": "junk"
    },
    {
      "id": "5192774c-6972-4622-b6e4-7f3b4627e497",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "sponsor",
      "raw_text": "Carrick Therapeutics",
      "normalized_text": "carrick therapeutics",
      "context": "NCT06600789: An ongoing trial by Carrick Therapeutics Limited",
      "source_url": "https://fdaaa.trialstracker.net/trial/NCT06600789/",
      "fingerprint": "488272a05a0baf4d986974cea1914a364afe02232186e80dc93e515262c883f1",
      "canonical_text": "CARRICKTHERAPEUTICS",
      "mention_class": "junk"
    },
    {
      "id": "2211f9e5-190f-4e25-b3a4-0f917ae380f7",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "other",
      "raw_text": "Phase 1/2",
      "normalized_text": "phase 1/2",
      "context": "Title  A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439",
      "source_url": "https://fdaaa.trialstracker.net/trial/NCT06600789/",
      "fingerprint": "3dcf6dae65abba5d9c7df6ec5422c1f3363a0974f52d6475901d9295216bffa1",
      "canonical_text": "PHASE12",
      "mention_class": "junk"
    },
    {
      "id": "31e81764-64c6-4824-bc14-cc50b0c8d892",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "other",
      "raw_text": "Phase 1/2 Study",
      "normalized_text": "phase 1/2 study",
      "context": "Title  A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439",
      "source_url": "https://fdaaa.trialstracker.net/trial/NCT06600789/",
      "fingerprint": "a3848d54c108179b35b4f7ca0b0366124b34db2fd78acf59309ec3e65b87f79c",
      "canonical_text": "PHASE12STUDY",
      "mention_class": "junk"
    },
    {
      "id": "979cb23f-5869-4520-8e2c-eb30ce8de4de",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "other",
      "raw_text": "A Modular, Multi-Part, Multi-Arm",
      "normalized_text": "a modular, multi-part, multi-arm",
      "context": "Title  A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439",
      "source_url": "https://fdaaa.trialstracker.net/trial/NCT06600789/",
      "fingerprint": "56712a5c44d246d4dc922355fee164d94cc1873fe16215090a1a2053b29dfb80",
      "canonical_text": "AMODULARMULTIPARTMULTIARM",
      "mention_class": "junk"
    },
    {
      "id": "1e2cdce4-71ba-4c64-b0fd-f70ee0ef5db7",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "other",
      "raw_text": "Safety",
      "normalized_text": "safety",
      "context": "Title  A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439",
      "source_url": "https://fdaaa.trialstracker.net/trial/NCT06600789/",
      "fingerprint": "624f9ff6f0ccf745e3c76aa17ae081a258df43c86e13d03c9ab17ba785c8fb7a",
      "canonical_text": "SAFETY",
      "mention_class": "junk"
    },
    {
      "id": "71389e55-4936-41fe-a9a9-5a49a6c0518c",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "other",
      "raw_text": "Tolerability",
      "normalized_text": "tolerability",
      "context": "Title  A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439",
      "source_url": "https://fdaaa.trialstracker.net/trial/NCT06600789/",
      "fingerprint": "51751470c3a4ba8c823afbdff5d009d8e1456054e6be9b439ccd5f9dcc84a05d",
      "canonical_text": "TOLERABILITY",
      "mention_class": "junk"
    },
    {
      "id": "7c5e644d-b688-4704-bf9a-dd7201f51dc8",
      "created_at": "2025-12-14T21:11:48.796165+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "34a411d6-1484-4373-b8ed-33570d700971",
      "result_id": "cb1cb0be-7fc9-4cbc-8b99-14fa80360220",
      "mention_type": "other",
      "raw_text": "Safety and Tolerability",
      "normalized_text": "safety and tolerability",
      "context": "Title  A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439",
      "source_url": "https://fdaaa.trialstracker.net/trial/NCT06600789/",
      "fingerprint": "51e0ad2fe566f71de40a5d5302a6e3287e5c8c67b16c7398d9aff190c5a520ce",
      "canonical_text": "SAFETYANDTOLERABILITY",
      "mention_class": "junk"
    },
    {
      "id": "4495ba8d-a070-4780-a95b-02500aab4800",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "other",
      "raw_text": "U.S. Food and Drug Administration (FDA)",
      "normalized_text": "u.s. food and drug administration (fda)",
      "context": "the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439",
      "source_url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "292d25637256d0ce49847a95237c44e034f1e1eff02db73ad5c228c1ebc27e0a",
      "canonical_text": "USFOODANDDRUGADMINISTRATIONFDA",
      "mention_class": "junk"
    },
    {
      "id": "884254c3-c8b1-4b15-a7fb-ffb30fb4f982",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "other",
      "raw_text": "Food and Drug Administration",
      "normalized_text": "food and drug administration",
      "context": "the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application",
      "source_url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "b5bd0c11bdf647da1ce9828dc1a306144e85915a5d8eb00227b810d1446f9490",
      "canonical_text": "FOODANDDRUGADMINISTRATION",
      "mention_class": "junk"
    },
    {
      "id": "5222577e-a832-4520-ad22-fc8da3efb855",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "other",
      "raw_text": "(FDA)",
      "normalized_text": "(fda)",
      "context": "U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application",
      "source_url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "844ca094087e1b3ea425fcb4795c182c3c6747808b339f708da49f502763b927",
      "canonical_text": "FDA",
      "mention_class": "junk"
    },
    {
      "id": "02a91d42-f3b4-4118-ae17-56a2b3cca3cd",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "other",
      "raw_text": "(IND)",
      "normalized_text": "(ind)",
      "context": "Company’s Investigational New Drug (IND) application for CT7439",
      "source_url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "c7b71e487ffe51183e6c6f3fd90c7ee56eadd52f351f3351234e89ec3684017c",
      "canonical_text": "IND",
      "mention_class": "junk"
    },
    {
      "id": "705c00c1-959b-48db-b917-294a7bc66a0a",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "target",
      "raw_text": "(CDK12/13)",
      "normalized_text": "(cdk12/13)",
      "context": "cyclin dependent kinase 12/13 (CDK12/13) inhibitor.",
      "source_url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "fingerprint": "292afd53f7ab2421affc7109d17ddc590b4668f35947a39f5294c97621b82a0c",
      "canonical_text": "CDK1213",
      "mention_class": "drug_code_like"
    },
    {
      "id": "afe2323b-69de-455a-95f4-527437b0a387",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "other",
      "raw_text": "A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study",
      "normalized_text": "a modular, multi-part, multi-arm, phase 1/2 study",
      "context": "A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
      "fingerprint": "ea079ab67b92748d75572292357d3631aa5196d0b51ba3b4d48ff7e5621d9940",
      "canonical_text": "AMODULARMULTIPARTMULTIARMPHASE12STUDY",
      "mention_class": "junk"
    },
    {
      "id": "67b902af-6b50-4b60-b574-111084f1ae69",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "other",
      "raw_text": "Anticancer Treatments",
      "normalized_text": "anticancer treatments",
      "context": "CT7439 Alone and in Combination With Anticancer Treatments in Participants With Solid Malignancies",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
      "fingerprint": "38928a2634d8ba7a4c797eee259ce7419b361b0f4df8e85e3c8ea93de1948075",
      "canonical_text": "ANTICANCERTREATMENTS",
      "mention_class": "junk"
    },
    {
      "id": "17df6e9b-7fa7-4937-8d56-bcb49db32ef9",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "indication",
      "raw_text": "Solid Malignancies",
      "normalized_text": "solid malignancies",
      "context": "Anticancer Treatments in Participants With Solid Malignancies",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
      "fingerprint": "8b9673e9be7e4424c356e8477ee9d387ae69efa32cc887f7670c8c1ca252d39b",
      "canonical_text": "SOLIDMALIGNANCIES",
      "mention_class": "junk"
    },
    {
      "id": "0e76d997-e3c3-4cd4-a6d7-6e1789a402d1",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "other",
      "raw_text": "U.S. FDA",
      "normalized_text": "u.s. fda",
      "context": "Carrick Therapeutics Declares the U.S. FDA Approval the IND for CT7439",
      "source_url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
      "fingerprint": "84175e376d2cf8d1780e7a44589b39e89e583472f34bf869fce0429b000fbddc",
      "canonical_text": "USFDA",
      "mention_class": "junk"
    },
    {
      "id": "466666e9-2938-4ca2-89bd-c65bfa8766ef",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "other",
      "raw_text": "September 13, 2023",
      "normalized_text": "september 13, 2023",
      "context": "As of September 13, 2023, there are 1 investigational drugs for the CDC7 and CDK12 and CDK13 target",
      "source_url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
      "fingerprint": "8318adf5c4f5cf0172e23154c437d50e8112def587163d1968865a7e1fd18437",
      "canonical_text": "SEPTEMBER132023",
      "mention_class": "drug_code_like"
    },
    {
      "id": "0d25172b-c4c0-407a-8eee-8386d3669a2b",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "other",
      "raw_text": "1 investigational drugs",
      "normalized_text": "1 investigational drugs",
      "context": "there are 1 investigational drugs for the CDC7 and CDK12 and CDK13 target",
      "source_url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
      "fingerprint": "e011c4519da27bc411d9dfd87e37e221b6ac6bd751f5f0864eb54d10cdd6f931",
      "canonical_text": "1INVESTIGATIONALDRUGS",
      "mention_class": "junk"
    },
    {
      "id": "7cac91b9-73e6-42ed-8980-3f5c9ae88454",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "target",
      "raw_text": "CDC7",
      "normalized_text": "cdc7",
      "context": "investigational drugs for the CDC7 and CDK12 and CDK13 target",
      "source_url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
      "fingerprint": "aea4164d474d5cc8f07eb72e6979e1cafb7f5f1887ff6a454092fddca82e6012",
      "canonical_text": "CDC7",
      "mention_class": "drug_code_like"
    },
    {
      "id": "ca02b3d0-4957-4ce9-8d77-c3f3a6565144",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "other",
      "raw_text": "4 applicable indications",
      "normalized_text": "4 applicable indications",
      "context": "including 4 applicable indications,2 R&D institutions involved, and as many as 29 patents.",
      "source_url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
      "fingerprint": "c9cd6acd81eee1ca1d2795c09f0aaf8831a2f52c8f414e07cfa64258255be0e1",
      "canonical_text": "4APPLICABLEINDICATIONS",
      "mention_class": "junk"
    },
    {
      "id": "a2037a6c-13f0-472e-b7ff-fee90a2c8f89",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "other",
      "raw_text": "2 R&D institutions",
      "normalized_text": "2 r&d institutions",
      "context": "including 4 applicable indications,2 R&D institutions involved, and as many as 29 patents.",
      "source_url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
      "fingerprint": "65ffb940e3cee10512400ad2519e6c91a5528543eba3ae8f5e73e749a75ef2d0",
      "canonical_text": "2RDINSTITUTIONS",
      "mention_class": "drug_code_like"
    },
    {
      "id": "98b56a6c-4ed0-486c-81a5-f55535479553",
      "created_at": "2025-12-14T21:11:49.021578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "result_id": "80c8d086-5d83-4aeb-ad2e-cac91748067e",
      "mention_type": "other",
      "raw_text": "29 patents",
      "normalized_text": "29 patents",
      "context": "and as many as 29 patents.",
      "source_url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
      "fingerprint": "52f094451ca2ccee4c896f73c6a32a216f7d6b78241dd3bf487e0a5d4582c64a",
      "canonical_text": "29PATENTS",
      "mention_class": "drug_code_like"
    },
    {
      "id": "b1fd45a5-a2e8-4dc9-b716-4489b5efd2e1",
      "created_at": "2025-12-14T21:11:49.516088+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "a0262855-a203-489b-873f-25c60d7f6499",
      "result_id": "5c478f1a-59eb-4cb1-900e-0267627cafd7",
      "mention_type": "drug_code",
      "raw_text": "CT-7439",
      "normalized_text": "ct-7439",
      "context": "Synonyms CT-7439, CT7439 Clinical Trials associated with CT-7439 NCT06600789",
      "source_url": "https://synapse.patsnap.com/drug/8fb030514b004a0eb2b730b10ce2bbd0",
      "fingerprint": "e61265a70d56619ed9fd9fc0697716fc5af610426e25e16637f91b7f3f28cff1",
      "canonical_text": "CT7439",
      "mention_class": "drug_code_like"
    },
    {
      "id": "91b8ab6f-dd5b-4b89-b10a-84034c0d11e3",
      "created_at": "2025-12-14T21:11:49.516088+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "a0262855-a203-489b-873f-25c60d7f6499",
      "result_id": "5c478f1a-59eb-4cb1-900e-0267627cafd7",
      "mention_type": "modality",
      "raw_text": "administered by mouth",
      "normalized_text": "administered by mouth",
      "context": "CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
      "fingerprint": "780fbfffbd8cf823e3dc2edb0964ec5bbe3f1202b2288b12d9a0ac6facbf04ce",
      "canonical_text": "ADMINISTEREDBYMOUTH",
      "mention_class": "junk"
    },
    {
      "id": "7c408026-30af-4073-a80d-8c373b4beb4f",
      "created_at": "2025-12-14T21:11:49.516088+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "a0262855-a203-489b-873f-25c60d7f6499",
      "result_id": "5c478f1a-59eb-4cb1-900e-0267627cafd7",
      "mention_type": "modality",
      "raw_text": "by mouth",
      "normalized_text": "by mouth",
      "context": "CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
      "fingerprint": "bb6cf28c39c6c769596ea18a947b5067308c4067eaf71811ab9f325ab4be1674",
      "canonical_text": "BYMOUTH",
      "mention_class": "junk"
    },
    {
      "id": "2fb44e14-54f5-4023-9bca-2da09b333b50",
      "created_at": "2025-12-14T21:11:49.516088+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "a0262855-a203-489b-873f-25c60d7f6499",
      "result_id": "5c478f1a-59eb-4cb1-900e-0267627cafd7",
      "mention_type": "modality",
      "raw_text": "once a day",
      "normalized_text": "once a day",
      "context": "CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
      "fingerprint": "af0b4f40256f83ab6d022f40036a634ef6dc41ae36d81508afdb9aeca4fad96f",
      "canonical_text": "ONCEADAY",
      "mention_class": "junk"
    },
    {
      "id": "a912f80f-5695-4056-9472-cb7d3281b6b9",
      "created_at": "2025-12-14T21:11:49.516088+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "a0262855-a203-489b-873f-25c60d7f6499",
      "result_id": "5c478f1a-59eb-4cb1-900e-0267627cafd7",
      "mention_type": "modality",
      "raw_text": "monotherapy",
      "normalized_text": "monotherapy",
      "context": "CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
      "fingerprint": "97b83a6bac80edef92eefa17b385b61ad9a29147dac43ac31194d36b585c8270",
      "canonical_text": "MONOTHERAPY",
      "mention_class": "junk"
    },
    {
      "id": "d30233d8-36fb-4794-a61a-6dd5fb06adcf",
      "created_at": "2025-12-14T21:11:49.516088+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "a0262855-a203-489b-873f-25c60d7f6499",
      "result_id": "5c478f1a-59eb-4cb1-900e-0267627cafd7",
      "mention_type": "other",
      "raw_text": "single starting dose",
      "normalized_text": "single starting dose",
      "context": "CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/",
      "fingerprint": "ae7cd52b67bc5079812faf0ab18f8928bcc1853c5df004aeb9b0cc52cd018777",
      "canonical_text": "SINGLESTARTINGDOSE",
      "mention_class": "junk"
    },
    {
      "id": "530e3220-993c-472a-b59c-0f17248d47e8",
      "created_at": "2025-12-14T21:11:49.516088+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "a0262855-a203-489b-873f-25c60d7f6499",
      "result_id": "5c478f1a-59eb-4cb1-900e-0267627cafd7",
      "mention_type": "other",
      "raw_text": "Clinical Study ID",
      "normalized_text": "clinical study id",
      "context": "Clinical Study ID NCT06600789",
      "source_url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "fingerprint": "a04d722b7ead11a6d35809b9fcbc2b0f05e37272dfb5f515aafdd72f503e19dd",
      "canonical_text": "CLINICALSTUDYID",
      "mention_class": "junk"
    },
    {
      "id": "61a21890-1cfe-4df9-ac42-1861e2fe10da",
      "created_at": "2025-12-14T21:11:49.516088+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "a0262855-a203-489b-873f-25c60d7f6499",
      "result_id": "5c478f1a-59eb-4cb1-900e-0267627cafd7",
      "mention_type": "modality",
      "raw_text": "dual inhibitor of CDK12/13",
      "normalized_text": "dual inhibitor of cdk12/13",
      "context": "CT7439, a dual inhibitor of CDK12/13 and a cyclin K glue degrader",
      "source_url": "https://link.springer.com/article/10.1186/s13058-025-02101-x",
      "fingerprint": "84c228df3ea0c5709bb75452ac4a717b28a99459a7af791926f33d39691e60ec",
      "canonical_text": "DUALINHIBITOROFCDK1213",
      "mention_class": "junk"
    },
    {
      "id": "ddb7476a-03c9-4eb6-928a-a88bde8657f6",
      "created_at": "2025-12-14T21:11:49.516088+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "a0262855-a203-489b-873f-25c60d7f6499",
      "result_id": "5c478f1a-59eb-4cb1-900e-0267627cafd7",
      "mention_type": "other",
      "raw_text": "Synonyms",
      "normalized_text": "synonyms",
      "context": "Synonyms CT-7439, CT7439",
      "source_url": "https://synapse.patsnap.com/drug/8fb030514b004a0eb2b730b10ce2bbd0",
      "fingerprint": "e202efd231c55003d2b02a608bf490175d3f32057e03c6f458d8f6fe38f838de",
      "canonical_text": "SYNONYMS",
      "mention_class": "junk"
    },
    {
      "id": "3f6541ff-e16a-41ba-8f63-b6ee9c9d3b57",
      "created_at": "2025-12-14T21:11:49.516088+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "a0262855-a203-489b-873f-25c60d7f6499",
      "result_id": "5c478f1a-59eb-4cb1-900e-0267627cafd7",
      "mention_type": "other",
      "raw_text": "Clinical Trials",
      "normalized_text": "clinical trials",
      "context": "Clinical Trials associated with CT-7439 NCT06600789",
      "source_url": "https://synapse.patsnap.com/drug/8fb030514b004a0eb2b730b10ce2bbd0",
      "fingerprint": "76fb260d65f023181265783e782608c14f2bda7d3d875a4ac6ae0d62f9105f1f",
      "canonical_text": "CLINICALTRIALS",
      "mention_class": "junk"
    },
    {
      "id": "844e3d93-4736-4e1c-a9cf-ea88a1e1f1a2",
      "created_at": "2025-12-14T21:11:49.516088+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "a0262855-a203-489b-873f-25c60d7f6499",
      "result_id": "5c478f1a-59eb-4cb1-900e-0267627cafd7",
      "mention_type": "other",
      "raw_text": "8fb030514b004a0eb2b730b10ce2bbd0",
      "normalized_text": "8fb030514b004a0eb2b730b10ce2bbd0",
      "context": "https://synapse.patsnap.com/drug/8fb030514b004a0eb2b730b10ce2bbd0",
      "source_url": "https://synapse.patsnap.com/drug/8fb030514b004a0eb2b730b10ce2bbd0",
      "fingerprint": "1b039b899c3f4b1e8ae09726e3f19429e6a54615c4a252271fda2edba9202c7f",
      "canonical_text": "8FB030514B004A0EB2B730B10CE2BBD0",
      "mention_class": "junk"
    },
    {
      "id": "567c13bc-c6ad-4d74-a234-28a58c9b0902",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "drug_code",
      "raw_text": "CCR-20",
      "normalized_text": "ccr-20",
      "context": "doi: 10.1158/1078-0432.CCR-20-0394. To test this hypothesis, the phase II TRITON2 study of rucaparib included",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
      "fingerprint": "a62e2e7bd1da4614aab6727ec48288263dbf9e4f889aae2dca84590defd072f2",
      "canonical_text": "CCR20",
      "mention_class": "drug_code_like"
    },
    {
      "id": "2639b4ba-2ca8-4002-b871-b035bbf24744",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "EudraCT Number",
      "normalized_text": "eudract number",
      "context": "EudraCT Number:2016-003162-13",
      "source_url": "https://ichgcp.net/eu-clinical-trials-registry/trial/2016-003162-13/IT",
      "fingerprint": "db297817a288117d9591bee975ff9457e645222b263c781763a7f10bc448760c",
      "canonical_text": "EUDRACTNUMBER",
      "mention_class": "junk"
    },
    {
      "id": "bd0d34cf-9c45-417a-9d76-fbf7e0c0c37d",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "Sponsor's Protocol Code Number",
      "normalized_text": "sponsor's protocol code number",
      "context": "Sponsor's Protocol Code Number:CO-338-052",
      "source_url": "https://ichgcp.net/eu-clinical-trials-registry/trial/2016-003162-13/IT",
      "fingerprint": "5bf10f8756e8726098f1ffa4273c3a0bfdf5e5673d7c2008023b09f1c6daf257",
      "canonical_text": "SPONSORSPROTOCOLCODENUMBER",
      "mention_class": "junk"
    },
    {
      "id": "932ec2ec-8ddb-4996-889d-c53a29e42fa3",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "drug_code",
      "raw_text": "CO-338-052",
      "normalized_text": "co-338-052",
      "context": "Sponsor's Protocol Code Number:CO-338-052",
      "source_url": "https://ichgcp.net/eu-clinical-trials-registry/trial/2016-003162-13/IT",
      "fingerprint": "89c3d7896dbabc3a1eb3760080797229c6cf59ab23cd82808a15ab1b148b1756",
      "canonical_text": "CO338052",
      "mention_class": "drug_code_like"
    },
    {
      "id": "d545b5e8-125b-4776-aff0-2481dce1781a",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "drug_code",
      "raw_text": "CO-338",
      "normalized_text": "co-338",
      "context": "A.4.1  | Sponsor's protocol code number  | CO-338-052 A.5.4  | Other Identifiers  | Name: IND Number: 129,840",
      "source_url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT",
      "fingerprint": "ecaab66f851496a83097e1f98087e2f864616f99f87eb9a2e7efdbb5e7c2f1db",
      "canonical_text": "CO338",
      "mention_class": "drug_code_like"
    },
    {
      "id": "a197b4c4-f011-42ce-b2d2-b6cdc0ce2ab9",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "sponsor",
      "raw_text": "Food and Drug Administration",
      "normalized_text": "food and drug administration",
      "context": "On May 15, 2020, the Food and Drug Administration granted accelerated approval",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "3408adb2c7c5c151e593acb203614e3831e87ece8c0ffebe1bbdef0929184911",
      "canonical_text": "FOODANDDRUGADMINISTRATION",
      "mention_class": "junk"
    },
    {
      "id": "78ab1770-5691-4443-84d0-71d51dacfa6c",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "drug_name",
      "raw_text": "RUBRACA",
      "normalized_text": "rubraca",
      "context": "rucaparib (RUBRACA, Clovis Oncology, Inc.)",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "2429daa6723fc1f35f4f2dfac08a36497bf3a27d6545b4414565115e9b008bc9",
      "canonical_text": "RUBRACA",
      "mention_class": "junk"
    },
    {
      "id": "ba5d97c2-59fc-4cc3-baa5-07b1cfd76755",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "sponsor",
      "raw_text": "Clovis Oncology, Inc.",
      "normalized_text": "clovis oncology, inc.",
      "context": "(RUBRACA, Clovis Oncology, Inc.)",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "92e25e5d945a01e950a408229314c76b43e92d0ee8b987ac092493c02d1abe2a",
      "canonical_text": "CLOVISONCOLOGYINC",
      "mention_class": "junk"
    },
    {
      "id": "0cc76588-dad8-4eb3-ac1b-1bf9d641c93b",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "trial_id",
      "raw_text": "TRITON2",
      "normalized_text": "triton2",
      "context": "Efficacy was investigated in TRITON2 (NCT02952534)",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "455cdaef6454a9698f37d356f3aff60b493fe7475b44f6db2955b5ee4ae370ec",
      "canonical_text": "TRITON2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "6f840d72-9756-4cd6-b4fe-ccdbb0156702",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "indication",
      "raw_text": "brca-mutated-metastatic-castration-resistant-prostate",
      "normalized_text": "brca-mutated-metastatic-castration-resistant-prostate",
      "context": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "31a133e4f481bfbe33588c99d538009b02dbe48c6a459b82fb2569e7898e9541",
      "canonical_text": "BRCAMUTATEDMETASTATICCASTRATIONRESISTANTPROSTATE",
      "mention_class": "junk"
    },
    {
      "id": "9c71e1c3-0b00-4cb0-96e5-6ee2caaf7837",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "other",
      "raw_text": "32086346",
      "normalized_text": "32086346",
      "context": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
      "fingerprint": "d913dc0db77bbf3ab3637614939e5481b8e65e9d93b4632ed0ed0b48bd3fa340",
      "canonical_text": "32086346",
      "mention_class": "junk"
    },
    {
      "id": "a244b12e-260a-4eae-9e7a-fbfee7a43eb0",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "other",
      "raw_text": "phase II",
      "normalized_text": "phase ii",
      "context": "the phase II TRITON2 study of rucaparib",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
      "fingerprint": "02c45503c4ee8aa86ab89816fda00cdda103994578e0ef23ac918ff6e29094fb",
      "canonical_text": "PHASEII",
      "mention_class": "junk"
    },
    {
      "id": "4cc04e60-1945-4d44-abe6-0e5ffabb1591",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "other",
      "raw_text": "non-BRCA",
      "normalized_text": "non-brca",
      "context": "deleterious non-BRCA DDR gene alterations.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
      "fingerprint": "2b1f3d8fe1ee3537fccbce91d9d5fb8fef65095de5cf6ea91560579f1398913f",
      "canonical_text": "NONBRCA",
      "mention_class": "junk"
    },
    {
      "id": "0224dd43-72f0-4fad-89a1-dd2673ffef9a",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "target",
      "raw_text": "DDR",
      "normalized_text": "ddr",
      "context": "deleterious non-BRCA DDR gene alterations.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
      "fingerprint": "d1dfa71e9edf836dbaf14e0c6a25ebc18c3392750ca9f051029d1a03745d6846",
      "canonical_text": "DDR",
      "mention_class": "junk"
    },
    {
      "id": "cb36494e-647d-4c40-b36a-796be316574f",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "target",
      "raw_text": "CHEK2",
      "normalized_text": "chek2",
      "context": "CHEK2 (n = 12)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
      "fingerprint": "3f9131cc9e5c28fd6b24f667b0fbb0e21c590bfa68f52206c5b2b53439f443fb",
      "canonical_text": "CHEK2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "3eac45aa-1b45-4e38-acb1-7ac7305eb02f",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "trial_id",
      "raw_text": "129,840",
      "normalized_text": "129,840",
      "context": "129,840, IND",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "0637b557848ec8616a979b46c52d3909e99d41b88ca63ec4fa1c2e8cfc7d2016",
      "canonical_text": "129840",
      "mention_class": "junk"
    },
    {
      "id": "4508b046-235f-4962-abdb-c6118907a4f5",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "other",
      "raw_text": "A.4.1",
      "normalized_text": "a.4.1",
      "context": "A.4.1  | Sponsor's protocol code number  | CO-338-052",
      "source_url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT",
      "fingerprint": "a63157bb961565f1eff5cf838c18317ced9f8f8f9a600cd6a6b6b8d9b1d33638",
      "canonical_text": "A41",
      "mention_class": "junk"
    },
    {
      "id": "c8eb1787-2a05-4447-ba17-772dded11c08",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "trial_id",
      "raw_text": "CO-338-052",
      "normalized_text": "co-338-052",
      "context": "A.4.1  | Sponsor's protocol code number  | CO-338-052",
      "source_url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT",
      "fingerprint": "cc0b871c2794e39262d5454269aef07d328427461f60a9e6ee5d8c6d4c741f08",
      "canonical_text": "CO338052",
      "mention_class": "drug_code_like"
    },
    {
      "id": "4150e0f2-b3a0-441b-acbf-c5d6da8e3e97",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "other",
      "raw_text": "A.5.4",
      "normalized_text": "a.5.4",
      "context": "A.5.4  | Other Identifiers  | Name: IND Number: 129,840",
      "source_url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT",
      "fingerprint": "5a997575f7a072d83b808205ef4da09e879cda8a96beb3897088eee3be67bf9b",
      "canonical_text": "A54",
      "mention_class": "junk"
    },
    {
      "id": "44e267bc-0add-40e1-828d-2b43e90e514d",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "other",
      "raw_text": "IND Number",
      "normalized_text": "ind number",
      "context": "Name: IND Number: 129,840",
      "source_url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT",
      "fingerprint": "c38301885ba29b9a860b1c50eaea0061fc822a13aaafeec6f560814b4bc4b1f7",
      "canonical_text": "INDNUMBER",
      "mention_class": "junk"
    },
    {
      "id": "2856380a-d9b5-4ea9-ac33-abc518d2c15a",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "other",
      "raw_text": "IT",
      "normalized_text": "it",
      "context": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT",
      "source_url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT",
      "fingerprint": "6ee4833e384ade99bc7e42599579b37ad02bf93f9b0eb6632c41020783a0b3f3",
      "canonical_text": "IT",
      "mention_class": "junk"
    },
    {
      "id": "bfd62f8c-058e-4af1-810f-6ab1d83a2c8c",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "target",
      "raw_text": "BRCA1",
      "normalized_text": "brca1",
      "context": "deleterious alteration in BRCA1 or BRCA2.",
      "source_url": "https://academic.oup.com/annonc/article/29/suppl_8/mdy284.002/5140957",
      "fingerprint": "4c2c05bdc058557a1a8524a45151f253190881d2ed182cd9ed95abd444b3dba2",
      "canonical_text": "BRCA1",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "8ea1555a-7767-4518-81eb-9c0a80a0b442",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "target",
      "raw_text": "BRCA2",
      "normalized_text": "brca2",
      "context": "deleterious alteration in BRCA1 or BRCA2.",
      "source_url": "https://academic.oup.com/annonc/article/29/suppl_8/mdy284.002/5140957",
      "fingerprint": "db0044411012a73d82faa784471d88999b5d026fc8e3eb5120262af2dbb545d9",
      "canonical_text": "BRCA2",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "e058544c-6dcb-46e6-87cb-c20a09ae0e34",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "other",
      "raw_text": "mdy284.002",
      "normalized_text": "mdy284.002",
      "context": "https://academic.oup.com/annonc/article/29/suppl_8/mdy284.002/5140957",
      "source_url": "https://academic.oup.com/annonc/article/29/suppl_8/mdy284.002/5140957",
      "fingerprint": "cd93a04cba109406e8141c4fd6a5ee61406dcd18a0b4d17ae42641b3442333de",
      "canonical_text": "MDY284002",
      "mention_class": "drug_code_like"
    },
    {
      "id": "8e817e7d-1f3d-44ea-b752-c1973024b628",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "other",
      "raw_text": "5140957",
      "normalized_text": "5140957",
      "context": "https://academic.oup.com/annonc/article/29/suppl_8/mdy284.002/5140957",
      "source_url": "https://academic.oup.com/annonc/article/29/suppl_8/mdy284.002/5140957",
      "fingerprint": "63f6e0e95788eca9f2aca64c69e7e2367feeb5cbefc50c828dc88625a6db8d2d",
      "canonical_text": "5140957",
      "mention_class": "junk"
    },
    {
      "id": "f0c45d5b-3851-4836-bf46-de70e9382dde",
      "created_at": "2025-12-14T21:11:49.754261+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "result_id": "6365525b-1bb0-4726-bf17-94e7f2f41e18",
      "mention_type": "other",
      "raw_text": "ORG STUDY ID",
      "normalized_text": "org study id",
      "context": "ORG STUDY ID: CO-338-052",
      "source_url": "https://www.mycancergenome.org/content/clinical_trials/NCT02952534/",
      "fingerprint": "7724cf3d330f0f8f3167f4dc6aed60a5ec109fbd0e7b38338a0a35934c58dc20",
      "canonical_text": "ORGSTUDYID",
      "mention_class": "junk"
    },
    {
      "id": "20a0a330-92b1-4f07-a1a3-2c5a3e2a8a46",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "2016-003162-13/IT",
      "normalized_text": "2016-003162-13/it",
      "context": "https://ichgcp.net/eu-clinical-trials-registry/trial/2016-003162-13/IT",
      "source_url": "https://ichgcp.net/eu-clinical-trials-registry/trial/2016-003162-13/IT",
      "fingerprint": "5516befa533f415b555a448fe6e89fef738c95a612125573e5a93e35e3c4e089",
      "canonical_text": "201600316213IT",
      "mention_class": "trial_id_like"
    },
    {
      "id": "19090d2d-9b96-4785-be77-d3823aae0cc4",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "sponsor",
      "raw_text": "www.hra.nhs.uk",
      "normalized_text": "www.hra.nhs.uk",
      "context": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "a68de86f0cd0ed85722b5489391013694b25fa3c20723d3b7ae6dcfce452f7b3",
      "canonical_text": "WWWHRANHSUK",
      "mention_class": "junk"
    },
    {
      "id": "21b59113-c4b7-44d7-b343-df3d9a112ed8",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "sponsor",
      "raw_text": "nhs",
      "normalized_text": "nhs",
      "context": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "65c7dac254387cef24af330de9ae9f1f7e2ed11cbbc4d9e8fce2c3c7e3b1be2c",
      "canonical_text": "NHS",
      "mention_class": "junk"
    },
    {
      "id": "ac4fa591-d4c1-4f1b-af10-49986e25cb16",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "IRAS ID",
      "normalized_text": "iras id",
      "context": "IRAS ID\n\n219516",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "96d08b76b0d92f14caf442875d74de7f67bd42688302d467023ce4bc3a5b0f27",
      "canonical_text": "IRASID",
      "mention_class": "junk"
    },
    {
      "id": "76cac6d2-9270-4cee-91bc-1aaf07b1941c",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "trial_id",
      "raw_text": "219516",
      "normalized_text": "219516",
      "context": "IRAS ID\n\n219516",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "f4d3b6bfcf3a4a2cee922cdedc4d8cd4b4767aa0b7e4ad517eee30b92e0f7dc6",
      "canonical_text": "219516",
      "mention_class": "junk"
    },
    {
      "id": "e86103af-9a10-4d7c-ac3c-0100a03ee96a",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc",
      "normalized_text": "triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc",
      "context": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "a788da86589be614e8b93da47f69d3ca634c00dc7dc40e64943b6fe5b4c7fa40",
      "canonical_text": "TRITON2AMULTICENTEROPENLABELPHASE2STUDYOFRUCAPARIBINMCRPC",
      "mention_class": "junk"
    },
    {
      "id": "72c8b1d1-26b1-4ed1-aa03-5255981507bc",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "modality",
      "raw_text": "multicenter",
      "normalized_text": "multicenter",
      "context": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "ab5507072cffadfeadfc6b6432256c685791dd483029846a80c339605531dcb6",
      "canonical_text": "MULTICENTER",
      "mention_class": "junk"
    },
    {
      "id": "361c196f-47c6-4f7a-96c0-0ec19ec1cac9",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "modality",
      "raw_text": "open-label",
      "normalized_text": "open-label",
      "context": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "source_url": "https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/triton2-a-multicenter-open-label-phase-2-study-of-rucaparib-in-mcrpc/",
      "fingerprint": "118c946621ef9c6de7c6ba7cf70d227fc9a0ff8082c24a4c8fc69eccbade95be",
      "canonical_text": "OPENLABEL",
      "mention_class": "junk"
    },
    {
      "id": "419d03fa-b11f-4f03-81ad-d83981e3cbbc",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "sponsor",
      "raw_text": "stanfordhealthcare.org",
      "normalized_text": "stanfordhealthcare.org",
      "context": "https://stanfordhealthcare.org/trials/a/NCT02952534.html",
      "source_url": "https://stanfordhealthcare.org/trials/a/NCT02952534.html",
      "fingerprint": "0a53350ef5d364ce48750aa5e80a23094c4cd2c73cd0322421fc505109f55d26",
      "canonical_text": "STANFORDHEALTHCAREORG",
      "mention_class": "junk"
    },
    {
      "id": "16be4a6d-2ff2-44c2-b88f-a25a17205074",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "indication",
      "raw_text": "Prostate Cancer",
      "normalized_text": "prostate cancer",
      "context": "Castration-resistant Prostate Cancer",
      "source_url": "https://stanfordhealthcare.org/trials/a/NCT02952534.html",
      "fingerprint": "1283aed9c61d10d402d8b5c6778d961f41b1e513dc6eb2f30732e460fd1c4c0b",
      "canonical_text": "PROSTATECANCER",
      "mention_class": "junk"
    },
    {
      "id": "1d37b168-fcae-42b0-babb-a84473a1672f",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "target",
      "raw_text": "Homologous Recombination Deficiency",
      "normalized_text": "homologous recombination deficiency",
      "context": "Associated With Homologous Recombination Deficiency",
      "source_url": "https://stanfordhealthcare.org/trials/a/NCT02952534.html",
      "fingerprint": "33d624e929cc2ffe006514e0c39558e2b376f36cbb5ea7e95903217255d54379",
      "canonical_text": "HOMOLOGOUSRECOMBINATIONDEFICIENCY",
      "mention_class": "junk"
    },
    {
      "id": "06437e6d-e829-4471-87d8-4f736cec8cda",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "target",
      "raw_text": "Homologous Recombination",
      "normalized_text": "homologous recombination",
      "context": "Homologous Recombination Deficiency",
      "source_url": "https://stanfordhealthcare.org/trials/a/NCT02952534.html",
      "fingerprint": "db9a104a8cc7ce8858cf2c29a2c5b02e9d73203e54cc6f9a69da006a19d4b39d",
      "canonical_text": "HOMOLOGOUSRECOMBINATION",
      "mention_class": "junk"
    },
    {
      "id": "904e3df1-8bb5-4995-b197-b76c241c5b05",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "NCT02952534.html",
      "normalized_text": "nct02952534.html",
      "context": "https://stanfordhealthcare.org/trials/a/NCT02952534.html",
      "source_url": "https://stanfordhealthcare.org/trials/a/NCT02952534.html",
      "fingerprint": "2c0cd5efa68a56c0e21bc12850d50d750820d1b61f7285a8d96498720f5c5017",
      "canonical_text": "NCT02952534HTML",
      "mention_class": "trial_id_like"
    },
    {
      "id": "e720718b-3a5c-46fb-8895-1a34a46e780b",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency",
      "normalized_text": "triton2: a multicenter, open-label phase 2 study of rucaparib in patients with metastatic castration-resistant prostate cancer associated with homologous recombination deficiency",
      "context": "TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency",
      "source_url": "https://stanfordhealthcare.org/trials/a/NCT02952534.html",
      "fingerprint": "ab0abb694022980771f65780841f01a041efa96463bbdc76509011f4356980b4",
      "canonical_text": "TRITON2AMULTICENTEROPENLABELPHASE2STUDYOFRUCAPARIBINPATIENTSWITHMETASTATICCASTRATIONRESISTANTPROSTATECANCERASSOCIATEDWITHHOMOLOGOUSRECOMBINATIONDEFICIENCY",
      "mention_class": "junk"
    },
    {
      "id": "69db0982-26cd-4d67-b993-046e10a262db",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "pubmed.ncbi.nlm.nih.gov",
      "normalized_text": "pubmed.ncbi.nlm.nih.gov",
      "context": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "fingerprint": "004279c76992a69a28b8acea8c916faeebbb73543e2c7db140da08dc46afff58",
      "canonical_text": "PUBMEDNCBINLMNIHGOV",
      "mention_class": "junk"
    },
    {
      "id": "27ecd9be-4f34-4a6f-91a1-4708178d2b38",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "600 mg",
      "normalized_text": "600 mg",
      "context": "rucaparib 600 mg BID",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "fingerprint": "5c76c4ef21d8e879f2a1d6ab3c1956bbd3329aa7a7889420fa90637418fd88ec",
      "canonical_text": "600MG",
      "mention_class": "drug_code_like"
    },
    {
      "id": "02ff5f98-cc1f-45ee-bd9f-1a68e7c50973",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "BID",
      "normalized_text": "bid",
      "context": "rucaparib 600 mg BID",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "fingerprint": "fc72f4301a7d0197ba005f16f0c49ad150b13d4e0981b351dd145096dc1d5b58",
      "canonical_text": "BID",
      "mention_class": "junk"
    },
    {
      "id": "28554f8c-b65b-4016-9ef7-d4242c278e16",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "10.1016/j.eururo.2023.05.021",
      "normalized_text": "10.1016/j.eururo.2023.05.021",
      "context": "DOI:  10.1016/j.eururo.2023.05.021",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "fingerprint": "2c67ed362f6c911da466872b84b2904017329ad1f1d86bbf58fc0ccb9f5942b1",
      "canonical_text": "101016JEURURO202305021",
      "mention_class": "junk"
    },
    {
      "id": "307e451c-8a65-4aa5-a18e-1afa8b26006b",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "10.1158/1078-0432.CCR-20-0394.",
      "normalized_text": "10.1158/1078-0432.ccr-20-0394.",
      "context": "doi: 10.1158/1078-0432.CCR-20-0394.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
      "fingerprint": "def326f9db1fb710f04730bf01969ed4f7ae6270599a495b2b639802d12693b9",
      "canonical_text": "10115810780432CCR200394",
      "mention_class": "junk"
    },
    {
      "id": "cc2994f3-c839-4797-b811-833b2b456b21",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "CCR-20-0394",
      "normalized_text": "ccr-20-0394",
      "context": "10.1158/1078-0432.CCR-20-0394.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
      "fingerprint": "f530f98a37fcabc9e9b1eb7b68b5be29109819ca6f4c3c836e730d4fb95b9617",
      "canonical_text": "CCR200394",
      "mention_class": "drug_code_like"
    },
    {
      "id": "dbb38cb9-2143-4985-845e-c0959ccaa3c9",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "sponsor",
      "raw_text": "www.cancer.fr",
      "normalized_text": "www.cancer.fr",
      "context": "https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "source_url": "https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "fingerprint": "9a2aca13969f3e45683c1197dfced0590998ad96b1d9d4ee3646e38693506c4d",
      "canonical_text": "WWWCANCERFR",
      "mention_class": "junk"
    },
    {
      "id": "f2b962a0-78c6-4e60-aaa2-59b2b40101f6",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "cancer.fr",
      "normalized_text": "cancer.fr",
      "context": "https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "source_url": "https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "fingerprint": "28274f82cbaf286f07c613f473b7c417680949554ec25efcf1ff9f382b7028fd",
      "canonical_text": "CANCERFR",
      "mention_class": "junk"
    },
    {
      "id": "d14ccd60-fe3b-4723-927c-c57ac0368467",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "EudraCT/ID-RCB",
      "normalized_text": "eudract/id-rcb",
      "context": "EudraCT/ID-RCB : 2016-003162-13",
      "source_url": "https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "fingerprint": "0854de19e3511f9edaf7960f0ab3666ea3239f326e23d62536ea3f329ad32ac4",
      "canonical_text": "EUDRACTIDRCB",
      "mention_class": "junk"
    },
    {
      "id": "3871d82b-20ff-44b2-a197-527df55183eb",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "ID-RCB",
      "normalized_text": "id-rcb",
      "context": "EudraCT/ID-RCB : 2016-003162-13",
      "source_url": "https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "fingerprint": "7a9b07338a6c495c0e91dd4fafd4ef7b1be9b971ed2513af2e8bdaaadde10af6",
      "canonical_text": "IDRCB",
      "mention_class": "junk"
    },
    {
      "id": "b2f6e773-0bf7-461d-94cc-acde9f879748",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "http://clinicaltrials.gov/show/NCT02952534",
      "normalized_text": "http://clinicaltrials.gov/show/nct02952534",
      "context": "Liens d'intérêt : http://clinicaltrials.gov/show/NCT02952534",
      "source_url": "https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "fingerprint": "ccfd49b3fa651f4df5038e4b507d9626fdc40983ed347d3a38b8ac629f0c5a6b",
      "canonical_text": "HTTPCLINICALTRIALSGOVSHOWNCT02952534",
      "mention_class": "trial_id_like"
    },
    {
      "id": "a401adbc-6012-4a87-ab79-42dc9fb9bb85",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "normalized_text": "etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "context": "https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "source_url": "https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "fingerprint": "194f9bdf5ff77fd969353870c1da81a30bb15df4b785a742a2efc3afc767b91c",
      "canonical_text": "ETUDETRITON2ETUDEDEPHASE2EVALUANTLEFFICACITEDURUCAPARIBCHEZDESPATIENTSAYANTUNCANCERDELAPROSTATEMETASTATIQUERESISTANTALAC",
      "mention_class": "junk"
    },
    {
      "id": "fe61d4df-e03a-4233-9eb0-494e087ff0a8",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "indication",
      "raw_text": "cancer-de-la-prostate-metastatique-resistant",
      "normalized_text": "cancer-de-la-prostate-metastatique-resistant",
      "context": "https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "source_url": "https://www.cancer.fr/personnes-malades/registre-des-essais-cliniques/etude-triton2-etude-de-phase-2-evaluant-l-efficacite-du-rucaparib-chez-des-patients-ayant-un-cancer-de-la-prostate-metastatique-resistant-a-la-c",
      "fingerprint": "ee4edeef541f75aefb1aa8edec0288e868148a5d59ea955792ab98d7221f2958",
      "canonical_text": "CANCERDELAPROSTATEMETASTATIQUERESISTANT",
      "mention_class": "junk"
    },
    {
      "id": "02a6102e-79a8-4e08-9952-98c61e5e7600",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "sponsor",
      "raw_text": "mayoclinic.elsevierpure.com",
      "normalized_text": "mayoclinic.elsevierpure.com",
      "context": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "source_url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "fingerprint": "f35087f2124bea2eff10fe9fade76f40a76c23f2e5d94c869709d6636196275f",
      "canonical_text": "MAYOCLINICELSEVIERPURECOM",
      "mention_class": "junk"
    },
    {
      "id": "a9925112-0dce-4a95-bcb4-b351de1958be",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "sponsor",
      "raw_text": "mayoclinic",
      "normalized_text": "mayoclinic",
      "context": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "source_url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "fingerprint": "9dc2a6fca105461744bee53ac99216dab9c65837708b4ab8c62e802e51c88c42",
      "canonical_text": "MAYOCLINIC",
      "mention_class": "junk"
    },
    {
      "id": "68433f1a-bedc-47e5-9471-cf5422db573a",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "elsevierpure",
      "normalized_text": "elsevierpure",
      "context": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "source_url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "fingerprint": "b16efc61e1327e05b1d9a2a514ed0ee1315db687ad63533ed576c3bb86c22503",
      "canonical_text": "ELSEVIERPURE",
      "mention_class": "junk"
    },
    {
      "id": "144b2297-4852-4d07-8e0e-735f42446bf9",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "10.1093/annonc/mdy284.002",
      "normalized_text": "10.1093/annonc/mdy284.002",
      "context": "doi: 10.1093/annonc/mdy284.002",
      "source_url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "fingerprint": "626ad62a6db60530bda6eb2a996a99d331894c341111e6bc5f366b2bd48995a8",
      "canonical_text": "101093ANNONCMDY284002",
      "mention_class": "junk"
    },
    {
      "id": "dc7ced7a-0e8e-4928-99b9-53471d027ecb",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "Annals of oncology",
      "normalized_text": "annals of oncology",
      "context": "Annals of oncology : official journal of the European Society for Medical Oncology.",
      "source_url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "fingerprint": "fce766ed5842bf70771d7723aa82c9b2d68e07c6bd8e1b4305e250c21fcfa890",
      "canonical_text": "ANNALSOFONCOLOGY",
      "mention_class": "junk"
    },
    {
      "id": "a0fbf381-3495-4b40-8076-31babf9e6bed",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "sponsor",
      "raw_text": "European Society for Medical Oncology",
      "normalized_text": "european society for medical oncology",
      "context": "official journal of the European Society for Medical Oncology.",
      "source_url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "fingerprint": "fe8aeb8fc613168534d669ce1aef8e45c4107150873d1a02baafe37d37177e19",
      "canonical_text": "EUROPEANSOCIETYFORMEDICALONCOLOGY",
      "mention_class": "junk"
    },
    {
      "id": "f235a869-9c9a-4f19-989d-5e79848f062f",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "2018 Oct 1",
      "normalized_text": "2018 oct 1",
      "context": "2018 Oct 1;29:viii272.",
      "source_url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "fingerprint": "92642e0ec8d601db1df09c14253c01f406309aee2210f1f02be9a583a8c13131",
      "canonical_text": "2018OCT1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "b05e62ad-3307-4ba7-86cd-1ab726e98b92",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "29:viii272",
      "normalized_text": "29:viii272",
      "context": "2018 Oct 1;29:viii272.",
      "source_url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "fingerprint": "aa15276dc99332b3f8ae987d193728edbf2507327047d2ec3375fafa704e5521",
      "canonical_text": "29VIII272",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e93360e1-9d43-4039-abc9-c553979de706",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "normalized_text": "preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "context": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "source_url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "fingerprint": "c8b49eb8a42a7621bc308edc75da01d3c99609f44bb09be9c7591bc217bcf291",
      "canonical_text": "PRELIMINARYRESULTSFROMTRITON2APHASEIISTUDYOFRUCAPARIBIN",
      "mention_class": "junk"
    },
    {
      "id": "4c1dadd5-abf0-4cea-ad38-e3cf913fcf5a",
      "created_at": "2025-12-14T21:11:50.249768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "result_id": "063746cc-47bf-4b80-85ab-07a35de8ceb2",
      "mention_type": "other",
      "raw_text": "phase-ii",
      "normalized_text": "phase-ii",
      "context": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "source_url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "fingerprint": "e860e3ec8166bcdfa92a12a3f12a8c70f9fa6c687b41f60582c0ad08458598f6",
      "canonical_text": "PHASEII",
      "mention_class": "junk"
    },
    {
      "id": "ae22f9ab-5a0b-49de-8847-04a7063484ba",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "patent_id",
      "raw_text": "US10130636B2",
      "normalized_text": "us10130636b2",
      "context": "Publication number     US10130636B2 Application number     US15/920,643",
      "source_url": "https://patents.google.com/patent/US10130636B2/en",
      "fingerprint": "78dfe3853bd50e8d21328896d6e6a5eeab5ccdac769363ca0121ca311b27f80e",
      "canonical_text": "US10130636B2",
      "mention_class": "patent_id_like"
    },
    {
      "id": "1d37f204-5da6-4423-ae1c-09b56dacc4b1",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "drug_code",
      "raw_text": "US15",
      "normalized_text": "us15",
      "context": "Publication number     US10130636B2 Application number     US15/920,643",
      "source_url": "https://patents.google.com/patent/US10130636B2/en",
      "fingerprint": "d0c60db40e9291f43f89247eadda9bf5c1c42630b683f7a18df0728c30b35392",
      "canonical_text": "US15",
      "mention_class": "drug_code_like"
    },
    {
      "id": "995cfdb6-1588-4a71-9176-88770c556e2f",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "trial_id",
      "raw_text": "TRITON2 (NCT02952534)",
      "normalized_text": "triton2 (nct02952534)",
      "context": "Efficacy was investigated in TRITON2 (NCT02952534), an ongoing, multi-center, single arm clinical trial",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "318d269045c335e5ed1ae92d1b62c9e920e9bf57cf6c848bbb6c14f45152fd7b",
      "canonical_text": "TRITON2NCT02952534",
      "mention_class": "trial_id_like"
    },
    {
      "id": "85a2020b-fe17-41e0-bfa7-5777f9a3a57c",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "multi-center",
      "normalized_text": "multi-center",
      "context": "an ongoing, multi-center, single arm clinical trial",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "a8032726605ac30e7c5d2bad9167e063bcf01941bba0f628584da3caa805db94",
      "canonical_text": "MULTICENTER",
      "mention_class": "junk"
    },
    {
      "id": "a700b3f8-4404-4223-8686-546de3f62a60",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "single arm",
      "normalized_text": "single arm",
      "context": "an ongoing, multi-center, single arm clinical trial",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "e1f2bedc53c5481674ca7097e6605b7dcefcef7df150bed1d6910ae17620d829",
      "canonical_text": "SINGLEARM",
      "mention_class": "junk"
    },
    {
      "id": "9bde8e94-d764-48c1-be34-3c521bdd5d03",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "May 15, 2020",
      "normalized_text": "may 15, 2020",
      "context": "On May 15, 2020, the Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.)",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "6f2b70ce483c0c9bdaf0acb66642dae3b5ff76674bf42c089cbcaf84c38ef9c7",
      "canonical_text": "MAY152020",
      "mention_class": "drug_code_like"
    },
    {
      "id": "577fd835-7efc-421e-bb77-103e2c10f739",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "accelerated approval",
      "normalized_text": "accelerated approval",
      "context": "the Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.)",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "e50695c6b561a8be3595488df12476448a3a432fbd584594c1e0fb4db3defb16",
      "canonical_text": "ACCELERATEDAPPROVAL",
      "mention_class": "junk"
    },
    {
      "id": "96096f43-2146-4360-9778-bdd98c2873c6",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "target",
      "raw_text": "brca-mutated",
      "normalized_text": "brca-mutated",
      "context": "URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "3890b6c300543b7949c025b5c676554cbf11eecfdbc94766b9cccced95e10e06",
      "canonical_text": "BRCAMUTATED",
      "mention_class": "junk"
    },
    {
      "id": "48caf8b3-da95-4626-96aa-86e848e02d89",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "indication",
      "raw_text": "metastatic",
      "normalized_text": "metastatic",
      "context": "URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "f44cdc8ce42db7253b7b708c62464fded8b7076e8f61ef76af7c88bd4200ea46",
      "canonical_text": "METASTATIC",
      "mention_class": "junk"
    },
    {
      "id": "7c4aa5b9-b6ba-4885-9db9-0f98eabfda7f",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "indication",
      "raw_text": "castration-resistant",
      "normalized_text": "castration-resistant",
      "context": "URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "1ed925f67f7cf4db09756086737f870b8c39c26b5372c8107689dcba75074b95",
      "canonical_text": "CASTRATIONRESISTANT",
      "mention_class": "junk"
    },
    {
      "id": "ef146df9-bc6f-4323-a28c-19cf3654cbcc",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "indication",
      "raw_text": "prostate",
      "normalized_text": "prostate",
      "context": "URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "936fb090fa4ef11d94a20cabfd35362f05920e5edebed4e6a7969d6711eca853",
      "canonical_text": "PROSTATE",
      "mention_class": "junk"
    },
    {
      "id": "fcb7ba08-1c9d-475d-84b7-f4d1afd9a89c",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "indication",
      "raw_text": "metastatic-castration-resistant-prostate",
      "normalized_text": "metastatic-castration-resistant-prostate",
      "context": "URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "fd989d01489caf5a54ccde1733b667e9d68a112fc21f8cbfcef1f233c6667880",
      "canonical_text": "METASTATICCASTRATIONRESISTANTPROSTATE",
      "mention_class": "junk"
    },
    {
      "id": "57747ccb-3080-4f18-8f96-3938060ac0b9",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "patent_id",
      "raw_text": "6,495,541",
      "normalized_text": "6,495,541",
      "context": "for U.S. Patent 6,495,541 directed to the rucaparib composition of matter.",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "6403771f8504886e8dc698e39d4fd1c5af7da52e42097d74d4f45d0825a4dee9",
      "canonical_text": "6495541",
      "mention_class": "junk"
    },
    {
      "id": "1180104d-63c9-43e1-b7cf-61e26d6128de",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "normalized_text": "rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "context": "URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
      "fingerprint": "45ae23aeba7e72f86873e023f104f3903d196526d05d41ee38b109d08f273416",
      "canonical_text": "RUCAPARIBBRCAMUTATEDMETASTATICCASTRATIONRESISTANTPROSTATE",
      "mention_class": "junk"
    },
    {
      "id": "0b282f14-04d4-44b3-98a8-e556eb8875b7",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "33145877",
      "normalized_text": "33145877",
      "context": "URL: https://pubmed.ncbi.nlm.nih.gov/33145877/",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/33145877/",
      "fingerprint": "707cf9d02b27b36043e2e8d55156bfb1bbf5cce3c7dc5272f34e8e8099c9804a",
      "canonical_text": "33145877",
      "mention_class": "junk"
    },
    {
      "id": "4b287d57-33b6-4379-86ce-bd04bdc7dedf",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "single-arm",
      "normalized_text": "single-arm",
      "context": "the ongoing multicenter, open-label single-arm trial TRITON2.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/33145877/",
      "fingerprint": "51367fa7e6d236ec1ffc35839ad6d84a50beddef89613975a839a8ce7811260f",
      "canonical_text": "SINGLEARM",
      "mention_class": "junk"
    },
    {
      "id": "1c7ae805-37dc-4457-a30e-0ab1d56f13f1",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "doi:",
      "normalized_text": "doi:",
      "context": "doi: 10.1002/onco.13585.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/33145877/",
      "fingerprint": "abc14bbb14b24fcf7132208a4e811ae3491971a3cfc17233b5fe80b15f0312d8",
      "canonical_text": "DOI",
      "mention_class": "junk"
    },
    {
      "id": "2829fc9a-4e17-42ce-bbfb-a5ff0c14e3b7",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "10.1002/onco.13585",
      "normalized_text": "10.1002/onco.13585",
      "context": "doi: 10.1002/onco.13585.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/33145877/",
      "fingerprint": "44fa535326815a2560f3f3481db4c7953a84f2d4a41e947615e75ee478531577",
      "canonical_text": "101002ONCO13585",
      "mention_class": "drug_code_like"
    },
    {
      "id": "93724ddc-c76a-4ca9-b421-2e567f071361",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "5203",
      "normalized_text": "5203",
      "context": "URL: https://drugcentral.org/drugcard/5203",
      "source_url": "https://drugcentral.org/drugcard/5203",
      "fingerprint": "342ea8c72defb77fd59c22df3342cc236547b76369e533c6ec656ddb44e0e8e8",
      "canonical_text": "5203",
      "mention_class": "junk"
    },
    {
      "id": "aad8eeb5-34ea-4e25-8009-77ee3d218e8e",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "EQ 200MG BASE",
      "normalized_text": "eq 200mg base",
      "context": "EQ 200MG BASE RUBRACA ZR PHARMA N209115 Dec. 19, 2016 RX TABLET ORAL 7351701 July 23, 2024",
      "source_url": "https://drugcentral.org/drugcard/5203",
      "fingerprint": "d5ff20beb23b8291df9bbde3b6970e789ea5d8615524ccef63711351dc282520",
      "canonical_text": "EQ200MGBASE",
      "mention_class": "drug_code_like"
    },
    {
      "id": "3a43c5fb-42d5-4d4d-84a2-24d7414f9985",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "200MG",
      "normalized_text": "200mg",
      "context": "EQ 200MG BASE RUBRACA ZR PHARMA N209115 Dec. 19, 2016 RX TABLET ORAL 7351701 July 23, 2024",
      "source_url": "https://drugcentral.org/drugcard/5203",
      "fingerprint": "1094d2817159be3be907f1507b20ddfcfcb1a687a6d2dda685b3da99b14fbfb4",
      "canonical_text": "200MG",
      "mention_class": "drug_code_like"
    },
    {
      "id": "81bf24f5-451d-4bca-b1c5-4f95bc7031c6",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "sponsor",
      "raw_text": "ZR PHARMA",
      "normalized_text": "zr pharma",
      "context": "RUBRACA ZR PHARMA N209115 Dec. 19, 2016",
      "source_url": "https://drugcentral.org/drugcard/5203",
      "fingerprint": "015a9e80fbe029574e200349137bf1509fb12796a1cf9cedc671a23369807be8",
      "canonical_text": "ZRPHARMA",
      "mention_class": "junk"
    },
    {
      "id": "5675f959-6612-479b-9170-55d6ebfa8241",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "N209115",
      "normalized_text": "n209115",
      "context": "ZR PHARMA N209115 Dec. 19, 2016 RX TABLET ORAL",
      "source_url": "https://drugcentral.org/drugcard/5203",
      "fingerprint": "ad89eac34e5d0078cbc16e254a393151094ec6fc1a8c6fbace6f8fad6ac326f8",
      "canonical_text": "N209115",
      "mention_class": "drug_code_like"
    },
    {
      "id": "25410267-9ffc-4ed9-9c28-da80ff5b6dd3",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "Dec. 19, 2016",
      "normalized_text": "dec. 19, 2016",
      "context": "ZR PHARMA N209115 Dec. 19, 2016 RX TABLET ORAL",
      "source_url": "https://drugcentral.org/drugcard/5203",
      "fingerprint": "cda78751908d3cb027f7a08ec28d1a0daba5ff71707cb84c413682e9c9276900",
      "canonical_text": "DEC192016",
      "mention_class": "drug_code_like"
    },
    {
      "id": "c663bcf2-2abd-4b47-8737-2ce07579fb48",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "RX",
      "normalized_text": "rx",
      "context": "Dec. 19, 2016 RX TABLET ORAL 7351701 July 23, 2024",
      "source_url": "https://drugcentral.org/drugcard/5203",
      "fingerprint": "d707a37562b0f27d5ae903cc923667a2719f9683dd4124a94457a7c897a8e435",
      "canonical_text": "RX",
      "mention_class": "junk"
    },
    {
      "id": "91b262bb-5e0f-4a6e-aff0-d29f354c1de2",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "modality",
      "raw_text": "TABLET",
      "normalized_text": "tablet",
      "context": "Dec. 19, 2016 RX TABLET ORAL 7351701 July 23, 2024",
      "source_url": "https://drugcentral.org/drugcard/5203",
      "fingerprint": "f5c31f2db7baa4041a4555f7201f5556cab612ea84272e698a927e5dd84cf8dd",
      "canonical_text": "TABLET",
      "mention_class": "junk"
    },
    {
      "id": "a1cd5caf-5dec-4648-bc27-4757d2b3d5f0",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "modality",
      "raw_text": "ORAL",
      "normalized_text": "oral",
      "context": "RX TABLET ORAL 7351701 July 23, 2024",
      "source_url": "https://drugcentral.org/drugcard/5203",
      "fingerprint": "16876d597ed48418674febe04dd685e929d081419b917f39e2cc8ae6a3417b2c",
      "canonical_text": "ORAL",
      "mention_class": "junk"
    },
    {
      "id": "6bf08d99-48c7-4a61-bafa-99a6c4162be6",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "patent_id",
      "raw_text": "7351701",
      "normalized_text": "7351701",
      "context": "RX TABLET ORAL 7351701 July 23, 2024",
      "source_url": "https://drugcentral.org/drugcard/5203",
      "fingerprint": "5171a3540f61c221fb1b8d61a77f1dba1c4b0f7e5fab0400b6432115097d395f",
      "canonical_text": "7351701",
      "mention_class": "junk"
    },
    {
      "id": "f1005dfe-c726-45fa-985e-1f034f211ec7",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "patent_id",
      "raw_text": "7531530",
      "normalized_text": "7531530",
      "context": "RX TABLET ORAL 7531530 July 23, 2024",
      "source_url": "https://drugcentral.org/drugcard/5203",
      "fingerprint": "feac10101c1410cfd9f1d50e6d01662228300ab213cc456d552288930b8d7a5e",
      "canonical_text": "7531530",
      "mention_class": "junk"
    },
    {
      "id": "40646305-2c0f-457b-80a9-45aa04d984a6",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "July 23, 2024",
      "normalized_text": "july 23, 2024",
      "context": "RX TABLET ORAL 7351701 July 23, 2024",
      "source_url": "https://drugcentral.org/drugcard/5203",
      "fingerprint": "6130e68a97779f3943125445482f30d79a7bb4e76ed2a96858728eafda9a762f",
      "canonical_text": "JULY232024",
      "mention_class": "drug_code_like"
    },
    {
      "id": "6831e956-649f-4375-9074-32e7f93fc1bc",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "1466301",
      "normalized_text": "1466301",
      "context": "URL: https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "bab6d79684f8599c348e42828e3d3e4ac96cf474e5f6e3acacd77fc9b83777aa",
      "canonical_text": "1466301",
      "mention_class": "junk"
    },
    {
      "id": "02db87a5-bdb8-420c-a88a-acb6c1875b8c",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "000155837022001810",
      "normalized_text": "000155837022001810",
      "context": "URL: https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "02c83058b983201bac07664e75baaaeb02ceb557752f9d2c85ec13ede73023e3",
      "canonical_text": "000155837022001810",
      "mention_class": "junk"
    },
    {
      "id": "029a973c-0234-4140-b610-3595e0e536b2",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "clvs-20211231x10k.htm",
      "normalized_text": "clvs-20211231x10k.htm",
      "context": "URL: https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "0d01b6311787f6554976f7ecb67f5833acaae87bb0a31354c0837f519ad0e6db",
      "canonical_text": "CLVS20211231X10KHTM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "3c15c2d8-5039-4c86-bff8-1d4a10fd1674",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "patent term extension",
      "normalized_text": "patent term extension",
      "context": "We were granted patent term extension to November 22, 2023 ... for U.S. Patent 6,495,541 directed to the rucaparib composition of matter.",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "47e57ce670e6909d17a942064509a83f016643f3ded67e24a195495824b5e29f",
      "canonical_text": "PATENTTERMEXTENSION",
      "mention_class": "junk"
    },
    {
      "id": "61feccfb-b4ec-44ab-b679-1edd1d8f4917",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "November 22, 2023",
      "normalized_text": "november 22, 2023",
      "context": "We were granted patent term extension to November 22, 2023 ... for U.S. Patent 6,495,541",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "30b6de09c5107bc68107c12dfae313f408904c45672b9ca64535244ae4dac9cd",
      "canonical_text": "NOVEMBER222023",
      "mention_class": "drug_code_like"
    },
    {
      "id": "9054d8a7-1fa3-430c-a1ef-13745a9c2f10",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "patent_id",
      "raw_text": "U.S. Patent 6,495,541",
      "normalized_text": "u.s. patent 6,495,541",
      "context": "for U.S. Patent 6,495,541 directed to the rucaparib composition of matter.",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "216114305546c2953071a5036a1d6a4f675a905e0f3a6add04524b20145942cf",
      "canonical_text": "USPATENT6495541",
      "mention_class": "patent_id_like"
    },
    {
      "id": "867f7362-876f-4c3e-a0f3-c8751804cf92",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "rucaparib composition of matter",
      "normalized_text": "rucaparib composition of matter",
      "context": "U.S. Patent 6,495,541 directed to the rucaparib composition of matter.",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "addd6462ecd034c6afd1d40c81a39d8318197244cddbabe71a55c149e8de87ac",
      "canonical_text": "RUCAPARIBCOMPOSITIONOFMATTER",
      "mention_class": "junk"
    },
    {
      "id": "4408bb6e-9ee7-4d4f-addc-16697e2de74b",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "rucaparib camsylate salt/polymorph",
      "normalized_text": "rucaparib camsylate salt/polymorph",
      "context": "include the rucaparib camsylate salt/polymorph patent family ... expires in 2031",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "1d665cf149db840e0b57ff231df7922fbc7b61c79bc995a58256a4fd98f1e2b9",
      "canonical_text": "RUCAPARIBCAMSYLATESALTPOLYMORPH",
      "mention_class": "junk"
    },
    {
      "id": "693fdd25-3dc6-4b4b-9f1c-757cf93fdd76",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "rucaparib camsylate salt/polymorph patent family",
      "normalized_text": "rucaparib camsylate salt/polymorph patent family",
      "context": "include the rucaparib camsylate salt/polymorph patent family ... expires in 2031",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "cc932e7ca34d9818e537d6a0648127ea22c26c068443f5b93477faef359ca589",
      "canonical_text": "RUCAPARIBCAMSYLATESALTPOLYMORPHPATENTFAMILY",
      "mention_class": "junk"
    },
    {
      "id": "e8f451a6-32a9-4d92-b101-c34e2e7f14f3",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "2031",
      "normalized_text": "2031",
      "context": "rucaparib camsylate salt/polymorph patent family ... expires in 2031",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "873622529a1602953f09d653d8adb46faf1d1978a22cee65afab1fd5a12ee1e5",
      "canonical_text": "2031",
      "mention_class": "junk"
    },
    {
      "id": "e8746ae5-e91f-4bb3-8006-033b01934bb4",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "high dosage strength rucaparib tablets",
      "normalized_text": "high dosage strength rucaparib tablets",
      "context": "high dosage strength rucaparib tablets ... expires in 2035.",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "6281c65451439ba2d75c638bc130a4f7421da383eab8b9696219ca77ddb007d7",
      "canonical_text": "HIGHDOSAGESTRENGTHRUCAPARIBTABLETS",
      "mention_class": "junk"
    },
    {
      "id": "a4724986-e342-4ce9-a7c1-55b7a60eef59",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "modality",
      "raw_text": "tablets",
      "normalized_text": "tablets",
      "context": "high dosage strength rucaparib tablets ... expires in 2035.",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "94bd04405b57534d698e1a0921fac3b77e7799e145cd2a12925b91fdcccf1634",
      "canonical_text": "TABLETS",
      "mention_class": "junk"
    },
    {
      "id": "b6304b92-5204-4c8e-aa43-e6d509057ad1",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "2035",
      "normalized_text": "2035",
      "context": "high dosage strength rucaparib tablets ... expires in 2035.",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "f9e4ccd4e028324fbddb9f376b75e0c082e9e74b8284e2e727aa7ee29def4eb0",
      "canonical_text": "2035",
      "mention_class": "junk"
    },
    {
      "id": "2f8ddd7f-2a2b-4f7e-bd24-8097a738800b",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "1315-News",
      "normalized_text": "1315-news",
      "context": "URL: https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "b8b83d69a1aced72c6105b5d42683fe03466020823b918741479382db233b51c",
      "canonical_text": "1315NEWS",
      "mention_class": "drug_code_like"
    },
    {
      "id": "84a30e50-cf1a-4194-8016-fda3be88ee25",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "347824",
      "normalized_text": "347824",
      "context": "URL: https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "c583ae77b919cfe2c1491353b3f849929e0d25cd586c57034f85e068f8007b30",
      "canonical_text": "347824",
      "mention_class": "junk"
    },
    {
      "id": "1fffe69a-465d-4c0a-bef4-52cd9329d52c",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "sponsor",
      "raw_text": "Clovis-Oncology",
      "normalized_text": "clovis-oncology",
      "context": "URL: https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "e57836b8854353c126c17868b9c213c41ec7bd15fe81b428e10c2c5945b4ed41",
      "canonical_text": "CLOVISONCOLOGY",
      "mention_class": "junk"
    },
    {
      "id": "f704acc9-4c1b-47d6-b34c-88c7cf773eca",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "Notice-of-Allowance",
      "normalized_text": "notice-of-allowance",
      "context": "URL: https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "2eb62a353448b538a263670f924a81d750d64d6a0d65f68021fca7cd2daad8cb",
      "canonical_text": "NOTICEOFALLOWANCE",
      "mention_class": "junk"
    },
    {
      "id": "ac585ec9-f1cd-4858-ad78-55974874d7a0",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "High-Dosage-Strength-Tablet-Patent",
      "normalized_text": "high-dosage-strength-tablet-patent",
      "context": "URL: https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "8c0b28f3c83255c44988d2e2b70bb8cbb96405a7e8070be1ea47b15521637258",
      "canonical_text": "HIGHDOSAGESTRENGTHTABLETPATENT",
      "mention_class": "junk"
    },
    {
      "id": "ad32c43a-9096-430c-abc3-7e43d4b572f7",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "Rucaparib-High-Dosage-Strength-Tablet-Patent",
      "normalized_text": "rucaparib-high-dosage-strength-tablet-patent",
      "context": "URL: https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "886d1fb55567d34265998c14e7f818750d888cdbd45e21995f3d628da06c24c6",
      "canonical_text": "RUCAPARIBHIGHDOSAGESTRENGTHTABLETPATENT",
      "mention_class": "junk"
    },
    {
      "id": "8ed285d8-38f0-4648-8098-b167d0006188",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "Notice of Allowance",
      "normalized_text": "notice of allowance",
      "context": "Notice of Allowance ... in United States Patent Application 14/828,065 with claims directed to high dosage strength rucaparib camsylate formulations.",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "503801d7fe9aab66ac72b26cf3849f12af65c00498f9a9003c0f6ac1117b9fad",
      "canonical_text": "NOTICEOFALLOWANCE",
      "mention_class": "junk"
    },
    {
      "id": "967e7a30-6974-4743-b68b-269dae7845ff",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "patent_id",
      "raw_text": "United States Patent Application 14/828,065",
      "normalized_text": "united states patent application 14/828,065",
      "context": "Notice of Allowance ... in United States Patent Application 14/828,065 with claims directed to high dosage strength rucaparib camsylate formulations.",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "2e01f5228edcbd16f5a307f7943bf0bb0139633016e481929bd72939fbe94a5e",
      "canonical_text": "UNITEDSTATESPATENTAPPLICATION14828065",
      "mention_class": "junk"
    },
    {
      "id": "f34935f4-819e-41ef-8c84-707d27da88b4",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "patent_id",
      "raw_text": "14/828,065",
      "normalized_text": "14/828,065",
      "context": "United States Patent Application 14/828,065 with claims directed to high dosage strength rucaparib camsylate formulations.",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "8091a6703e869acbef18e3b0a16470ff40a67442afe6f395926cce7ebfd28c7e",
      "canonical_text": "14828065",
      "mention_class": "junk"
    },
    {
      "id": "3bc6ea18-bf7f-4a26-a69e-a90d1199e457",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "rucaparib camsylate formulations",
      "normalized_text": "rucaparib camsylate formulations",
      "context": "claims directed to high dosage strength rucaparib camsylate formulations.",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "c9eb8998a02cb79454d451b1ecc53149f5e0bd8bbed73bb2fce5e6b2ffb458ec",
      "canonical_text": "RUCAPARIBCAMSYLATEFORMULATIONS",
      "mention_class": "junk"
    },
    {
      "id": "5a0cba06-f7f5-44fd-9563-dc5332fb861a",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "high dosage strength rucaparib formulation patent",
      "normalized_text": "high dosage strength rucaparib formulation patent",
      "context": "the high dosage strength rucaparib formulation patent will expire in 2035",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "dc2638955abc7e1b61e5c566e568ddd73f52ecd932f79eff1f37479aafb3a5ff",
      "canonical_text": "HIGHDOSAGESTRENGTHRUCAPARIBFORMULATIONPATENT",
      "mention_class": "junk"
    },
    {
      "id": "a9b165ec-3ce3-4959-9afd-ec60a7d42762",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "Orange Book-listed",
      "normalized_text": "orange book-listed",
      "context": "the 10th Orange Book-listed patent for rucaparib.",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "e4c839d7ec270efc09b8892a13ce4e474df4546422a2b0f2d673e900d2cf9433",
      "canonical_text": "ORANGEBOOKLISTED",
      "mention_class": "junk"
    },
    {
      "id": "73e3e96a-2528-4848-810d-ca0e6c09ac41",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "other",
      "raw_text": "10th Orange Book-listed patent",
      "normalized_text": "10th orange book-listed patent",
      "context": "the 10th Orange Book-listed patent for rucaparib.",
      "source_url": "https://www.americanpharmaceuticalreview.com/1315-News/347824-Clovis-Oncology-Announces-Notice-of-Allowance-for-Rucaparib-High-Dosage-Strength-Tablet-Patent/",
      "fingerprint": "5b84390a6c8ff87f31da5a0599c1327fe00413ad455c80fb2ba3576ded04c02c",
      "canonical_text": "10THORANGEBOOKLISTEDPATENT",
      "mention_class": "junk"
    },
    {
      "id": "1ec977a2-24a6-4fc0-bdaa-a796cc704e18",
      "created_at": "2025-12-14T21:19:21.297341+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "result_id": "3449d20a-228c-4000-896b-f5fdcc54b9fd",
      "mention_type": "patent_id",
      "raw_text": "US15/920,643",
      "normalized_text": "us15/920,643",
      "context": "Application number US15/920,643",
      "source_url": "https://patents.google.com/patent/US10130636B2/en",
      "fingerprint": "0498dbfcd1d75b00065ff21f2646ec63d87b6024c21ad40ec80e9d53a7f100e6",
      "canonical_text": "US15920643",
      "mention_class": "patent_id_like"
    },
    {
      "id": "cf6c6d9a-dc7b-4a05-8350-117aec345491",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "trial_id",
      "raw_text": "NCT02975934",
      "normalized_text": "nct02975934",
      "context": "center Phase 2 single-arm study of Rubraca in men with mCRPC The TRITON3 study (NCT02975934) is a Phase 3 comparative study in men with mCRPC",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "2c1bb8dd2306c4582a04776c2731b1c79b0f560768192e3f4014e33fa23eacce",
      "canonical_text": "NCT02975934",
      "mention_class": "trial_id_like"
    },
    {
      "id": "8e71f3df-5830-48cd-b61c-a06cec8a355e",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "trial_id",
      "raw_text": "NCT04455750",
      "normalized_text": "nct04455750",
      "context": "lliance for Clinical Trials in Oncology is sponsoring the Phase 3 CASPAR study (NCT04455750)",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837021001668/clvs-20201231x10k.htm",
      "fingerprint": "f745318521658633006d236cc3ca559e0b48f24688d2ad147fd256a257f4a227",
      "canonical_text": "NCT04455750",
      "mention_class": "trial_id_like"
    },
    {
      "id": "1c90b629-d1b2-460b-a552-87cc2461a7e9",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "drug_code",
      "raw_text": "W81XWH",
      "normalized_text": "w81xwh",
      "context": "TRITON2 was funded by Clovis Oncology. Grant W81XWH-17-1-0124",
      "source_url": "https://www.mdpi.com/1718-7729/29/6/333",
      "fingerprint": "53df26de691cdac01157ec2dd37d2faca07775b2e49e0c7728625673c8fd5a8d",
      "canonical_text": "W81XWH",
      "mention_class": "drug_code_like"
    },
    {
      "id": "6b048523-efd1-463f-a0c8-7a6979dbb43f",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "TRITON3",
      "normalized_text": "triton3",
      "context": "The TRITON3 study (NCT02975934) is a Phase 3 comparative study",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "31e95afd1b7484c22f58a798397f247accfd2404380dc36351de037f2cc6451c",
      "canonical_text": "TRITON3",
      "mention_class": "drug_code_like"
    },
    {
      "id": "d1e9da6a-d5a7-481d-9640-a0b4f2f533cf",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "Phase 3",
      "normalized_text": "phase 3",
      "context": "NCT02975934) is a Phase 3 comparative study in men with mCRPC",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "385f8dc5007252764743cdfb6618a8cae778b4ee2d29d34b105544890ff2e6ef",
      "canonical_text": "PHASE3",
      "mention_class": "junk"
    },
    {
      "id": "1859efe4-e5a6-492d-a415-0ec07aa167a5",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "comparative",
      "normalized_text": "comparative",
      "context": "is a Phase 3 comparative study in men with mCRPC",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837022001810/clvs-20211231x10k.htm",
      "fingerprint": "537470cf85b8e0e6a1f74b814127ed2cf0bc35e5490563ba50d10b969e38711b",
      "canonical_text": "COMPARATIVE",
      "mention_class": "junk"
    },
    {
      "id": "fe36a582-28b5-495a-8c60-aeeb05b422c1",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "000155837021001668",
      "normalized_text": "000155837021001668",
      "context": "https://www.sec.gov/Archives/edgar/data/1466301/000155837021001668/clvs-20201231x10k.htm",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837021001668/clvs-20201231x10k.htm",
      "fingerprint": "df8af5c4ba34a3dc67898561858a82ec34575265020dca0a538a13c4bc548163",
      "canonical_text": "000155837021001668",
      "mention_class": "junk"
    },
    {
      "id": "8bd446ae-7682-43c0-bfb1-4e155c5a3606",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "clvs-20201231x10k.htm",
      "normalized_text": "clvs-20201231x10k.htm",
      "context": "https://www.sec.gov/Archives/edgar/data/1466301/000155837021001668/clvs-20201231x10k.htm",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837021001668/clvs-20201231x10k.htm",
      "fingerprint": "e858fabcb0338e92c4c0be2eb6dcdc91bce4e2d3235df3c0207e405d42d7ab7f",
      "canonical_text": "CLVS20201231X10KHTM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "14994dcd-dfdb-4b7c-947e-b31720de247f",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "sponsor",
      "raw_text": "Alliance for Clinical Trials in Oncology",
      "normalized_text": "alliance for clinical trials in oncology",
      "context": "The Alliance for Clinical Trials in Oncology is sponsoring the Phase 3 CASPAR study",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837021001668/clvs-20201231x10k.htm",
      "fingerprint": "0f36a93352f82918983388dbd7614c0e52555f818c01e6058eefeec17d0ba827",
      "canonical_text": "ALLIANCEFORCLINICALTRIALSINONCOLOGY",
      "mention_class": "junk"
    },
    {
      "id": "700ac127-5a33-4383-896d-856101acc454",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "CASPAR",
      "normalized_text": "caspar",
      "context": "Phase 3 CASPAR study (NCT04455750)",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1466301/000155837021001668/clvs-20201231x10k.htm",
      "fingerprint": "224b6ec1aee25e5cf48282a4c5b938c0a013017a2f7a7afdfd7d1a8b57c8aa24",
      "canonical_text": "CASPAR",
      "mention_class": "junk"
    },
    {
      "id": "f09787af-9ba8-44a9-a073-ea52d10d8ca2",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "clovis-oncology-s",
      "normalized_text": "clovis-oncology-s",
      "context": "https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations",
      "source_url": "https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations",
      "fingerprint": "fbc02946a3f8475843217feae0c748e588754916b8ecac87b0fb1289ead79dfd",
      "canonical_text": "CLOVISONCOLOGYS",
      "mention_class": "junk"
    },
    {
      "id": "d65731ca-88ae-4e01-b527-0d05ce661d6b",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "brca1-2",
      "normalized_text": "brca1-2",
      "context": "https://www.biospace.com/.../mcrpc-in-patients-with-brca1-2-gene-mutations",
      "source_url": "https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations",
      "fingerprint": "6bac5b7f58c19d70b12fbf4ebbb398831bed906e93a537a4cac254483fd65694",
      "canonical_text": "BRCA12",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "6eb74ef6-598a-487a-8f84-833a063e752c",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "drug_name",
      "raw_text": "Rubraca®",
      "normalized_text": "rubraca®",
      "context": "TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer",
      "source_url": "https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations",
      "fingerprint": "ade6f4f4143bbe7fa56c087ceb1f28d1fc2d7ccb05e81209ee0f1def0820e998",
      "canonical_text": "RUBRACA",
      "mention_class": "junk"
    },
    {
      "id": "d44ac19d-416e-430a-863e-d66e961246e4",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "target",
      "raw_text": "BRCA1/2",
      "normalized_text": "brca1/2",
      "context": "harboring BRCA1/2 mutations",
      "source_url": "https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations",
      "fingerprint": "365c0c9a67dff47bee7526403446eb0b9c1d5396fc69b61e6c55c4b4e59cd3fe",
      "canonical_text": "BRCA12",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "ae1bf0b2-b00c-4189-befb-bd481746e564",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "target",
      "raw_text": "BRCA1/2 mutations",
      "normalized_text": "brca1/2 mutations",
      "context": "harboring BRCA1/2 mutations",
      "source_url": "https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations",
      "fingerprint": "27ebb0beb226fcf4b2c41b06b2d1589d91594be6c52097816617e386346836d0",
      "canonical_text": "BRCA12MUTATIONS",
      "mention_class": "drug_code_like"
    },
    {
      "id": "15d70960-8d92-4057-a949-82b47dc6fc4f",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "Grade 1-4",
      "normalized_text": "grade 1-4",
      "context": "Most common adverse reactions in TRITON2 (≥ 20%; Grade 1-4) were fatigue/asthenia",
      "source_url": "https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations",
      "fingerprint": "fd727aff8e05c088593e46e4d459a4bae284346f79d5c884bab5c960bd7c4d9e",
      "canonical_text": "GRADE14",
      "mention_class": "drug_code_like"
    },
    {
      "id": "8eb5cde0-57b2-49d3-8547-3d43da200bb3",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "fatigue/asthenia",
      "normalized_text": "fatigue/asthenia",
      "context": "Most common adverse reactions in TRITON2 (≥ 20%; Grade 1-4) were fatigue/asthenia (62%)",
      "source_url": "https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations",
      "fingerprint": "e8776eac6aac86345df17374ea1c02aa94ea17dc167cd31ce42859ce61805561",
      "canonical_text": "FATIGUEASTHENIA",
      "mention_class": "junk"
    },
    {
      "id": "3f08b6f1-b58d-4482-8678-ea4e412b0edf",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "nausea",
      "normalized_text": "nausea",
      "context": "fatigue/asthenia (62%), nausea (52%), anemia (43%)",
      "source_url": "https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations",
      "fingerprint": "c40be050a634b7cc0af2652842f3d780c39252d0b4dde03b6649d87f22da551e",
      "canonical_text": "NAUSEA",
      "mention_class": "junk"
    },
    {
      "id": "f7a3d327-050b-4faf-9b1b-481373717218",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "anemia",
      "normalized_text": "anemia",
      "context": "fatigue/asthenia (62%), nausea (52%), anemia (43%)",
      "source_url": "https://www.biospace.com/journal-of-clinical-oncology-publishes-additional-data-from-clovis-oncology-s-triton2-clinical-trial-evaluating-rubraca-rucaparib-for-the-treatment-of-mcrpc-in-patients-with-brca1-2-gene-mutations",
      "fingerprint": "5a6acf3435fa6bbab53214aae3e429db89adb7b1f83d6223b304317103017f5f",
      "canonical_text": "ANEMIA",
      "mention_class": "junk"
    },
    {
      "id": "88407f47-42ef-4e8e-9ad5-e47a78a899b2",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "1718-7729",
      "normalized_text": "1718-7729",
      "context": "https://www.mdpi.com/1718-7729/29/6/333",
      "source_url": "https://www.mdpi.com/1718-7729/29/6/333",
      "fingerprint": "9531deeb16a9cd173321445b2df7a5483bbe19f178ceefd53b3f85d04bd7dc3c",
      "canonical_text": "17187729",
      "mention_class": "junk"
    },
    {
      "id": "280906fe-1a8e-445f-824e-2fed6c4eb48e",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "sponsor",
      "raw_text": "Clovis Oncology",
      "normalized_text": "clovis oncology",
      "context": "TRITON2 was funded by Clovis Oncology.",
      "source_url": "https://www.mdpi.com/1718-7729/29/6/333",
      "fingerprint": "7a1079fc1708e0b0cb74847356f4eb328b20d8480e709f700c88d878da23993d",
      "canonical_text": "CLOVISONCOLOGY",
      "mention_class": "junk"
    },
    {
      "id": "38c944f8-4d36-438c-86ff-0f0f72d2dec6",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "Grant W81XWH-17-1-0124",
      "normalized_text": "grant w81xwh-17-1-0124",
      "context": "Grant W81XWH-17-1-0124",
      "source_url": "https://www.mdpi.com/1718-7729/29/6/333",
      "fingerprint": "1cb9c474d51eab0d6b3508c2eca085017330e8b594c06a787f5f45b83a973d72",
      "canonical_text": "GRANTW81XWH1710124",
      "mention_class": "drug_code_like"
    },
    {
      "id": "5e49d09c-eb72-4950-8331-38b0c2c1a4d2",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "W81XWH-17-1-0124",
      "normalized_text": "w81xwh-17-1-0124",
      "context": "Grant W81XWH-17-1-0124",
      "source_url": "https://www.mdpi.com/1718-7729/29/6/333",
      "fingerprint": "84b50b44ece052632f560e31510887312f7369f653c6cdfd9ed4465eee377c45",
      "canonical_text": "W81XWH1710124",
      "mention_class": "drug_code_like"
    },
    {
      "id": "b6f86b9b-83ab-43e5-9ab0-5531c1e15568",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "target",
      "raw_text": "PARP1",
      "normalized_text": "parp1",
      "context": "inhibitor of the PARP1, PARP2, and PARP3 enzymes",
      "source_url": "https://ascopost.com/issues/august-25-2020-supplement-genitourinary-cancers-almanac/phase-ii-triton2-study-in-metastatic-castration-resistant-prostate-cancer/",
      "fingerprint": "6e76a87125d8b5cff015210d77abc1a921a4eb05b1b00b4eec97f87892a7ada8",
      "canonical_text": "PARP1",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "2e2ecfe9-f9c2-49f2-bdab-d56259a5bb6e",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "target",
      "raw_text": "PARP2",
      "normalized_text": "parp2",
      "context": "inhibitor of the PARP1, PARP2, and PARP3 enzymes",
      "source_url": "https://ascopost.com/issues/august-25-2020-supplement-genitourinary-cancers-almanac/phase-ii-triton2-study-in-metastatic-castration-resistant-prostate-cancer/",
      "fingerprint": "1616f61c82ab7bd6de81f80320ae93acbf426e155e84bd92cc5e4721164cb8ae",
      "canonical_text": "PARP2",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "b319bc8c-ce51-4774-af63-779fb9ae68e9",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "target",
      "raw_text": "PARP3",
      "normalized_text": "parp3",
      "context": "inhibitor of the PARP1, PARP2, and PARP3 enzymes",
      "source_url": "https://ascopost.com/issues/august-25-2020-supplement-genitourinary-cancers-almanac/phase-ii-triton2-study-in-metastatic-castration-resistant-prostate-cancer/",
      "fingerprint": "4cd4b92a26cfa4ebf8b26c381baa5de1b5d33c2b623a23dec00011c7bdd1f339",
      "canonical_text": "PARP3",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "49a5684a-72ae-47a6-bb13-9b44dc415a78",
      "created_at": "2025-12-14T21:19:22.525022+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "result_id": "28f71f56-1dda-4fa4-a253-6a5ec8320c42",
      "mention_type": "other",
      "raw_text": "deleterious mutation",
      "normalized_text": "deleterious mutation",
      "context": "Have a deleterious mutation in BRCA1/2 or ATM",
      "source_url": "https://stanfordhealthcare.org/trials/a/NCT02952534.html",
      "fingerprint": "e84100e0e6ecd5818196ec14d3938a97a69779f1e793e18f90d329b0f97d33c1",
      "canonical_text": "DELETERIOUSMUTATION",
      "mention_class": "junk"
    },
    {
      "id": "3d7957cd-81ef-46c7-9dc5-06de48d7935c",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "drug_code",
      "raw_text": "MRTX849",
      "normalized_text": "mrtx849",
      "context": "Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRAS^{G12C",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "f71a60287f56b30388b5f199bb5ae03eacd8a6bc5ce9d90ae888afefd71917d9",
      "canonical_text": "MRTX849",
      "mention_class": "drug_code_like"
    },
    {
      "id": "49d5217c-3740-4d32-8c33-755c3353868b",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "drug_code",
      "raw_text": "G12C",
      "normalized_text": "g12c",
      "context": "X849) is an oral, highly selective, small-molecule, covalent inhibitor of KRAS^{G12C}. 600 mg once daily, 1,200 mg once daily, or 600 mg orally twice a day",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "c9d36392cda0e728ded7e39d99e6d2b1830f3755804b47de5dcd4ae923b6804e",
      "canonical_text": "G12C",
      "mention_class": "drug_code_like"
    },
    {
      "id": "0ab17734-6f8f-4940-81c2-32caebfab035",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "trial_id",
      "raw_text": "NCT04685135",
      "normalized_text": "nct04685135",
      "context": "0 mg adagrasib (twice a day orally) or 75 mg/m^{2} docetaxel ClinicalTrials.gov/NCT04685135",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/40783289/",
      "fingerprint": "dd7a743b56dd5d93afdc2a279bd691fef3dfa02a4e18346f11e9cf36909a57e4",
      "canonical_text": "NCT04685135",
      "mention_class": "trial_id_like"
    },
    {
      "id": "a2f78499-4e81-46b7-af05-46cfff25898b",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "trial_id",
      "raw_text": "NCT05953350",
      "normalized_text": "nct05953350",
      "context": "(RP2D) was HCQ (600 mg, bid) plus palbociclib (200 mg, qd). ClinicalTrials.gov/NCT05953350",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "df02c42bbb03ba7ff7ad3beb78f131f63370c422564a6d4d6cf7e83dd3660375",
      "canonical_text": "NCT05953350",
      "mention_class": "trial_id_like"
    },
    {
      "id": "b01c4e52-7fa0-4554-9bf2-63d6403062fc",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "trial_id",
      "raw_text": "NCT03456076",
      "normalized_text": "nct03456076",
      "context": "Efficacy was demonstrated in a global, randomized, open-label trial (ALINA, NCT03456076) to receive alectinib 600 mg orally twice daily or platinum-based chemotherapy",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "2d979930a060f49908525fedd5ed4a2f8071498f103d9f25af50121643534a55",
      "canonical_text": "NCT03456076",
      "mention_class": "trial_id_like"
    },
    {
      "id": "5557606d-5a62-4d22-ab10-1885ff078abb",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "trial_id",
      "raw_text": "NCT05853575",
      "normalized_text": "nct05853575",
      "context": "Registration Number     NCT05853575 two dosing regimens of adagrasib (600 mg BID versus 400 mg BID)",
      "source_url": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "fingerprint": "1c3eb058eeaa20535c5cabcc47c50af0b8d858f269160889a59c8b2c9404874d",
      "canonical_text": "NCT05853575",
      "mention_class": "trial_id_like"
    },
    {
      "id": "2962fbf2-a5db-4137-9445-ec4765caa4ac",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "35167329",
      "normalized_text": "35167329",
      "context": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "531e54b0b793d9fe5db2e7038f5f686d31c5b269229b0ecdfdd39a3a0833b799",
      "canonical_text": "35167329",
      "mention_class": "junk"
    },
    {
      "id": "3feec34f-f6fc-4547-bd3a-79143251900d",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "drug_name",
      "raw_text": "Adagrasib",
      "normalized_text": "adagrasib",
      "context": "Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRAS^{G12C}.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "9ac8072ff44db9bb361072b82be56e15f1a5632443ed486bf7ee362928511170",
      "canonical_text": "ADAGRASIB",
      "mention_class": "junk"
    },
    {
      "id": "42cd339f-6aa5-4061-bbca-0dbcbfe63194",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "modality",
      "raw_text": "small-molecule",
      "normalized_text": "small-molecule",
      "context": "Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRAS^{G12C}.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "c941ef74f48b74e3367f473c9118c4488d1b25414ea2c3d099f004689b55ed0f",
      "canonical_text": "SMALLMOLECULE",
      "mention_class": "junk"
    },
    {
      "id": "fa0e91d2-4c8a-4fb3-b9d9-46e78b394877",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "target",
      "raw_text": "KRAS^{G12C}",
      "normalized_text": "kras^{g12c}",
      "context": "Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRAS^{G12C}.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "e6a517ccfc3c7fe3b09244a872510eb992c682e7dbb3f3c2cf34654ecec93d8a",
      "canonical_text": "KRASG12C",
      "mention_class": "drug_code_like"
    },
    {
      "id": "a54fe4c5-dddc-4aa0-93a4-36effd45cc7f",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "target",
      "raw_text": "KRAS",
      "normalized_text": "kras",
      "context": "covalent inhibitor of KRAS^{G12C}.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "64933eeb4a3c266982817596669a050f7553335783f5ac965156214ebd42d928",
      "canonical_text": "KRAS",
      "mention_class": "protein_gene_like"
    },
    {
      "id": "d777f0dd-df5d-4475-9a92-6f8ce8819bef",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "target",
      "raw_text": "G12C",
      "normalized_text": "g12c",
      "context": "covalent inhibitor of KRAS^{G12C}.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "c45e1b3781789cf4b5d32440fd8357a333333d9b3442b6fd665cd91e7e38483a",
      "canonical_text": "G12C",
      "mention_class": "drug_code_like"
    },
    {
      "id": "066d5f04-ff00-48fe-9275-12e72facde60",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "600 mg once daily",
      "normalized_text": "600 mg once daily",
      "context": "600 mg once daily, 1,200 mg once daily, or 600 mg orally twice a day",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "5512ab9e2d737266c36f05dd124001b68d704b32666449fd830d1c723eaca4c5",
      "canonical_text": "600MGONCEDAILY",
      "mention_class": "drug_code_like"
    },
    {
      "id": "5992eb5e-ec5e-430c-8cb6-f10fcdb8e15c",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "1,200 mg once daily",
      "normalized_text": "1,200 mg once daily",
      "context": "600 mg once daily, 1,200 mg once daily, or 600 mg orally twice a day",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "ef5586abace05f45c92ec0e6fff5fa7982158c58ad07684a2a180a1023814f34",
      "canonical_text": "1200MGONCEDAILY",
      "mention_class": "drug_code_like"
    },
    {
      "id": "cd583897-67cb-42df-8f7c-b10155a24ff9",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "600 mg orally twice a day",
      "normalized_text": "600 mg orally twice a day",
      "context": "600 mg once daily, 1,200 mg once daily, or 600 mg orally twice a day",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "20b759393348ba8e22b9d8a08dc9ca51b6566c1bea950702ec1b4acd31b94bfb",
      "canonical_text": "600MGORALLYTWICEADAY",
      "mention_class": "drug_code_like"
    },
    {
      "id": "5d993162-2b62-4f69-9da6-f494d6f76267",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "40783289",
      "normalized_text": "40783289",
      "context": "https://pubmed.ncbi.nlm.nih.gov/40783289/",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/40783289/",
      "fingerprint": "4cf6e4a3b681e3d788c02ae8c852ec40635834f541eb00ff601d478d93ebf64b",
      "canonical_text": "40783289",
      "mention_class": "junk"
    },
    {
      "id": "7ac0a499-a456-4d82-b4f8-b3e4e8c3d10f",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "drug_name",
      "raw_text": "docetaxel",
      "normalized_text": "docetaxel",
      "context": "receive 600 mg adagrasib (twice a day orally) or 75 mg/m^{2} docetaxel",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/40783289/",
      "fingerprint": "3f97bdeb0b22700e04f6371c35d2d7e307ec1a390fd9a46754b22a5d40197477",
      "canonical_text": "DOCETAXEL",
      "mention_class": "junk"
    },
    {
      "id": "30d545e0-7b96-41ba-b2b0-a2a2f8731f82",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "600 mg adagrasib (twice a day orally)",
      "normalized_text": "600 mg adagrasib (twice a day orally)",
      "context": "receive 600 mg adagrasib (twice a day orally) or 75 mg/m^{2} docetaxel",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/40783289/",
      "fingerprint": "fe062ca4856289900b9f2f4c9c63e07855b50c8fd4c418a1ca5c898ebcdecb15",
      "canonical_text": "600MGADAGRASIBTWICEADAYORALLY",
      "mention_class": "junk"
    },
    {
      "id": "f8f7065d-0257-4b2b-b62b-cc989d3b1d1f",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "twice a day orally",
      "normalized_text": "twice a day orally",
      "context": "receive 600 mg adagrasib (twice a day orally) or 75 mg/m^{2} docetaxel",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/40783289/",
      "fingerprint": "941d9987912f0337a338f7a10f561172a7ed92f2cb3daf1afabc909ea3b635bb",
      "canonical_text": "TWICEADAYORALLY",
      "mention_class": "junk"
    },
    {
      "id": "befa9817-2121-4938-afc8-9e72d4609dc0",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "75 mg/m^{2}",
      "normalized_text": "75 mg/m^{2}",
      "context": "receive 600 mg adagrasib (twice a day orally) or 75 mg/m^{2} docetaxel",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/40783289/",
      "fingerprint": "a75e83ce1de90bd51b232debe91629fa17a53a9a97ec5e77066ff4ebe1fdffe5",
      "canonical_text": "75MGM2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "24ce1038-f253-48e8-b645-beb6fd778374",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "mg/m^{2}",
      "normalized_text": "mg/m^{2}",
      "context": "75 mg/m^{2} docetaxel",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/40783289/",
      "fingerprint": "199d94adc51303d97648e5a400946319619414af1e72e9b11040e756715285aa",
      "canonical_text": "MGM2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "3f16abf5-e65a-4fbd-ab57-c4e6c1a702a5",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "trial_id",
      "raw_text": "ClinicalTrials.gov/NCT04685135",
      "normalized_text": "clinicaltrials.gov/nct04685135",
      "context": "ClinicalTrials.gov/NCT04685135",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/40783289/",
      "fingerprint": "7331bec6d885e39e09de6b90536cf1286e316a55f4bb563533429b5057f6583c",
      "canonical_text": "CLINICALTRIALSGOVNCT04685135",
      "mention_class": "trial_id_like"
    },
    {
      "id": "f06781c7-ff44-4af2-8e3a-8c3ec9b08bc8",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "39731909",
      "normalized_text": "39731909",
      "context": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "a9e8e7630ca1ac62a1536e6ce80fd44c2f604a4b4f4d83ac87208c727bcf00aa",
      "canonical_text": "39731909",
      "mention_class": "junk"
    },
    {
      "id": "84ed3b6c-3ffc-40bc-929a-d6df47340f6a",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "RP2D",
      "normalized_text": "rp2d",
      "context": "The recommended phase 2 dose (RP2D) was HCQ (600 mg, bid) plus palbociclib (200 mg, qd).",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "5d353e2c69582768dbc139ce1b3b27f95b45764d0b70e56ec3ef6aa60b9cd4fb",
      "canonical_text": "RP2D",
      "mention_class": "drug_code_like"
    },
    {
      "id": "ef14a1b5-e934-4965-8640-65e82f090e69",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "drug_name",
      "raw_text": "HCQ",
      "normalized_text": "hcq",
      "context": "The recommended phase 2 dose (RP2D) was HCQ (600 mg, bid) plus palbociclib (200 mg, qd).",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "dbeb544121f0f5e6af94860a90460bad9bc9dea78e329ab49368e7497479934f",
      "canonical_text": "HCQ",
      "mention_class": "junk"
    },
    {
      "id": "a33969d9-ed8d-42d1-8848-254c8078e0cf",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "drug_name",
      "raw_text": "palbociclib",
      "normalized_text": "palbociclib",
      "context": "The recommended phase 2 dose (RP2D) was HCQ (600 mg, bid) plus palbociclib (200 mg, qd).",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "f1ad94229a5d002b11252d857058e52f241f8bdbb85e0cdf2f14ee1d6d0eb6cd",
      "canonical_text": "PALBOCICLIB",
      "mention_class": "junk"
    },
    {
      "id": "594f91ab-57c0-45bd-9c16-f86c42b41cd3",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "600 mg, bid",
      "normalized_text": "600 mg, bid",
      "context": "HCQ (600 mg, bid) plus palbociclib (200 mg, qd).",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "f5869b46fa74930f1d65551b003edf1ef687a7ac8da0521d42ef8a1449fa65b7",
      "canonical_text": "600MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "5b6d3ebf-12b0-406e-b05c-65cd6c5d3ce1",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "200 mg, qd",
      "normalized_text": "200 mg, qd",
      "context": "HCQ (600 mg, bid) plus palbociclib (200 mg, qd).",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "f8a77fe9c37595ed8b4cd9fb25f4a277f347ccf379b180cb411fae93ecedc7a8",
      "canonical_text": "200MGQD",
      "mention_class": "drug_code_like"
    },
    {
      "id": "1bbce5db-608f-4151-8127-b4e81e00cebc",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "qd",
      "normalized_text": "qd",
      "context": "palbociclib (200 mg, qd).",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "06b8a7fad7789c9d4d7a71ebad41fafb87c27b1cb5307adf68bd2c0f75c7aa15",
      "canonical_text": "QD",
      "mention_class": "junk"
    },
    {
      "id": "b57537dc-55ed-4488-94e4-c1e838c15262",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "trial_id",
      "raw_text": "ClinicalTrials.gov/NCT05953350",
      "normalized_text": "clinicaltrials.gov/nct05953350",
      "context": "ClinicalTrials.gov/NCT05953350",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "53fd451bd1e989b46c8303ff0b1670b53b3ea46d26812a67ac307632e34de7a7",
      "canonical_text": "CLINICALTRIALSGOVNCT05953350",
      "mention_class": "trial_id_like"
    },
    {
      "id": "d9b3c76c-bd1d-4237-904b-a90140512de3",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "16740761",
      "normalized_text": "16740761",
      "context": "https://pubmed.ncbi.nlm.nih.gov/16740761/",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/16740761/",
      "fingerprint": "4566355d11e7db58798547fcac2977ba37d2af7c8e64b9684f74cfce9478d42d",
      "canonical_text": "16740761",
      "mention_class": "junk"
    },
    {
      "id": "e0ada65b-ae08-4c3b-8a2a-8dbd1f5ef7d0",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "drug_name",
      "raw_text": "celecoxib",
      "normalized_text": "celecoxib",
      "context": "received increasing doses of celecoxib from 200 to 800 mg twice daily (bid) and a fixed dose of erlotinib.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/16740761/",
      "fingerprint": "1dce4ed0e4b44053a08d193fdd80543c3d5dc4daa3f3393c10af32ad27bacf3e",
      "canonical_text": "CELECOXIB",
      "mention_class": "junk"
    },
    {
      "id": "1fc331a2-b21c-45c5-a422-6b6a0734c760",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "drug_name",
      "raw_text": "erlotinib",
      "normalized_text": "erlotinib",
      "context": "received increasing doses of celecoxib from 200 to 800 mg twice daily (bid) and a fixed dose of erlotinib.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/16740761/",
      "fingerprint": "f48720f6cbdf61f2d634b10427f9673c066837583b663b220cb9a8457ff93380",
      "canonical_text": "ERLOTINIB",
      "mention_class": "junk"
    },
    {
      "id": "7a6b93cf-c8f6-4fcc-9157-7068286ddb86",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "200 to 800 mg twice daily (bid)",
      "normalized_text": "200 to 800 mg twice daily (bid)",
      "context": "received increasing doses of celecoxib from 200 to 800 mg twice daily (bid) and a fixed dose of erlotinib.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/16740761/",
      "fingerprint": "e88d15d0683b9973eb5a15cf3f3a9a4c82ecbd3475eb46677583e5120322371d",
      "canonical_text": "200TO800MGTWICEDAILYBID",
      "mention_class": "junk"
    },
    {
      "id": "f759e6e0-4eca-4e50-ac34-b67af4f0bbcb",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "twice daily (bid)",
      "normalized_text": "twice daily (bid)",
      "context": "200 to 800 mg twice daily (bid) and a fixed dose of erlotinib.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/16740761/",
      "fingerprint": "eef5d764224b4aa3a36484ece2962f62559b4229abb67bd393ae53980dcf6c78",
      "canonical_text": "TWICEDAILYBID",
      "mention_class": "junk"
    },
    {
      "id": "c1752212-21c8-4e02-a9c8-d13f05a2d977",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "OBD",
      "normalized_text": "obd",
      "context": "with an OBD of celecoxib of 600 mg bid.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/16740761/",
      "fingerprint": "8956e4714913d22ada69799ac5f45c0f29abdc840000a37ed0dc796ded4d3fe7",
      "canonical_text": "OBD",
      "mention_class": "junk"
    },
    {
      "id": "c757b126-0408-4aa9-878b-3638724733bd",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "sponsor",
      "raw_text": "fda.gov",
      "normalized_text": "fda.gov",
      "context": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "8d6b1fa8e0d3a96fb18eb8f0d65d745ec91c8cfef1a908c3370a66d28ee4fcea",
      "canonical_text": "FDAGOV",
      "mention_class": "junk"
    },
    {
      "id": "f7429648-f1ab-4b43-9fd3-99afb868af13",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "resources-information-approved-drugs",
      "normalized_text": "resources-information-approved-drugs",
      "context": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "7cf6935ec7e768b66fed109340bb65edcb255d48372aaaa806a709347edf8490",
      "canonical_text": "RESOURCESINFORMATIONAPPROVEDDRUGS",
      "mention_class": "junk"
    },
    {
      "id": "5bae8b55-cc06-463e-9183-5c8d69e761a9",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "normalized_text": "fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "context": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "8682906459c381b7aa23f5d08bb3046ec978ae3886bc62c3fa515f57c2777a7d",
      "canonical_text": "FDAAPPROVESALECTINIBADJUVANTTREATMENTALKPOSITIVENONSMALLCELLLUNGCANCER",
      "mention_class": "junk"
    },
    {
      "id": "55634360-c137-4915-b639-b1b36cecabb7",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "drug_name",
      "raw_text": "alectinib",
      "normalized_text": "alectinib",
      "context": "to receive alectinib 600 mg orally twice daily or platinum-based chemotherapy",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "9db21bc2322eaea61f0e42a81e4bc69db1ac678fabc128ccb340c927b08c84d3",
      "canonical_text": "ALECTINIB",
      "mention_class": "junk"
    },
    {
      "id": "7f5212f8-2ff2-4f1b-9805-211383e500cd",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "indication",
      "raw_text": "adjuvant-treatment",
      "normalized_text": "adjuvant-treatment",
      "context": "fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "80c99db3aebbc5d43cead2e3d80423375972f59e72f033f368f3cb531020f3bb",
      "canonical_text": "ADJUVANTTREATMENT",
      "mention_class": "junk"
    },
    {
      "id": "776928bd-607b-42bd-b80a-6d4dc73c3650",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "target",
      "raw_text": "alk-positive",
      "normalized_text": "alk-positive",
      "context": "fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "554046a6e907a6bf16102b3a34956da61ee79c698c12749debde4512c5721ff0",
      "canonical_text": "ALKPOSITIVE",
      "mention_class": "junk"
    },
    {
      "id": "3f04af40-b213-416e-bc13-ccaf4a9796c9",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "indication",
      "raw_text": "non-small-cell-lung-cancer",
      "normalized_text": "non-small-cell-lung-cancer",
      "context": "fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "a68b9702aaeca0c24782e1dc91e281704509dd57337c40728f7330fe60ba2aeb",
      "canonical_text": "NONSMALLCELLLUNGCANCER",
      "mention_class": "junk"
    },
    {
      "id": "4ea2babc-296d-47fd-bbfb-c396e5c6983c",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "indication",
      "raw_text": "alk-positive-non-small-cell-lung-cancer",
      "normalized_text": "alk-positive-non-small-cell-lung-cancer",
      "context": "fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "9bcd26a69d9de2e333390f3142eb8b4276337811cb636a6001bb26e19e2da473",
      "canonical_text": "ALKPOSITIVENONSMALLCELLLUNGCANCER",
      "mention_class": "junk"
    },
    {
      "id": "bb82337b-fa71-4b97-90bc-b33bdfaba4dd",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "global",
      "normalized_text": "global",
      "context": "Efficacy was demonstrated in a global, randomized, open-label trial (ALINA, NCT03456076)",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "ac7029ed8176f60ff8f3e9b8d928387b9bba05a068972a998a1cced314a46edd",
      "canonical_text": "GLOBAL",
      "mention_class": "junk"
    },
    {
      "id": "6b9ef5f2-7606-45ce-914e-9ad1e760c847",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "randomized",
      "normalized_text": "randomized",
      "context": "Efficacy was demonstrated in a global, randomized, open-label trial (ALINA, NCT03456076)",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "651c0ff111125ac117637a6c76b883e3d0cde33ba646d723190fcd2dc96dff5f",
      "canonical_text": "RANDOMIZED",
      "mention_class": "junk"
    },
    {
      "id": "6fcfa587-e6ce-41ee-9b80-f19b64e72d5c",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "ALINA",
      "normalized_text": "alina",
      "context": "Efficacy was demonstrated in a global, randomized, open-label trial (ALINA, NCT03456076)",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "845334147416a0def19a43b9d266bb4e31a3d2110526b2d04982e22bfe97400f",
      "canonical_text": "ALINA",
      "mention_class": "junk"
    },
    {
      "id": "1d334868-3f3d-4a74-aeb4-06a66a6f549e",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "alectinib 600 mg orally twice daily",
      "normalized_text": "alectinib 600 mg orally twice daily",
      "context": "to receive alectinib 600 mg orally twice daily or platinum-based chemotherapy",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "21d31f711e2bf439bde0e350164482571638d5c0767270f61b8564b4ccfcb57b",
      "canonical_text": "ALECTINIB600MGORALLYTWICEDAILY",
      "mention_class": "junk"
    },
    {
      "id": "0b2085a8-c1e4-49c7-923f-a1c916b6a8f8",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "600 mg orally twice daily",
      "normalized_text": "600 mg orally twice daily",
      "context": "to receive alectinib 600 mg orally twice daily or platinum-based chemotherapy",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "8782e0478f1b5f79c1eb3757e4a075a4c0ccbd47b07f11ef07e7cfa20142c44b",
      "canonical_text": "600MGORALLYTWICEDAILY",
      "mention_class": "junk"
    },
    {
      "id": "5f0d46a1-624a-44fb-9c2e-020d6b5c4687",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "modality",
      "raw_text": "platinum-based chemotherapy",
      "normalized_text": "platinum-based chemotherapy",
      "context": "to receive alectinib 600 mg orally twice daily or platinum-based chemotherapy",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "ac95eeccc696d16dc0facdd6c80f122b40575250c8d8455e121fa9bb645730f5",
      "canonical_text": "PLATINUMBASEDCHEMOTHERAPY",
      "mention_class": "junk"
    },
    {
      "id": "0ae3f91c-039d-440b-8a3b-38fa82724851",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "modality",
      "raw_text": "chemotherapy",
      "normalized_text": "chemotherapy",
      "context": "to receive alectinib 600 mg orally twice daily or platinum-based chemotherapy",
      "source_url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer",
      "fingerprint": "beba8e0b769f5a4752e3e4d9a948c1796a4b3e584116bbaf82978fbe10ce878a",
      "canonical_text": "CHEMOTHERAPY",
      "mention_class": "junk"
    },
    {
      "id": "1ef71a03-ef78-4cdd-8aa5-ff1237534b6b",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "sponsor",
      "raw_text": "trial.medpath.com",
      "normalized_text": "trial.medpath.com",
      "context": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "source_url": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "fingerprint": "23a0b8b3b30a11995aa606e880efb843f15b7e54a9a4280f5190fda946ed3663",
      "canonical_text": "TRIALMEDPATHCOM",
      "mention_class": "junk"
    },
    {
      "id": "acc09648-06cb-49f6-bbdc-321d12e5f196",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "clinical-trial",
      "normalized_text": "clinical-trial",
      "context": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "source_url": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "fingerprint": "23595838fff920a023369685ac067c311d80f095c0902bea260aca5c4fd0fe29",
      "canonical_text": "CLINICALTRIAL",
      "mention_class": "junk"
    },
    {
      "id": "7616e627-dc52-497a-8fb9-7f0e0950e0fb",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "a7d943543a8814fc",
      "normalized_text": "a7d943543a8814fc",
      "context": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "source_url": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "fingerprint": "a71b1cd1bc7ff603055380038015fed5d613ac274fb637050b0baa1c628f4473",
      "canonical_text": "A7D943543A8814FC",
      "mention_class": "drug_code_like"
    },
    {
      "id": "8e4165b3-6d0a-460f-9130-b2b17b5b6e01",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "normalized_text": "nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "context": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "source_url": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "fingerprint": "5cf426d6680d5b28414ff621f524e3170e504f8c9c548645cce2d8bdd32f4009",
      "canonical_text": "NCT05853575RANDOMIZEDSTUDYADAGRASIBNONSMALLCELLLUNGCANCER",
      "mention_class": "trial_id_like"
    },
    {
      "id": "da43e510-ae00-4cf7-b8e3-36dd4d4a3cd4",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "randomized-study",
      "normalized_text": "randomized-study",
      "context": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "source_url": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "fingerprint": "9f2bb69927e6dadd3ad8875a3fc675fce5291454dba74763878b275c21564ace",
      "canonical_text": "RANDOMIZEDSTUDY",
      "mention_class": "junk"
    },
    {
      "id": "941ca1c3-8ffe-49ba-9a17-fa6badadc45c",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "Registration Number",
      "normalized_text": "registration number",
      "context": "Registration Number     NCT05853575",
      "source_url": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "fingerprint": "3a2680b850536886a40b40e73061e2c7930535467578c8ce34004c84a21d67a7",
      "canonical_text": "REGISTRATIONNUMBER",
      "mention_class": "junk"
    },
    {
      "id": "2b5b0214-eeb1-4da7-a6dd-bea6984de22a",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "two dosing regimens",
      "normalized_text": "two dosing regimens",
      "context": "two dosing regimens of adagrasib (600 mg BID versus 400 mg BID)",
      "source_url": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "fingerprint": "51b0ba3af82c1ce11a6dcabc937b101902f3f488ee39e35b54b937180a092a58",
      "canonical_text": "TWODOSINGREGIMENS",
      "mention_class": "junk"
    },
    {
      "id": "d3617524-8816-47b2-9586-1a0e2ae1f4ac",
      "created_at": "2025-12-14T21:19:23.200543+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "result_id": "c0cd243d-294f-47c3-991c-34c3953a723b",
      "mention_type": "other",
      "raw_text": "400 mg BID",
      "normalized_text": "400 mg bid",
      "context": "adagrasib (600 mg BID versus 400 mg BID)",
      "source_url": "https://trial.medpath.com/clinical-trial/a7d943543a8814fc/nct05853575-randomized-study-adagrasib-non-small-cell-lung-cancer",
      "fingerprint": "e5275783bb41376ae2ac2ae0ebe2a53013f403bccd7a64e1330a08f64aa8d472",
      "canonical_text": "400MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "f21f1d22-1b1a-4ea4-a70c-639cef4d9b75",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "trial_id",
      "raw_text": "NCT03785249",
      "normalized_text": "nct03785249",
      "context": "tumors harboring the KRAS G12C mutation. Trial registration: ClinicalTrials.gov NCT03785249.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "be120eaf98aabdb2b3f3ebee1e00d4e72ab7e0bb817687a4bcfeccda026343d2",
      "canonical_text": "NCT03785249",
      "mention_class": "trial_id_like"
    },
    {
      "id": "4a500242-271a-49fa-9aff-ab52200c1c75",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "trial_id",
      "raw_text": "NCT00516243",
      "normalized_text": "nct00516243",
      "context": "non E (Poly E) 400, 600, 800 twice daily Trial registration: ClinicalTrials.gov NCT00516243.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/22827973/",
      "fingerprint": "51e167f3d0c0440d231c82487e3244ce4d4ff0a006880966bd8b21eccd46fd69",
      "canonical_text": "NCT00516243",
      "mention_class": "trial_id_like"
    },
    {
      "id": "d8c1561f-d9f2-4945-927d-e191f22ab1d7",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "indication",
      "raw_text": "advanced solid tumors",
      "normalized_text": "advanced solid tumors",
      "context": "patients with advanced solid tumors harboring the KRAS G12C mutation",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "11540bc3d1ae25e6dc0d639ce50923ae0b641127c6170baf85ad3f2b98b73051",
      "canonical_text": "ADVANCEDSOLIDTUMORS",
      "mention_class": "junk"
    },
    {
      "id": "95fbde59-f6ae-4be4-b9de-acc474b9eeb6",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "target",
      "raw_text": "KRAS G12C mutation",
      "normalized_text": "kras g12c mutation",
      "context": "advanced solid tumors harboring the KRAS G12C mutation.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "2d4d2a405bb0d40f7b26039e2104c881941d06bc0efaa28cdc01004923478108",
      "canonical_text": "KRASG12CMUTATION",
      "mention_class": "drug_code_like"
    },
    {
      "id": "5c818111-34d2-4dff-ad7e-9070e8d7bd46",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "target",
      "raw_text": "KRAS G12C",
      "normalized_text": "kras g12c",
      "context": "advanced solid tumors harboring the KRAS G12C mutation.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35167329/",
      "fingerprint": "cfe141829f3763664a7352c4ba192cca96802ace748eef840c881b7f8778061f",
      "canonical_text": "KRASG12C",
      "mention_class": "drug_code_like"
    },
    {
      "id": "20ce7559-c030-4ca2-90c4-dd9f6932d224",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "drug_code",
      "raw_text": "BAY 43-9006",
      "normalized_text": "bay 43-9006",
      "context": "Patients and methods: BAY 43-9006 (50 to 800 mg) was administered once or twice daily",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/15613696/",
      "fingerprint": "7112c6d207ab2197ad14114a5f6d77fa62bd6487764c4ea3b2e8bea0eefbde2c",
      "canonical_text": "BAY439006",
      "mention_class": "drug_code_like"
    },
    {
      "id": "68825830-7b09-47a9-a20a-f2264f19cf56",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "drug_name",
      "raw_text": "Sorafenib",
      "normalized_text": "sorafenib",
      "context": "Sorafenib (100-600 mg) was given as a single dose followed by a 7-day wash-out period",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/18477034/",
      "fingerprint": "bebcb7085b0acc54687103e86469aa7060a93dd6171d7eebfcc281ebf6ae2097",
      "canonical_text": "SORAFENIB",
      "mention_class": "junk"
    },
    {
      "id": "a81629da-80be-462a-850c-46cc9239cdc4",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "drug_name",
      "raw_text": "salirasib",
      "normalized_text": "salirasib",
      "context": "Methods: Patients with advanced cancers received salirasib twice daily for 21 days every 4 weeks.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/19484470/",
      "fingerprint": "d2ff6a38807ee8e9c6aba0d545f1af5c5c4a6b20bcf260368f7f2d22d9ac9c5d",
      "canonical_text": "SALIRASIB",
      "mention_class": "junk"
    },
    {
      "id": "1d3a98a2-c7a5-421a-b35f-aec2e65a7e73",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "indication",
      "raw_text": "advanced cancers",
      "normalized_text": "advanced cancers",
      "context": "Methods: Patients with advanced cancers received salirasib twice daily",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/19484470/",
      "fingerprint": "a975e7c1df7176194ce123456ee37c454bfe6aa1862a635336ef0e67a2c2c993",
      "canonical_text": "ADVANCEDCANCERS",
      "mention_class": "junk"
    },
    {
      "id": "8728c9f7-7933-4ff1-9c80-48b76d74a9e4",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "drug_name",
      "raw_text": "hydroxychloroquine",
      "normalized_text": "hydroxychloroquine",
      "context": "hydroxychloroquine (HCQ; 600 mg, bis in die [bid]) plus increasing doses of palbociclib",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "ff4032d9a3cee1c8c24d90d846aeecd505d6669f9257e3b3c6048007a0bbf744",
      "canonical_text": "HYDROXYCHLOROQUINE",
      "mention_class": "junk"
    },
    {
      "id": "2a9883fe-9610-4576-a25c-8414d4744fd5",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "other",
      "raw_text": "bis in die [bid]",
      "normalized_text": "bis in die [bid]",
      "context": "hydroxychloroquine (HCQ; 600 mg, bis in die [bid])",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "ed8215b9b3563a8c36b257276b75c047ef6282aa91c00cb3c7555d14b593979e",
      "canonical_text": "BISINDIEBID",
      "mention_class": "junk"
    },
    {
      "id": "a5d83e48-1110-4ded-a4f3-6d5eb0d69ff8",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "other",
      "raw_text": "quaque die [qd]",
      "normalized_text": "quaque die [qd]",
      "context": "palbociclib (100, 150, or 200 mg, quaque die [qd]).",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "7b8f077163b04bc0d9941e0ada9eb1f45a5e7bdcdbf8fe54fe86ec504fc83381",
      "canonical_text": "QUAQUEDIEQD",
      "mention_class": "junk"
    },
    {
      "id": "164163ed-8399-4a6b-82ad-55e1229eca93",
      "created_at": "2025-12-14T21:19:24.116325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "result_id": "cb4dbfc6-fe24-482c-b74a-7894f0606416",
      "mention_type": "other",
      "raw_text": "ClinicalTrials.gov:",
      "normalized_text": "clinicaltrials.gov:",
      "context": "The clinical trial registration number is ClinicalTrials.gov: NCT05953350.",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/39731909/",
      "fingerprint": "a9dc8a0237e8b28ed4efdbdcc5296b6b58e6d489b56d91d4eb9818bef05bb677",
      "canonical_text": "CLINICALTRIALSGOV",
      "mention_class": "junk"
    },
    {
      "id": "7006e6a2-c3c8-421c-917e-4434e1de5ded",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "US20210393527A1",
      "normalized_text": "us20210393527a1",
      "context": "US20210393527A1 US17/333,528 * the dose of the compound or pharmaceutically acceptable salt the",
      "source_url": "https://patents.google.com/patent/US20210393527A1/en",
      "fingerprint": "9c6eb8348672865e6550141c4b1e060b8cda79c04994e274fb2615044e3543b1",
      "canonical_text": "US20210393527A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "61dd89e9-3952-4699-8eb8-792ae46a08e0",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "drug_code",
      "raw_text": "US17",
      "normalized_text": "us17",
      "context": "US20210393527A1 US17/333,528 * the dose of the compound or pharmaceutically acceptable salt thereof",
      "source_url": "https://patents.google.com/patent/US20210393527A1/en",
      "fingerprint": "67e5803ddfc7c5e5115810c19f787f80edaa56141625871b1465efcee95ea1b9",
      "canonical_text": "US17",
      "mention_class": "drug_code_like"
    },
    {
      "id": "0622330f-5921-4f1e-a813-f7850ff22665",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "WO2023034916A1",
      "normalized_text": "wo2023034916a1",
      "context": "WO2023034916A1 PCT/US2022/075838 Compound A is administered at a daily dose of about 400 mg BI",
      "source_url": "https://patents.google.com/patent/WO2023034916A1/ko",
      "fingerprint": "b3155777eda02e0470c90d7c2d3f4bd2b996682a9f08744d25eb7d9671f90cde",
      "canonical_text": "WO2023034916A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "d479e46e-ee4b-41bc-b8d5-56ee6b7ea883",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "US2022",
      "normalized_text": "us2022",
      "context": "WO2023034916A1 PCT/US2022/075838 Compound A is administered at a daily dose of about 400 mg BID, about 60",
      "source_url": "https://patents.google.com/patent/WO2023034916A1/ko",
      "fingerprint": "13a417c4a39a3404bf7d5e95630bb4d7b3f29ca949ea1d1ada05eec420b0fc7b",
      "canonical_text": "US2022",
      "mention_class": "drug_code_like"
    },
    {
      "id": "9e9c2246-1eae-4ef6-942c-9da2729321bb",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "drug_code",
      "raw_text": "US2022",
      "normalized_text": "us2022",
      "context": "WO2023034916A1 PCT/US2022/075838 Compound A is administered at a daily dose of about 400 mg BID, about 60",
      "source_url": "https://patents.google.com/patent/WO2023034916A1/ko",
      "fingerprint": "523194c66ac95671cce0da691420524570b6588721f8eb35a7d8c5c5e12abf9d",
      "canonical_text": "US2022",
      "mention_class": "drug_code_like"
    },
    {
      "id": "643eefc4-d9f9-47c8-a765-ca29f7c3c67f",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "WO2021231792A1",
      "normalized_text": "wo2021231792a1",
      "context": "WO2021231792A1 PCT/US2021/032335 in a dose of about 50 mg BID, 150 mg BID, 350 mg BID, or 600",
      "source_url": "https://patents.google.com/patent/WO2021231792A1/fr",
      "fingerprint": "dc342162a4e0ad128058410068415a2fc2424e9b246bf7b6afecd4b7dc2fdf99",
      "canonical_text": "WO2021231792A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "651cbad9-2e95-40e4-9bfa-37fd22899d52",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "US2021",
      "normalized_text": "us2021",
      "context": "WO2021231792A1 PCT/US2021/032335 in a dose of about 50 mg BID, 150 mg BID, 350 mg BID, or 600 mg BID,",
      "source_url": "https://patents.google.com/patent/WO2021231792A1/fr",
      "fingerprint": "0388602b394f1ea3def9b5b9d6fe37ceed9ba9fd191f4a7b021426783cb79bef",
      "canonical_text": "US2021",
      "mention_class": "drug_code_like"
    },
    {
      "id": "75df5b4b-99e7-40cb-b302-0b27113584d0",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "drug_code",
      "raw_text": "US2021",
      "normalized_text": "us2021",
      "context": "WO2021231792A1 PCT/US2021/032335 in a dose of about 50 mg BID, 150 mg BID, 350 mg BID, or 600 mg BID,",
      "source_url": "https://patents.google.com/patent/WO2021231792A1/fr",
      "fingerprint": "aebdacf72dc09a5c54705a22c40986d8fa0453b94e435a03e0ae885ab402acfc",
      "canonical_text": "US2021",
      "mention_class": "drug_code_like"
    },
    {
      "id": "91884684-4a8a-4b37-98fb-489541be0d59",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "US20230226030A1",
      "normalized_text": "us20230226030a1",
      "context": "US20230226030A1 US17/760,298 Compound A is administered once daily ora dosage of 300 mg, 400 mg",
      "source_url": "https://patents.google.com/patent/US20230226030A1/en",
      "fingerprint": "4af1f66cf335e0c78ceb718330d992d7c3425f8c4d81628ab9d5608c32c8b9c4",
      "canonical_text": "US20230226030A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "13cc454d-d24d-4e1c-8001-2e4ed10ce793",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "EP4504192A1",
      "normalized_text": "ep4504192a1",
      "context": "EP4504192A1 EP23720027.4A In some embodiments, the dose of tipifarnib is about 600 mg BID.",
      "source_url": "https://patents.google.com/patent/EP4504192A1/en",
      "fingerprint": "dc0d5de8557b5aea6a4d64fd475b65f89223932f97272360a051402de65ecede",
      "canonical_text": "EP4504192A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "dcea692d-4a3d-40de-9cb7-2d57096f2ec8",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "EP23720027",
      "normalized_text": "ep23720027",
      "context": "EP4504192A1 EP23720027.4A In some embodiments, the dose of tipifarnib is about 600 mg BID.",
      "source_url": "https://patents.google.com/patent/EP4504192A1/en",
      "fingerprint": "be9d701efb7af87536284233d49f7e69cfd53e8d055221db7857de635ecb0867",
      "canonical_text": "EP23720027",
      "mention_class": "patent_id_like"
    },
    {
      "id": "33772bb4-e9c1-4c43-a0d3-61b542cad53c",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "US17/333,528",
      "normalized_text": "us17/333,528",
      "context": "US20210393527A1 US17/333,528",
      "source_url": "https://patents.google.com/patent/US20210393527A1/en",
      "fingerprint": "b8cc28e4cc1a47fd757a8190d8b9838a2ca95d364f3d4187d7c86bd1b14c5de0",
      "canonical_text": "US17333528",
      "mention_class": "patent_id_like"
    },
    {
      "id": "fb468837-daad-4599-8ccb-3304d4188707",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "other",
      "raw_text": "pharmaceutically acceptable salt",
      "normalized_text": "pharmaceutically acceptable salt",
      "context": "the dose of the compound or pharmaceutically acceptable salt thereof",
      "source_url": "https://patents.google.com/patent/US20210393527A1/en",
      "fingerprint": "bc0ab218d28e2f81bb86d9578129c17acdc97c304c1c53a5abc0ea697b066316",
      "canonical_text": "PHARMACEUTICALLYACCEPTABLESALT",
      "mention_class": "junk"
    },
    {
      "id": "fe5170e6-6896-410e-afd6-1b32451b1d82",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "other",
      "raw_text": "1.2 g BID",
      "normalized_text": "1.2 g bid",
      "context": "1.2 g BID; or about 2.4 g BID.",
      "source_url": "https://patents.google.com/patent/US20210393527A1/en",
      "fingerprint": "9bdb8f1fe57d2230eba505f3b724be805cfb8c72d8d10302beb0935fdd21e9f1",
      "canonical_text": "12GBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "2820a572-d5bb-445f-9686-5d8b93812ffb",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "other",
      "raw_text": "2.4 g BID",
      "normalized_text": "2.4 g bid",
      "context": "or about 2.4 g BID.",
      "source_url": "https://patents.google.com/patent/US20210393527A1/en",
      "fingerprint": "32b1dd223fa22ef8f7b89540b6996b6611f33b92bc1b4d45928f035c94ce138b",
      "canonical_text": "24GBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "dc3af521-be57-40eb-a7f9-34cf2b6368e3",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "PCT/US2022/075838",
      "normalized_text": "pct/us2022/075838",
      "context": "WO2023034916A1 PCT/US2022/075838",
      "source_url": "https://patents.google.com/patent/WO2023034916A1/ko",
      "fingerprint": "33f85f3e930bd64fe8fa787e21eea99478adea122f7ee8581d624b097b7e9791",
      "canonical_text": "PCTUS2022075838",
      "mention_class": "patent_id_like"
    },
    {
      "id": "533a09f9-afb7-4796-9bd3-abf0d1bfdd48",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "drug_code",
      "raw_text": "Compound A",
      "normalized_text": "compound a",
      "context": "Compound A is administered at a daily dose",
      "source_url": "https://patents.google.com/patent/WO2023034916A1/ko",
      "fingerprint": "ad1e191cd6e26494364021ad12dd5be113039f2da59fd77c8ed530332cfa5610",
      "canonical_text": "COMPOUNDA",
      "mention_class": "junk"
    },
    {
      "id": "bcaa34e6-eab5-4478-840f-4afa58966a3e",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "other",
      "raw_text": "800 mg BID",
      "normalized_text": "800 mg bid",
      "context": "about 600 mg BID, or about 800 mg BID",
      "source_url": "https://patents.google.com/patent/WO2023034916A1/ko",
      "fingerprint": "6df5aaeef9d2288adfb24745450b0ebe835044a4ec420f744ae159b7d3ee560c",
      "canonical_text": "800MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e9ae7c9a-667d-4266-8fb2-5d0939a7d0d4",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "PCT/US2021/032335",
      "normalized_text": "pct/us2021/032335",
      "context": "WO2021231792A1 PCT/US2021/032335",
      "source_url": "https://patents.google.com/patent/WO2021231792A1/fr",
      "fingerprint": "439ef3ac872f646ee201aff58b573d0d9a8e7fab456776bbde3b99ad8cbaee24",
      "canonical_text": "PCTUS2021032335",
      "mention_class": "patent_id_like"
    },
    {
      "id": "96bb2632-6e87-4611-8d2c-7d002313abad",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "other",
      "raw_text": "50 mg BID",
      "normalized_text": "50 mg bid",
      "context": "in a dose of about 50 mg BID, 150 mg BID",
      "source_url": "https://patents.google.com/patent/WO2021231792A1/fr",
      "fingerprint": "dbf4e1b86e09a17059c6e686363eb6792f2bb5ec7b0364e5538a9de5fd02d8f4",
      "canonical_text": "50MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "729a79d8-bb10-4f45-b35c-3e89b1d1f9f7",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "other",
      "raw_text": "150 mg BID",
      "normalized_text": "150 mg bid",
      "context": "50 mg BID, 150 mg BID, 350 mg BID",
      "source_url": "https://patents.google.com/patent/WO2021231792A1/fr",
      "fingerprint": "f9d4292b095d2276a01bc2bb23cdb99db4d70d44b33a913715276b8435f4619f",
      "canonical_text": "150MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "069c9001-17f5-4b80-9df4-be76b6847744",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "other",
      "raw_text": "350 mg BID",
      "normalized_text": "350 mg bid",
      "context": "150 mg BID, 350 mg BID, or 600 mg BID,",
      "source_url": "https://patents.google.com/patent/WO2021231792A1/fr",
      "fingerprint": "809431518b04e8d89f50d95dce6d8825e4f32dd6a72cd5c419ecbdde33495c2b",
      "canonical_text": "350MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "86814f7e-6df4-48e2-b850-69c980f2215b",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "US17/760,298",
      "normalized_text": "us17/760,298",
      "context": "US20230226030A1 US17/760,298",
      "source_url": "https://patents.google.com/patent/US20230226030A1/en",
      "fingerprint": "bdceb1463737720b3e2a33467f27523af3dd0a52a8264c31651e2b0e2af00413",
      "canonical_text": "US17760298",
      "mention_class": "patent_id_like"
    },
    {
      "id": "870c722e-6582-4cdd-96bd-0a3ef405970f",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "other",
      "raw_text": "once daily",
      "normalized_text": "once daily",
      "context": "Compound A is administered once daily ora dosage",
      "source_url": "https://patents.google.com/patent/US20230226030A1/en",
      "fingerprint": "cae9e2f23a1186e65e228e6446ee300df004541ca167520347295a7d7ecaf19a",
      "canonical_text": "ONCEDAILY",
      "mention_class": "junk"
    },
    {
      "id": "18815f19-b82b-4514-b97f-18265a9b2e45",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "other",
      "raw_text": "300 mg",
      "normalized_text": "300 mg",
      "context": "dosage of 300 mg, 400 mg or 600 mg is administered BID.",
      "source_url": "https://patents.google.com/patent/US20230226030A1/en",
      "fingerprint": "97811032d2faf41ef1b10faae887a752ba01936d2e8eb8f9ab73f37cab4cbb1a",
      "canonical_text": "300MG",
      "mention_class": "drug_code_like"
    },
    {
      "id": "c3781870-18d4-4517-92c2-52ba81d981ec",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "other",
      "raw_text": "400 mg",
      "normalized_text": "400 mg",
      "context": "dosage of 300 mg, 400 mg or 600 mg is administered BID.",
      "source_url": "https://patents.google.com/patent/US20230226030A1/en",
      "fingerprint": "bb6a12eaa574b577e029312957ca66eaf75ad1e9c98cc837b59c46ffa9a01e0c",
      "canonical_text": "400MG",
      "mention_class": "drug_code_like"
    },
    {
      "id": "f079e444-4b8f-48a8-9f78-4b7d875c9dea",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "patent_id",
      "raw_text": "EP23720027.4A",
      "normalized_text": "ep23720027.4a",
      "context": "EP4504192A1 EP23720027.4A",
      "source_url": "https://patents.google.com/patent/EP4504192A1/en",
      "fingerprint": "b38d70613b3e6e43524965c222042382539ec24ee8201e2080838d30b3efac80",
      "canonical_text": "EP237200274A",
      "mention_class": "patent_id_like"
    },
    {
      "id": "a3aef9dc-e995-42cf-90ad-5cff69e121be",
      "created_at": "2025-12-14T21:19:24.484927+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "result_id": "fcbc6264-d8cc-440a-a698-3bb2e5f95f26",
      "mention_type": "drug_name",
      "raw_text": "tipifarnib",
      "normalized_text": "tipifarnib",
      "context": "the dose of tipifarnib is about 600 mg BID.",
      "source_url": "https://patents.google.com/patent/EP4504192A1/en",
      "fingerprint": "89afa435859768a52dbe5b0de22185db2aa71da5ccd4d57435c1e4a34ecabf61",
      "canonical_text": "TIPIFARNIB",
      "mention_class": "junk"
    },
    {
      "id": "6bb16cf8-9cd6-4357-b303-9bb7c73e032f",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "trial_id",
      "raw_text": "NCT05263986",
      "normalized_text": "nct05263986",
      "context": "Trial | NCT05263986 Following the PK lead-in period, patients will receive MRTX849 600 mg BID (an i",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT05263986/",
      "fingerprint": "cc0c883f74ba2d70ef3017c07c52a95c28eb513af2398e506b28d1cda7c4e0b7",
      "canonical_text": "NCT05263986",
      "mention_class": "trial_id_like"
    },
    {
      "id": "dcde7954-2960-4ff4-ba61-dbd12857b6d8",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "Phase 1/1b",
      "normalized_text": "phase 1/1b",
      "context": "Phase 1/1b, NSCLC 600 mg BID (n=14)",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
      "fingerprint": "7835cc9ff2220a11c10682764863da6495fa9018921c15ae74e4bc10c95968a9",
      "canonical_text": "PHASE11B",
      "mention_class": "junk"
    },
    {
      "id": "e427bd3a-1da2-4d8b-87b6-a0cb4c4a9852",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "indication",
      "raw_text": "NSCLC",
      "normalized_text": "nsclc",
      "context": "Phase 1/1b, NSCLC 600 mg BID (n=14)",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
      "fingerprint": "b57fad439882d7616370972c7a694eb8c1ce726220d3984ef5baa6ec836c6121",
      "canonical_text": "NSCLC",
      "mention_class": "junk"
    },
    {
      "id": "2d0f3b6d-8dbd-4d8f-ae55-b588b6d075fd",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "(n=14)",
      "normalized_text": "(n=14)",
      "context": "Phase 1/1b, NSCLC 600 mg BID (n=14)",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
      "fingerprint": "1ff27056644e6ce6d90de86f68df954806abd771225f3a958f24790a4ffef831",
      "canonical_text": "N14",
      "mention_class": "junk"
    },
    {
      "id": "092c4d6f-3cb5-4e8b-9890-6e71ca000c05",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "trial_id",
      "raw_text": "KRYSTAL-1",
      "normalized_text": "krystal-1",
      "context": "KRYSTAL-1: Adagrasib (MRTX849) KRAS G12C Inhibitor in NSCLC",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
      "fingerprint": "a25d3a7e1a29b9342e10c3165b2a023f08fc290ccb35f77f6197e87a73aacdc6",
      "canonical_text": "KRYSTAL1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "45420564-0bb8-4ebc-ba05-17e4ff8ec5f7",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "drug_code",
      "raw_text": "(MRTX849)",
      "normalized_text": "(mrtx849)",
      "context": "Adagrasib (MRTX849) KRAS G12C Inhibitor",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
      "fingerprint": "0fcdbe95ca41acec3b0bd1315b4a3b2cc111086fc2440e2775e89099de88c46a",
      "canonical_text": "MRTX849",
      "mention_class": "drug_code_like"
    },
    {
      "id": "4b3d44a5-7755-4440-bdda-09d0df3e4c87",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "modality",
      "raw_text": "KRAS G12C Inhibitor",
      "normalized_text": "kras g12c inhibitor",
      "context": "KRAS G12C Inhibitor in NSCLC",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
      "fingerprint": "59c436a58cb0357d5559b07bf0252d86651201cbb18b1d94e29a7a4553b2da3d",
      "canonical_text": "KRASG12CINHIBITOR",
      "mention_class": "junk"
    },
    {
      "id": "d9ec28e7-593c-4599-8cf6-e42e01202801",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "1576263",
      "normalized_text": "1576263",
      "context": "URL: https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
      "fingerprint": "d00aef016c497772b68abde5dd4fae190fd9ff8a14e85d66d221a838f83f3833",
      "canonical_text": "1576263",
      "mention_class": "junk"
    },
    {
      "id": "6cc4926f-d2c1-4036-b54d-938bd8ff6abb",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "000119312521005786",
      "normalized_text": "000119312521005786",
      "context": "URL: https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
      "fingerprint": "cb114f8e636afcc281853c90b0bfce5978de485268907e2a970dda1f4406dc15",
      "canonical_text": "000119312521005786",
      "mention_class": "junk"
    },
    {
      "id": "dbdb7935-0cbe-497a-8488-7aa3a25aeaf3",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "d44280dex991.htm",
      "normalized_text": "d44280dex991.htm",
      "context": "URL: https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
      "source_url": "https://www.sec.gov/Archives/edgar/data/1576263/000119312521005786/d44280dex991.htm",
      "fingerprint": "2f2debdceb84712bbaae6796d1adae7ea7004bd269e0ec08e1d157d0bd66868d",
      "canonical_text": "D44280DEX991HTM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "a6cba9ae-77f4-4a0a-91c1-12af6acbc4a3",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "drug_name",
      "raw_text": "KRAZATI",
      "normalized_text": "krazati",
      "context": "The recommended dosage of KRAZATI is 600 mg orally twice daily until disease progression or unacceptable toxicity.^{1}",
      "source_url": "https://www.krazatihcp.com/nsclc/dosing",
      "fingerprint": "1771d73a03b3f026c3533e97eb9a2f017bb312a63354db76292add26816872c6",
      "canonical_text": "KRAZATI",
      "mention_class": "junk"
    },
    {
      "id": "d533c0c5-2caf-4d0e-b97e-1bfbb9fd263d",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "orally twice daily",
      "normalized_text": "orally twice daily",
      "context": "The recommended dosage of KRAZATI is 600 mg orally twice daily until disease progression or unacceptable toxicity.^{1}",
      "source_url": "https://www.krazatihcp.com/nsclc/dosing",
      "fingerprint": "0ab973bafbaddf6d29e9823db5581253b6e3c3919d5e6a129709a239ac65d873",
      "canonical_text": "ORALLYTWICEDAILY",
      "mention_class": "junk"
    },
    {
      "id": "598145c6-1fba-420a-a613-58b21c02b6b1",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "twice daily",
      "normalized_text": "twice daily",
      "context": "The recommended dosage of KRAZATI is 600 mg orally twice daily until disease progression or unacceptable toxicity.^{1}",
      "source_url": "https://www.krazatihcp.com/nsclc/dosing",
      "fingerprint": "b6379b0ce65a72e44f3df45e07bbad2af7d9f601bf53c8ad81cbd0c547e42ffe",
      "canonical_text": "TWICEDAILY",
      "mention_class": "junk"
    },
    {
      "id": "0b1288f3-97cf-4a1e-bb78-38f313bad68e",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "disease progression",
      "normalized_text": "disease progression",
      "context": "until disease progression or unacceptable toxicity.^{1}",
      "source_url": "https://www.krazatihcp.com/nsclc/dosing",
      "fingerprint": "5cb7a712448c995149c9ec49a965d87410f3b1c2f339d724ef08020ce957a705",
      "canonical_text": "DISEASEPROGRESSION",
      "mention_class": "junk"
    },
    {
      "id": "c41414f2-546d-42ee-b075-d9dd1b24139e",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "unacceptable toxicity",
      "normalized_text": "unacceptable toxicity",
      "context": "until disease progression or unacceptable toxicity.^{1}",
      "source_url": "https://www.krazatihcp.com/nsclc/dosing",
      "fingerprint": "1509ae992d7a0f65303ce104c5aefc0d013a9677b2e43c7d29a8f7793b3b78c1",
      "canonical_text": "UNACCEPTABLETOXICITY",
      "mention_class": "junk"
    },
    {
      "id": "38fd121d-7479-4ce6-8fcb-c82cd73c8054",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "toxicity.^{1}",
      "normalized_text": "toxicity.^{1}",
      "context": "until disease progression or unacceptable toxicity.^{1}",
      "source_url": "https://www.krazatihcp.com/nsclc/dosing",
      "fingerprint": "537b4ec13dc57fe547e1c312c18b16cd93d234663715da908226382e71c11bb5",
      "canonical_text": "TOXICITY1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "2c63513c-3f07-4228-ba8b-28881ad21855",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "^{1}",
      "normalized_text": "^{1}",
      "context": "unacceptable toxicity.^{1}",
      "source_url": "https://www.krazatihcp.com/nsclc/dosing",
      "fingerprint": "a505ba7fc14947e8d1b7896af4ce63865c38878fe17360cc9e9ef01137c5598b",
      "canonical_text": "1",
      "mention_class": "junk"
    },
    {
      "id": "2ad57de2-14c9-46bb-b999-ba6817344c3a",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "600 MG BID^{1}",
      "normalized_text": "600 mg bid^{1}",
      "context": "## KRAZATI RECOMMENDED DOSAGE: 600 MG BID^{1}",
      "source_url": "https://www.krazatihcp.com/nsclc/dosing",
      "fingerprint": "e3412bcbec5fe7f885d71f939713166874cb9324ba36b0f53f62d4b05e3adbf4",
      "canonical_text": "600MGBID1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "2930c21e-3b09-4ed0-845d-e26afab3352e",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "BID^{1}",
      "normalized_text": "bid^{1}",
      "context": "## KRAZATI RECOMMENDED DOSAGE: 600 MG BID^{1}",
      "source_url": "https://www.krazatihcp.com/nsclc/dosing",
      "fingerprint": "100a45222ce6345b0aa7f9429dbb12e4707c49664039485edfeb9612b0883cb0",
      "canonical_text": "BID1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "2d235fa9-92ec-4d42-8594-12e9c8566ff5",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "sponsor",
      "raw_text": "www.krazatihcp.com",
      "normalized_text": "www.krazatihcp.com",
      "context": "URL: https://www.krazatihcp.com/nsclc/dosing",
      "source_url": "https://www.krazatihcp.com/nsclc/dosing",
      "fingerprint": "e9e003e932231546fa2f42b381b702e77baac7512b193ebad6b7ad4cd376e19a",
      "canonical_text": "WWWKRAZATIHCPCOM",
      "mention_class": "junk"
    },
    {
      "id": "da6658bb-201d-4791-8942-4e3afaeecbb2",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "trial_id",
      "raw_text": "KRYSTAL-12",
      "normalized_text": "krystal-12",
      "context": "KRYSTAL-1 and KRYSTAL-12 STUDY DESIGNS",
      "source_url": "https://www.krazatihcp.com/nsclc/study-design",
      "fingerprint": "52a401c069c5a2de09108427891ae7bc5056c0f5ba30f661c6f1ecad50279c0b",
      "canonical_text": "KRYSTAL12",
      "mention_class": "drug_code_like"
    },
    {
      "id": "ed780885-4517-4703-ab05-881e2b802e36",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "STUDY DESIGNS",
      "normalized_text": "study designs",
      "context": "KRYSTAL-1 and KRYSTAL-12 STUDY DESIGNS",
      "source_url": "https://www.krazatihcp.com/nsclc/study-design",
      "fingerprint": "1ecec96f9c71deb1ff5c2850f503ed6c807490a6a479d7bc27c680dd7cab6816",
      "canonical_text": "STUDYDESIGNS",
      "mention_class": "junk"
    },
    {
      "id": "34580767-3019-425a-9f33-c75f71714609",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "PK lead-in period",
      "normalized_text": "pk lead-in period",
      "context": "Following the PK lead-in period, patients will receive MRTX849 600 mg BID",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT05263986/",
      "fingerprint": "b66549f9f05fde319ef0d362b1bd3fb43b5092428600544e70f03be2256c7e95",
      "canonical_text": "PKLEADINPERIOD",
      "mention_class": "junk"
    },
    {
      "id": "67c761db-5215-4653-a31e-429adfb4c44a",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "PK",
      "normalized_text": "pk",
      "context": "Following the PK lead-in period, patients will receive MRTX849 600 mg BID",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT05263986/",
      "fingerprint": "f071ca857018da7134365eb192b11c67b24251898ac468672359e73ec83ae760",
      "canonical_text": "PK",
      "mention_class": "junk"
    },
    {
      "id": "f43139c7-3e5c-4df7-a1ef-cf82583d012a",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "12 hours",
      "normalized_text": "12 hours",
      "context": "an interval of approximate 12 hours between 2 doses",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT05263986/",
      "fingerprint": "d4d22a3b8c749df299ab45dc3eaf7752c3e9d3c987fdd9aaa47405f9c0b00a4c",
      "canonical_text": "12HOURS",
      "mention_class": "drug_code_like"
    },
    {
      "id": "3f7fdb7d-da1a-494c-9810-07f47ab34877",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "2 doses",
      "normalized_text": "2 doses",
      "context": "an interval of approximate 12 hours between 2 doses",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT05263986/",
      "fingerprint": "f46558b3f33fcca099ccdd8e6d2cb0245e75ee35ed053ca3d9476cb089a55133",
      "canonical_text": "2DOSES",
      "mention_class": "drug_code_like"
    },
    {
      "id": "eb7c5e1f-6f44-4145-8337-3d8a949e3277",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "sponsor",
      "raw_text": "purdue.edu",
      "normalized_text": "purdue.edu",
      "context": "URL: https://cdek.pharmacy.purdue.edu/trial/NCT05263986/",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT05263986/",
      "fingerprint": "adb01c866c411d811e66f358761199a2d3a4a50e83ac6cb19beeb45b37722044",
      "canonical_text": "PURDUEEDU",
      "mention_class": "junk"
    },
    {
      "id": "0280c7b1-1f43-444b-891d-39814d32bdd4",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "cdek.pharmacy.purdue.edu",
      "normalized_text": "cdek.pharmacy.purdue.edu",
      "context": "URL: https://cdek.pharmacy.purdue.edu/trial/NCT05263986/",
      "source_url": "https://cdek.pharmacy.purdue.edu/trial/NCT05263986/",
      "fingerprint": "ca5a2bfc50dc10aeb5d2329378837a0032a7d2fba0796fd5506222715a3e6a7c",
      "canonical_text": "CDEKPHARMACYPURDUEEDU",
      "mention_class": "junk"
    },
    {
      "id": "24822a78-025d-49e7-9f56-00a5228cce24",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "37099736",
      "normalized_text": "37099736",
      "context": "URL: https://pubmed.ncbi.nlm.nih.gov/37099736/",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37099736/",
      "fingerprint": "1ff08f4baf94f558b3912f6871d2ca46fb2110b43c8ae60224552f319f05fb49",
      "canonical_text": "37099736",
      "mention_class": "junk"
    },
    {
      "id": "ebf6b852-6e0c-43a6-9d8b-30e070f46642",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "phase Ib cohort",
      "normalized_text": "phase ib cohort",
      "context": "KRYSTAL-1 study (ClinicalTrials.gov identifier: NCT03785249; phase Ib cohort)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37099736/",
      "fingerprint": "1f9b437a6e88a35d81dafe34b70052a4bed852af1665c25f0e996be90a6ca4b0",
      "canonical_text": "PHASEIBCOHORT",
      "mention_class": "junk"
    },
    {
      "id": "126bae0a-9b9d-4b90-a64d-2b942868ffaf",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "phase Ib",
      "normalized_text": "phase ib",
      "context": "NCT03785249; phase Ib cohort",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/37099736/",
      "fingerprint": "a4357cadbbba36c038d90b29ad52d814e7489c1e937654847ae7c24ffad4f951",
      "canonical_text": "PHASEIB",
      "mention_class": "junk"
    },
    {
      "id": "914a85d7-af9a-4f52-a012-d4481aa1e3b5",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "registration-enabling",
      "normalized_text": "registration-enabling",
      "context": "registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib 600 mg BID",
      "source_url": "https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
      "fingerprint": "09a24e72b4b5b7e7ef5c538c37c2c7ca002303a233534c8d5c4524430114a543",
      "canonical_text": "REGISTRATIONENABLING",
      "mention_class": "junk"
    },
    {
      "id": "4917d76b-bdb3-416b-a446-860902b38c58",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "target",
      "raw_text": "krasg12c-mutated",
      "normalized_text": "krasg12c-mutated",
      "context": "URL: https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
      "source_url": "https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
      "fingerprint": "16edf9d7c1141e04706c6d42fd55953530187fcfd2815ebc7b10dc4757cf06f9",
      "canonical_text": "KRASG12CMUTATED",
      "mention_class": "drug_code_like"
    },
    {
      "id": "8ebb90c0-2c70-47c8-8d8f-bb6dd60dc7e2",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "target",
      "raw_text": "krasg12c",
      "normalized_text": "krasg12c",
      "context": "URL: https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
      "source_url": "https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
      "fingerprint": "562531ba50cd5633987103e28424fd6b6594879abb0f71ab40fafd3f74c2df9d",
      "canonical_text": "KRASG12C",
      "mention_class": "drug_code_like"
    },
    {
      "id": "c812adab-5f7a-48a4-b971-cd43918c7fce",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "advanced",
      "normalized_text": "advanced",
      "context": "URL: https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
      "source_url": "https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
      "fingerprint": "c54f609c3b310b5311461acfbdc51412053f8797b56284c1485fa689474a055b",
      "canonical_text": "ADVANCED",
      "mention_class": "junk"
    },
    {
      "id": "6f2d7677-0636-4738-9ffc-d340dcc90907",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "301556249",
      "normalized_text": "301556249",
      "context": "URL: https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
      "source_url": "https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
      "fingerprint": "dc8ce03dcd1cb1b1e52d17005c425a422ea6ab4bfe1194b44b8b8747af43eae8",
      "canonical_text": "301556249",
      "mention_class": "junk"
    },
    {
      "id": "f820b11d-12fd-496e-87e4-18cfd0dc69eb",
      "created_at": "2025-12-14T21:19:25.916886+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "query_id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "result_id": "2771207e-89f9-4b7c-96df-390649b80311",
      "mention_type": "other",
      "raw_text": "investigational",
      "normalized_text": "investigational",
      "context": "URL: https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
      "source_url": "https://www.prnewswire.com/news-releases/investigational-adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer-301556249.html",
      "fingerprint": "3baaeb4343ce918f8721646ce1607e66964571485c8ba35f604507d3e029d93c",
      "canonical_text": "INVESTIGATIONAL",
      "mention_class": "junk"
    }
  ],
  "candidates": [
    {
      "id": "8c6ff63a-8df7-438c-b80e-66aea4df9322",
      "created_at": "2025-12-14T21:11:48.44321+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "6a137165-e9f6-4aad-b8d8-1b99300b40fd",
      "candidate_type": "drug_asset",
      "raw_identifier": "cdk1213-inhibitor",
      "normalized_identifier": "cdk1213-inhibitor",
      "fingerprint": "86f12289cf03fd2d25a13a489c51cb62f0b4c182e07636a87fc210fe0847e09f",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CDK1213INHIBITOR",
      "mention_class": "drug_code_like"
    },
    {
      "id": "b15af8f0-d273-4caf-ae9c-b3c36b276d36",
      "created_at": "2025-12-14T21:11:49.134511+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "466666e9-2938-4ca2-89bd-c65bfa8766ef",
      "candidate_type": "drug_asset",
      "raw_identifier": "September 13, 2023",
      "normalized_identifier": "september 13, 2023",
      "fingerprint": "ec73158be5a6ecdeae4bce75b56def64a4190b10535c0c28c778d2862c4643f5",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "SEPTEMBER132023",
      "mention_class": "drug_code_like"
    },
    {
      "id": "20739a1c-35fe-4733-b734-cfb6278134ae",
      "created_at": "2025-12-14T21:11:48.531749+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "18350a8f-9feb-4ebb-845b-94a76e631e36",
      "candidate_type": "drug_asset",
      "raw_identifier": "CT7439 Capsules",
      "normalized_identifier": "ct7439 capsules",
      "fingerprint": "ac04b1d70b78e6a236d16f35c9b04d5691a3680aadaa93807d3491ff8bee3010",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CT7439CAPSULES",
      "mention_class": "drug_code_like"
    },
    {
      "id": "6631a38f-8ca4-4f78-a806-9d8627fe5247",
      "created_at": "2025-12-14T21:11:48.586925+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "0bf57061-0a4c-4de4-b7f7-fa201c3f78ab",
      "candidate_type": "drug_asset",
      "raw_identifier": "0.5 mg",
      "normalized_identifier": "0.5 mg",
      "fingerprint": "449dd1f217928897f8b6433345596635ed5eed98d1721ce14d13ae383f3d5c2c",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "05MG",
      "mention_class": "drug_code_like"
    },
    {
      "id": "d564a0dd-b64a-416a-9465-dac7c03043fa",
      "created_at": "2025-12-14T21:11:49.232111+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "a2037a6c-13f0-472e-b7ff-fee90a2c8f89",
      "candidate_type": "drug_asset",
      "raw_identifier": "2 R&D institutions",
      "normalized_identifier": "2 r&d institutions",
      "fingerprint": "818a68dc21e5fcab49daf92c66b3904490786c7c55717d2dd5fad63bcbee0178",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "2RDINSTITUTIONS",
      "mention_class": "drug_code_like"
    },
    {
      "id": "18030ae9-f8aa-4b76-a62f-ef4a90e8579e",
      "created_at": "2025-12-14T21:11:49.936601+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "c8eb1787-2a05-4447-ba17-772dded11c08",
      "candidate_type": "drug_asset",
      "raw_identifier": "CO-338-052",
      "normalized_identifier": "co-338-052",
      "fingerprint": "37c8caab32b4c86adcd06bfd9f0275b8f4a32694b649fe0ee1e5100f4627cc28",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CO338052",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e896fb9d-3767-43b0-89fa-da754d4df7a3",
      "created_at": "2025-12-14T21:11:49.079971+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "705c00c1-959b-48db-b917-294a7bc66a0a",
      "candidate_type": "drug_asset",
      "raw_identifier": "(CDK12/13)",
      "normalized_identifier": "(cdk12/13)",
      "fingerprint": "a2c29910c22a7ca65182066251d92bb5dbe019262a1a65aa8c6ec0d2dd1fdacf",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CDK1213",
      "mention_class": "drug_code_like"
    },
    {
      "id": "96046d6a-40d3-4a75-9553-f0eed7a9c44a",
      "created_at": "2025-12-14T21:11:50.507221+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "f235a869-9c9a-4f19-989d-5e79848f062f",
      "candidate_type": "drug_asset",
      "raw_identifier": "2018 Oct 1",
      "normalized_identifier": "2018 oct 1",
      "fingerprint": "95ef16edfbb3246d9e406f16d81e71fbe2e6493df23413db37d2c5d7521b3621",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "2018OCT1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "97367dd2-5b27-48ab-b340-9525f72186f8",
      "created_at": "2025-12-14T21:11:49.183319+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "7cac91b9-73e6-42ed-8980-3f5c9ae88454",
      "candidate_type": "drug_asset",
      "raw_identifier": "CDC7",
      "normalized_identifier": "cdc7",
      "fingerprint": "6a3bd6383efbfc5ca4381954814f4ad7b05df7569665e7862394d3e862540199",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CDC7",
      "mention_class": "drug_code_like"
    },
    {
      "id": "79647f6d-9a0b-4502-a5c2-3c33bca1d3b6",
      "created_at": "2025-12-14T21:11:49.886687+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "cb36494e-647d-4c40-b36a-796be316574f",
      "candidate_type": "drug_asset",
      "raw_identifier": "CHEK2",
      "normalized_identifier": "chek2",
      "fingerprint": "252633e6c240b62beed9870d3fe4505e62d235021d9311f893f52e8b752db536",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CHEK2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "9433a014-6cdc-4f10-8956-aa9f56f0dd8d",
      "created_at": "2025-12-14T21:11:49.283226+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "98b56a6c-4ed0-486c-81a5-f55535479553",
      "candidate_type": "drug_asset",
      "raw_identifier": "29 patents",
      "normalized_identifier": "29 patents",
      "fingerprint": "4f9ae049bc50c371344542e66c755690a705f9d0fd041cc837cbbd017dbecb9c",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "29PATENTS",
      "mention_class": "drug_code_like"
    },
    {
      "id": "5eded8f6-63e0-4e0a-ad6e-139cc1c0473e",
      "created_at": "2025-12-14T21:11:49.995825+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "e058544c-6dcb-46e6-87cb-c20a09ae0e34",
      "candidate_type": "drug_asset",
      "raw_identifier": "mdy284.002",
      "normalized_identifier": "mdy284.002",
      "fingerprint": "588f0ef7f4f406c04d7b42331a57958925a403c1f62289d3e12b568332d4d565",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "MDY284002",
      "mention_class": "drug_code_like"
    },
    {
      "id": "6358f1a1-7975-4676-92be-6e0fcfdcff4c",
      "created_at": "2025-12-14T21:11:49.826796+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "d545b5e8-125b-4776-aff0-2481dce1781a",
      "candidate_type": "drug_asset",
      "raw_identifier": "CO-338",
      "normalized_identifier": "co-338",
      "fingerprint": "72bed55149c634133cd78271adc802321d8ff39156fa573300dc3bc724eaa797",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CO338",
      "mention_class": "drug_code_like"
    },
    {
      "id": "74c623de-39c8-418a-b532-27e0ec8a9034",
      "created_at": "2025-12-14T21:11:50.559232+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "b05e62ad-3307-4ba7-86cd-1ab726e98b92",
      "candidate_type": "drug_asset",
      "raw_identifier": "29:viii272",
      "normalized_identifier": "29:viii272",
      "fingerprint": "5c8f515fa80f244ef4d61feab57691ee4388dd188ebb98e480a235acc0f165ac",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "29VIII272",
      "mention_class": "drug_code_like"
    },
    {
      "id": "26134e8e-6042-47e6-b8c9-e7b91b3f610c",
      "created_at": "2025-12-14T21:11:50.317677+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "567c13bc-c6ad-4d74-a234-28a58c9b0902",
      "candidate_type": "drug_asset",
      "raw_identifier": "CCR-20",
      "normalized_identifier": "ccr-20",
      "fingerprint": "59553905162f77748ef408deb7e2c2e7ead7580ee686b957a5efb3f6ffaa2056",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CCR20",
      "mention_class": "drug_code_like"
    },
    {
      "id": "735336d5-727d-496d-bc38-258b4d55f76d",
      "created_at": "2025-12-14T21:11:50.404395+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "27ecd9be-4f34-4a6f-91a1-4708178d2b38",
      "candidate_type": "drug_asset",
      "raw_identifier": "600 mg",
      "normalized_identifier": "600 mg",
      "fingerprint": "c7edb10dd4c7c71dcbc8f7ee655718d95d87a7843804a4684daa7bb76dee818e",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "600MG",
      "mention_class": "drug_code_like"
    },
    {
      "id": "46d8dc14-1c83-462a-be27-291e8380e036",
      "created_at": "2025-12-14T21:11:50.454033+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "cc2994f3-c839-4797-b811-833b2b456b21",
      "candidate_type": "drug_asset",
      "raw_identifier": "CCR-20-0394",
      "normalized_identifier": "ccr-20-0394",
      "fingerprint": "3d3e943ffc2b1bf29431b30baf9f2f6a72e4fc49d9a81f9ad4170a94bb0e1b94",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CCR200394",
      "mention_class": "drug_code_like"
    },
    {
      "id": "241c481b-3074-4ffd-9816-831034a2599d",
      "created_at": "2025-12-14T21:19:21.445812+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "ae22f9ab-5a0b-49de-8847-04a7063484ba",
      "candidate_type": "patent_id",
      "raw_identifier": "US10130636B2",
      "normalized_identifier": "us10130636b2",
      "fingerprint": "4b5c5bf18f96a692b6c4761fd6564f2f37b9efb13dfae51247a3fc055469a4da",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "US10130636B2",
      "mention_class": "patent_id_like"
    },
    {
      "id": "e3c4d0be-f0b1-4510-9c52-18ab3be35f8f",
      "created_at": "2025-12-14T21:19:21.854894+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "5675f959-6612-479b-9170-55d6ebfa8241",
      "candidate_type": "drug_asset",
      "raw_identifier": "N209115",
      "normalized_identifier": "n209115",
      "fingerprint": "2c59471de03a2d6750576a6b3806b54699cb8d22692b7fbae0b9bc8e46873b19",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "N209115",
      "mention_class": "drug_code_like"
    },
    {
      "id": "fcce1865-23a4-4d84-b1f2-54364f0cce62",
      "created_at": "2025-12-14T21:19:22.224157+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "2f8ddd7f-2a2b-4f7e-bd24-8097a738800b",
      "candidate_type": "drug_asset",
      "raw_identifier": "1315-News",
      "normalized_identifier": "1315-news",
      "fingerprint": "d3bb3a413831d3b41ed0fd5087359089aff77a26de70aa895a72204daf89323a",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "1315NEWS",
      "mention_class": "drug_code_like"
    },
    {
      "id": "566511e8-2dc1-4e5e-bb12-17a99cec1510",
      "created_at": "2025-12-14T21:19:22.592834+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "1c90b629-d1b2-460b-a552-87cc2461a7e9",
      "candidate_type": "drug_asset",
      "raw_identifier": "W81XWH",
      "normalized_identifier": "w81xwh",
      "fingerprint": "043e7c88c4113a9133edb22348cbff995cf074083a5b7815beca5491c4f2bf4e",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "W81XWH",
      "mention_class": "drug_code_like"
    },
    {
      "id": "15e0cea1-1e0b-496b-8d6c-4d0750726edc",
      "created_at": "2025-12-14T21:19:22.949715+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "5e49d09c-eb72-4950-8331-38b0c2c1a4d2",
      "candidate_type": "drug_asset",
      "raw_identifier": "W81XWH-17-1-0124",
      "normalized_identifier": "w81xwh-17-1-0124",
      "fingerprint": "481571c5be5bf736d6ab0492a25fc65d82199dfb0fe5474c575f2ffbfd11e72e",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "W81XWH1710124",
      "mention_class": "drug_code_like"
    },
    {
      "id": "b49f8eb2-6560-4c67-985f-ee02817d2a3e",
      "created_at": "2025-12-14T21:19:23.330442+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "49d5217c-3740-4d32-8c33-755c3353868b",
      "candidate_type": "drug_asset",
      "raw_identifier": "G12C",
      "normalized_identifier": "g12c",
      "fingerprint": "6f6d9ae60f32b390a97fc541c124dbf71b728e96045ca7d35d7d9b15a405c457",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "G12C",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e7c4bda8-5825-4e30-9a3c-07cd462aacfa",
      "created_at": "2025-12-14T21:19:23.660042+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "24ce1038-f253-48e8-b645-beb6fd778374",
      "candidate_type": "drug_asset",
      "raw_identifier": "mg/m^{2}",
      "normalized_identifier": "mg/m^{2}",
      "fingerprint": "903cbc370853695afba6806f3bcddb8ee132dfc4fb16edfb1d85f3bd1f960e98",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "MGM2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e1bc1b99-cd71-4f39-b12a-fab01fa802d2",
      "created_at": "2025-12-14T21:19:24.706488+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "d479e46e-ee4b-41bc-b8d5-56ee6b7ea883",
      "candidate_type": "drug_asset",
      "raw_identifier": "US2022",
      "normalized_identifier": "us2022",
      "fingerprint": "bd492d7e1f450bd4bfcb7d4a071d627ec0f5594d3ba06b5de3989b131e03c4d9",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "US2022",
      "mention_class": "drug_code_like"
    },
    {
      "id": "1ecf80b8-1a36-41b2-92ed-db1d12e8865a",
      "created_at": "2025-12-14T21:19:25.020998+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "33772bb4-e9c1-4c43-a0d3-61b542cad53c",
      "candidate_type": "patent_id",
      "raw_identifier": "US17/333,528",
      "normalized_identifier": "us17/333,528",
      "fingerprint": "60fdfa878369d75056a5b45a5c662f87354f349788a2e0a2b1dcaf07009ea19c",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "US17333528",
      "mention_class": "patent_id_like"
    },
    {
      "id": "ba3a6e31-846f-487c-b971-2a8b88470eb8",
      "created_at": "2025-12-14T21:19:25.329763+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "96bb2632-6e87-4611-8d2c-7d002313abad",
      "candidate_type": "drug_asset",
      "raw_identifier": "50 mg BID",
      "normalized_identifier": "50 mg bid",
      "fingerprint": "0c697e228cbc0bcdfaee5c6ab37a534e2b3a63ab0011d58e33a19115d3109677",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "50MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "2f83532f-a11b-49e6-9155-a62f2aebaa08",
      "created_at": "2025-12-14T21:19:25.654833+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "f079e444-4b8f-48a8-9f78-4b7d875c9dea",
      "candidate_type": "patent_id",
      "raw_identifier": "EP23720027.4A",
      "normalized_identifier": "ep23720027.4a",
      "fingerprint": "24ddc26c047fabf5e0ad9314763b66f9ec10e3dc2d5b138e13dac1a856a921cf",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "EP237200274A",
      "mention_class": "patent_id_like"
    },
    {
      "id": "f552754f-b520-4b52-81da-7ed3a300c66e",
      "created_at": "2025-12-14T21:19:26.033141+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "dbdb7935-0cbe-497a-8488-7aa3a25aeaf3",
      "candidate_type": "drug_asset",
      "raw_identifier": "d44280dex991.htm",
      "normalized_identifier": "d44280dex991.htm",
      "fingerprint": "54493bdd46ad763487676d4bd270c4e71e0a9257a894f743877c514432ff3a02",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "D44280DEX991HTM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "3030d441-d95b-4e04-8562-657cef822d40",
      "created_at": "2025-12-14T21:19:26.340349+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "3f7fdb7d-da1a-494c-9810-07f47ab34877",
      "candidate_type": "drug_asset",
      "raw_identifier": "2 doses",
      "normalized_identifier": "2 doses",
      "fingerprint": "ca44fd4b4543847415e68a39766505e8a81a30cb982699b894c38d8869bb1615",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "2DOSES",
      "mention_class": "drug_code_like"
    },
    {
      "id": "ef8fe21c-266e-4b93-a2ce-380522ce4d4f",
      "created_at": "2025-12-14T21:19:21.535845+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "1d37f204-5da6-4423-ae1c-09b56dacc4b1",
      "candidate_type": "drug_asset",
      "raw_identifier": "US15",
      "normalized_identifier": "us15",
      "fingerprint": "d2b995915df865a566b4554f71accb3b49d243ec2bcbdd350c3214a37f50b697",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "US15",
      "mention_class": "drug_code_like"
    },
    {
      "id": "58559b14-68c2-4029-873a-4b1ef4a05966",
      "created_at": "2025-12-14T21:19:21.928496+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "25410267-9ffc-4ed9-9c28-da80ff5b6dd3",
      "candidate_type": "drug_asset",
      "raw_identifier": "Dec. 19, 2016",
      "normalized_identifier": "dec. 19, 2016",
      "fingerprint": "784adf350a15d5274538565f2365dfd076052c6a6abe9767863a4cd19d44d8f0",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "DEC192016",
      "mention_class": "drug_code_like"
    },
    {
      "id": "eb9a05b7-51bc-43a5-8a49-9578547c4d8a",
      "created_at": "2025-12-14T21:19:22.275541+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "1ec977a2-24a6-4fc0-bdaa-a796cc704e18",
      "candidate_type": "patent_id",
      "raw_identifier": "US15/920,643",
      "normalized_identifier": "us15/920,643",
      "fingerprint": "620469e40b251d62c210fc812e78cb37be4b9839a5c88aa77dead8d2a9fdb6ce",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "US15920643",
      "mention_class": "patent_id_like"
    },
    {
      "id": "409c9790-abe5-4bb2-9531-4d26c0870ff6",
      "created_at": "2025-12-14T21:19:22.653207+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "6b048523-efd1-463f-a0c8-7a6979dbb43f",
      "candidate_type": "drug_asset",
      "raw_identifier": "TRITON3",
      "normalized_identifier": "triton3",
      "fingerprint": "5db2c73c95d0ae55bd3bcf4af36d4eab4de88f0745452cb1838679dc1e35f973",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "TRITON3",
      "mention_class": "drug_code_like"
    },
    {
      "id": "db8352a8-cb58-4e43-b8ba-32caf25bd0c3",
      "created_at": "2025-12-14T21:19:23.387521+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "fa0e91d2-4c8a-4fb3-b9d9-46e78b394877",
      "candidate_type": "drug_asset",
      "raw_identifier": "KRAS^{G12C}",
      "normalized_identifier": "kras^{g12c}",
      "fingerprint": "4e520776d8c17d5eda2c5dbd684b02cbf4734c58957812f6b46d00dcd3f03366",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "KRASG12C",
      "mention_class": "drug_code_like"
    },
    {
      "id": "ab8e9b06-e91a-4eb0-8dec-16438aa6ed40",
      "created_at": "2025-12-14T21:19:23.716578+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "84ed3b6c-3ffc-40bc-929a-d6df47340f6a",
      "candidate_type": "drug_asset",
      "raw_identifier": "RP2D",
      "normalized_identifier": "rp2d",
      "fingerprint": "b877e80b116df04a24c2c89b524d47f53bac319ba2ef17e6fad7265f483ecb84",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "RP2D",
      "mention_class": "drug_code_like"
    },
    {
      "id": "13dbeee7-1fe6-49ad-8935-adae8847e898",
      "created_at": "2025-12-14T21:19:24.758173+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "643eefc4-d9f9-47c8-a765-ca29f7c3c67f",
      "candidate_type": "patent_id",
      "raw_identifier": "WO2021231792A1",
      "normalized_identifier": "wo2021231792a1",
      "fingerprint": "ad5f7f2324fd0b26aab4b033f06b25ae3c3d80dd2180fd222d8dce1fecbf4193",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "WO2021231792A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "fa2405f2-e22b-4188-b91e-81f7794bc571",
      "created_at": "2025-12-14T21:19:25.069471+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "fe5170e6-6896-410e-afd6-1b32451b1d82",
      "candidate_type": "drug_asset",
      "raw_identifier": "1.2 g BID",
      "normalized_identifier": "1.2 g bid",
      "fingerprint": "b4da52f685e025e37c09ee6d49c7f697667294330972d700ebe31faa257e5354",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "12GBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "60997eed-fd23-4577-a47b-80f7c9a81b65",
      "created_at": "2025-12-14T21:19:25.381197+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "729a79d8-bb10-4f45-b35c-3e89b1d1f9f7",
      "candidate_type": "drug_asset",
      "raw_identifier": "150 mg BID",
      "normalized_identifier": "150 mg bid",
      "fingerprint": "982bcb1a7836912b0436c2b0492c27fd7f314b6a7939840166957812b4446882",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "150MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "3cf5bcaa-d2da-4f3e-a25f-10dab2791806",
      "created_at": "2025-12-14T21:19:26.08603+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "38fd121d-7479-4ce6-8fcb-c82cd73c8054",
      "candidate_type": "drug_asset",
      "raw_identifier": "toxicity.^{1}",
      "normalized_identifier": "toxicity.^{1}",
      "fingerprint": "8f76853fa83b9a6e1249ca219226ecfdf640b3071385f04d599a4910ec4b7b0f",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "TOXICITY1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e6d9feba-a74d-4a38-9a01-808f09a5c4a2",
      "created_at": "2025-12-14T21:19:26.391994+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "4917d76b-bdb3-416b-a446-860902b38c58",
      "candidate_type": "drug_asset",
      "raw_identifier": "krasg12c-mutated",
      "normalized_identifier": "krasg12c-mutated",
      "fingerprint": "7fd54836f37255c803e8a8f38c06e71e0cd5b291a1c7cb85e7c711ca3b12cc8f",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "KRASG12CMUTATED",
      "mention_class": "drug_code_like"
    },
    {
      "id": "a73a3821-8208-4332-8203-fa1cc83a7774",
      "created_at": "2025-12-14T21:19:21.602604+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "9bde8e94-d764-48c1-be34-3c521bdd5d03",
      "candidate_type": "drug_asset",
      "raw_identifier": "May 15, 2020",
      "normalized_identifier": "may 15, 2020",
      "fingerprint": "ca2d2c4fb56638790e060d3fb616ab4a08ef0ccb3c84b75148081f7d13eb6fe5",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "MAY152020",
      "mention_class": "drug_code_like"
    },
    {
      "id": "fd52ced0-38cc-43f3-b8e3-146d71c2e295",
      "created_at": "2025-12-14T21:19:21.983233+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "40646305-2c0f-457b-80a9-45aa04d984a6",
      "candidate_type": "drug_asset",
      "raw_identifier": "July 23, 2024",
      "normalized_identifier": "july 23, 2024",
      "fingerprint": "230ff416664a1181374e1e9ec6af9b8d0763673da6f666c0b6f8c272fca3e02b",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "JULY232024",
      "mention_class": "drug_code_like"
    },
    {
      "id": "b0c730fb-71f6-4b20-b84f-f2cc0701e085",
      "created_at": "2025-12-14T21:19:22.71781+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "8bd446ae-7682-43c0-bfb1-4e155c5a3606",
      "candidate_type": "drug_asset",
      "raw_identifier": "clvs-20201231x10k.htm",
      "normalized_identifier": "clvs-20201231x10k.htm",
      "fingerprint": "05ff93b8f6ae66d9b81fd692bd2ba40a2c6d090e0dae91e94e8605c43bc29486",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CLVS20201231X10KHTM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "dd74879b-8741-4f6a-ab69-1f3ed8235f1c",
      "created_at": "2025-12-14T21:19:23.443195+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "066d5f04-ff00-48fe-9275-12e72facde60",
      "candidate_type": "drug_asset",
      "raw_identifier": "600 mg once daily",
      "normalized_identifier": "600 mg once daily",
      "fingerprint": "a9376aec1191b0e0a292e6529af0d3a09e2faa0e765c067cdb38cfd4de07b769",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "600MGONCEDAILY",
      "mention_class": "drug_code_like"
    },
    {
      "id": "9b31bf3d-671c-4ccc-8388-427ef2392729",
      "created_at": "2025-12-14T21:19:23.776716+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "5b6d3ebf-12b0-406e-b05c-65cd6c5d3ce1",
      "candidate_type": "drug_asset",
      "raw_identifier": "200 mg, qd",
      "normalized_identifier": "200 mg, qd",
      "fingerprint": "43207a064472ef72b47663a6af21f8603fced6e7340d1c4a5e41b82e3b03753c",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "200MGQD",
      "mention_class": "drug_code_like"
    },
    {
      "id": "60b07377-762a-439a-a44b-0e3f1988ac88",
      "created_at": "2025-12-14T21:19:24.820587+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "651cbad9-2e95-40e4-9bfa-37fd22899d52",
      "candidate_type": "drug_asset",
      "raw_identifier": "US2021",
      "normalized_identifier": "us2021",
      "fingerprint": "cb2cb688843760cd6202f590989a60e3ffc948b7ce50b67b20afc8da602fa5c5",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "US2021",
      "mention_class": "drug_code_like"
    },
    {
      "id": "1aa67360-7e14-4d39-ba88-cdb1933d6595",
      "created_at": "2025-12-14T21:19:25.120061+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "2820a572-d5bb-445f-9686-5d8b93812ffb",
      "candidate_type": "drug_asset",
      "raw_identifier": "2.4 g BID",
      "normalized_identifier": "2.4 g bid",
      "fingerprint": "f8509c5060a8e7739296a90dd639344ed1dbbe5d77d471e4ba3a314e0748d971",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "24GBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "2f8bf499-d750-435a-8eaa-90019c2f55e5",
      "created_at": "2025-12-14T21:19:25.442274+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "069c9001-17f5-4b80-9df4-be76b6847744",
      "candidate_type": "drug_asset",
      "raw_identifier": "350 mg BID",
      "normalized_identifier": "350 mg bid",
      "fingerprint": "fd36424b3254b04fce81d33698147aa7e5275bfa1cb18897f5af1b48d5fd608e",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "350MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "f4c1ebc0-ffcb-4fbb-a7a1-7fe2546c88e0",
      "created_at": "2025-12-14T21:19:26.137092+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "2ad57de2-14c9-46bb-b999-ba6817344c3a",
      "candidate_type": "drug_asset",
      "raw_identifier": "600 MG BID^{1}",
      "normalized_identifier": "600 mg bid^{1}",
      "fingerprint": "f98d2cf2d6c11ffe734f24243b8c61efc9e8e2727ab9386b299ae1a5d6152823",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "600MGBID1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "4a39fe71-22e0-48ac-b9b8-747586eab338",
      "created_at": "2025-12-14T21:19:21.66905+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "2829fc9a-4e17-42ce-bbfb-a5ff0c14e3b7",
      "candidate_type": "drug_asset",
      "raw_identifier": "10.1002/onco.13585",
      "normalized_identifier": "10.1002/onco.13585",
      "fingerprint": "b23689b5685195603b5d8bf64337a491d3f0dc4899479517f5125bd7b98808fd",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "101002ONCO13585",
      "mention_class": "drug_code_like"
    },
    {
      "id": "6ab4eee0-df11-41e4-b655-6301556aea2d",
      "created_at": "2025-12-14T21:19:22.049695+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "029a973c-0234-4140-b610-3595e0e536b2",
      "candidate_type": "drug_asset",
      "raw_identifier": "clvs-20211231x10k.htm",
      "normalized_identifier": "clvs-20211231x10k.htm",
      "fingerprint": "c75bbbee29c59acb7ba1fb951a026accc4cfd1f2e3a5cae3ab96a591bd725f61",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CLVS20211231X10KHTM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "191cf48a-04e2-40f3-8d7c-0f2a5180a825",
      "created_at": "2025-12-14T21:19:22.779441+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "ae1bf0b2-b00c-4189-befb-bd481746e564",
      "candidate_type": "drug_asset",
      "raw_identifier": "BRCA1/2 mutations",
      "normalized_identifier": "brca1/2 mutations",
      "fingerprint": "7e9f7f970cc115b25e3355fc06ea2ff73cce657d267ce239ced538033bdc57d5",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "BRCA12MUTATIONS",
      "mention_class": "drug_code_like"
    },
    {
      "id": "306638fd-967c-44ba-94cd-cde87de4e611",
      "created_at": "2025-12-14T21:19:23.495989+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "5992eb5e-ec5e-430c-8cb6-f10fcdb8e15c",
      "candidate_type": "drug_asset",
      "raw_identifier": "1,200 mg once daily",
      "normalized_identifier": "1,200 mg once daily",
      "fingerprint": "2a7681b7b9bb819215e1b950deb37b087d04068037ffbd9ab65471e34ddcabcf",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "1200MGONCEDAILY",
      "mention_class": "drug_code_like"
    },
    {
      "id": "eb96a34b-9a0f-44f1-85bd-590666acfbc8",
      "created_at": "2025-12-14T21:19:23.8365+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "7616e627-dc52-497a-8fb9-7f0e0950e0fb",
      "candidate_type": "drug_asset",
      "raw_identifier": "a7d943543a8814fc",
      "normalized_identifier": "a7d943543a8814fc",
      "fingerprint": "c66c820d85bd87e7dde2730f34d1295bab1ffdc279ad2edb86092f63eef35b64",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "A7D943543A8814FC",
      "mention_class": "drug_code_like"
    },
    {
      "id": "d2b804cf-b3a2-45f8-8f1e-fbdd4f8cfaf8",
      "created_at": "2025-12-14T21:19:24.198964+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "95fbde59-f6ae-4be4-b9de-acc474b9eeb6",
      "candidate_type": "drug_asset",
      "raw_identifier": "KRAS G12C mutation",
      "normalized_identifier": "kras g12c mutation",
      "fingerprint": "af306c1907971d48439c06f73c1599a97488348c6c7c6d2d98221f6995aeeecb",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "KRASG12CMUTATION",
      "mention_class": "drug_code_like"
    },
    {
      "id": "8dbe0bd1-5eb2-4b49-b63e-2b073887a6fb",
      "created_at": "2025-12-14T21:19:24.550019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "7006e6a2-c3c8-421c-917e-4434e1de5ded",
      "candidate_type": "patent_id",
      "raw_identifier": "US20210393527A1",
      "normalized_identifier": "us20210393527a1",
      "fingerprint": "eed18a93718f6b501add061f48c318ff6814dfd818ac774b3fce226a0f9793eb",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "US20210393527A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "0a405e75-fe44-4abf-bb14-ec75285de8bf",
      "created_at": "2025-12-14T21:19:24.874712+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "91884684-4a8a-4b37-98fb-489541be0d59",
      "candidate_type": "patent_id",
      "raw_identifier": "US20230226030A1",
      "normalized_identifier": "us20230226030a1",
      "fingerprint": "0f22e346d75b6c24855f037b69bb6be992e6d92da781ade8681098b3c2bb4855",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "US20230226030A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "4a758b19-3991-4066-8499-c37012257322",
      "created_at": "2025-12-14T21:19:25.17098+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "dc3af521-be57-40eb-a7f9-34cf2b6368e3",
      "candidate_type": "patent_id",
      "raw_identifier": "PCT/US2022/075838",
      "normalized_identifier": "pct/us2022/075838",
      "fingerprint": "a96550f6d7ba476631e6bc7219718e771fbc7e9a2aa6d1f196259ee39521c4fc",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "PCTUS2022075838",
      "mention_class": "patent_id_like"
    },
    {
      "id": "9c6495b5-6f72-48bb-a015-e32d6227a933",
      "created_at": "2025-12-14T21:19:25.502257+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "86814f7e-6df4-48e2-b850-69c980f2215b",
      "candidate_type": "patent_id",
      "raw_identifier": "US17/760,298",
      "normalized_identifier": "us17/760,298",
      "fingerprint": "386c7be7a6398b1e66e85c64236170f4271aefb191b8403808394f06430f7ba7",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "US17760298",
      "mention_class": "patent_id_like"
    },
    {
      "id": "5c7a135b-b30b-42d0-928c-47c631120ba1",
      "created_at": "2025-12-14T21:19:26.187775+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "2930c21e-3b09-4ed0-845d-e26afab3352e",
      "candidate_type": "drug_asset",
      "raw_identifier": "BID^{1}",
      "normalized_identifier": "bid^{1}",
      "fingerprint": "1db0127d7608e27878b4179a4589515abf680acd1d346b1dc6ea0fd44a8bd3a7",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "BID1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "5e09acef-2c73-4eb0-9d2b-14b4466a909f",
      "created_at": "2025-12-14T21:19:21.734548+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "aad8eeb5-34ea-4e25-8009-77ee3d218e8e",
      "candidate_type": "drug_asset",
      "raw_identifier": "EQ 200MG BASE",
      "normalized_identifier": "eq 200mg base",
      "fingerprint": "bcd27f43ddd9f27e3861c4dfea886529b08d4a21fa1e4755a87fb2d9585cbf1f",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "EQ200MGBASE",
      "mention_class": "drug_code_like"
    },
    {
      "id": "93657b74-6cc8-4f27-90fa-3e2b534f2293",
      "created_at": "2025-12-14T21:19:22.106979+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "61feccfb-b4ec-44ab-b679-1edd1d8f4917",
      "candidate_type": "drug_asset",
      "raw_identifier": "November 22, 2023",
      "normalized_identifier": "november 22, 2023",
      "fingerprint": "4328c47a4f472754bb5c221f16569022531df87dbe58b5ab2ce7fc26961cd60d",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "NOVEMBER222023",
      "mention_class": "drug_code_like"
    },
    {
      "id": "5048a2e4-9b0b-4b02-a8ed-85dffc96566f",
      "created_at": "2025-12-14T21:19:22.847775+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "15d70960-8d92-4057-a949-82b47dc6fc4f",
      "candidate_type": "drug_asset",
      "raw_identifier": "Grade 1-4",
      "normalized_identifier": "grade 1-4",
      "fingerprint": "65944219476ce7acaa3d1a1e8405465b32b8c58f319c0e387e3683e928c0f52f",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "GRADE14",
      "mention_class": "drug_code_like"
    },
    {
      "id": "bcb6cbbe-f952-4b8b-8cc4-fbcbc275a3fe",
      "created_at": "2025-12-14T21:19:23.558195+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "cd583897-67cb-42df-8f7c-b10155a24ff9",
      "candidate_type": "drug_asset",
      "raw_identifier": "600 mg orally twice a day",
      "normalized_identifier": "600 mg orally twice a day",
      "fingerprint": "42db0e4c19ad75480d8d34083086938cea8216605201ed5a97727684379f7b53",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "600MGORALLYTWICEADAY",
      "mention_class": "drug_code_like"
    },
    {
      "id": "58d07231-d9cf-4dc1-946f-ea42408eb838",
      "created_at": "2025-12-14T21:19:23.890222+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "d3617524-8816-47b2-9586-1a0e2ae1f4ac",
      "candidate_type": "drug_asset",
      "raw_identifier": "400 mg BID",
      "normalized_identifier": "400 mg bid",
      "fingerprint": "6a2588a22ac38db3694350a16b4292b246304253ff76f4ea73fd8fe8902a3e93",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "400MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "8b5e2ed9-9e92-4737-bd63-79e3e4fd7b0f",
      "created_at": "2025-12-14T21:19:24.253113+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "20ce7559-c030-4ca2-90c4-dd9f6932d224",
      "candidate_type": "drug_asset",
      "raw_identifier": "BAY 43-9006",
      "normalized_identifier": "bay 43-9006",
      "fingerprint": "aaa863bd6e47fbe2d1b3329e7116a60a993b996fe5bf13db8a5f047af5c35ce9",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "BAY439006",
      "mention_class": "drug_code_like"
    },
    {
      "id": "dc7db731-b472-421a-85fa-6743614dbe3f",
      "created_at": "2025-12-14T21:19:24.601873+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "61dd89e9-3952-4699-8eb8-792ae46a08e0",
      "candidate_type": "drug_asset",
      "raw_identifier": "US17",
      "normalized_identifier": "us17",
      "fingerprint": "2baf23ef565f5fde5cd1b3c1e8fb7b69564fab531b900bcba5f3992d80b8bac1",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "US17",
      "mention_class": "drug_code_like"
    },
    {
      "id": "c1abecfe-b364-4f1a-bd67-6a45bda4f610",
      "created_at": "2025-12-14T21:19:24.921787+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "13cc454d-d24d-4e1c-8001-2e4ed10ce793",
      "candidate_type": "patent_id",
      "raw_identifier": "EP4504192A1",
      "normalized_identifier": "ep4504192a1",
      "fingerprint": "e4c8ebe5e32884f396fe5772a29201c46300399f75053608e4892ab4858508a5",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "EP4504192A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "6bc4a20a-14a3-4a2f-ba8e-ec70edfda952",
      "created_at": "2025-12-14T21:19:25.219988+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "bcaa34e6-eab5-4478-840f-4afa58966a3e",
      "candidate_type": "drug_asset",
      "raw_identifier": "800 mg BID",
      "normalized_identifier": "800 mg bid",
      "fingerprint": "67f0413051cdc864749de2d3b4a747d01d1de2b44e9681c2a6c7cab0d42ceca5",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "800MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e3826659-7359-4e1e-b4e1-4c8c7378f7a1",
      "created_at": "2025-12-14T21:19:25.557012+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "18815f19-b82b-4514-b97f-18265a9b2e45",
      "candidate_type": "drug_asset",
      "raw_identifier": "300 mg",
      "normalized_identifier": "300 mg",
      "fingerprint": "f116c9d081457bd559a66e4164b8a1b7b70edc458e7dc9583eb438c75537c874",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "300MG",
      "mention_class": "drug_code_like"
    },
    {
      "id": "4287199b-51b0-481a-8f7f-a2ba9ef0ccf0",
      "created_at": "2025-12-14T21:19:26.238809+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "da6658bb-201d-4791-8942-4e3afaeecbb2",
      "candidate_type": "drug_asset",
      "raw_identifier": "KRYSTAL-12",
      "normalized_identifier": "krystal-12",
      "fingerprint": "a09facd7a9cd095dc0485f0d1b6b5c49010f73023591a7db260aa36e6f02ee55",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "KRYSTAL12",
      "mention_class": "drug_code_like"
    },
    {
      "id": "2326c378-5072-46a4-aca6-d5fd5d3321c9",
      "created_at": "2025-12-14T21:19:21.79774+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "3a43c5fb-42d5-4d4d-84a2-24d7414f9985",
      "candidate_type": "drug_asset",
      "raw_identifier": "200MG",
      "normalized_identifier": "200mg",
      "fingerprint": "d319c84f6c93505b72f84cb98aa17b79bf661b21a65d0f68bca7a52597df4861",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "200MG",
      "mention_class": "drug_code_like"
    },
    {
      "id": "92b103f8-351c-41f3-9b6b-c7d7e99583d9",
      "created_at": "2025-12-14T21:19:22.167585+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "9054d8a7-1fa3-430c-a1ef-13745a9c2f10",
      "candidate_type": "patent_id",
      "raw_identifier": "U.S. Patent 6,495,541",
      "normalized_identifier": "u.s. patent 6,495,541",
      "fingerprint": "1a3bd08732b7b4a1a6da66ad8ff85ae1a4d1340fd2873f2994a4f9e58ec9c294",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "USPATENT6495541",
      "mention_class": "patent_id_like"
    },
    {
      "id": "07f49e9d-96eb-4aab-8d3f-2f4c53df0a1f",
      "created_at": "2025-12-14T21:19:22.897798+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "38c944f8-4d36-438c-86ff-0f0f72d2dec6",
      "candidate_type": "drug_asset",
      "raw_identifier": "Grant W81XWH-17-1-0124",
      "normalized_identifier": "grant w81xwh-17-1-0124",
      "fingerprint": "9362d757255bcbfff219e1508838f229b9edebc52cb12f72482b974e67cf8961",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "GRANTW81XWH1710124",
      "mention_class": "drug_code_like"
    },
    {
      "id": "2099d9dd-0cb6-4b7c-aa41-fbf528f9fb75",
      "created_at": "2025-12-14T21:19:23.276355+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "3d7957cd-81ef-46c7-9dc5-06de48d7935c",
      "candidate_type": "drug_asset",
      "raw_identifier": "MRTX849",
      "normalized_identifier": "mrtx849",
      "fingerprint": "0873c5ea35651c9959568fa1fbddbd9359641e159966a5fc9ac8b712296b6142",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "MRTX849",
      "mention_class": "drug_code_like"
    },
    {
      "id": "cd40634f-d4c4-41b6-ac69-50041cd99d64",
      "created_at": "2025-12-14T21:19:23.606021+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "befa9817-2121-4938-afc8-9e72d4609dc0",
      "candidate_type": "drug_asset",
      "raw_identifier": "75 mg/m^{2}",
      "normalized_identifier": "75 mg/m^{2}",
      "fingerprint": "69ab4c749e83e5ead5a91cf8957c8bb4b1b26807f4504cc3e35f8bb6713f9948",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "75MGM2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "55784079-fb78-4675-83fa-81f820596867",
      "created_at": "2025-12-14T21:19:24.655218+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "0622330f-5921-4f1e-a813-f7850ff22665",
      "candidate_type": "patent_id",
      "raw_identifier": "WO2023034916A1",
      "normalized_identifier": "wo2023034916a1",
      "fingerprint": "94be0a534100f911a35382cdc2d5dc6abf63b4bfa5647542d7566531d6744d09",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "WO2023034916A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "0c6f1e4d-6992-485e-8393-590e57f9067b",
      "created_at": "2025-12-14T21:19:24.973421+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "dcea692d-4a3d-40de-9cb7-2d57096f2ec8",
      "candidate_type": "patent_id",
      "raw_identifier": "EP23720027",
      "normalized_identifier": "ep23720027",
      "fingerprint": "669258748b6443b7b8125d76cdf1baf44457c2730fd64380c7699bd1e6fd481b",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "EP23720027",
      "mention_class": "patent_id_like"
    },
    {
      "id": "224838e5-182e-40b6-9a88-20eec827889d",
      "created_at": "2025-12-14T21:19:25.270807+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "e9ae7c9a-667d-4266-8fb2-5d0939a7d0d4",
      "candidate_type": "patent_id",
      "raw_identifier": "PCT/US2021/032335",
      "normalized_identifier": "pct/us2021/032335",
      "fingerprint": "735bf2b6a6d693a87ca0da648465541f88634cad7ca42f3a3316c147fa0e27d0",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "PCTUS2021032335",
      "mention_class": "patent_id_like"
    },
    {
      "id": "e9125f57-7503-4548-94a9-4487895e788a",
      "created_at": "2025-12-14T21:19:25.605664+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "c3781870-18d4-4517-92c2-52ba81d981ec",
      "candidate_type": "drug_asset",
      "raw_identifier": "400 mg",
      "normalized_identifier": "400 mg",
      "fingerprint": "1a98cf4b79efa1dc1bd0e09aca7f33391f2ef234ef3b1b76aa1c568884b5b8e0",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "400MG",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e0b832df-dd0b-450e-b428-eac3daef4912",
      "created_at": "2025-12-14T21:19:25.98199+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "092c4d6f-3cb5-4e8b-9890-6e71ca000c05",
      "candidate_type": "drug_asset",
      "raw_identifier": "KRYSTAL-1",
      "normalized_identifier": "krystal-1",
      "fingerprint": "749e913dbca70e5f4ad2c4c163d070d7af122e15aa141c057e193e0b866268b6",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "KRYSTAL1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "021a1e3b-945b-4e3d-b850-0f316f5a2756",
      "created_at": "2025-12-14T21:19:26.290756+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "f43139c7-3e5c-4df7-a1ef-cf82583d012a",
      "candidate_type": "drug_asset",
      "raw_identifier": "12 hours",
      "normalized_identifier": "12 hours",
      "fingerprint": "c4e907483ab0e3450bf9831f2bc4f360d44c843fee6a649237fbe2d69185067c",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "12HOURS",
      "mention_class": "drug_code_like"
    },
    {
      "id": "37f1935e-1967-4fe5-aeaa-9b550022bfa8",
      "created_at": "2025-12-14T21:05:23.211881+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "74f75da4-8cf5-4438-92d3-a3a13c9e7a1f",
      "candidate_type": "drug_asset",
      "raw_identifier": "CT7439",
      "normalized_identifier": "ct7439",
      "fingerprint": "3ede575e8c9fb092f5718b078d616a8c2aa07d11a297f74353765f47bdf67522",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CT7439",
      "mention_class": "drug_code_like"
    },
    {
      "id": "477a22c3-7b25-473c-a0ac-79891aa08f1a",
      "created_at": "2025-12-14T21:05:23.310851+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "35f67d53-1be7-4951-a5a3-b6cb874757ab",
      "candidate_type": "drug_asset",
      "raw_identifier": "TRITON2",
      "normalized_identifier": "triton2",
      "fingerprint": "24663b3765c8872499291c1e2eff90e536af5568b41cf9ad0f3e1387e4dca2e3",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "TRITON2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "67f622f5-de71-4fb1-8cbe-1298bbf3610a",
      "created_at": "2025-12-14T21:05:23.379926+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "edc6dbd6-dfb6-4359-b437-dd8e803c19a8",
      "candidate_type": "drug_asset",
      "raw_identifier": "600 mg BID",
      "normalized_identifier": "600 mg bid",
      "fingerprint": "4d51870cb739212153aefbdc190fc22d401ff66c3c3b87485bd2189f11cb27c8",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "600MGBID",
      "mention_class": "drug_code_like"
    },
    {
      "id": "51c64d01-cd8d-4daf-8461-21fbbf1f819e",
      "created_at": "2025-12-14T21:05:23.80708+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "1cf4ca9b-7578-4ff3-9de7-ee43ec167907",
      "candidate_type": "patent_id",
      "raw_identifier": "WO2020219650A1",
      "normalized_identifier": "wo2020219650a1",
      "fingerprint": "be24d84b275c7659d3b29b1b2e3d1bd37b96bc0b9f9f470181948e1862584390",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "WO2020219650A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "2c6f1521-7db5-4f35-bd91-3525da611adb",
      "created_at": "2025-12-14T21:05:23.873977+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "0a4454bf-393a-453c-9a24-5764b824725d",
      "candidate_type": "drug_asset",
      "raw_identifier": "US2020",
      "normalized_identifier": "us2020",
      "fingerprint": "db1ad041ff8959035fdb0b4e8ba9e34f76afd57239817b5f13647c9421ac169b",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "US2020",
      "mention_class": "drug_code_like"
    },
    {
      "id": "5de4dc34-9168-4107-a3e1-a3e644ec6491",
      "created_at": "2025-12-14T21:05:23.933955+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "d06d5969-4a72-4296-b9d7-a5f3a832a19b",
      "candidate_type": "patent_id",
      "raw_identifier": "WO2024222726A1",
      "normalized_identifier": "wo2024222726a1",
      "fingerprint": "5397e2015d9d66b3d6fe38fb71c26ca0107b838fff0022249618dd3b639dbbcd",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "WO2024222726A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "3bd33a37-8c3c-4267-84ea-7c6ff238e586",
      "created_at": "2025-12-14T21:05:23.99265+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "7f7508f3-1fec-46bd-a820-f1b7d3137e24",
      "candidate_type": "drug_asset",
      "raw_identifier": "CN2024",
      "normalized_identifier": "cn2024",
      "fingerprint": "c332ab5d1da0fd3cdc9b92bd52babb5af29745a06ba260663d95892b36f0d431",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CN2024",
      "mention_class": "drug_code_like"
    },
    {
      "id": "fc699d9b-0b5a-4bc5-9934-8ffa66a3b016",
      "created_at": "2025-12-14T21:05:24.051311+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "c0865f07-9324-485d-9bb4-f8eb575c3a0e",
      "candidate_type": "patent_id",
      "raw_identifier": "WO2024175065A1",
      "normalized_identifier": "wo2024175065a1",
      "fingerprint": "092b36453c208120107acf2838470c0f95665bf837365a0c081bf98dac5c88c3",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "WO2024175065A1",
      "mention_class": "patent_id_like"
    },
    {
      "id": "2cfd142f-73bc-4dd2-8976-2df9ce1be01a",
      "created_at": "2025-12-14T21:05:24.109718+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "1ba2eab1-561e-4404-ba7a-1a6885791836",
      "candidate_type": "drug_asset",
      "raw_identifier": "YJ9069",
      "normalized_identifier": "yj9069",
      "fingerprint": "4fe37e2e0a82e5c0712a3102d4cea180877c78caa270843e27710263b4d3d021",
      "status": "validated",
      "metadata": {},
      "canonical_identifier": "YJ9069",
      "mention_class": "drug_code_like"
    },
    {
      "id": "cca4c90b-71fb-42cb-bc24-7d3f496757b3",
      "created_at": "2025-12-14T21:05:24.260348+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "70726ce2-995d-4891-9350-7c44b83dd132",
      "candidate_type": "drug_asset",
      "raw_identifier": "NCT02",
      "normalized_identifier": "nct02",
      "fingerprint": "dad4c07b3eb45720a5aa0382f5e8765af42e1fa37d2d49db60e191badc7e9bd8",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "NCT02",
      "mention_class": "drug_code_like"
    },
    {
      "id": "939ecf63-6400-4277-806b-55ce5ac268df",
      "created_at": "2025-12-14T21:05:24.320768+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "1ba64664-8905-4a2e-9f5e-d6b6d2da6721",
      "candidate_type": "drug_asset",
      "raw_identifier": "GC69730",
      "normalized_identifier": "gc69730",
      "fingerprint": "b61de7c2a93fd88a8232d38bbe5bfe4f3afa16409c92da18f79ad7f6892840d8",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "GC69730",
      "mention_class": "drug_code_like"
    },
    {
      "id": "6f4811ee-e6d9-44c3-8c6b-c135e6ec502f",
      "created_at": "2025-12-14T21:05:24.377535+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "d4b7729c-5d2e-4f12-8dd1-6eb42644d120",
      "candidate_type": "drug_asset",
      "raw_identifier": "DC50",
      "normalized_identifier": "dc50",
      "fingerprint": "28cd6c42aa00987f25b557c56b7495ff24b702c6976cfdcb93840ee2af946ecb",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "DC50",
      "mention_class": "drug_code_like"
    },
    {
      "id": "ecc804fa-9558-48a0-bfb7-3cbad0b29c4b",
      "created_at": "2025-12-14T21:05:24.431389+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "d7774a6d-0379-432a-bf1e-afd2311c596e",
      "candidate_type": "patent_id",
      "raw_identifier": "PCT/US2020/029483",
      "normalized_identifier": "pct/us2020/029483",
      "fingerprint": "8cb143d2a33dca6db07ad3860e3c10df8838b30fe818507120dfbcb9b4cd6971",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "PCTUS2020029483",
      "mention_class": "patent_id_like"
    },
    {
      "id": "ec40958b-7fd5-48cf-bb6d-4625f4879a37",
      "created_at": "2025-12-14T21:05:24.483451+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "ec9de1ab-79e0-4cb9-986b-3cc6c49a7ae0",
      "candidate_type": "patent_id",
      "raw_identifier": "PCT/CN2024/089497",
      "normalized_identifier": "pct/cn2024/089497",
      "fingerprint": "52a02e7e5fcdc36ce21a5f7e57460adfdff719dc77eb5a8a0ef9ff743a3ec5a4",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "PCTCN2024089497",
      "mention_class": "patent_id_like"
    },
    {
      "id": "12e221ae-1ab3-41f2-ae46-2878f7ae34b1",
      "created_at": "2025-12-14T21:05:24.53429+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "2072e8b9-a859-4b51-865b-45a68d2b9692",
      "candidate_type": "patent_id",
      "raw_identifier": "PCT/CN2024/078146",
      "normalized_identifier": "pct/cn2024/078146",
      "fingerprint": "0e02a5cfe609c5159d93c1f2b6ed1b4062f1e7a6c4ec4c8bf8b4e32407d11743",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "PCTCN2024078146",
      "mention_class": "patent_id_like"
    },
    {
      "id": "0023ab96-522d-43f9-bf0b-ea782be78a31",
      "created_at": "2025-12-14T21:05:24.597039+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "cfe14b3d-cc24-41ce-ac7a-88d250f3c0f8",
      "candidate_type": "drug_asset",
      "raw_identifier": "PP-C8",
      "normalized_identifier": "pp-c8",
      "fingerprint": "661369af9a95fb9911fd0841fccd57099f25f57a016531e1b169f19329fa78a7",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "PPC8",
      "mention_class": "drug_code_like"
    },
    {
      "id": "a0cb1f69-1908-4906-8f48-9ad42e1de0ef",
      "created_at": "2025-12-14T21:05:24.683136+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "f3753dc3-e3b0-4195-b072-afde6a17d75a",
      "candidate_type": "drug_asset",
      "raw_identifier": "pp-c8.html",
      "normalized_identifier": "pp-c8.html",
      "fingerprint": "7e781cef43cb3887555d53508ffa80f39e4de79ec78fa0b66f225b53d45e5920",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "PPC8HTML",
      "mention_class": "drug_code_like"
    },
    {
      "id": "eea144c7-8ff4-44fa-b649-22decbf35ee6",
      "created_at": "2025-12-14T21:05:24.737047+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "9f8de751-78f6-41c8-bf00-43fbcade13b0",
      "candidate_type": "drug_asset",
      "raw_identifier": "CDK12-Cyclin K",
      "normalized_identifier": "cdk12-cyclin k",
      "fingerprint": "254354f989f4667fb6cd03b7d91cbcf821c6f704577c6901e5f069cd31a63b76",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CDK12CYCLINK",
      "mention_class": "drug_code_like"
    },
    {
      "id": "e76d1bce-d3f3-4aa4-a7ce-be6e926da611",
      "created_at": "2025-12-14T21:05:24.794642+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "79c44b1f-e936-486d-89a2-a524c3da6682",
      "candidate_type": "drug_asset",
      "raw_identifier": "412 nM",
      "normalized_identifier": "412 nm",
      "fingerprint": "3625f76715eea6c22b576ee4c9c4528b265ab38bcf8a97eb64f96a29b820b69b",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "412NM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "62d2051e-b12d-4c56-9298-c469e7f889d1",
      "created_at": "2025-12-14T21:05:24.850688+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "aee4c5ed-211d-4307-b0b0-da4fcbbc2267",
      "candidate_type": "drug_asset",
      "raw_identifier": "CAS#3053716-98-3",
      "normalized_identifier": "cas#3053716-98-3",
      "fingerprint": "638753917a8b128d9c921d1eb6fad58d44114efc1688c6e986703a91f13d3249",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CAS3053716983",
      "mention_class": "drug_code_like"
    },
    {
      "id": "2bc7e1da-553c-4db5-a82d-15ded27b9617",
      "created_at": "2025-12-14T21:05:25.144777+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "7b39c49a-e629-472d-8539-b26f9f76ba78",
      "candidate_type": "drug_asset",
      "raw_identifier": "IND-for-CT7439",
      "normalized_identifier": "ind-for-ct7439",
      "fingerprint": "046874e430eb9e3de73b4d428bcd3ed4fbcef79d355b37dc07d270be9e073684",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "INDFORCT7439",
      "mention_class": "drug_code_like"
    },
    {
      "id": "dc289c44-f03b-4a35-a3e0-e9c9e16c5110",
      "created_at": "2025-12-14T21:05:25.201595+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "d2226810-2d51-40cc-89fb-65bec6d1877c",
      "candidate_type": "drug_asset",
      "raw_identifier": "CT7439_001",
      "normalized_identifier": "ct7439_001",
      "fingerprint": "b8038298258e622c898835bbe47c1e466ff90160da34484fc5d7756ff08ff06e",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CT7439001",
      "mention_class": "drug_code_like"
    },
    {
      "id": "62b92df9-ab2f-487a-8b5f-464db7d8e6a4",
      "created_at": "2025-12-14T21:05:25.48923+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "6c141619-719e-4355-9e19-a646fdb4ff64",
      "candidate_type": "drug_asset",
      "raw_identifier": "detail/25",
      "normalized_identifier": "detail/25",
      "fingerprint": "430fd9f9b5838b05c3cc43ceb838fa3a0b9f40818c47bac901d79a60e224e149",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "DETAIL25",
      "mention_class": "drug_code_like"
    },
    {
      "id": "0be8bbfb-26d9-4118-a3bf-f133baeddd82",
      "created_at": "2025-12-14T21:05:25.541088+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "a29c962d-3516-4015-90b0-62238500e3fe",
      "candidate_type": "drug_asset",
      "raw_identifier": "detail/20",
      "normalized_identifier": "detail/20",
      "fingerprint": "3379baa0ff7d918b0af07e52bcb120c03c3d6588ce382c41c34872d8b28d8b93",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "DETAIL20",
      "mention_class": "drug_code_like"
    },
    {
      "id": "ba2e5868-dd5a-42c6-92c2-d7595319219d",
      "created_at": "2025-12-14T21:05:25.829907+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "8638cd5b-1724-4f8c-9e23-1abadafb4234",
      "candidate_type": "drug_asset",
      "raw_identifier": "SR-4835",
      "normalized_identifier": "sr-4835",
      "fingerprint": "dc03c2997994adb9a3c59bc2c34446b264a38e966ad067dbf05fa46364e949bf",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "SR4835",
      "mention_class": "drug_code_like"
    },
    {
      "id": "fa83ce86-87e5-4228-816b-91b5ceee6793",
      "created_at": "2025-12-14T21:05:25.881262+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "863acc1a-39f7-484b-8bde-2d3af221c2a7",
      "candidate_type": "drug_asset",
      "raw_identifier": "THZ531",
      "normalized_identifier": "thz531",
      "fingerprint": "a3c0c0eb7cf41d8bbe513340366a6a8cdd67e4c573b47d49e3966f4de918f973",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "THZ531",
      "mention_class": "drug_code_like"
    },
    {
      "id": "a4e6fd0e-2f83-4253-a689-636596772d69",
      "created_at": "2025-12-14T21:05:25.936425+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "d0e3f3ee-009d-49a2-bf68-85e249d52baf",
      "candidate_type": "drug_asset",
      "raw_identifier": "HQ461",
      "normalized_identifier": "hq461",
      "fingerprint": "f0bd7f1d894f21b3b282dfd62c3f31ee805bc2606da5660aa120085068d7240c",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "HQ461",
      "mention_class": "drug_code_like"
    },
    {
      "id": "a2e6fb28-8404-4c06-92ce-d5551f6f6f05",
      "created_at": "2025-12-14T21:05:25.988169+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "82c9a057-bb2c-4e46-95f1-1146430df3e4",
      "candidate_type": "drug_asset",
      "raw_identifier": "PC-6230201",
      "normalized_identifier": "pc-6230201",
      "fingerprint": "8d50a561e61716c24ddd6d4f0e1efeffeb15a1fe87291d92a4a11bc2cc4af413",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "PC6230201",
      "mention_class": "drug_code_like"
    },
    {
      "id": "a7ec5169-66a6-4681-ade0-207c2f3e92cb",
      "created_at": "2025-12-14T21:05:26.048184+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "dda70989-ec92-48b9-a379-aabba38e9ba7",
      "candidate_type": "drug_asset",
      "raw_identifier": "PDB: 6TD3",
      "normalized_identifier": "pdb: 6td3",
      "fingerprint": "cd3b8d8dd6b2838ff4ab9bbb302535cd8c08f4a37da31ba3042ed999da2728c5",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "PDB6TD3",
      "mention_class": "drug_code_like"
    },
    {
      "id": "78c5bf45-3ee4-4137-9fc0-8b4f8d25f326",
      "created_at": "2025-12-14T21:05:26.100685+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "8093204c-c6fd-44ae-8c27-83dc2e564ecb",
      "candidate_type": "drug_asset",
      "raw_identifier": "6TD3",
      "normalized_identifier": "6td3",
      "fingerprint": "b767999fd03552a19f1603224a62cfb351bee6b37915f06f13a45a0ca2552483",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "6TD3",
      "mention_class": "drug_code_like"
    },
    {
      "id": "1a621c07-964d-41f8-b1b7-c0fb6319bde0",
      "created_at": "2025-12-14T21:05:26.161347+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "4e06bc69-d593-46bd-96a1-6b73f56ad7b1",
      "candidate_type": "drug_asset",
      "raw_identifier": "pan-CDK/CDK12",
      "normalized_identifier": "pan-cdk/cdk12",
      "fingerprint": "7ff1871cdc084b33b5ee6c39d24efded1fcbdb5ebbf09f4f3b28e7b6489cea41",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "PANCDKCDK12",
      "mention_class": "drug_code_like"
    },
    {
      "id": "90d75058-a6bb-44a3-9ba3-0d99e9134212",
      "created_at": "2025-12-14T21:05:26.212987+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "2a7a69b5-af72-4af8-a643-238f41b80187",
      "candidate_type": "drug_asset",
      "raw_identifier": "dCeMM2/3/4",
      "normalized_identifier": "dcemm2/3/4",
      "fingerprint": "879f9bd023e8f9c1d2e659bc8b79d1f48e5192cc4ae3986d6eb3800c4803200b",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "DCEMM234",
      "mention_class": "drug_code_like"
    },
    {
      "id": "61ff64e1-ad14-4f9d-bf4a-dc2f00ae042a",
      "created_at": "2025-12-14T21:05:26.269497+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "8ca0fcf9-addb-47a7-8a73-d96660689c20",
      "candidate_type": "drug_asset",
      "raw_identifier": "PC-62302",
      "normalized_identifier": "pc-62302",
      "fingerprint": "dee094c6ccb3d1587ef55143a173af2ec200cfe822bba59f4547ce98dee2fe0d",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "PC62302",
      "mention_class": "drug_code_like"
    },
    {
      "id": "8cd376dc-345c-4705-af8a-28d002479aa6",
      "created_at": "2025-12-14T21:05:26.319816+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "8d985b10-423e-4122-9bde-3111a6dc60e7",
      "candidate_type": "drug_asset",
      "raw_identifier": "PC-6230201_COA.pdf",
      "normalized_identifier": "pc-6230201_coa.pdf",
      "fingerprint": "23082a01705b099d744d5d455b65c82b51db9e3adbd9892a50f36cdedb59df73",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "PC6230201COAPDF",
      "mention_class": "drug_code_like"
    },
    {
      "id": "c670cf37-0a55-411f-82b3-1f9b57ffa53e",
      "created_at": "2025-12-14T21:05:26.369308+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "22090a7a-ba1d-41d7-9b1a-49e6381add16",
      "candidate_type": "drug_asset",
      "raw_identifier": "dCeMM2",
      "normalized_identifier": "dcemm2",
      "fingerprint": "46b16ae1c1aa5a67faeac8ccaf44df25c4543d92d399750241f15cb89f0b68ed",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "DCEMM2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "7ccf22f7-e1bb-479d-97da-6b8fd439d091",
      "created_at": "2025-12-14T21:05:26.423287+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "3472d1c1-bc61-4ffa-b071-1934df81c348",
      "candidate_type": "drug_asset",
      "raw_identifier": "Catalog No.: 7525",
      "normalized_identifier": "catalog no.: 7525",
      "fingerprint": "f9d5ab225ce4dac1bc1999c12f3fdfd5093717f537040359982ae632c7cd2a2c",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CATALOGNO7525",
      "mention_class": "drug_code_like"
    },
    {
      "id": "c007b8b4-afd6-4326-a5e4-f4f244cf1fda",
      "created_at": "2025-12-14T21:05:26.477065+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "14492e5f-a50e-4992-8ce5-ab125a6db39b",
      "candidate_type": "drug_asset",
      "raw_identifier": "Batch No.: 1",
      "normalized_identifier": "batch no.: 1",
      "fingerprint": "7f53d1e7b105e862bcb42d9eddc96e1223cce138df685cd30a887c3299ecfe80",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "BATCHNO1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "ae884985-0966-4b7f-a9a1-41637228b314",
      "created_at": "2025-12-14T21:05:26.533336+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "bb342203-fd1b-4d55-8aab-5e39b9baab01",
      "candidate_type": "drug_asset",
      "raw_identifier": "7525_1_coa.pdf",
      "normalized_identifier": "7525_1_coa.pdf",
      "fingerprint": "5e577f2482f6ecf118f691ef1779b90d4ffbe7e4d0f8ce0ad29e2b08b9a6eab8",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "75251COAPDF",
      "mention_class": "drug_code_like"
    },
    {
      "id": "0e875f77-6750-4ed3-ba20-1da0d13827b5",
      "created_at": "2025-12-14T21:05:26.585373+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "2e148f59-bc85-4139-b2f7-c4f41e194818",
      "candidate_type": "drug_asset",
      "raw_identifier": "Catalog Number: 7525",
      "normalized_identifier": "catalog number: 7525",
      "fingerprint": "18505c2f762446251f950f532e53306ab34423f9b834efe567418c36565115f0",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CATALOGNUMBER7525",
      "mention_class": "drug_code_like"
    },
    {
      "id": "c4438a21-8d9f-4412-aeaf-55507149fff2",
      "created_at": "2025-12-14T21:05:26.642696+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "9400f914-9e4a-4041-8bda-4a41421f3ced",
      "candidate_type": "drug_asset",
      "raw_identifier": "7525_sds.pdf",
      "normalized_identifier": "7525_sds.pdf",
      "fingerprint": "dd3893b90dda0f0f2cfe2852f925ee310402cd20aee2b5e3aff672f9ea2b7e17",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "7525SDSPDF",
      "mention_class": "drug_code_like"
    },
    {
      "id": "058ee194-32ee-4b23-951d-cac623d26b43",
      "created_at": "2025-12-14T21:05:26.948004+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "1d34b568-26c5-43ee-9437-525adf50c3d6",
      "candidate_type": "drug_asset",
      "raw_identifier": "THZ531R",
      "normalized_identifier": "thz531r",
      "fingerprint": "ff208b907abde30acece2102679e066a7bcdf676745ae0792b1243370f8792c6",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "THZ531R",
      "mention_class": "drug_code_like"
    },
    {
      "id": "4e41150a-b671-44a6-a03e-13e866bb078f",
      "created_at": "2025-12-14T21:05:26.997909+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "678f8418-c629-44fa-aaf5-6bf803773674",
      "candidate_type": "drug_asset",
      "raw_identifier": "S6595",
      "normalized_identifier": "s6595",
      "fingerprint": "ba734edfb28d516e34abc5e08b1bf343ffbd4ce8621f00cd5b5168062120879a",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "S6595",
      "mention_class": "drug_code_like"
    },
    {
      "id": "8ac08946-70c0-4168-b834-6d193fc26717",
      "created_at": "2025-12-14T21:05:27.053324+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "a16b4552-c267-4e70-9d61-ca31743cb463",
      "candidate_type": "drug_asset",
      "raw_identifier": "S659503",
      "normalized_identifier": "s659503",
      "fingerprint": "2cef35fa5dcdc7b34844c041cd52041b55f81af58442a0a0f68a6cb54e62ad2f",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "S659503",
      "mention_class": "drug_code_like"
    },
    {
      "id": "5bedc926-38cf-42ba-9d85-07d0c4efd210",
      "created_at": "2025-12-14T21:05:27.106736+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "ac4abd7c-e638-41ec-8ed5-9313970ddab0",
      "candidate_type": "drug_asset",
      "raw_identifier": "CDK12和CDK13",
      "normalized_identifier": "cdk12和cdk13",
      "fingerprint": "036b828aeaf262eff438f36317285375b23bcc92ae4c3f40589745c5b1767717",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CDK12CDK13",
      "mention_class": "drug_code_like"
    },
    {
      "id": "d5b10eec-7089-4421-a85c-68c514c016d6",
      "created_at": "2025-12-14T21:05:27.179223+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "0715d488-5e4a-4e7c-ab5b-f55921cbb3cb",
      "candidate_type": "drug_asset",
      "raw_identifier": "158 nM",
      "normalized_identifier": "158 nm",
      "fingerprint": "cfa3605aa18a99a40b6c7244d3fce465f7fa7111c92f8ca88b0ac2d537d4930b",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "158NM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "7b83bdbd-d5f6-4d58-b1cc-3171f11a6724",
      "created_at": "2025-12-14T21:05:27.230275+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "fa74e977-4780-44b0-95cb-0e02c368aa90",
      "candidate_type": "drug_asset",
      "raw_identifier": "69 nM",
      "normalized_identifier": "69 nm",
      "fingerprint": "161f2d243d78df7feaca08834d1d3999bd159c6ce4f68d8e0947e660331bad47",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "69NM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "dfbc2550-474f-422e-8ac6-11bd84f38f61",
      "created_at": "2025-12-14T21:05:27.283264+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "c5ddaafc-b906-498c-be3a-14cc3b02381d",
      "candidate_type": "drug_asset",
      "raw_identifier": "S659503-DataSheet.pdf",
      "normalized_identifier": "s659503-datasheet.pdf",
      "fingerprint": "7fc8dd1a677bd58df9241edd8c3a505ba36b341acba4c1e4f7890d1fadad757e",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "S659503DATASHEETPDF",
      "mention_class": "drug_code_like"
    },
    {
      "id": "1acce3b5-7a91-44a1-8bad-5cb2e921a385",
      "created_at": "2025-12-14T21:05:27.333294+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "c82ad802-91e3-4e14-8e47-2210dbcaf2d5",
      "candidate_type": "drug_asset",
      "raw_identifier": "S8894",
      "normalized_identifier": "s8894",
      "fingerprint": "7469f17dd363c35cd6c9e732d83813294d0d144384cafdb8ace6e481ed45d58e",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "S8894",
      "mention_class": "drug_code_like"
    },
    {
      "id": "f22917fa-132a-47e1-a97e-d20d28193f0e",
      "created_at": "2025-12-14T21:05:27.391495+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "6a873750-df67-4e03-a988-30f38d6722e2",
      "candidate_type": "drug_asset",
      "raw_identifier": "S889402",
      "normalized_identifier": "s889402",
      "fingerprint": "d7dfafaa0eed90406ab20f040ebd3aedbaac62ab754b7358df6bfdc8dfd091fb",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "S889402",
      "mention_class": "drug_code_like"
    },
    {
      "id": "2acb3c46-5455-4cea-953a-a6229388a492",
      "created_at": "2025-12-14T21:05:27.443273+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "95d32ef5-3422-48a3-872f-69485ed45a12",
      "candidate_type": "drug_asset",
      "raw_identifier": "CDK12 and CDK13",
      "normalized_identifier": "cdk12 and cdk13",
      "fingerprint": "f53bee4e3abdb65d620a0aa868dd18f8bb903477d660adbe18eeb2b25bd5f8a1",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "CDK12ANDCDK13",
      "mention_class": "drug_code_like"
    },
    {
      "id": "cd735674-93a3-4f6c-a122-916703fd43e5",
      "created_at": "2025-12-14T21:05:27.495967+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "14a7e866-63e4-46bc-b664-8ad50986dbd7",
      "candidate_type": "drug_asset",
      "raw_identifier": "99 nM",
      "normalized_identifier": "99 nm",
      "fingerprint": "bf236e05ab6bb98003ab29c77ce91c79ec367f0ec2d2da278bc064f567810ea4",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "99NM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "08574e55-2a81-4324-bffa-76d5bf5815ba",
      "created_at": "2025-12-14T21:05:27.558118+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "29587e1f-bb6a-4f62-9443-4ab188bca1df",
      "candidate_type": "drug_asset",
      "raw_identifier": "98 nM",
      "normalized_identifier": "98 nm",
      "fingerprint": "7090be2b8f6f9a954120e9257ec0bc24d9edeebe99a04c464349624068014584",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "98NM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "1d610808-00a6-4414-9e7d-46d0c63bfc2d",
      "created_at": "2025-12-14T21:05:27.645979+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "336f98b7-dc73-45a5-8533-fa398ac9ccaa",
      "candidate_type": "drug_asset",
      "raw_identifier": "4.9 nM",
      "normalized_identifier": "4.9 nm",
      "fingerprint": "50c5d023af69ff4313e62f9e904574f7f243300f97a1cc8d19b0f4e6b181630f",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "49NM",
      "mention_class": "drug_code_like"
    },
    {
      "id": "37a87f48-2abb-4a7f-b57a-4c876c5badca",
      "created_at": "2025-12-14T21:05:27.702141+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "077c4773-6802-404d-931b-dbb99a62ca41",
      "candidate_type": "drug_asset",
      "raw_identifier": "S889402-DataSheet.pdf",
      "normalized_identifier": "s889402-datasheet.pdf",
      "fingerprint": "4cb22cba61383fe05e6b8929a8b45ee129f89fadca46425b80afb8c12f45c4cd",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "S889402DATASHEETPDF",
      "mention_class": "drug_code_like"
    },
    {
      "id": "293d6f6e-1d87-4e55-944f-4a35f9154a07",
      "created_at": "2025-12-14T21:05:27.777811+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "0beb593b-8d5c-4b84-922a-f019c2b9cf25",
      "candidate_type": "drug_asset",
      "raw_identifier": "Scheme 1",
      "normalized_identifier": "scheme 1",
      "fingerprint": "36bd2ca73aa5ac002e21be553a8bcd9ddc511dc8333e5d3f7cb89d9c5077846f",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "SCHEME1",
      "mention_class": "drug_code_like"
    },
    {
      "id": "21273f9c-3222-40b3-baf8-9bc4fe4f531c",
      "created_at": "2025-12-14T21:05:27.82761+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "aaa04ca7-c728-4901-bb3a-0624c08c2612",
      "candidate_type": "drug_asset",
      "raw_identifier": "Scheme 2",
      "normalized_identifier": "scheme 2",
      "fingerprint": "f6200f003f36733dd4304a174cc9449ec4ac26d2ad626768b266e6a094e1fb71",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "SCHEME2",
      "mention_class": "drug_code_like"
    },
    {
      "id": "064b15fc-dcb2-404d-b9e7-35caf1c21b02",
      "created_at": "2025-12-14T21:05:27.886901+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "49bd0b6c-4b0b-464f-92d4-45be171931c8",
      "candidate_type": "drug_asset",
      "raw_identifier": "BioTHZ531",
      "normalized_identifier": "biothz531",
      "fingerprint": "d44b1c15438a1adf81da8965f959584dcf0d0a122609938340937891aaad2983",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "BIOTHZ531",
      "mention_class": "drug_code_like"
    },
    {
      "id": "319ae177-1ee6-419a-8977-07f422925471",
      "created_at": "2025-12-14T21:05:27.95891+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "2cbe01a9-cea0-4e10-a186-e88d3233eda9",
      "candidate_type": "drug_asset",
      "raw_identifier": "10.1038%2Fnchembio.2166",
      "normalized_identifier": "10.1038%2fnchembio.2166",
      "fingerprint": "456710e8bcc14fadafcabd56bb403e8f7af924652bd72bbfc562d657cfb591b8",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "1010382FNCHEMBIO2166",
      "mention_class": "drug_code_like"
    },
    {
      "id": "cfe06521-00ec-466f-969e-2ca153b74caf",
      "created_at": "2025-12-14T21:05:28.024671+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "9f103df7-1f4b-425e-ba14-485fba265a75",
      "candidate_type": "drug_asset",
      "raw_identifier": "MOESM153",
      "normalized_identifier": "moesm153",
      "fingerprint": "a1c3557bdaebc1d6058da2b8d2cf4d48e4f44ce120aca864559437458815d314",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "MOESM153",
      "mention_class": "drug_code_like"
    },
    {
      "id": "88dee3c8-f4cb-4246-b1d8-dc19da517e63",
      "created_at": "2025-12-14T21:05:28.076984+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "586a9b4e-6c67-4341-8fc2-6f3f0e0ac926",
      "candidate_type": "drug_asset",
      "raw_identifier": "BFnchembio2166",
      "normalized_identifier": "bfnchembio2166",
      "fingerprint": "e3297bc2a08842ab80b7846183e8eeb66832991efee49984eefd5591b236bb90",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "BFNCHEMBIO2166",
      "mention_class": "drug_code_like"
    },
    {
      "id": "d56e79d4-360e-45fc-a265-7b350011c38e",
      "created_at": "2025-12-14T21:05:28.129489+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "099a05e5-10f5-4760-8164-c030970b1413",
      "candidate_type": "drug_asset",
      "raw_identifier": "nchembio2166",
      "normalized_identifier": "nchembio2166",
      "fingerprint": "aac3393c8e781977ac703daec1dce85eecbd4c4524dcb7015fbde168cb8e2b5d",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "NCHEMBIO2166",
      "mention_class": "drug_code_like"
    },
    {
      "id": "9f5c88f0-be0b-4476-858d-f02dba7c4dfc",
      "created_at": "2025-12-14T21:05:28.197958+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "5e16e62d-b8e4-4dc8-a7be-e91e16c9514c",
      "candidate_type": "drug_asset",
      "raw_identifier": "Scheme 3",
      "normalized_identifier": "scheme 3",
      "fingerprint": "ef8be1cfeb5bc1cef5f45ce27bd89b7f2a942e700f0b03a883497e52145afb9e",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "SCHEME3",
      "mention_class": "drug_code_like"
    },
    {
      "id": "100d337e-0c06-42ce-8081-76a96feda62c",
      "created_at": "2025-12-14T21:05:28.254451+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "130d6e31-b45d-43e2-9216-53571a61df2d",
      "candidate_type": "drug_asset",
      "raw_identifier": "uuid%3A",
      "normalized_identifier": "uuid%3a",
      "fingerprint": "523661a00cb5b4afb962dcd625aefa335b7f431ff27d2bf0692c79fa009fe505",
      "status": "pending",
      "metadata": {},
      "canonical_identifier": "UUID3A",
      "mention_class": "drug_code_like"
    },
    {
      "id": "a25159a7-8705-4003-8597-b2942db53c1c",
      "created_at": "2025-12-14T21:05:24.200359+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "source_mention_id": "b0515e49-f7d3-4f90-9f81-5cf324527f23",
      "candidate_type": "drug_asset",
      "raw_identifier": "YJ1206",
      "normalized_identifier": "yj1206",
      "fingerprint": "49df4e7bb944e40cce133b1a17139e0144423c77507bad6ddfd81d2601bcdf25",
      "status": "validated",
      "metadata": {},
      "canonical_identifier": "YJ1206",
      "mention_class": "drug_code_like"
    }
  ],
  "queries": [
    {
      "id": "25eccb9f-e1d6-4b3f-8ee1-0155015ee880",
      "created_at": "2025-12-14T21:05:22.80005+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "1592efb5-800e-4a68-a65d-ea47d4712e6c",
      "worker_id": "w1:clinical-trials",
      "phase": "recall",
      "query_text": "CDK12 臨床試験 NCT",
      "query_fingerprint": "681ebb3863f00fa282c1cd02e27f40fe7ab5b20e0305fcd348a64e5609eda03b"
    },
    {
      "id": "e8d8a339-ddd5-49d8-acdc-9d8210107d60",
      "created_at": "2025-12-14T21:05:23.528451+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "worker_id": "w2:pipelines",
      "phase": "recall",
      "query_text": "CDK12 PROTAC 蛋白降解 专利 WO",
      "query_fingerprint": "4fd9655bfe86f3611aad1765571340d9e750387ae5692dfa462c4d6f6dc72a84"
    },
    {
      "id": "3bf5926a-8516-45fa-92ad-debe525ad9b8",
      "created_at": "2025-12-14T21:05:24.95284+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "928d0769-43d1-4b86-bb24-5074a6b34bfe",
      "worker_id": "w3:patents",
      "phase": "recall",
      "query_text": "CDK12 첫 환자 투여 1상 보도자료",
      "query_fingerprint": "b55e8011dd7c1b045394d08b401e11cccb353bb6ad7ebc1c2ce9c7fc99a4a640"
    },
    {
      "id": "2eac9975-cce2-4921-9326-92d5201b02b5",
      "created_at": "2025-12-14T21:05:25.316158+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "5b0751a1-c768-4bf0-9e15-8efd843e8464",
      "worker_id": "w4:geography",
      "phase": "recall",
      "query_text": "CDK12 communiqué de presse Phase 1 premier patient",
      "query_fingerprint": "7881b9820f92a9c594ebe77740c7996407f7f68ff530b70e9d5907a9b866120d"
    },
    {
      "id": "f006bd32-9f42-46cd-9925-ee5dfa545b1f",
      "created_at": "2025-12-14T21:05:25.654218+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "worker_id": "w5:clinical-trials",
      "phase": "recall",
      "query_text": "CDK12 inhibitor pipeline PDF filetype:pdf",
      "query_fingerprint": "b698889adaff841f18ef1607c136de6da67fa03df0172fc8b347922b9648bb27"
    },
    {
      "id": "3cb6719b-95e1-4e8b-b3c8-ef22187ca69d",
      "created_at": "2025-12-14T21:05:26.750918+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "worker_id": "w6:pipelines",
      "phase": "recall",
      "query_text": "CDK12 compound IC50 PDF filetype:pdf",
      "query_fingerprint": "c385a7a06eb3948b9435caf2b15d8527c1acd5269f319db7a880871f6ac155f9"
    },
    {
      "id": "9c231c26-fd47-43f0-82bf-1cc907b0e84c",
      "created_at": "2025-12-14T21:11:48.126231+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "d2f4fb81-4778-4058-b4b1-342e28739366",
      "worker_id": "w1:clinical-trials",
      "phase": "recall",
      "query_text": "\"CT7439\" target",
      "query_fingerprint": "2ccc2f78e2387ad544d538431c9278b08a58fd49323858c7db42ec2773874513"
    },
    {
      "id": "34a411d6-1484-4373-b8ed-33570d700971",
      "created_at": "2025-12-14T21:11:48.687253+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "3b78e997-1ae8-47f4-9e8d-dca61c59898c",
      "worker_id": "w2:pipelines",
      "phase": "recall",
      "query_text": "\"CT7439\" Phase 1",
      "query_fingerprint": "2475c039aa32e756cbf5f0320dca4cb6469724a0fdfd4cdb5c2fdf1c37d0692d"
    },
    {
      "id": "3112bbc4-425c-4563-96ef-5c243271736a",
      "created_at": "2025-12-14T21:11:48.911916+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "5856e479-c4bb-43e8-aa3c-07366651e41b",
      "worker_id": "w3:patents",
      "phase": "recall",
      "query_text": "\"CT7439\" patent",
      "query_fingerprint": "c3d6bbe5a1101adc14f20a61f11df265edba66b54ec0c8ff5a8e15334371d1ec"
    },
    {
      "id": "a0262855-a203-489b-873f-25c60d7f6499",
      "created_at": "2025-12-14T21:11:49.389049+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "725c899d-d463-4361-bd7d-851285f11dec",
      "worker_id": "w4:geography",
      "phase": "recall",
      "query_text": "\"CT7439\" company pipeline pdf",
      "query_fingerprint": "59580a8e176bb3c9bcb10e2f1d03acacee1b4e3a3e27e88775648aca778d5cdb"
    },
    {
      "id": "81f29207-d9e2-470c-a7ff-e756a096f216",
      "created_at": "2025-12-14T21:11:49.625175+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "b809b25b-b592-40b2-b8bd-6bed52ff954c",
      "worker_id": "w5:clinical-trials",
      "phase": "recall",
      "query_text": "\"TRITON2\" target",
      "query_fingerprint": "1949bf414060bd76a746eb87b13912119f305b8eb9bef2dd4b69cf4ddbe6084b"
    },
    {
      "id": "e571949a-5162-48fe-a4bc-dc4944ccb72b",
      "created_at": "2025-12-14T21:11:50.095839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "60369d26-7b34-4b7c-9898-722de41ede16",
      "worker_id": "w6:pipelines",
      "phase": "recall",
      "query_text": "\"TRITON2\" Phase 1",
      "query_fingerprint": "4a34538028703254654fb203223f4ff684397350e0b3f7b3d0c8135c5dd63904"
    },
    {
      "id": "e87f89d1-687e-4136-80d9-f93e21707d3a",
      "created_at": "2025-12-14T21:19:21.054514+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "bd86c8d7-dc8a-40e4-b46c-06fc13a38819",
      "worker_id": "w1:clinical-trials",
      "phase": "recall",
      "query_text": "\"TRITON2\" patent",
      "query_fingerprint": "33ef5316073fb4e4083824f1f4c8ae03c6de634e95c50125b115d86c1698b485"
    },
    {
      "id": "f2c1e325-94cf-4dce-b454-4f169a3289d0",
      "created_at": "2025-12-14T21:19:22.388873+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "4894a635-f0e3-4de6-ac3d-f040c55bad39",
      "worker_id": "w2:pipelines",
      "phase": "recall",
      "query_text": "\"TRITON2\" company pipeline pdf",
      "query_fingerprint": "38542035a2a32cf428dc084a77605496351cefd045660d5bb7613a4fb3f73f81"
    },
    {
      "id": "05f4df6a-babb-476a-87a5-d8ee927be062",
      "created_at": "2025-12-14T21:19:23.068245+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "fd833113-2f98-4a81-9daf-eb3f3c1d169a",
      "worker_id": "w3:patents",
      "phase": "recall",
      "query_text": "\"600 mg BID\" target",
      "query_fingerprint": "cef62bb6a455e7d548699809d6db7f214f70f639a2941589aa0373e0259e515e"
    },
    {
      "id": "fc6d0f22-5999-407b-ab10-37ded4503b6e",
      "created_at": "2025-12-14T21:19:23.994462+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "7f10e15e-2087-471b-bd84-5b6d2f509655",
      "worker_id": "w4:geography",
      "phase": "recall",
      "query_text": "\"600 mg BID\" Phase 1",
      "query_fingerprint": "f7e39dc52e3a6139af0f61f157e24542cbb50fd5cfdb3d8a02412de2cc5d6e8f"
    },
    {
      "id": "1eb18841-7304-41f1-9a31-286f80bb90fb",
      "created_at": "2025-12-14T21:19:24.355539+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "b3079587-e330-4c13-8c86-a2a68c0d3316",
      "worker_id": "w5:clinical-trials",
      "phase": "recall",
      "query_text": "\"600 mg BID\" patent",
      "query_fingerprint": "cc22b5cfda9f8c8f1edc40f5028562dade9aa79374d32f93921a19a0aa6c989a"
    },
    {
      "id": "4169b856-1490-4e01-9992-b3f8b6804e73",
      "created_at": "2025-12-14T21:19:25.764326+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "cycle_id": "575e25a3-0b92-4c0a-a070-cf316bc0950d",
      "worker_id": "w6:pipelines",
      "phase": "recall",
      "query_text": "\"600 mg BID\" company pipeline pdf",
      "query_fingerprint": "ec3d3223831cacee12921904fc9053bce9ad4e3ab661fb5989be75aeb2ac2f48"
    }
  ],
  "cycles": [
    {
      "id": "1592efb5-800e-4a68-a65d-ea47d4712e6c",
      "created_at": "2025-12-14T21:05:22.462643+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 0,
      "worker_id": "w1:clinical-trials",
      "phase": "recall",
      "planned_query": "CDK12 臨床試験 NCT",
      "success": true,
      "metrics": {
        "urls_count": 6,
        "policy_phase": "broad",
        "mentions_count": 37,
        "identifier_yield": 3,
        "identifier_sample": [
          "CT7439",
          "TRITON2",
          "600 mg BID"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "created_at": "2025-12-14T21:05:23.458747+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 0,
      "worker_id": "w2:pipelines",
      "phase": "recall",
      "planned_query": "CDK12 PROTAC 蛋白降解 专利 WO",
      "success": true,
      "metrics": {
        "urls_count": 8,
        "policy_phase": "broad",
        "mentions_count": 43,
        "identifier_yield": 18,
        "identifier_sample": [
          "WO2020219650A1",
          "US2020",
          "WO2024222726A1",
          "CN2024",
          "WO2024175065A1",
          "YJ9069"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "928d0769-43d1-4b86-bb24-5074a6b34bfe",
      "created_at": "2025-12-14T21:05:24.903542+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 0,
      "worker_id": "w3:patents",
      "phase": "recall",
      "planned_query": "CDK12 첫 환자 투여 1상 보도자료",
      "success": true,
      "metrics": {
        "urls_count": 7,
        "policy_phase": "broad",
        "mentions_count": 45,
        "identifier_yield": 2,
        "identifier_sample": [
          "IND-for-CT7439",
          "CT7439_001"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "5b0751a1-c768-4bf0-9e15-8efd843e8464",
      "created_at": "2025-12-14T21:05:25.254978+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 0,
      "worker_id": "w4:geography",
      "phase": "recall",
      "planned_query": "CDK12 communiqué de presse Phase 1 premier patient",
      "success": true,
      "metrics": {
        "urls_count": 6,
        "policy_phase": "broad",
        "mentions_count": 37,
        "identifier_yield": 2,
        "identifier_sample": [
          "detail/25",
          "detail/20"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "created_at": "2025-12-14T21:05:25.603813+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 0,
      "worker_id": "w5:clinical-trials",
      "phase": "recall",
      "planned_query": "CDK12 inhibitor pipeline PDF filetype:pdf",
      "success": true,
      "metrics": {
        "urls_count": 6,
        "policy_phase": "broad",
        "mentions_count": 34,
        "identifier_yield": 16,
        "identifier_sample": [
          "SR-4835",
          "THZ531",
          "HQ461",
          "PC-6230201",
          "PDB: 6TD3",
          "6TD3"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "created_at": "2025-12-14T21:05:26.700278+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 0,
      "worker_id": "w6:pipelines",
      "phase": "recall",
      "planned_query": "CDK12 compound IC50 PDF filetype:pdf",
      "success": true,
      "metrics": {
        "urls_count": 5,
        "policy_phase": "broad",
        "mentions_count": 68,
        "identifier_yield": 23,
        "identifier_sample": [
          "THZ531R",
          "S6595",
          "S659503",
          "CDK12和CDK13",
          "158 nM",
          "69 nM"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "d2f4fb81-4778-4058-b4b1-342e28739366",
      "created_at": "2025-12-14T21:11:48.036988+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 1,
      "worker_id": "w1:clinical-trials",
      "phase": "recall",
      "planned_query": "\"CT7439\" target",
      "success": true,
      "metrics": {
        "urls_count": 6,
        "policy_phase": "pivot",
        "mentions_count": 56,
        "identifier_yield": 3,
        "identifier_sample": [
          "cdk1213-inhibitor",
          "CT7439 Capsules",
          "0.5 mg"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "3b78e997-1ae8-47f4-9e8d-dca61c59898c",
      "created_at": "2025-12-14T21:11:48.637078+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 1,
      "worker_id": "w2:pipelines",
      "phase": "recall",
      "planned_query": "\"CT7439\" Phase 1",
      "success": true,
      "metrics": {
        "urls_count": 7,
        "policy_phase": "pivot",
        "mentions_count": 48,
        "identifier_yield": 0,
        "identifier_sample": [],
        "planned_queries_count": 0
      }
    },
    {
      "id": "5856e479-c4bb-43e8-aa3c-07366651e41b",
      "created_at": "2025-12-14T21:11:48.862409+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 1,
      "worker_id": "w3:patents",
      "phase": "recall",
      "planned_query": "\"CT7439\" patent",
      "success": true,
      "metrics": {
        "urls_count": 7,
        "policy_phase": "pivot",
        "mentions_count": 50,
        "identifier_yield": 5,
        "identifier_sample": [
          "(CDK12/13)",
          "September 13, 2023",
          "CDC7",
          "2 R&D institutions",
          "29 patents"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "725c899d-d463-4361-bd7d-851285f11dec",
      "created_at": "2025-12-14T21:11:49.336115+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 1,
      "worker_id": "w4:geography",
      "phase": "recall",
      "planned_query": "\"CT7439\" company pipeline pdf",
      "success": true,
      "metrics": {
        "urls_count": 8,
        "policy_phase": "pivot",
        "mentions_count": 53,
        "identifier_yield": 0,
        "identifier_sample": [],
        "planned_queries_count": 0
      }
    },
    {
      "id": "b809b25b-b592-40b2-b8bd-6bed52ff954c",
      "created_at": "2025-12-14T21:11:49.57386+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 1,
      "worker_id": "w5:clinical-trials",
      "phase": "recall",
      "planned_query": "\"TRITON2\" target",
      "success": true,
      "metrics": {
        "urls_count": 7,
        "policy_phase": "pivot",
        "mentions_count": 38,
        "identifier_yield": 4,
        "identifier_sample": [
          "CO-338",
          "CHEK2",
          "CO-338-052",
          "mdy284.002"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "60369d26-7b34-4b7c-9898-722de41ede16",
      "created_at": "2025-12-14T21:11:50.04571+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 1,
      "worker_id": "w6:pipelines",
      "phase": "recall",
      "planned_query": "\"TRITON2\" Phase 1",
      "success": true,
      "metrics": {
        "urls_count": 7,
        "policy_phase": "pivot",
        "mentions_count": 58,
        "identifier_yield": 5,
        "identifier_sample": [
          "CCR-20",
          "600 mg",
          "CCR-20-0394",
          "2018 Oct 1",
          "29:viii272"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "bd86c8d7-dc8a-40e4-b46c-06fc13a38819",
      "created_at": "2025-12-14T21:19:20.851518+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 2,
      "worker_id": "w1:clinical-trials",
      "phase": "recall",
      "planned_query": "\"TRITON2\" patent",
      "success": true,
      "metrics": {
        "urls_count": 6,
        "policy_phase": "pivot",
        "mentions_count": 67,
        "identifier_yield": 14,
        "identifier_sample": [
          "US10130636B2",
          "US15",
          "May 15, 2020",
          "10.1002/onco.13585",
          "EQ 200MG BASE",
          "200MG"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "4894a635-f0e3-4de6-ac3d-f040c55bad39",
      "created_at": "2025-12-14T21:19:22.334209+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 2,
      "worker_id": "w2:pipelines",
      "phase": "recall",
      "planned_query": "\"TRITON2\" company pipeline pdf",
      "success": true,
      "metrics": {
        "urls_count": 7,
        "policy_phase": "pivot",
        "mentions_count": 46,
        "identifier_yield": 7,
        "identifier_sample": [
          "W81XWH",
          "TRITON3",
          "clvs-20201231x10k.htm",
          "BRCA1/2 mutations",
          "Grade 1-4",
          "Grant W81XWH-17-1-0124"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "fd833113-2f98-4a81-9daf-eb3f3c1d169a",
      "created_at": "2025-12-14T21:19:23.019156+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 2,
      "worker_id": "w3:patents",
      "phase": "recall",
      "planned_query": "\"600 mg BID\" target",
      "success": true,
      "metrics": {
        "urls_count": 6,
        "policy_phase": "pivot",
        "mentions_count": 68,
        "identifier_yield": 12,
        "identifier_sample": [
          "MRTX849",
          "G12C",
          "KRAS^{G12C}",
          "600 mg once daily",
          "1,200 mg once daily",
          "600 mg orally twice a day"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "7f10e15e-2087-471b-bd84-5b6d2f509655",
      "created_at": "2025-12-14T21:19:23.941009+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 2,
      "worker_id": "w4:geography",
      "phase": "recall",
      "planned_query": "\"600 mg BID\" Phase 1",
      "success": true,
      "metrics": {
        "urls_count": 6,
        "policy_phase": "pivot",
        "mentions_count": 24,
        "identifier_yield": 2,
        "identifier_sample": [
          "KRAS G12C mutation",
          "BAY 43-9006"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "b3079587-e330-4c13-8c86-a2a68c0d3316",
      "created_at": "2025-12-14T21:19:24.305764+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 2,
      "worker_id": "w5:clinical-trials",
      "phase": "recall",
      "planned_query": "\"600 mg BID\" patent",
      "success": true,
      "metrics": {
        "urls_count": 5,
        "policy_phase": "pivot",
        "mentions_count": 32,
        "identifier_yield": 22,
        "identifier_sample": [
          "US20210393527A1",
          "US17",
          "WO2023034916A1",
          "US2022",
          "WO2021231792A1",
          "US2021"
        ],
        "planned_queries_count": 0
      }
    },
    {
      "id": "575e25a3-0b92-4c0a-a070-cf316bc0950d",
      "created_at": "2025-12-14T21:19:25.713219+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 2,
      "worker_id": "w6:pipelines",
      "phase": "recall",
      "planned_query": "\"600 mg BID\" company pipeline pdf",
      "success": true,
      "metrics": {
        "urls_count": 6,
        "policy_phase": "pivot",
        "mentions_count": 52,
        "identifier_yield": 9,
        "identifier_sample": [
          "KRYSTAL-1",
          "d44280dex991.htm",
          "toxicity.^{1}",
          "600 MG BID^{1}",
          "BID^{1}",
          "KRYSTAL-12"
        ],
        "planned_queries_count": 0
      }
    }
  ],
  "draft_assets": [
    {
      "id": "1d087654-a3e1-4324-abcb-e06389f9dbe2",
      "created_at": "2025-12-14T21:05:28.988306+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "4.9 nM",
      "identifier_canonical": "49NM",
      "identifier_aliases_raw": [
        "4.9 nM"
      ],
      "evidence_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "evidence_snippet": "IC50 of 4.9 nM for CDK13.",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
          "snippet": "IC50 of 4.9 nM for CDK13."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "04b33c81-94e3-44d0-b510-a3c86cff1084",
      "created_at": "2025-12-14T21:05:29.046988+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "600 mg BID",
      "identifier_canonical": "600MGBID",
      "identifier_aliases_raw": [
        "600 mg BID"
      ],
      "evidence_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "evidence_snippet": "rucaparib 600 mg BID",
      "evidence_source_type": "paper",
      "discovered_by_worker_id": "w1:clinical-trials",
      "discovered_by_cycle_id": "1592efb5-800e-4a68-a65d-ea47d4712e6c",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
          "snippet": "rucaparib 600 mg BID"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "1180effe-40b1-4426-8c3a-b036e4ce89ea",
      "created_at": "2025-12-14T21:05:29.046473+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "412 nM",
      "identifier_canonical": "412NM",
      "identifier_aliases_raw": [
        "412 nM"
      ],
      "evidence_url": "https://www.glpbio.com/pp-c8.html",
      "evidence_snippet": "DC50 values of 416 and 412 nM, respectively.",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w2:pipelines",
      "discovered_by_cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.glpbio.com/pp-c8.html",
          "snippet": "DC50 values of 416 and 412 nM, respectively."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "ef85c5ab-cd64-4ead-b58b-b0da652c1baa",
      "created_at": "2025-12-14T21:05:29.047144+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "10.1038%2Fnchembio.2166",
      "identifier_canonical": "1010382FNCHEMBIO2166",
      "identifier_aliases_raw": [
        "10.1038%2Fnchembio.2166"
      ],
      "evidence_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "evidence_snippet": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
          "snippet": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "fbfc46e5-5d45-43f5-9291-ab0780dc6125",
      "created_at": "2025-12-14T21:05:29.047748+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "7525_1_coa.pdf",
      "identifier_canonical": "75251COAPDF",
      "identifier_aliases_raw": [
        "7525_1_coa.pdf"
      ],
      "evidence_url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "evidence_snippet": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
          "snippet": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254="
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "385fd1cc-931e-4c6d-9960-1d0f6b7a1d3b",
      "created_at": "2025-12-14T21:05:29.058797+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "69 nM",
      "identifier_canonical": "69NM",
      "identifier_aliases_raw": [
        "69 nM"
      ],
      "evidence_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "evidence_snippet": "IC50值分别为158 nM和69 nM。",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
          "snippet": "IC50值分别为158 nM和69 nM。"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "88a50bd4-61b5-46db-8661-83081c07745b",
      "created_at": "2025-12-14T21:05:29.058197+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "6TD3",
      "identifier_canonical": "6TD3",
      "identifier_aliases_raw": [
        "6TD3"
      ],
      "evidence_url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
      "evidence_snippet": "CDK12 (PDB: 6TD3) with key residues highlighted.",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
          "snippet": "CDK12 (PDB: 6TD3) with key residues highlighted."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
            "term": "CDK12",
            "snippet": "CDK12 (PDB: 6TD3) with key residues highlighted."
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "7bee5533-60b0-4768-b87f-434f1fe46630",
      "created_at": "2025-12-14T21:05:29.071527+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "158 nM",
      "identifier_canonical": "158NM",
      "identifier_aliases_raw": [
        "158 nM"
      ],
      "evidence_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "evidence_snippet": "IC50值分别为158 nM和69 nM。",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
          "snippet": "IC50值分别为158 nM和69 nM。"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "8a1001a1-cd8b-4d42-99ab-345d5f4080b1",
      "created_at": "2025-12-14T21:05:29.133557+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "Catalog No.: 7525",
      "identifier_canonical": "CATALOGNO7525",
      "identifier_aliases_raw": [
        "Catalog No.: 7525"
      ],
      "evidence_url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "evidence_snippet": "Product Name: dCeMM2 Catalog No.: 7525 Batch No.: 1",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
          "snippet": "Product Name: dCeMM2 Catalog No.: 7525 Batch No.: 1"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "5ed18ea1-9769-4104-b8c7-50627c916697",
      "created_at": "2025-12-14T21:05:29.134841+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "99 nM",
      "identifier_canonical": "99NM",
      "identifier_aliases_raw": [
        "99 nM"
      ],
      "evidence_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "evidence_snippet": "with IC50 of 99 nM and Kd of 98 nM for CDK12",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
          "snippet": "with IC50 of 99 nM and Kd of 98 nM for CDK12"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
            "term": "CDK12",
            "snippet": "with IC50 of 99 nM and Kd of 98 nM for CDK12"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "72cc5779-51d9-4079-89ee-0c3bd07e86e2",
      "created_at": "2025-12-14T21:05:29.180435+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CDK12和CDK13",
      "identifier_canonical": "CDK12CDK13",
      "identifier_aliases_raw": [
        "CDK12和CDK13"
      ],
      "evidence_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "evidence_snippet": "THZ531是CDK12和CDK13的选择性抑制剂",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
          "snippet": "THZ531是CDK12和CDK13的选择性抑制剂"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
            "term": "CDK12",
            "snippet": "THZ531是CDK12和CDK13的选择性抑制剂"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "46e0e4b6-4117-40a6-a274-185d39265694",
      "created_at": "2025-12-14T21:05:29.240271+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CN2024",
      "identifier_canonical": "CN2024",
      "identifier_aliases_raw": [
        "CN2024"
      ],
      "evidence_url": "https://patents.google.com/patent/WO2024222726A1/zh",
      "evidence_snippet": "Publication number WO2024222726A1 PCT/CN2024/089497",
      "evidence_source_type": "patent",
      "discovered_by_worker_id": "w2:pipelines",
      "discovered_by_cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://patents.google.com/patent/WO2024222726A1/zh",
          "snippet": "Publication number WO2024222726A1 PCT/CN2024/089497"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "23398b4a-fb43-49db-b5c2-86e73f1553ff",
      "created_at": "2025-12-14T21:05:29.280699+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "detail/20",
      "identifier_canonical": "DETAIL20",
      "identifier_aliases_raw": [
        "detail/20"
      ],
      "evidence_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "evidence_snippet": "press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "evidence_source_type": "press_release",
      "discovered_by_worker_id": "w4:geography",
      "discovered_by_cycle_id": "5b0751a1-c768-4bf0-9e15-8efd843e8464",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
          "snippet": "press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "e0fa7467-4489-4f03-9927-d7f676abd626",
      "created_at": "2025-12-14T21:05:29.313262+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "DC50",
      "identifier_canonical": "DC50",
      "identifier_aliases_raw": [
        "DC50"
      ],
      "evidence_url": "https://www.glpbio.com/pp-c8.html",
      "evidence_snippet": "Catalog No.GC69730 PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM, respectively.",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w2:pipelines",
      "discovered_by_cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.glpbio.com/pp-c8.html",
          "snippet": "Catalog No.GC69730 PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM, respectively."
        },
        {
          "url": "https://www.glpbio.com/pp-c8.html",
          "snippet": "PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM, respectively."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.glpbio.com/pp-c8.html",
            "term": "CDK12",
            "snippet": "Catalog No.GC69730 PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM, respectively."
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "7b397281-3962-44d1-bf27-5ec38dcfda85",
      "created_at": "2025-12-14T21:05:29.122901+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "BFnchembio2166",
      "identifier_canonical": "BFNCHEMBIO2166",
      "identifier_aliases_raw": [
        "BFnchembio2166"
      ],
      "evidence_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "evidence_snippet": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
          "snippet": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "e9a7c05d-26d0-49b9-852e-568d626349c2",
      "created_at": "2025-12-14T21:05:29.140615+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "7525_sds.pdf",
      "identifier_canonical": "7525SDSPDF",
      "identifier_aliases_raw": [
        "7525_sds.pdf"
      ],
      "evidence_url": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=",
      "evidence_snippet": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=",
          "snippet": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855="
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "68bee142-3fd2-47aa-8246-acbecd655e22",
      "created_at": "2025-12-14T21:05:29.241406+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CDK12 and CDK13",
      "identifier_canonical": "CDK12ANDCDK13",
      "identifier_aliases_raw": [
        "CDK12 and CDK13"
      ],
      "evidence_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "evidence_snippet": "dual inhibitor of CDK12 and CDK13 with IC50 of 99 nM",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
          "snippet": "dual inhibitor of CDK12 and CDK13 with IC50 of 99 nM"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
            "term": "CDK12",
            "snippet": "dual inhibitor of CDK12 and CDK13 with IC50 of 99 nM"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "12339ee5-ea4c-4cf3-9caa-bb5760e95ef7",
      "created_at": "2025-12-14T21:05:29.317764+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CT7439_001",
      "identifier_canonical": "CT7439001",
      "identifier_aliases_raw": [
        "CT7439_001"
      ],
      "evidence_url": "https://ichgcp.net/clinical-trials-registry/NCT06600789",
      "evidence_snippet": "Other Study ID Numbers  * CT7439_001",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w3:patents",
      "discovered_by_cycle_id": "928d0769-43d1-4b86-bb24-5074a6b34bfe",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://ichgcp.net/clinical-trials-registry/NCT06600789",
          "snippet": "Other Study ID Numbers  * CT7439_001"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "e9a41c6c-2259-4d9c-9855-d26717d683c5",
      "created_at": "2025-12-14T21:05:29.351746+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "HQ461",
      "identifier_canonical": "HQ461",
      "identifier_aliases_raw": [
        "HQ461"
      ],
      "evidence_url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
      "evidence_snippet": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4. treated with either SR-4835 or the covalent CDK12/13 inhibitor",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
          "snippet": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4. treated with either SR-4835 or the covalent CDK12/13 inhibitor"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
            "term": "CDK12",
            "snippet": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4. treated with either SR-4835 or the covalent CDK12/13 inhibitor"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "a1b4478e-1aee-4832-bbe1-bf5307afbb2e",
      "created_at": "2025-12-14T21:05:29.420301+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "pan-CDK/CDK12",
      "identifier_canonical": "PANCDKCDK12",
      "identifier_aliases_raw": [
        "pan-CDK/CDK12"
      ],
      "evidence_url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
      "evidence_snippet": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4.",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
          "snippet": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
            "term": "CDK12",
            "snippet": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4."
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "01f6d7ec-3ca7-40fc-ba28-f3c245dd49a8",
      "created_at": "2025-12-14T21:05:29.484851+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "S659503-DataSheet.pdf",
      "identifier_canonical": "S659503DATASHEETPDF",
      "identifier_aliases_raw": [
        "S659503-DataSheet.pdf"
      ],
      "evidence_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "evidence_snippet": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
          "snippet": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "64dd0aa4-9a39-4d3d-98b9-7b68f484fe5b",
      "created_at": "2025-12-14T21:05:29.551019+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "S889402",
      "identifier_canonical": "S889402",
      "identifier_aliases_raw": [
        "S889402"
      ],
      "evidence_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "evidence_snippet": "製品コードS8894 バッチS889402",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
          "snippet": "製品コードS8894 バッチS889402"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "0ff52dcf-cbbc-4382-8b3d-9c1cd1d5e373",
      "created_at": "2025-12-14T21:05:29.131145+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "BioTHZ531",
      "identifier_canonical": "BIOTHZ531",
      "identifier_aliases_raw": [
        "BioTHZ531"
      ],
      "evidence_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "evidence_snippet": "Scheme 2. The synthesis of BioTHZ531",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
          "snippet": "Scheme 2. The synthesis of BioTHZ531"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "ecfc755a-b4ad-40a9-bf28-1a80303960ef",
      "created_at": "2025-12-14T21:05:29.216798+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "98 nM",
      "identifier_canonical": "98NM",
      "identifier_aliases_raw": [
        "98 nM"
      ],
      "evidence_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "evidence_snippet": "Kd of 98 nM for CDK12",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
          "snippet": "Kd of 98 nM for CDK12"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
            "term": "CDK12",
            "snippet": "Kd of 98 nM for CDK12"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "6bbf8141-92af-4fd6-ab39-da8b760be927",
      "created_at": "2025-12-14T21:05:29.349104+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "PC-62302",
      "identifier_canonical": "PC62302",
      "identifier_aliases_raw": [
        "PC-62302"
      ],
      "evidence_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "evidence_snippet": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
          "snippet": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf"
        },
        {
          "url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
          "snippet": "Cat. No. : PC-62302 THZ531 (THZ-531) isa first-in-class, selective CDK12 and CDK13 covalent inhibit"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
            "term": "CDK12",
            "snippet": "Cat. No. : PC-62302 THZ531 (THZ-531) isa first-in-class, selective CDK12 and CDK13 covalent inhibit"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "90ae822b-96e7-4991-a591-a2cd043e7fad",
      "created_at": "2025-12-14T21:05:29.419025+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "NCT02",
      "identifier_canonical": "NCT02",
      "identifier_aliases_raw": [
        "NCT02"
      ],
      "evidence_url": "https://pubmed.ncbi.nlm.nih.gov/34289372/",
      "evidence_snippet": "NCT02 is identified as a candidate with minimal risk of non-specific toxicity. NCT02",
      "evidence_source_type": "paper",
      "discovered_by_worker_id": "w2:pipelines",
      "discovered_by_cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/34289372/",
          "snippet": "NCT02 is identified as a candidate with minimal risk of non-specific toxicity. NCT02"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "d0e28c64-3a9d-45e3-aa60-19904ee2edb3",
      "created_at": "2025-12-14T21:05:29.514771+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "S889402-DataSheet.pdf",
      "identifier_canonical": "S889402DATASHEETPDF",
      "identifier_aliases_raw": [
        "S889402-DataSheet.pdf"
      ],
      "evidence_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "evidence_snippet": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
          "snippet": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "3d42d933-6ecd-49be-941d-48f40c73a4f8",
      "created_at": "2025-12-14T21:05:29.553896+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "US2020",
      "identifier_canonical": "US2020",
      "identifier_aliases_raw": [
        "US2020"
      ],
      "evidence_url": "https://patents.google.com/patent/WO2020219650A1/zh",
      "evidence_snippet": "Publication number WO2020219650A1 PCT/US2020/029483",
      "evidence_source_type": "patent",
      "discovered_by_worker_id": "w2:pipelines",
      "discovered_by_cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://patents.google.com/patent/WO2020219650A1/zh",
          "snippet": "Publication number WO2020219650A1 PCT/US2020/029483"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "27cb32f6-34b9-4fb3-96a6-ef060fd961a4",
      "created_at": "2025-12-14T21:05:29.130366+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "Batch No.: 1",
      "identifier_canonical": "BATCHNO1",
      "identifier_aliases_raw": [
        "Batch No.: 1"
      ],
      "evidence_url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "evidence_snippet": "Product Name: dCeMM2 Catalog No.: 7525 Batch No.: 1",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
          "snippet": "Product Name: dCeMM2 Catalog No.: 7525 Batch No.: 1"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "12eb0b33-401c-4ee0-b82b-ceb43919b782",
      "created_at": "2025-12-14T21:05:29.152565+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "Catalog Number: 7525",
      "identifier_canonical": "CATALOGNUMBER7525",
      "identifier_aliases_raw": [
        "Catalog Number: 7525"
      ],
      "evidence_url": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=",
      "evidence_snippet": "Catalog Number: 7525",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://documents.tocris.com/pdfs/tocris_msds/7525_sds.pdf?1765505855=",
          "snippet": "Catalog Number: 7525"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "d0beae0b-abba-4581-a776-9d2a7e762258",
      "created_at": "2025-12-14T21:05:29.238499+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CAS#3053716-98-3",
      "identifier_canonical": "CAS3053716983",
      "identifier_aliases_raw": [
        "CAS#3053716-98-3"
      ],
      "evidence_url": "https://www.medkoo.com/products/60512",
      "evidence_snippet": "CAS#3053716-98-3",
      "evidence_source_type": "vendor",
      "discovered_by_worker_id": "w2:pipelines",
      "discovered_by_cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.medkoo.com/products/60512",
          "snippet": "CAS#3053716-98-3"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "52ad8b05-6667-48fa-be37-625a5b1305e6",
      "created_at": "2025-12-14T21:05:29.277607+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CDK12-Cyclin K",
      "identifier_canonical": "CDK12CYCLINK",
      "identifier_aliases_raw": [
        "CDK12-Cyclin K"
      ],
      "evidence_url": "https://www.glpbio.com/pp-c8.html",
      "evidence_snippet": "PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM, respectively.",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w2:pipelines",
      "discovered_by_cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.glpbio.com/pp-c8.html",
          "snippet": "PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM, respectively."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.glpbio.com/pp-c8.html",
            "term": "CDK12",
            "snippet": "PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM, respectively."
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "dc63122f-d07d-4f93-a9dc-e086006441b7",
      "created_at": "2025-12-14T21:05:29.340785+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "GC69730",
      "identifier_canonical": "GC69730",
      "identifier_aliases_raw": [
        "GC69730"
      ],
      "evidence_url": "https://www.glpbio.com/pp-c8.html",
      "evidence_snippet": "Catalog No.GC69730 PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM,",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w2:pipelines",
      "discovered_by_cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.glpbio.com/pp-c8.html",
          "snippet": "Catalog No.GC69730 PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM,"
        },
        {
          "url": "https://www.glpbio.com/pp-c8.html",
          "snippet": "Catalog No.GC69730"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.glpbio.com/pp-c8.html",
            "term": "CDK12",
            "snippet": "Catalog No.GC69730 PP-C8 induces degradation of CDK12-Cyclin K with DC50 values of 416 and 412 nM,"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "f408fea1-77ae-4f1a-b5a8-eb12100ef22c",
      "created_at": "2025-12-14T21:05:29.34219+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "dCeMM2/3/4",
      "identifier_canonical": "DCEMM234",
      "identifier_aliases_raw": [
        "dCeMM2/3/4"
      ],
      "evidence_url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
      "evidence_snippet": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4.",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
          "snippet": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://pubs.rsc.org/en/content/articlepdf/2025/cb/d4cb00190g",
            "term": "CDK12",
            "snippet": "pan-CDK/CDK12 inhibitors, such as CR8, HQ461, and dCeMM2/3/4."
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "40397ad2-8316-421c-900f-0958f5fedc8f",
      "created_at": "2025-12-14T21:05:29.407552+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "PDB: 6TD3",
      "identifier_canonical": "PDB6TD3",
      "identifier_aliases_raw": [
        "PDB: 6TD3"
      ],
      "evidence_url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
      "evidence_snippet": "CDK12 (PDB: 6TD3) with key residues highlighted.",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
          "snippet": "CDK12 (PDB: 6TD3) with key residues highlighted."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
            "term": "CDK12",
            "snippet": "CDK12 (PDB: 6TD3) with key residues highlighted."
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "a9d4247e-4978-43fa-a828-76ec250df874",
      "created_at": "2025-12-14T21:05:29.409778+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "PC-6230201",
      "identifier_canonical": "PC6230201",
      "identifier_aliases_raw": [
        "PC-6230201"
      ],
      "evidence_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_COA.pdf",
      "evidence_snippet": "Batch No. : PC-6230201 CAS No. : 1702809-17-3",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_COA.pdf",
          "snippet": "Batch No. : PC-6230201 CAS No. : 1702809-17-3"
        },
        {
          "url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
          "snippet": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "3538d0b8-db45-4fec-af37-099d77707838",
      "created_at": "2025-12-14T21:05:29.347759+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "nchembio2166",
      "identifier_canonical": "NCHEMBIO2166",
      "identifier_aliases_raw": [
        "nchembio2166"
      ],
      "evidence_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "evidence_snippet": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
          "snippet": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "57d94e70-8684-4b07-b911-c08709a01ed4",
      "created_at": "2025-12-14T21:05:29.413568+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "PC-6230201_COA.pdf",
      "identifier_canonical": "PC6230201COAPDF",
      "identifier_aliases_raw": [
        "PC-6230201_COA.pdf"
      ],
      "evidence_url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_COA.pdf",
      "evidence_snippet": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_COA.pdf",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_COA.pdf",
          "snippet": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_COA.pdf"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "20fd7831-7e52-4e93-9753-27d59514c6fb",
      "created_at": "2025-12-14T21:05:29.483017+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "pp-c8.html",
      "identifier_canonical": "PPC8HTML",
      "identifier_aliases_raw": [
        "pp-c8.html"
      ],
      "evidence_url": "https://www.glpbio.com/pp-c8.html",
      "evidence_snippet": "https://www.glpbio.com/pp-c8.html",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w2:pipelines",
      "discovered_by_cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.glpbio.com/pp-c8.html",
          "snippet": "https://www.glpbio.com/pp-c8.html"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "49ffb8ea-25a2-4d58-9398-e35d730a3c8c",
      "created_at": "2025-12-14T21:05:29.548997+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "Scheme 3",
      "identifier_canonical": "SCHEME3",
      "identifier_aliases_raw": [
        "Scheme 3",
        "Scheme 3."
      ],
      "evidence_url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "evidence_snippet": "Scheme 3. The synthesis of THZ531R",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
          "snippet": "Scheme 3. The synthesis of THZ531R"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "0d8f0e91-9f61-44a3-a768-c58a5f00d308",
      "created_at": "2025-12-14T21:05:29.625432+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "YJ1206",
      "identifier_canonical": "YJ1206",
      "identifier_aliases_raw": [
        "YJ1206"
      ],
      "evidence_url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
      "evidence_snippet": "12/13 PROTAC degrader, YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206",
      "evidence_source_type": "paper",
      "discovered_by_worker_id": "w2:pipelines",
      "discovered_by_cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
          "snippet": "12/13 PROTAC degrader, YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
            "term": "CDK12",
            "snippet": "12/13 PROTAC degrader, YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206"
          },
          "modality": {
            "url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
            "term": "degrader",
            "snippet": "12/13 PROTAC degrader, YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206"
          },
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 1.0,
        "modality_match_score": 1.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": null,
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": true,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "bb148eeb-3429-4334-a7cf-0163c18bcacc",
      "created_at": "2025-12-14T21:05:29.349839+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "detail/25",
      "identifier_canonical": "DETAIL25",
      "identifier_aliases_raw": [
        "detail/25"
      ],
      "evidence_url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "evidence_snippet": "press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "evidence_source_type": "press_release",
      "discovered_by_worker_id": "w4:geography",
      "discovered_by_cycle_id": "5b0751a1-c768-4bf0-9e15-8efd843e8464",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
          "snippet": "press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "1ae69191-25b3-4ff9-b060-647f15c9d361",
      "created_at": "2025-12-14T21:05:29.424575+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "PP-C8",
      "identifier_canonical": "PPC8",
      "identifier_aliases_raw": [
        "PP-C8"
      ],
      "evidence_url": "https://pubmed.ncbi.nlm.nih.gov/34864331/",
      "evidence_snippet": "we have synthesized a potent PROTAC degrader PP-C8",
      "evidence_source_type": "paper",
      "discovered_by_worker_id": "w2:pipelines",
      "discovered_by_cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/",
          "snippet": "we have synthesized a potent PROTAC degrader PP-C8"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": {
            "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/",
            "term": "degrader",
            "snippet": "we have synthesized a potent PROTAC degrader PP-C8"
          },
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.5,
        "modality_match_score": 1.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "c7b91994-ae89-4fbb-a9f0-4d91307f4266",
      "created_at": "2025-12-14T21:05:29.543752+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "S8894",
      "identifier_canonical": "S8894",
      "identifier_aliases_raw": [
        "S8894"
      ],
      "evidence_url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
      "evidence_snippet": "製品コードS8894 バッチS889402",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
          "snippet": "製品コードS8894 バッチS889402"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "786c4f02-dd84-403b-90b3-7aeba718057e",
      "created_at": "2025-12-14T21:05:29.621456+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "uuid%3A",
      "identifier_canonical": "UUID3A",
      "identifier_aliases_raw": [
        "uuid%3A"
      ],
      "evidence_url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "evidence_snippet": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
          "snippet": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "e6de0fda-1880-4e17-8d70-24753e9d9140",
      "created_at": "2025-12-14T21:05:30.365045+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "dCeMM2",
      "identifier_canonical": "DCEMM2",
      "identifier_aliases_raw": [
        "dCeMM2"
      ],
      "evidence_url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
      "evidence_snippet": "Product Name: dCeMM2 Catalog No.: 7525 Batch No.: 1",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://documents.tocris.com/pdfs/tocris_coa/7525_1_coa.pdf?1765531254=",
          "snippet": "Product Name: dCeMM2 Catalog No.: 7525 Batch No.: 1"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "1b80c6b0-1db9-432c-b0a2-52141efe489b",
      "created_at": "2025-12-14T21:05:29.422082+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "S659503",
      "identifier_canonical": "S659503",
      "identifier_aliases_raw": [
        "S659503"
      ],
      "evidence_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "evidence_snippet": "目录号：S6595 批次号：S659503",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
          "snippet": "目录号：S6595 批次号：S659503"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "4e050151-83fd-4b1f-a5d7-4ea86ebc58cf",
      "created_at": "2025-12-14T21:05:29.519145+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "Scheme 1",
      "identifier_canonical": "SCHEME1",
      "identifier_aliases_raw": [
        "Scheme 1",
        "Scheme 1."
      ],
      "evidence_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "evidence_snippet": "Scheme 1. The synthesis of THZ531",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
          "snippet": "Scheme 1. The synthesis of THZ531"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "d9520259-fddb-4fe1-b612-df314368681b",
      "created_at": "2025-12-14T21:05:29.554502+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "Scheme 2",
      "identifier_canonical": "SCHEME2",
      "identifier_aliases_raw": [
        "Scheme 2",
        "Scheme 2."
      ],
      "evidence_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "evidence_snippet": "Scheme 2. The synthesis of BioTHZ531",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
          "snippet": "Scheme 2. The synthesis of BioTHZ531"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "e5230f66-1900-44bf-8c6f-4b803f24a71e",
      "created_at": "2025-12-14T21:05:29.630442+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "YJ9069",
      "identifier_canonical": "YJ9069",
      "identifier_aliases_raw": [
        "YJ9069"
      ],
      "evidence_url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
      "evidence_snippet": "we develop a selective CDK12/13 PROTAC degrader, YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206",
      "evidence_source_type": "paper",
      "discovered_by_worker_id": "w2:pipelines",
      "discovered_by_cycle_id": "84ca5c22-5819-4f51-a2eb-09a653f12fdc",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
          "snippet": "we develop a selective CDK12/13 PROTAC degrader, YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
            "term": "CDK12",
            "snippet": "we develop a selective CDK12/13 PROTAC degrader, YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206"
          },
          "modality": {
            "url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
            "term": "degrader",
            "snippet": "we develop a selective CDK12/13 PROTAC degrader, YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206"
          },
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 1.0,
        "modality_match_score": 1.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": null,
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": true,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "d530155b-bd2c-4e50-8a7f-a533851e96e2",
      "created_at": "2025-12-14T21:05:29.423064+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "S6595",
      "identifier_canonical": "S6595",
      "identifier_aliases_raw": [
        "S6595"
      ],
      "evidence_url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
      "evidence_snippet": "目录号：S6595 批次号：S659503",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
          "snippet": "目录号：S6595 批次号：S659503"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "c95e3996-e1ee-4786-b072-aba6757447af",
      "created_at": "2025-12-14T21:05:29.543751+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "SR-4835",
      "identifier_canonical": "SR4835",
      "identifier_aliases_raw": [
        "SR-4835",
        "sr-4835"
      ],
      "evidence_url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
      "evidence_snippet": "concentrations of SR-4835 or THZ531 for 72 h. D Docking pose of SR-4835 and CR8 in the active site of CDK",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
          "snippet": "concentrations of SR-4835 or THZ531 for 72 h. D Docking pose of SR-4835 and CR8 in the active site of CDK"
        },
        {
          "url": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf",
          "snippet": "https://www.selleck.co.jp/datasheet/sr-4835-S889402-DataSheet.pdf"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "9bd05737-8fb4-4f02-be3c-25c0bbb6eb3b",
      "created_at": "2025-12-14T21:05:29.6036+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "THZ531R",
      "identifier_canonical": "THZ531R",
      "identifier_aliases_raw": [
        "THZ531R"
      ],
      "evidence_url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
      "evidence_snippet": "Scheme 1. The synthesis of THZ531 Scheme 3. The synthesis of THZ531R",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
          "snippet": "Scheme 1. The synthesis of THZ531 Scheme 3. The synthesis of THZ531R"
        },
        {
          "url": "https://ora.ox.ac.uk/objects/uuid%3A9d39c81e-0d3a-407a-9fb0-c128870235ab/files/md370f526b3ac0c2e93055747f79fc852",
          "snippet": "Scheme 3. The synthesis of THZ531R"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "47475d6f-e08f-4c54-8c51-42fc0b725678",
      "created_at": "2025-12-14T21:05:29.627077+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "TRITON2",
      "identifier_canonical": "TRITON2",
      "identifier_aliases_raw": [
        "TRITON2"
      ],
      "evidence_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "evidence_snippet": "Initial TRITON2 (NCT02952534) results",
      "evidence_source_type": "paper",
      "discovered_by_worker_id": "w1:clinical-trials",
      "discovered_by_cycle_id": "1592efb5-800e-4a68-a65d-ea47d4712e6c",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
          "snippet": "Initial TRITON2 (NCT02952534) results"
        },
        {
          "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate",
          "snippet": "Efficacy was investigated in TRITON2 (NCT02952534)"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "223b2478-68b2-415d-bac6-4f78b1d12c87",
      "created_at": "2025-12-14T21:05:30.429996+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "MOESM153",
      "identifier_canonical": "MOESM153",
      "identifier_aliases_raw": [
        "MOESM153"
      ],
      "evidence_url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "evidence_snippet": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "d98dad0d-0a99-4e2c-be1e-3fe19f36993e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://static-content.springer.com/esm/art%3A10.1038%2Fnchembio.2166/MediaObjects/41589_2016_BFnchembio2166_MOESM153_ESM.pdf",
          "snippet": "41589_2016_BFnchembio2166_MOESM153_ESM.pdf"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "1aa3d1de-93a5-4152-9d91-b2147fe88fa5",
      "created_at": "2025-12-14T21:05:29.630953+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "THZ531",
      "identifier_canonical": "THZ531",
      "identifier_aliases_raw": [
        "THZ531",
        "THZ-531",
        "thz531"
      ],
      "evidence_url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
      "evidence_snippet": "concentrations of SR-4835 or THZ531 for 72 h. D Docking pose of SR-4835 and CR8 in the active site of CDK12 (PDB: 6",
      "evidence_source_type": "pipeline_pdf",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "2ec0672d-f511-4a5e-ab14-8a719e73856e",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
          "snippet": "concentrations of SR-4835 or THZ531 for 72 h. D Docking pose of SR-4835 and CR8 in the active site of CDK12 (PDB: 6"
        },
        {
          "url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
          "snippet": "Product Name : THZ531"
        },
        {
          "url": "https://www.probechem.com/userfiles/Products/PDF/PC-62302/PC-6230201/PC-6230201_DataSheet.pdf",
          "snippet": "Cat. No. : PC-62302 THZ531 (THZ-531) isa first-in-class, selective CDK12 and CDK13 covalent inhibitor with IC50 of"
        },
        {
          "url": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf",
          "snippet": "https://www.selleck.cn/datasheet/thz531-S659503-DataSheet.pdf"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.nature.com/articles/s41420-023-01754-x.pdf",
            "term": "CDK12",
            "snippet": "concentrations of SR-4835 or THZ531 for 72 h. D Docking pose of SR-4835 and CR8 in the active site of CDK12 (PDB: 6"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "e203bd04-6b50-430d-8c6b-ad5d121efdab",
      "created_at": "2025-12-14T21:05:31.031621+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "IND-for-CT7439",
      "identifier_canonical": "INDFORCT7439",
      "identifier_aliases_raw": [
        "IND-for-CT7439"
      ],
      "evidence_url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "evidence_snippet": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
      "evidence_source_type": "press_release",
      "discovered_by_worker_id": "w3:patents",
      "discovered_by_cycle_id": "928d0769-43d1-4b86-bb24-5074a6b34bfe",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
          "snippet": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html",
            "term": "CDK12",
            "snippet": "https://www.globenewswire.com/fr/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 0,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "6d95e811-1e79-49aa-ab2b-4c918f32ceb4",
      "created_at": "2025-12-14T21:11:50.743612+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "600 mg",
      "identifier_canonical": "600MG",
      "identifier_aliases_raw": [
        "600 mg"
      ],
      "evidence_url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
      "evidence_snippet": "rucaparib 600 mg BID",
      "evidence_source_type": "paper",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "60369d26-7b34-4b7c-9898-722de41ede16",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/37277275/",
          "snippet": "rucaparib 600 mg BID"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "73732ba0-92a7-4d2a-a360-e90dd9d9df16",
      "created_at": "2025-12-14T21:11:50.747362+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "0.5 mg",
      "identifier_canonical": "05MG",
      "identifier_aliases_raw": [
        "0.5 mg"
      ],
      "evidence_url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "evidence_snippet": "CT7439 Capsules (0.5 mg, 1mg, 3mg)",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w1:clinical-trials",
      "discovered_by_cycle_id": "d2f4fb81-4778-4058-b4b1-342e28739366",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
          "snippet": "CT7439 Capsules (0.5 mg, 1mg, 3mg)"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "04d0aca1-165f-430e-9b0e-b2368fc891b8",
      "created_at": "2025-12-14T21:11:50.750118+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "29 patents",
      "identifier_canonical": "29PATENTS",
      "identifier_aliases_raw": [
        "29 patents"
      ],
      "evidence_url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
      "evidence_snippet": "and as many as 29 patents.",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w3:patents",
      "discovered_by_cycle_id": "5856e479-c4bb-43e8-aa3c-07366651e41b",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
          "snippet": "and as many as 29 patents."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "b95ea179-0cfa-4fa3-baf5-c6002992ee0f",
      "created_at": "2025-12-14T21:11:50.750767+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "29:viii272",
      "identifier_canonical": "29VIII272",
      "identifier_aliases_raw": [
        "29:viii272"
      ],
      "evidence_url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "evidence_snippet": "2018 Oct 1;29:viii272.",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "60369d26-7b34-4b7c-9898-722de41ede16",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
          "snippet": "2018 Oct 1;29:viii272."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "cd8b0353-9853-4a58-8f2f-5ec602717ab4",
      "created_at": "2025-12-14T21:11:50.758332+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CCR-20-0394",
      "identifier_canonical": "CCR200394",
      "identifier_aliases_raw": [
        "CCR-20-0394"
      ],
      "evidence_url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
      "evidence_snippet": "10.1158/1078-0432.CCR-20-0394.",
      "evidence_source_type": "paper",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "60369d26-7b34-4b7c-9898-722de41ede16",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
          "snippet": "10.1158/1078-0432.CCR-20-0394."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "131a4881-3353-428e-b28f-c4f5d24c3cf2",
      "created_at": "2025-12-14T21:11:50.793437+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "2018 Oct 1",
      "identifier_canonical": "2018OCT1",
      "identifier_aliases_raw": [
        "2018 Oct 1"
      ],
      "evidence_url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
      "evidence_snippet": "2018 Oct 1;29:viii272.",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "60369d26-7b34-4b7c-9898-722de41ede16",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://mayoclinic.elsevierpure.com/en/publications/preliminary-results-from-triton2-a-phase-ii-study-of-rucaparib-in",
          "snippet": "2018 Oct 1;29:viii272."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "8963d890-6968-4aa7-b77c-47849b6900db",
      "created_at": "2025-12-14T21:11:50.863132+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CDC7",
      "identifier_canonical": "CDC7",
      "identifier_aliases_raw": [
        "CDC7"
      ],
      "evidence_url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
      "evidence_snippet": "investigational drugs for the CDC7 and CDK12 and CDK13 target",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w3:patents",
      "discovered_by_cycle_id": "5856e479-c4bb-43e8-aa3c-07366651e41b",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
          "snippet": "investigational drugs for the CDC7 and CDK12 and CDK13 target"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
            "term": "CDK12",
            "snippet": "investigational drugs for the CDC7 and CDK12 and CDK13 target"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "3b80f4c2-adf2-4406-a913-e94316c95901",
      "created_at": "2025-12-14T21:11:50.809303+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CO-338",
      "identifier_canonical": "CO338",
      "identifier_aliases_raw": [
        "CO-338"
      ],
      "evidence_url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT",
      "evidence_snippet": "A.4.1  | Sponsor's protocol code number  | CO-338-052 A.5.4  | Other Identifiers  | Name: IND Number: 129,840",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "b809b25b-b592-40b2-b8bd-6bed52ff954c",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT",
          "snippet": "A.4.1  | Sponsor's protocol code number  | CO-338-052 A.5.4  | Other Identifiers  | Name: IND Number: 129,840"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "c1783565-134e-41b3-a7c6-210ff854cca8",
      "created_at": "2025-12-14T21:11:50.863598+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "cdk1213-inhibitor",
      "identifier_canonical": "CDK1213INHIBITOR",
      "identifier_aliases_raw": [
        "cdk1213-inhibitor",
        "CDK12-13-Inhibitor"
      ],
      "evidence_url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
      "evidence_snippet": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w1:clinical-trials",
      "discovered_by_cycle_id": "d2f4fb81-4778-4058-b4b1-342e28739366",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
          "snippet": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor"
        },
        {
          "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html",
          "snippet": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor",
            "term": "CDK12",
            "snippet": "https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "616c8428-f58e-4f9d-91fa-029c724ebb94",
      "created_at": "2025-12-14T21:11:50.941321+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "September 13, 2023",
      "identifier_canonical": "SEPTEMBER132023",
      "identifier_aliases_raw": [
        "September 13, 2023"
      ],
      "evidence_url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
      "evidence_snippet": "As of September 13, 2023, there are 1 investigational drugs for the CDC7 and CDK12 and CDK13 target",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w3:patents",
      "discovered_by_cycle_id": "5856e479-c4bb-43e8-aa3c-07366651e41b",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
          "snippet": "As of September 13, 2023, there are 1 investigational drugs for the CDC7 and CDK12 and CDK13 target"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
            "term": "CDK12",
            "snippet": "As of September 13, 2023, there are 1 investigational drugs for the CDC7 and CDK12 and CDK13 target"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "eccccab7-3f6b-4728-add0-65f3c765045a",
      "created_at": "2025-12-14T21:11:50.809146+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CCR-20",
      "identifier_canonical": "CCR20",
      "identifier_aliases_raw": [
        "CCR-20"
      ],
      "evidence_url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
      "evidence_snippet": "doi: 10.1158/1078-0432.CCR-20-0394. To test this hypothesis, the phase II TRITON2 study of rucaparib included",
      "evidence_source_type": "paper",
      "discovered_by_worker_id": "w6:pipelines",
      "discovered_by_cycle_id": "60369d26-7b34-4b7c-9898-722de41ede16",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
          "snippet": "doi: 10.1158/1078-0432.CCR-20-0394. To test this hypothesis, the phase II TRITON2 study of rucaparib included"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "9f074b8d-91fe-40e9-aa63-e191ef237d90",
      "created_at": "2025-12-14T21:11:50.867047+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CHEK2",
      "identifier_canonical": "CHEK2",
      "identifier_aliases_raw": [
        "CHEK2"
      ],
      "evidence_url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
      "evidence_snippet": "CHEK2 (n = 12)",
      "evidence_source_type": "paper",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "b809b25b-b592-40b2-b8bd-6bed52ff954c",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/32086346/",
          "snippet": "CHEK2 (n = 12)"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "929c3d49-712a-4ace-9ebe-db97a5571470",
      "created_at": "2025-12-14T21:11:50.813006+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "(CDK12/13)",
      "identifier_canonical": "CDK1213",
      "identifier_aliases_raw": [
        "(CDK12/13)"
      ],
      "evidence_url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
      "evidence_snippet": "cyclin dependent kinase 12/13 (CDK12/13) inhibitor.",
      "evidence_source_type": "press_release",
      "discovered_by_worker_id": "w3:patents",
      "discovered_by_cycle_id": "5856e479-c4bb-43e8-aa3c-07366651e41b",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
          "snippet": "cyclin dependent kinase 12/13 (CDK12/13) inhibitor."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind",
            "term": "CDK12",
            "snippet": "cyclin dependent kinase 12/13 (CDK12/13) inhibitor."
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "7b7f7d4f-a979-4c3a-a852-e6ce5550ab5f",
      "created_at": "2025-12-14T21:11:50.929986+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CT7439 Capsules",
      "identifier_canonical": "CT7439CAPSULES",
      "identifier_aliases_raw": [
        "CT7439 Capsules"
      ],
      "evidence_url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
      "evidence_snippet": "CT7439 Capsules (0.5 mg, 1mg, 3mg)",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w1:clinical-trials",
      "discovered_by_cycle_id": "d2f4fb81-4778-4058-b4b1-342e28739366",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies",
          "snippet": "CT7439 Capsules (0.5 mg, 1mg, 3mg)"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "f03315aa-61a9-4978-9a36-f564355e4591",
      "created_at": "2025-12-14T21:11:50.815377+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "2 R&D institutions",
      "identifier_canonical": "2RDINSTITUTIONS",
      "identifier_aliases_raw": [
        "2 R&D institutions"
      ],
      "evidence_url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
      "evidence_snippet": "including 4 applicable indications,2 R&D institutions involved, and as many as 29 patents.",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w3:patents",
      "discovered_by_cycle_id": "5856e479-c4bb-43e8-aa3c-07366651e41b",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://synapse.patsnap.com/blog/carrick-therapeutics-declares-the-us-fda-approval-the-ind-for-ct7439",
          "snippet": "including 4 applicable indications,2 R&D institutions involved, and as many as 29 patents."
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "3e0998f2-a4c6-44c6-97c6-045e82ec54b8",
      "created_at": "2025-12-14T21:11:50.930331+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "mdy284.002",
      "identifier_canonical": "MDY284002",
      "identifier_aliases_raw": [
        "mdy284.002"
      ],
      "evidence_url": "https://academic.oup.com/annonc/article/29/suppl_8/mdy284.002/5140957",
      "evidence_snippet": "https://academic.oup.com/annonc/article/29/suppl_8/mdy284.002/5140957",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "b809b25b-b592-40b2-b8bd-6bed52ff954c",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://academic.oup.com/annonc/article/29/suppl_8/mdy284.002/5140957",
          "snippet": "https://academic.oup.com/annonc/article/29/suppl_8/mdy284.002/5140957"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "4ac05075-e64d-40d8-997b-1baa882129bf",
      "created_at": "2025-12-14T21:11:50.823342+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CO-338-052",
      "identifier_canonical": "CO338052",
      "identifier_aliases_raw": [
        "CO-338-052"
      ],
      "evidence_url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT",
      "evidence_snippet": "A.4.1  | Sponsor's protocol code number  | CO-338-052",
      "evidence_source_type": "other",
      "discovered_by_worker_id": "w5:clinical-trials",
      "discovered_by_cycle_id": "b809b25b-b592-40b2-b8bd-6bed52ff954c",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003162-13/IT",
          "snippet": "A.4.1  | Sponsor's protocol code number  | CO-338-052"
        },
        {
          "url": "https://ichgcp.net/eu-clinical-trials-registry/trial/2016-003162-13/IT",
          "snippet": "Sponsor's Protocol Code Number:CO-338-052"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": null,
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 0.0,
        "overall_match_score": 0.0,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_target_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    },
    {
      "id": "9a378bc1-4f88-490a-b377-6da2b1b4dc68",
      "created_at": "2025-12-14T21:05:29.28145+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "identifier_raw": "CT7439",
      "identifier_canonical": "CT7439",
      "identifier_aliases_raw": [
        "CT7439",
        "CT-7439"
      ],
      "evidence_url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
      "evidence_snippet": "the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor Clinical trial deta",
      "evidence_source_type": "press_release",
      "discovered_by_worker_id": "w1:clinical-trials",
      "discovered_by_cycle_id": "1592efb5-800e-4a68-a65d-ea47d4712e6c",
      "confidence_discovery": 0.9,
      "enrichment_status": "pending",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "stage": null,
      "geography": null,
      "citations": [
        {
          "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
          "snippet": "the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor Clinical trial deta"
        },
        {
          "url": "https://synapse.patsnap.com/drug/8fb030514b004a0eb2b730b10ce2bbd0",
          "snippet": "Synonyms CT-7439, CT7439 Clinical Trials associated with CT-7439 NCT06600789"
        }
      ],
      "identifier_type": "drug_code",
      "match_scores": {
        "evidence": {
          "target": {
            "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase",
            "term": "CDK12",
            "snippet": "the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor Clinical trial deta"
          },
          "modality": null,
          "indication": null
        },
        "required": {
          "target": true,
          "modality": true,
          "indication": false
        },
        "target_match_score": 1.0,
        "overall_match_score": 0.5,
        "modality_match_score": 0.0,
        "indication_match_score": 1.0
      },
      "rejection_reason": "insufficient_modality_evidence",
      "extracted_context": {
        "scored_in_cycle": 1,
        "promotion_eligible": false,
        "finalization_overall_match_threshold": 0.7
      }
    }
  ],
  "final_assets": [
    {
      "id": "b5d556e0-db42-4320-91e0-801e992e7531",
      "created_at": "2025-12-14T21:05:31.090325+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "candidate_id": "a25159a7-8705-4003-8597-b2942db53c1c",
      "drug_name_code": "YJ1206",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "development_stage": null,
      "geography": null,
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/39353441/"
      ],
      "fingerprint": "4350155697da223e553f662036d364136d540601724e36f9424fabc4bb44ea38",
      "primary_identifier_raw": "YJ1206",
      "primary_identifier_canonical": "YJ1206",
      "identifier_aliases_raw": [
        "YJ1206"
      ],
      "evidence_snippet": "12/13 PROTAC degrader, YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206",
      "evidence_url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
      "evidence_source_type": "paper"
    },
    {
      "id": "bf041347-b488-45c4-9965-2c4a751f1b06",
      "created_at": "2025-12-14T21:05:31.225604+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "candidate_id": "2cfd142f-73bc-4dd2-8976-2df9ce1be01a",
      "drug_name_code": "YJ9069",
      "sponsor": null,
      "target": null,
      "modality": null,
      "indication": null,
      "development_stage": null,
      "geography": null,
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/39353441/"
      ],
      "fingerprint": "ef238a3a88a4e4366dcb477c6d87c1f30d59a7c956234c2629868eb744afc5e6",
      "primary_identifier_raw": "YJ9069",
      "primary_identifier_canonical": "YJ9069",
      "identifier_aliases_raw": [
        "YJ9069"
      ],
      "evidence_snippet": "we develop a selective CDK12/13 PROTAC degrader, YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206",
      "evidence_url": "https://pubmed.ncbi.nlm.nih.gov/39353441/",
      "evidence_source_type": "paper"
    }
  ],
  "metrics": [
    {
      "id": "925b816b-21b6-4dc4-b075-ede4bff830ad",
      "created_at": "2025-12-14T21:05:31.337091+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 0,
      "name": "cycle_summary",
      "value": {
        "new_mentions": 217,
        "policy_phase": "broad",
        "new_candidates": 64,
        "new_draft_assets": 58,
        "new_final_assets": 2,
        "draft_assets_total": 58,
        "final_assets_total": 2,
        "successful_workers": 6,
        "time_elapsed_seconds": 571.32,
        "unique_queries_total": 6,
        "new_identifier_tokens": 64,
        "persisted_draft_assets": 58
      }
    },
    {
      "id": "0d06df16-ff3d-493f-93df-76526ca2f2eb",
      "created_at": "2025-12-14T21:11:50.999178+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 1,
      "name": "cycle_summary",
      "value": {
        "new_mentions": 134,
        "policy_phase": "pivot",
        "new_candidates": 17,
        "new_draft_assets": 17,
        "new_final_assets": 0,
        "draft_assets_total": 75,
        "final_assets_total": 2,
        "successful_workers": 6,
        "time_elapsed_seconds": 950.98,
        "unique_queries_total": 12,
        "new_identifier_tokens": 17,
        "persisted_draft_assets": 19
      }
    },
    {
      "id": "9c783d63-d9e0-4fbc-a097-f121856bb27a",
      "created_at": "2025-12-14T21:19:26.447549+00:00",
      "run_id": "dfc71380-185d-4b6d-b28b-c6129c64bcea",
      "round_idx": 2,
      "name": "cycle_summary",
      "value": {
        "new_mentions": 223,
        "policy_phase": "pivot",
        "new_candidates": 66,
        "new_draft_assets": 52,
        "new_final_assets": 0,
        "draft_assets_total": 127,
        "final_assets_total": 2,
        "successful_workers": 6,
        "time_elapsed_seconds": 1406.43,
        "unique_queries_total": 18,
        "new_identifier_tokens": 66,
        "persisted_draft_assets": 53
      }
    }
  ]
}
